Nucleic acids encoding human TBC-1 protein and polymorphic markers thereof

ABSTRACT

The invention concerns genomic and cDNA sequences of the human TBC-1 Gene. The invention also concerns polypeptides encoded by the TBC-1 gene. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. The invention further encompasses biallelic markers of the TBC-1 gene useful in genetic analysis.

This application is a national stage application of International Application No. PCT/IB99/01444, filed Aug. 6, 1999, which claims the benefit of U.S. Provisional Application Ser. No. 60/095,653, filed Aug. 7, 1998, both of which are incorporated by reference herein in their entireties.

FIELD OF THE INVENTION

The invention concerns genomic and cDNA sequences of the human TBC-1 gene. The invention also concerns polypeptides encoded by the TBC-1 gene. The invention also deals with antibodies directed specifically against such polypeptides that are useful as diagnostic reagents. The invention further encompasses biallelic markers of the TBC-1 gene useful in genetic analysis.

BACKGROUND OF THE INVENTION

The incidence of prostate cancer has dramatically increased over the last decades. It averages 30-50/100,000 males in Western European countries as well as within the US White male population. In these countries, it has recently become the most commonly diagnosed malignancy, being one of every four cancers diagnosed in American males. Prostate cancer's incidence is very much population specific, since it varies from 2/100,000 in China, to over 80/100,000 among African-American males.

In France, the incidence of prostate cancer is 35/100,000 males and it is increasing by 10/100,000 per decade. Mortality due to prostate cancer is also growing accordingly. It is the second cause of cancer death among French males, and the first one among French males aged over 70. This makes prostate cancer a serious burden in terms of public health.

Prostate cancer is a latent disease. Many men carry prostate cancer cells without overt signs of disease. Autopsies of individuals dying of other causes show prostate cancer cells in 30% of men at age 50 and in 60% of men at age 80. Furthermore, prostate cancer can take up to 10 years to kill a patient after the initial diagnosis.

The progression of the disease usually goes from a well-defined mass within the prostate to a breakdown and invasion of the lateral margins of the prostate, followed by metastasis to regional lymph nodes, and metastasis to the bone marrow. Cancer metastasis to bone is common and often associated with uncontrollable pain.

Unfortunately, in 80% of cases, diagnosis of prostate cancer is established when the disease has already metastasized to the bones. Of special interest is the observation that prostate cancers frequently grow more rapidly in sites of metastasis than within the prostate itself.

Early-stage diagnosis of prostate cancer mainly relies today on Prostate Specific Antigen (PSA) dosage, and allows the detection of prostate cancer seven years before clinical symptoms become apparent. The effectiveness of PSA dosage diagnosis is however limited, due to its inability to discriminate between malignant and non-malignant affections of the organ and because not all prostate cancers give rise to an elevated serum PSA concentration. Furthermore, PSA dosage and other currently available approaches such as physical examination, tissue biopsy and bone scans are of limited value in predicting disease progression.

Therefore, there is a strong need for a reliable diagnostic procedure which would enable a more systematic early-stage prostate cancer prognosis.

Although an early-stage prostate cancer prognosis is important, the possibility of measuring the period of time during which treatment can be deferred is also interesting as currently available medicaments are expensive and generate important adverse effects. However, the aggressiveness of prostate tumors varies widely. Some tumors are relatively aggressive, doubling every six months whereas others are slow-growing, doubling once every five years. In fact, the majority of prostate cancers grows relatively slowly and never becomes clinically manifest. Very often, affected patients are among the elderly and die from another disease before prostate cancer actually develops. Thus, a significant question in treating prostate carcinoma is how to discriminate between tumors that will progress and those that will not progress during the expected lifetime of the patient.

Hence, there is also a strong need for detection means which may be used to evaluate the aggressiveness or the development potential of prostate cancer tumors once diagnosed.

Furthermore, at the present time, there is no means to predict prostate cancer susceptibility. It would also be very beneficial to detect individual susceptibility to prostate cancer. This could allow preventive treatment and a careful follow up of the development of the tumor.

A further consequence of the slow growth rate of prostate cancer is that few cancer cells are actively dividing at any one time, rendering prostate cancer generally resistant to radiation and chemotherapy. Surgery is the mainstay of treatment but it is largely ineffective and removes the ejaculatory ducts, resulting in impotence. Oral oestrogens and luteinizing releasing hormone analogs are also used for treatment of prostate cancer. These hormonal treatments provide marked improvement for many patients, but they only provide temporary relief. Indeed, most of these cancers soon relapse with the development of hormone-resistant tumor cells and the oestrogen treatment can lead to serious cardiovascular complications. Consequently, there is a strong need for preventive and curative treatment of prostate cancer.

Efficacy/tolerance prognosis could be precious in prostate cancer therapy. Indeed, hormonal therapy, the main treatment currently available, presents important side effects. The use of chemotherapy is limited because of the small number of patients with chemosensitive tumors. Furthermore the age profile of the prostate cancer patient and intolerance to chemotherapy make the systematic use of this treatment very difficult.

Therefore, a valuable assessment of the eventual efficacy of a medicament to be administered to a prostate cancer patent as well as the patent's eventual tolerance to it may permit to enhance the benefit/risk ratio of prostate cancer treatment.

It is known today that there is a familial risk of prostate cancer. Clinical studies in the 1950s had already demonstrated a familial aggregation in prostate cancer. Control-case clinical studies have been conducted more recently to attempt to evaluate the incidence of the genetic risk factors in the disease. Thus Steinberg et al., 1990, and McWhorter et al., 1992 confirm that the risk of prostate cancer is increased in subjects having one or more relatives already affected by the disease and when forms of early diagnosis in the relatives exist.

It is now well established that cancer is a disease caused by the deregulation of the expression of certain genes. In fact, the development of a tumor necessitates an important succession of steps. Each of these steps comprises the deregulation of an important gene intervening in the normal metabolism of the cell and the emergence of an abnormal cellular sub-clone which overwhelms the other cell types because of a proliferative advantage. The genetic origin of this concept has found confirmation in the isolation and the characterization of genes which could be responsible. These genes, commonly called “cancer genes”, have an important role in the normal metabolism of the cell and are capable of intervening in carcinogenesis following a change.

Recent studies have identified three groups of genes which are frequently mutated in cancer. The first group of genes, called oncogenes, are genes whose products activate cell proliferation. The normal non-mutant versions are called protooncogenes. The mutated forms are excessively or inappropriately active in promoting cell proliferation, and act in the cell in a dominant way in that a single mutant allele is enough to affect the cell phenotype. Activated oncogenes are rarely transmitted as germline mutations since they may probably be lethal when expressed in all the cells. Therefore oncogenes can only be investigated in tumor tissues.

The second group of genes which are frequently mutated in cancer, called tumor suppressor genes, are genes whose products inhibit cell growth. Mutant versions in cancer cells have lost their normal function, and act in the cell in a recessive way in that both copies of the gene must be inactivated in order to change the cell phenotype. Most importantly, the tumor phenotype can be rescued by the wild type allele, as shown by cell fusion experiments first described by Harris and colleagues (1969). Germline mutations of tumor suppressor genes may be transmitted and thus studied in both constitutional and tumor DNA from familial or sporadic cases. The current family of tumor suppressors includes DNA-binding transcription factors (i.e., p53, WT1), transcription regulators (i.e., RB, APC, probably BRCA1), protein kinase inhibitors (i.e., p16), among others (for review, see Haber D & Harlow E, 1997).

The third group of genes which are frequently mutated in cancer, called mutator genes, are responsible for maintaining genome integrity and/or low mutation rates. Loss of function of both alleles increases cell mutation rates, and as a consequence, proto-oncogenes and tumor suppressor genes may be mutated. Mutator genes can also be classified as tumor suppressor genes, except for the fact that tumorigenesis caused by this class of genes cannot be suppressed simply by restoration of a wild-type allele, as described above. Genes whose inactivation may lead to a mutator phenotype include mismatch repair genes (i.e., MLH1, MSH2), DNA helicases (i.e., BLM, WRN) or other genes involved in DNA repair and genomic stability (i.e., p53, possibly BRCA1 and BRCA2) (For review see Haber D & Harlow E, 1997; Fishel R & Wilson T. 1997; Ellis N A, 1997).

There is growing evidence that a critical event in the progression of a tumor cell from a non-metastatic to metastatic phenotype is the loss of function of metastasis-suppressor genes. These genes specifically suppress the ability of a cell to metastasize. Work from several groups has demonstrated that human chromosomes 8, 10, 11 and 17 encode prostate cancer metastasis suppressor activities. However, other human chromosomes such as chromosomes 1, 7, 13, 16, and 18 may also be associated to prostate cancer.

It thus remains to localize and to identify the genes specifically involved in the development and the progression of prostate cancers starting from the genetic analysis of the hereditary and the non-hereditary forms and to define their clinical implications in terns of prognosis and therapeutic innovations.

SUMMARY OF THE INVENTION

The present invention pertains to nucleic acid molecules comprising the genomic sequence of a novel human gene which encodes a TBC-1 protein. The TBC-1 genomic sequences comprise regulatory sequence located upstream (5′-end) and downstream (3′-end) of the transcribed portion of said gene, these regulatory sequences being also part of the invention. The human TBC-1 genomic sequence is included in a previously unknown candidate region of prostate cancer located on chromosome 4.

The invention also deals with the two complete cDNA sequences encoding the TBC-1 protein, as well as with the corresponding translation product.

Oligonucleotide probes or primers hybridizing specifically with a TBC-1 genomic or cDNA sequence are also part of the present invention, as well as DNA amplification and detection methods using said primers and probes.

A further object of the invention consists of recombinant vectors comprising any of the nucleic acid sequences described above, and in particular of recombinant vectors comprising a TBC-1 regulatory sequence or a sequence encoding a TBC-1 protein, as well as of cell hosts and transgenic non human animals comprising said nucleic acid sequences or recombinant vectors.

The invention also concerns a TBC-1-related biallelic marker and the use thereof.

Finally, the invention is directed to methods for the screening of substances or molecules that inhibit the expression of TBC-1, as well as with methods for the screening of substances or molecules that interact with a TBC-1 polypeptide.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1: An amino acid alignment of a portion of the amino acid sequence of the TBC-1 protein of SEQ ID No 5 with other proteins sharing amino acid homology with TBC-1. The amino acid numbering refers to the murine TBC-1.

BRIEF DESCRIPTION OF THE SEQUENCES PROVIDED IN THE SEQUENCE LISTING

SEQ ID No 1 contains a first part of the TBC-1 genomic sequence comprising the 5′ regulatory sequence and the exons 1,1bis, and 2.

SEQ ID No 2 contains a second part of the TBC-1 genomic sequence comprising the 12 last exons of the TBC-1 gene and the 3′regulatory sequence.

SEQ ID No 3 contains a first cDNA sequence of the TBC-1 gene.

SEQ ID No 4 contains a second cDNA sequence of the TBC-1 gene.

SEQ ID No 5 contains the amino acid sequence encoded by the cDNAs of SEQ ID Nos 3 and 4.

SEQ ID No 6 contains a primer containing the additional PU 5′ sequence described further in Example 3.

SEQ ID No 7 contains a primer containing the additional RP5′ sequence described further in Example 3.

In accordance with the regulations relating to Sequence Listings, the following codes have been used in the Sequence Listing to indicate the locations of biallelic markers within the sequences and to identify each of the alleles present at the polymorphic base. The code “r” in the sequences indicates that one allele of the polymorphic base is a guanine, while the other allele is an adenine. The code “y” in the sequences,indicates that one allele of the polymorphic base is a thymine, while the other allele is a cytosine. The code “m” in the sequences indicates that one allele of the polymorphic base is an adenine, while the other allele is an cytosine. The code “k” in the sequences indicates that one allele of the polymorphic base is a guanine, while the other allele is a thymine. The code “s” in the sequences indicates that one allele of the polymorphic base is a guanine, while the other allele is a cytosine. The code “w” in the sequences indicates that one allele of the polymorphic base is an adenine, while the other allele is an thymine. The nucleotide code of the original allele for each biallelic marker is the following:

Biallelic marker Original allele 99-430-352 G 99-20508-456 C 99-20469-213 C  5-254-227 A  5-257-353 C 99-20511-32 T 99-20511-221 A 99-20504-90 G 99-20493-238 A 99-20499-221 G 99-20499-364 A 99-20499-399 A  5-249-304 G 99-20485-269 A 99-20481-131 G 99-20481-419 T 99-20480-233 A

DETAILED DESCRIPTION OF THE INVENTION

The present invention concerns polynucleotides and polypeptides related to the human TBC-1 gene (also termed “TBC-1 gene” throughout the present specification), which is potentially involved in the regulation of the differentiation of various cell types in mammals. A deregulation or an alteration of TBC-1 expression, or alternatively an alteration in the amino acid sequence of the TBC-1 protein may be involved in the generation of a pathological state related to cell differentiation in a patient, more particularly to abnormal cell proliferation leading to cancer states, such as prostate cancer.

Definitions

Before describing the invention in greater detail, the following definitions are set forth to illustrate and define the meaning and scope of the terms used to describe the invention herein.

The term “TBC-1 gene”, when used herein, encompasses mRNA and cDNA sequences encoding the TBC-1 protein. In the case of a genomic sequence, the TBC-1 gene also includes native regulatory regions which control the expression of the coding sequence of the TBC-1 gene.

The term “functionally active fragment” of the TBC-1 protein is intended to designate a polypeptide carrying at least one of the structural features of the TBC-1 protein involved in at least one of the biological functions and/or activity of the TBC-1 protein.

A “heterologous” or “exogenous” polynucleotide designates a purified or isolated nucleic acid that has been placed, by genetic engineering techniques, in the environment of unrelated nucleotide sequences, such as the final polynucleotide construct does not occur naturally. An illustrative, but not limitative, embodiment of such a polynucleotide construct may be represented by a polynucleotide comprising (1) a regulatory polynucleotide derived from the TBC-1 gene sequence and (2) a polynucleotide encoding a cytokine, for example GM-CSF. The polypeptide encoded by the heterologous polynucleotide will be termed an heterologous polypeptide for the purpose of the present invention.

By a “biologically active fragment or variant” of a regulatory polynucleotide according to the present invention is intended a polynucleotide comprising or alternatively consisting in a fragment of said polynucleotide which is functional as a regulatory region for expressing a recombinant polypeptide or a recombinant polynucleotide in a recombinant cell host.

For the purpose of the invention, a nucleic acid or polynucleotide is “functional” as a regulatory region for expressing a recombinant polypeptide or a recombinant polynucleotide if said regulatory polynucleotide contains nucleotide sequences which contain transcriptional and translational regulatory information, and such sequences are “operatively linked” to nucleotide sequences which encode the desired polypeptide or the desired polynucleotide. An operable linkage is a linkage in which the regulatory nucleic acid and the DNA sequence sought to be expressed are linked in such a way as to permit gene expression.

A “promoter” refers to a DNA sequence recognized by the synthetic machinery of the cell required to initiate the specific transcription of a gene.

A sequence which is “operably linked” to a regulatory sequence such as a promoter means that said regulatory element is in the correct location and orientation in relation to the nucleic acid to control RNA polymerase initiation and expression of the nucleic acid of interest.

As used herein, the term “operably linked” refers to a linkage of polynucleotide elements in a functional relationship. For instance, a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence. More precisely, two DNA molecules (such as a polynucleotide containing a promoter region and a polynucleotide encoding a desired polypeptide or polynucleotide) are said to be “operably linked” if the nature of the linkage between the two polynucleotides does not (1) result in the introduction of a frame-shift mutation or (2) interfere with the ability of the polynucleotide containing the promoter to direct the transcription of the coding polynucleotide. The promoter polynucleotide would be operably linked to a polynucleotide encoding a desired polypeptide or a desired polynucleotide if the promoter is capable of effecting transcription of the polynucleotide of interest.

The term “primer” denotes a specific oligonucleotide sequence which is complementary to a target nucleotide sequence and used to hybridize to the target nucleotide sequence. A primer serves as an initiation point for nucleotide polymerization catalyzed by either DNA polymerase, RNA polymerase or reverse transcriptase.

The term “probe” denotes a defined nucleic acid segment (or nucleotide analog segment, e.g., polynucleotide as defined hereinbelow) which can be used to identify a specific polynucleotide sequence present in samples, said nucleic acid segment comprising a nucleotide sequence complementary of the specific polynucleotide sequence to be identified.

The terms “sample” or “material sample” are used herein to designate a solid or a liquid material suspected to contain a polynucleotide or a polypeptide of the invention. A solid material may be, for example, a tissue slice or biopsy within which is searched the presence of a polynucleotide encoding a TBC-1 protein, either a DNA or RNA molecule or within which is searched the presence of a native or a mutated TBC-1 protein, or alternatively the presence of a desired protein of interest the expression of which has been placed under the control of a TBC-1 regulatory polynucleotide. A liquid material may be, for example, any body fluid like serum, urine etc., or a liquid solution resulting from the extraction of nucleic acid or protein material of interest from a cell suspension or from cells in a tissue slice or biopsy. The term “biological sample” is also used and is more precisely defined within the Section dealing with DNA extraction.

As used herein, the term “purified” does not require absolute purity; rather, it is intended as a relative definition. Purification if starting material or natural material to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated. As an example, purification from 0.1% concentration to 10% concentration is two orders of magnitude.

The term “isolated” requires that the material be removed from its original environment (e.g. the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or DNA or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotide could be part of a vector and/or such polynucleotide or polypeptide could be part of a composition and still be isolated in that the vector or composition is not part of its natural environment.

The term “polypeptide” refers to a polymer of amino acids without regard to the length of the polymer; thus, peptides, oligopeptides, and proteins are included within the definition of polypeptide. This term also does not specify or exclude post-expression modifications of polypeptides, for example, polypeptides which include the covalent attachment of glycosyl groups, acetyl groups, phosphate groups, lipid groups and the like are expressly encompassed by the term polypeptide. Also included within the definition are polypeptides which contain one or more analogs of an amino acid (including, for example, non-naturally occurring amino acids, amino acids which only occur naturally in an unrelated biological system, modified amino acids from mammalian systems etc.), polypeptides with substituted linkages, as well as other modifications known in the art, both naturally occurring and non-naturally occurring.

The term “recombinant polypeptide” is used herein to refer to polypeptides that have been artificially designed and which comprise at least two polypeptide sequences that are not found as contiguous polypeptide sequences in their initial natural environment, or to refer to polypeptides which have been expressed from a recombinant polynucleotide.

The term “purified” is used herein to describe a polypeptide of the invention which has been separated from other compounds including, but not limited to nucleic acids, lipids, carbohydrates and other proteins. A polypeptide is substantially pure when at least about 50%, preferably 60 to 75% of a sample exhibits a single polypeptide sequence. A substantially pure polypeptide typically comprises about 50%, preferably 60 to 90% weight/weight of a protein sample, more usually about 95%, and preferably is over about 99% pure. Polypeptide purity or homogeneity is indicated by a number of means well known in the art, such as polyacrylamide gel electrophoresis of a sample, followed by visualizing a single polypeptide band upon staining the gel. For certain purposes higher resolution can be provided by using HPLC or other means well known in the art.

As used herein, the term “non-human animal” refers to any non-human vertebrate, birds and more usually mammals, preferably primates, farm animals such as swine, goats, sheep, donkeys, and horses, rabbits or rodents, more preferably rats or mice. As used herein, the term “animal” is used to refer to any vertebrate, preferable a mammal. Both the terms “animal” and “mammal” expressly embrace human subjects unless preceded with the term “non-human”.

As used herein, the term “antibody” refers to a polypeptide or group of polypeptides which are comprised of at least one binding domain, where an antibody binding domain is formed from the folding of variable domains of an antibody molecule to form three-dimensional binding spaces with an internal surface shape and charge distribution complementary to the features of an antigenic determinant of an antigen, which allows an immunological reaction with the antigen. Antibodies include recombinant proteins comprising the binding domains, as wells as fragments, including Fab, in Fab′, F(ab)₂, and F(ab′)₂ fragments.

As used herein, an “antigenic determinant” is the portion of an antigen molecule, in this case a TBC-1 polypeptide, that determines the specificity of the antigen-antibody reaction. An “epitope” refers to an antigenic determinant of a polypeptide. An epitope can comprise as few as 3 amino acids in a spatial conformation which is unique to the epitope. Generally an epitope consists of at least 6 such amino acids, and more usually at least 8-10 such amino acids. Methods for determining the amino acids which make up an epitope include x-ray crystallography, 2-dimensional nuclear magnetic resonance, and epitope mapping e.g. the Pepscan method described by Geysen et al. 1984; PCT Publication No. WO 84/03564; and PCT Publication No. WO 84/03506.

Throughout the present specification, the expression “nucleotide sequence” may be employed to designate indifferently a polynucleotide or an oligonucleotide or a nucleic acid. More precisely, the expression “nucleotide sequence” encompasses the nucleic material itself and is thus not restricted to the sequence information (i.e. the succession of letters chosen among the four base letters) that biochemically characterizes a specific DNA or RNA molecule.

As used interchangeably herein, the term “oligonucleotides”, and “polynucleotides” include RNA, DNA, or RNA/DNA hybrid sequences of more than one nucleotide in either single chain or duplex form. The term “nucleotide” as used herein as an adjective to describe molecules comprising RNA, DNA, or RNA/DNA hybrid sequences of any length in single-stranded or duplex form. The term “nucleotide” is also used herein as a noun to refer to individual nucleotides or varieties of nucleotides, meaning a molecule, or individual unit in a larger nucleic acid molecule, comprising a purine or pyrimidine, a ribose or deoxyribose sugar moiety, and a phosphate group, or phosphodiester linkage in the case of nucleotides within an oligonucleotide or polynucleotide. Although the term “nucleotide” is also used herein to encompass “modified nucleotides” which comprise at least one modification (a) an alternative linking group, (b) an analogous form of purine, (c) an analogous form of pyrimidine, or (d) an analogous sugar, for examples of analogous linking groups, purine, pyrimidines, and sugars see for example PCT publication No WO 95/04064. However, the polynucleotides of the invention are preferably comprised of greater than 50% conventional deoxyribose nucleotides, and most preferably greater than 90% conventional deoxyribose nucleotides. The polynucleotide sequences of the invention may be prepared by any known method, including synthetic, recombinant, ex vivo generation, or a combination thereof, as well as utilizing any purification methods known in the art.

The term “heterozygosity rate” is used herein to refer to the incidence of individuals in a population which are heterozygous at a particular allele. In a biallelic system, the heterozygosity rate is on average equal to 2P_(a)(1−P_(a)), where P_(a) is the frequency of the least common allele. In order to be useful in genetic studies, a genetic marker should have an adequate level of heterozygosity to allow a reasonable probability that a randomly selected person will be heterozygous.

The term “genotype” as used herein refers the identity of the alleles present in an individual or a sample. In the context of the present invention a genotype preferably refers to the description of the biallelic marker alleles present in an individual or a sample. The term “genotyping” a sample or an individual for a biallelic marker consists of determining the specific allele or the specific nucleotide carried by an individual at a biallelic marker.

The term “polymorphism” as used herein refers to the occurrence of two or more alternative genomic sequences or alleles between or among different genomes or individuals. “Polymorphic” refers to the condition in which two or more variants of a specific genomic sequence can be found in a population. A “polymorphic site” is the locus at which the variation occurs. A single nucleotide polymorphism is a single base pair change. Typically a single nucleotide polymorphism is the replacement of one nucleotide by another nucleotide at the polymorphic site. Deletion of a single nucleotide or insertion of a single nucleotide, also give rise to single nucleotide polymorphisms. In the context of the present invention “single nucleotide polymorphism” preferably refers to a single nucleotide substitution. However, the polymorphism can also involve an insertion or a deletion of at least one nucleotide, preferably between 1 and 5 nucleotides. Typically, between different genomes or between different individuals, the polymorphic site may be occupied by two different nucleotides.

The term “biallelic polymorphism” and “biallelic marker” are used interchangeably herein to refer to a single nucleotide polymorphism having two alleles at a fairly high frequency in the population. A “biallelic marker allele” refers to the nucleotide variants present at a biallelic marker site. Typically, the frequency of the less common allele of the biallelic markers of the present invention has been validated to be greater than 1%, preferably the frequency is greater than 10%, more preferably the frequency is at least 20% (i.e. heterozygosity rate of at least 0.32), even more preferably the frequency is at least 30% (i.e. heterozygosity rate of at least 0.42). A biallelic marker wherein the frequency of the less common allele is 30% or more is termed a “high quality biallelic marker”.

The location of nucleotides in a polynucleotide with respect to the center of the polynucleotide are described herein in the following manner. When a polynucleotide has an odd number of nucleotides, the nucleotide at an equal distance from the 3′ and 5′ ends of the polynucleotide is considered to be “at the center” of the polynucleotide, and any nucleotide immediately adjacent to the nucleotide at the center, or the nucleotide at the center itself is considered to be “within 1 nucleotide of the center.” With an odd number of nucleotides in a polynucleotide any of the five nucleotides positions in the middle of the polynucleotide would be considered to be within 2 nucleotides of the center, and so on. When a polynucleotide has an even number of nucleotides, there would be a bond and not a nucleotide at the center of the polynucleotide. Thus, either of the two central nucleotides would be considered to be “within 1 nucleotide of the center” and any of the four nucleotides in the middle of the polynucleotide would be considered to be “within 2 nucleotides of the center”, and so on. For polymorphisms which involve the substitution, insertion or deletion of 1 or more nucleotides, the polymorphism, allele or biallelic marker is “at the center” of a polynucleotide if the difference between the distance from the substituted, inserted, or deleted polynucleotides of the polymorphism and the 3′ end of the polynucleotide, and the distance from the substituted, inserted, or deleted polynucleotides of the polymorphism and the 5′ end of the polynucleotide is zero or one nucleotide. If this difference is 0 to 3, then the polymorphism is considered to be “within 1 nucleotide of the center.” If the difference is 0 to 5, the polymorphism is considered to be “within 2 nucleotides of the center.” If the difference is 0 to 7, the polymorphism is considered to be “within 3 nucleotides of the center,” and so on.

As used herein the terminology “defining a biallelic marker” means that a sequence includes a polymorphic base from a biallelic marker. The sequences defining a biallelic marker may be of any length consistent with their intended use, provided that they contain a polymorphic base from a biallelic marker. The sequence has between 1 and 500 nucleotides in length, preferably between 5, 10, 15, 20, 25, or 40 and 200 nucleotides and more preferably between 30 and 50 nucleotides in length. Each biallelic marker therefore corresponds to two forms of a polynucleotide sequence included in a gene, which, when compared with one another, present a nucleotide modification at one position. Preferably, the sequences defining a biallelic marker include a polymorphic base selected from the group consisting of the biallelic markers A1 to A19 and the complements thereof. In some embodiments the sequences defining a biallelic marker comprise one of the sequences selected from the group consisting of P1 to P7, P9 to P13, P15 to P19 and the complementary sequences thereto. Likewise, the term “marker” or “biallelic marker” requires that the sequence is of sufficient length to practically (although not necessarily unambiguously) identify the polymorphic allele, which usually implies a length of at least 4, 5, 6, 10, 15, 20, 25, or 40 nucleotides.

The term “upstream” is used herein to refer to a location which is toward the 5′ end of the polynucleotide from a specific reference point.

The terms “base paired” and “Watson & Crick base paired” are used interchangeably herein to refer to nucleotides which can be hydrogen bonded to one another be virtue of their sequence identities in a manner like that found in double-helical DNA with thymine or uracil residues linked to adenine residues by two hydrogen bonds and cytosine and guanine residues linked by three hydrogen bonds (See Stryer, L., Biochemistry, 4^(th) edition, 1995).

The terms “complementary” or “complement thereof” are used herein to refer to the sequences of polynucleotides which is capable of forming Watson & Crick base pairing with another specified polynucleotide throughout the entirety of the complementary region. For the purpose of the present invention, a first polynucleotide is deemed to be complementary to a second polynucleotide when each base in the first polynucleotide is paired with its complementary base. Complementary bases are, generally, A and T (or A and U), or C and G. “Complement” is used herein as a synonym from “complementary polynucleotide”, “complementary nucleic acid” and “complementary nucleotide sequence”. These terms are applied to pairs of polynucleotides based solely upon their sequences ad not any particular set of conditions-under which the two polynucleotides would actually bind.

Variants and Fragments

1. Polynucleotides

The invention also relates to variants and fragments of the polynucleotides described herein, particularly of a TBC-1 gene containing one or more biallelic markers according to the invention.

Variants of polynucleotides, as the term is used herein, are polynucleotides that differ from a reference polynucleotide. A variant of a polynucleotide may be a naturally occurring variant such as a naturally occurring allelic variant, or it may be a variant that is not known to occur naturally. Such non-naturally occurring variants of the polynucleotide may be made by mutagenesis techniques, including those applied to polynucleotides, cells or organisms. Generally, differences are limited so that the nucleotide sequences of the reference and the variant are closely similar overall and, in many regions, identical.

Variants of polynucleotides according to the invention include, without being limited to, nucleotide sequences that are at least 95% identical to any of SEQ ID Nos 1-4 or the sequences complementary thereto or to any polynucleotide fragment of at least 8 consecutive nucleotides of any of SEQ ID Nos 1-4 or the sequences complementary thereto, and preferably at least 98% identical, more particularly at least 99.5% identical, and most preferably at least 99.9% identical to any of SEQ ID Nos 1-4 or the sequences complementary thereto or to any polynucleotide fragment of at least 8 consecutive nucleotides of any of SEQ ID Nos 1-4 or the sequences complementary thereto.

Changes in the nucleotide of a variant may be silent, which means that they do not alter the amino acids encoded by the polynucleotide.

However, nucleotide changes may also result in amino acid substitutions, additions, deletions, fusions and truncations in the polypeptide encoded by the reference sequence. The substitutions, deletions or additions may involve one or more nucleotides. The variants may be altered in coding or non-coding regions or both. Alterations in the coding regions may produce conservative or non-conservative amino acid substitutions, deletions or additions.

In the context of the present invention, particularly preferred embodiments are those in which the polynucleotides encode polypeptides which retain substantially the same biological function or activity as the mature TBC-1 protein.

A polynucleotide fragment is a polynucleotide having a sequence that entirely is the same as part but not all of a given nucleotide sequence, preferably the nucleotide sequence of a TBC-1 gene, and variants thereof. The fragment can be a portion of an exon or of an intron of a TBC-1 gene. It can also be a portion of the regulatory sequences of the TBC-1 gene. Preferably, such fragments comprise the polymorphic base of a biallelic marker selected from the group consisting of the biallelic markers A1 to A19 and the complements thereof.

Such fragments may be “free-standing”, i.e. not part of or fused to other polynucleotides, or they may be comprised within a single larger polynucleotide of which they form a part or region. However, several fragments may be comprised within a single larger polynucleotide.

As representative examples of polynucleotide fragments of the invention, there may be mentioned those which have from about 4, 6, 8, 15, 20, 25, 40, 10 to 20, 10 to 30, 30 to 55, 50 to 100, 75 to 100 or 100 to 200 nucleotides in length. Preferred are those fragments having about 49 nucleotides in length, such as those of P1 to P7, P9 to P13, P15 to P19 or the sequences complementary thereto and containing at least one of the biallelic markers of a TBC-1 gene which are described herein.

2. Polypeptides

The invention also relates to variants, fragments, analogs and derivatives of the polypeptides described herein, including mutated TBC-1 proteins.

The variant may be 1) one in which one or more of the amino acid residues are substituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such substituted amino acid residue may or may not be one encoded by the genetic code, or 2) one in which one or more of the amino acid residues includes a substituent group, or 3) one in which the mutated TBC-1 is fused with another compound, such as a compound to increase the half-life of the polypeptide (for example, polyethylene glycol), or 4) one in which the additional amino acids are fused to the mutated TBC-1, such as a leader or secretory sequence or a sequence which is employed for purification of the mutated TBC-1 or a preprotein sequence. Such variants are deemed to be within the scope of those skilled in the art.

More particularly, a variant TBC-1 polypeptide comprises amino acid changes ranging from 1, 2, 3, 4, 5, 10 to 20 substitutions, additions or deletions of one amino acid, preferably from 1 to 10, more preferably from 1 to 5 and most preferably from 1 to 3 substitutions, additions or deletions of one amino acid. The preferred amino acid changes are those which have little or no influence on the biological activity or the capacity of the variant TBC-1 polypeptide to be recognized by antibodies raised against a native TBC-1 protein.

By homologous peptide according to the present invention is meant a polypeptide containing one or several aminoacid additions, deletions and/or substitutions in the amino acid sequence of a TBC-1 polypeptide. In the case of an aminoacid substitution, one or several—consecutive or non-consecutive—aminoacids are replaced by <<equivalent>> aminoacids.

The expression “equivalent” amino acid is used herein to designate any amino acid that may be substituted for one of the amino acids having similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydropathic nature of the polypeptide to be substantially unchanged. Generally, the following groups of amino acids represent equivalent changes: (1) Ala, Pro, Gly, Glu, Asp, Gln, Asn, Ser, Thr; (2) Cys, Ser, Tyr, Thr; (3) Val, Ile, Leu, Met, Ala, Phe; (4) Lys, Arg, His; (5) Phe, Tyr, Trp, His.

By an equivalent aminoacid according to the present invention is also meant the replacement of a residue in the L-form by a residue in the D form or the replacement of a Glutamic acid (E) residue by a Pyro-glutamic acid compound. The synthesis of peptides containing at least one residue in the D-form is, for example, described by Koch (1977).

A specific, but not restrictive, embodiment of a modified peptide molecule of interest according to the present invention, which consists in a peptide molecule which is resistant to proteolysis, is a peptide in which the —CONH— peptide bond is modified and replaced by a (CH₂NH) reduced bond, a (NHCO) retro inverso bond, a (CH₂—O) methylene-oxy bond, a (CH₂—S) thiomethylene bond, a (CH₂CH₃) carba bond, a (CO—CH₂) cetomethylene bond, a (CHOH—CH₂) hydroxyethylene bond), a (N—N) bound, a E-alcene bond or also a CH═CH— bond.

The polypeptide accoding to the invention could have post-translational modifications. For example, it can present the following modifications: acylation, disulfide bond formation, prenylation, carboxymethylation and phosphorylation.

A polypeptide fragment is a polypeptide having a sequence that entirely is the same as part but not all of a given polypeptide sequence, preferably a polypeptide encoded by a TBC-1 gene and variants thereof. Preferred fragments include those regions possessing antigenic properties and which can be used to raise antibodies against the TBC-1 protein.

Such fragments may be “free-standing”, i.e. not part of or fused to other polypeptides, or they may be comprised within a single larger polypeptide of which they form a part or region. However, several fragments may be comprised within a single larger polypeptide.

As representative examples of polypeptide fragments of the invention, there may be mentioned those which comprise at least about 5, 6, 7, 8, 9 or 10 to 15, 10 to 20, 15 to 40, or 30 to 55 amino acids of the TBC-1. In some embodiments, the fragments contain at least one amino acid mutation in the TBC-1 protein.

Identity between Nucleic Acids or Polypeptides

The terms “percentage of sequence identity” and “percentage homology” are used interchangeably herein to refer to comparisons among polynucleotides and polypeptides, and are determined by comparing two optimally aligned sequences over a comparison window, wherein the portion of the polynucleotide or polypeptide sequence in the comparison window may comprise additions or deletions (i.e, gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The percentage is calculated by determining the number of positions at which the identical nucleic acid base or amino acid residue occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. Homology is evaluated using any of the variety of sequence comparison algorithms and programs known in the art. Such algorithms and programs include, but are by no means limited to, TBLASTN, BLASTP, FASTA, TFASTA, and CLUSTALW (Pearson and Lipman, 1988; Altschul et al., 1990; Thompson et al., 1994; Higgins et al., 1996; Altschul et al., 1993). In a particularly preferred embodiment, protein and nucleic acid sequence homologies are evaluated using the Basic Local Alignment Search Tool (“BLAST”) which is well known in the art (see, e.g., Karlin and Altschul, 1990; Altschul et al., 1990, 1993, 1997). In particular, five specific BLAST programs are used to perform the following task:

(1) BLASTP and BLAST3 compare an amino acid query sequence against a protein sequence database;

(2) BLASTN compares a nucleotide query sequence against a nucleotide sequence database;

(3) BLASTX compares the six-frame conceptual translation products of a query nucleotide sequence (both strands) against a protein sequence database;

(4) TBLASTN compares a query protein sequence against a nucleotide sequence database translated in all six reading frames (both strands); and

(5) TBLASTX compares the six-frame translations of a nucleotide query sequence against the six-frame translations of a nucleotide sequence database.

The BLAST programs identify homologous sequences by identifying similar segments, which are referred to herein as “high-scoring segment pairs,” between a query amino or nucleic acid sequence and a test sequence which is preferably obtained from a protein or nucleic acid sequence database. High-scoring segment pairs are preferably identified (i.e., aligned) by means of a scoring matrix, many of which are known in the art Preferably, the scoring matrix used is the BLOSUM62 matrix (Gonnet et al., 1992; Henikoff and Henikoff, 1993). Less preferably, the PAM or PAM250 matrices may also be used (see, e.g., Schwartz and Dayhoff, eds., 1978). The BLAST programs evaluate the statistical significance of all high-scoring segment pairs identified, and preferably selects those segments which satisfy a user-specified threshold of significance, such as a user-specified percent homology. Preferably, the statistical significance of a high-scoring segment pair is evaluated using the statistical significance formula of Karlin (see, e.g., Karlin and Altschul, 1990).

Stringent Hybridization Conditions

By way of example and not limitation, procedures using conditions of high stringency are as follows: Prehybridization of filters containing DNA is carried out for 8 h to overnight at 65° C. in buffer composed of 6×SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 μ/ml denatured salmon sperm DNA. Filters are hybridized for 48 h at 65° C., the preferred hybridization temperature, in prehybridization mixture containing 100 μg/ml denatured salmon sperm DNA and 5-20×10⁶ cpm of ³²P-labeled probe. Alternatively, the hybridization step can be performed at 65° C. in the presence of SSC buffer, 1×SSC corresponding to 0.15M NaCl and 0.05 M Na citrate. Subsequently, filter washes can be done at 37° C. for 1 h in a solution containing 2×SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA, followed by a wash in 0.1×SSC at 50° C. for 45 min. Alternatively, filter washes can be performed in a solution containing 2×SSC and 0. 1% SDS, or 0.5×SSC and 0.1% SDS, or 0.1×SSC and 0.1% SDS at 68° C. for 15 minute intervals. Following the wash steps, the hybridized probes are detectable by autoradiography. Other conditions of high stringency which may be used are well known in the art and as cited in Sambrook et al., 1989; and Ausubel et al., 1989, are incorporated herein in their entirety. These hybridization conditions are suitable for a nucleic acid molecule of about 20 nucleotides in length. There is no need to say that the hybridization conditions described above are to be adapted according to the length of the desired nucleic acid, following techniques well known to the one skilled in the art. The suitable hybridization conditions may for example be adapted according to the teachings disclosed in the book of Hames and Higgins (1985) or in Sambrook et al.(1989).

Candidate Region on the Chromosome 4 (Linkage Analysis)

In order to localize the prostate cancer gene(s) starting from families, a systematic familial study of genetic link research is carried out using markers of the microsatellite type described at the Genethon laboratory by the Jean Weissenbach team (Dib et al., 1996).

The studies of genetic link or of “linkage” are based on the principle according to which two neighboring sequences on a chromosome do not present (or very rarely present) recombinations by crossing-over during meiosis. To do this, microsatellite DNA sequences (chromosomal markers) constantly co-inherited with the disease studied are searched for in a family having a predisposition for this disease. These DNA sequences organized in the form of a repetition of di-, tri- or tetranucleotides are systematically present along the genome, and thus allow the identification of chromosomal fragments harboring them. More than 5000 microsatellite markers, have been localized with precision on the genome as a result of the first studies on the genetic map carried out at Genethon under the supervision of Jean Weissenbach, and on the physical map (using the “Yeast Artificial Chromosomes”), work conducted by Daniel Cohen at C.E.P.H. and at Genethon (Chumakov et al, 1995). Genetic link analysis calculates the probabilities of recombinations of the target gene with the chromosomal markers used, according to the genealogical tree, the transmission of the disease, and the transmission of the markers. Thus if a particular allele of a given marker is transmitted with the disease more often than chance would have it (recombination level of between 0 and 0.5), it is possible to deduce that the target gene in question is found in the neighborhood of the marker. Using this technique, it has been possible to localize several genes of genetic predisposition to familial cancers. In order to be able to be included in a genetic link study, the families affected by a hereditary form of the disease must satisfy the “informativeness” criteria: several affected subjects (and whose constitutional DNA is available) per generation, and at best having a large number of siblings.

By linkage analysis, the inventors have identified a candidate region for prostate cancer on chromosome 4. Indeed, the LOD scores at 2 points between the disease and the markers on a total population of approximately fifty families present a value of 2.49 for marker D4S398 which indicates a probable genetic link with this marker. The curve of the variation of the LOD score on a map of 5 markers is centered on D4S398 and the value higher than 3.3 indicates that a gene involved in familial prostate cancer is probably found in the region located between markers D4S2978 and D4S3018, or a space of approximately 9.7 cM.

Homologies of the Novel Human Gene Translation Product with a Known Murine Protein

A novel human gene was found in this candidate region. It presents a good probability to be involved in cancer. Database homology searches have allowed the inventors to determine that the translation product of this novel human gene has significant identity with a murine protein called tbc1. Therefore, the novel human gene of the invention has thus been called TBC-1 throughout the present specification. TBC-1 comprises an open Reading frame that encodes a novel protein, the TBC-1 protein. Based on sequence similarity, an alignment of a portion of the TBC-1 amino acid sequence with the known tbc-1 murine protein, it is expected that TBC1 protein may play a role in the cell cycle and in differentiation of various tissues. Indeed, the TBC1 protein contains a 200 amino acid domain called the TBC domain that is homologous to regions in the tre2-oncogene and in the yeast regulators of mitosis BUB2 and cdc16.

The cDNA of the murine tbc1 gene has been described in U.S. Pat. No. 5,700,927 and it encodes a putative protein product of 1141 amino acids. The N-terminus of the murine tbc1 protein contains stretches of cysteines and histidines which may form zinc finger structures in the mature polypeptides. The N-terminus also comprises short stretches of basic amino acids which may be involved in a nuclear localization signal. The TBC domain of the murine tbc1 protein contains several tyrosine residues which are conserved in BUB2 and cdc16. The C-terminus of the murine tbc1 protein contains a long stretch of evenly spaced leucine residues which are susceptible to form a leucine zipper motif.

The murine tbc1 gene has been shown to be highly expressed in testis and kidney. However, lower levels of expression have also be identified in lung, spleen, brain, and heart. Moreover, murine tbc1 is a nuclear protein which is expressed in a cell-and stage-specific manner.

Studies of murine bone marrow have demonstrated that erythroid cells and megakaryocytes expressed substantial levels of the murine tbc1 protein, but none was detected in mature neutrophils. Similarly, spermatogonia do not express murine tbc1, but primary and secondary spermatocytes express abundant tbc1. Later in the differentiation of the germ cells, the tbc1 levels appear to decrease in spermatids and active sperm. The differentiation program of spermatogonia to spermatocytes therefore involves a significant upregulation of murine tbc1 expression.

The general distribution of murine tbc is not tissue-specific, but is cell-specific within individual tissues and intimately linked to tissue differentiation. The developmental expression of murine tbc1, particularly in hematopoictic and germ cells, suggests that this gene plays a role in the terminal differentiation program of several tissues.

Consequently, an alteration in the expression of the TBC-1 gene or in the amino acid sequence of the TBC-1 protein leading to an altered biological activity of the latter is likely to cause, directly or indirectly, cell proliferation disorders and thus diseases related to an abnormal cell proliferation such as cancer, particularly prostate cancer.

Genomic Sequence of TBC-1

The present invention concerns the genomic sequence of TBC-1. The present invention encompasses the TBC-1 gene, or TBC-1 genomic sequences consisting of, consisting essentially of, or comprising a sequence selected from the group consisting of SEQ ID Nos 1 and 2, a sequence complementary thereto, as well as fragments and variants thereof. These polynucleotides may be purified, isolated, or recombinant.

The inventors have sequenced two portions of the TBC-1 genomic sequence. The first portion of the TBC-1 gene sequence contains the three first exons of the TBC-1 gene, designated as Exon 1, Exon 1bis and Exon 2, and the 5′ regulatory sequence located upstream of the transcribed sequences. The sequence of the first portion of the genomic sequence is disclosed in SEQ ID No 1. The second portion contains the twelve last exons of the TBC-1 gene, designated as exons A, B, C, D, E, F, G, H, I, J, K, and L, and the 3′ regulatory sequence which is located downstream of the transcribed sequences.

The exon positions in SEQ ID Nos 1 and 2 are detailed below in Table A.

TABLE A Begin- Begin- Exon ning End Intron ning End Position in Position in SEQ ID No 1 SEQ ID No 1 1 2001 2077 1 2078 12739 lbis 12292 12373 lbis 12374 12739 2 12740 13249 2 13250 at least 17590 Position in Position in SEQ ID No 2 SEQ ID No 2 A 4661 4789 A 4790  6115 B 6116 6202 B 6203  9918 C 9919 10199 C 10200 14520 D 14521 14660 D 14661 50256 E 50257 50442 E 50443 56255 F 56256 56417 F 56418 63325 G 63326 63484 G 63485 76035 H 76036 76280 H 76281 78363 I 78364 78523 I 78524 85294 J 85295 85464 J 85465 93416 K 93417 93590 K 93591 97475 L 97476 97960

Intron 1 refers to the nucleotide sequence located between Exon 1 and Exon 2; Intron 1bis refers to the nucleotide sequence located between Exon 1bis and Exon 2; Intron A refers to the nucleotide sequence located between Exon A and Exon B; and so on. The position of the introns is detailed in Table A.

The TBC-1 introns defined hereinafter for the purpose of the present invention are not exactly what is generally understood as “introns” by the one skilled in the art and will consequently be further defined below.

Generally, an intron is defined as a nucleotide sequence that is present both in the genomic DNA and in the unspliced mRNA molecule, and which is absent from the mRNA molecule which has already gone through splicing events. In the case of the TBC-1 gene, the inventors have found that at least two different spliced mRNA molecules are produced when this gene is transcribed, as it will be described in detail in a further section of the specification. The first spliced mRNA molecule comprises Exons 1 and 2. Thus, the genomic nucleotide sequence comprised between Exon 1 and Exon 2 is an intronic sequence as regards to this fist mRNA molecule, despite the fact that this intronic sequence contains Exon 1bis. In contrast, Exon 1bis is of course an exonic nucleotide sequence as regards to the second TBC-1 mRNA molecule.

For the purpose of the present invention and in order to make a clear and unambiguous designation of the different nucleic acids encompassed, it has been postulated that the polynucleotides contained both in any of the nucleotide sequences of SEQ ID Nos 1 or 2 and in any of the nucleotide sequences of SEQ ID Nos 3 or 4 are considered as exonic sequences. Conversely, the polynucleotides contained in any of the nucleotide sequences of SEQ ID Nos 1 or 2 but which are absent both from the nucleotide sequence of SEQ ID No 3 and from the nucleotide sequence of SEQ ID No 4 are considered as intronic sequences.

The nucleic acids defining the TBC-1 introns described above, as well as their fragments and variants, may be used as oligonucleotide primers or probes in order to detect the presence of a copy of the TBC-1 gene in a test sample, or alternatively in order to amplify a target nucleotide sequence within the TBC-1 intronic sequences.

Thus, the invention embodies purified, isolated, or recombinant polynucleotides comprising a nucleotide sequence selected from the group consisting of the 15 exons of the TBC-1 gene which are described in the present invention, or a sequence complementary thereto. The invention also deals with purified, isolated, or recombinant nucleic acids comprising a combination of at least two exons of the TBC-1 gene, wherein the polynucleotides are arranged within the nucleic acid, from the 5′-end to the 3′-end of said nucleic acid, in the same order as in SEQ ID Nos 1 and 2.

Thus, the invention embodies purified, isolated, or recombinant polynucleotides comprising a nucleotide sequence selected from the group consisting of the introns of the TBC-1 gene, or a sequence complementary thereto.

The invention also encompasses a purified, isolated, or recombinant polynucleotide comprising a nucleotide sequence having at least 70, 75, 80, 85, 90, or 95% nucleotide identity with a sequence selected from the group consisting of SEQ ID Nos 1 and 2 or a complementary sequence thereto or a fragment thereof. The nucleotide differences as regards to the nucleotide sequence of SEQ ID Nos 1 or 2 may be generally randomly distributed throughout the entire nucleic acid. Nevertheless, preferred nucleic acids are those wherein the nucleotide differences as regards to the nucleotide sequence of SEQ ID Nos 1 or 2 are predominantly located outside the coding sequences contained in the exons. These nucleic acids, as well as their fragments and variants, may be used as oligonucleotide primers or probes in order to detect the presence of a copy of the TBC-1 gene in a test sample, or alternatively in order to amplify a target nucleotide sequence within the TBC-1 sequences.

Another object of the invention consists of a purified, isolated, or recombinant nucleic acid that hybridizes with a sequence selected from the group consisting of SEQ ID Nos 1 and 2 or a complementary sequence thereto or a variant thereof, under the stringent hybridization conditions as defined above.

Particularly preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80,90, 100, 150, 200, 500, or 1000 nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID Nos 1 and 2, or the complements thereof. Additionally preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 1-1000, 1001-2000, 2001-3000, 3001-4000, 4001-5000, 5001-6000, 6001-7000, 7001-8000, 8001-9000, 9001-10000, 10001-11000, 11001-12000, 12001-13000, 13001-14000, 14001-15000, 15001-16000, 16001-17000, and 17001-17590. Other preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 2 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 2: 1-5000, 5001-10000, 10001-15000, 15001-20000, 20001-25000, 25001-30000, 30001-35000, 35001-40000, 40001-45000, 45001-50000, 50001-55000, 55001-60000, 60001-65000, 65001-70000, 70001-75000, 75001-80000, 80001-85000, 85001-90000, 90001-95000, and 95001-99960.

While this section is entitled “Genomic Sequences of TBC-1,” it should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section, flanking the genomic sequences of TBC-1 on either side or between two or more such genomic sequences.

TBC-1 cDNA Sequences

The inventors have discovered that the expression of the TBC-1 gene leads to the production of at least two mRNA molecules, respectively a first and a second TBC-1 transcription product, as the results of alternative splicing events. They result from two distinct first exons, namely Exon 1 and Exon 1bis.

The first transcription product comprises Exons 1, 2, A, B, C, D, E, F, G, H, I, J, K, and L. This cDNA of SEQ ID No 3 includes a 5′-UTR region, spanning the whole Exon 1 and part of Exon 2. This 5′-UTR region starts from the nucleotide at position 1 and ends at the nucleotide at position 170 of the nucleotide sequence of SEQ ID No 3. The cDNA of SEQ ID No 3 includes a 3′-UTR region starting from the nucleotide at position 3726 and ending at the nucleotide at position 3983 of the nucleotide sequence of SEQ ID No 3. This first transcription product harbors a polyadenylation signal located between the nucleotide at position 3942 and the nucleotide at position 3947 of the nucleotide sequence of SEQ ID No 3.

The second TBC-1 transcription product comprises Exons 1bis, 2, A, B, C, D, E, F, G, H, I, J, K, and L. This cDNA of SEQ ID No 4 includes a 5′-UTR region starting from the nucleotide at position 1 and ending at the nucleotide at position 175 of the nucleotide sequence of SEQ ID No 4. This second cDNA also includes a 3′-UTR region starting from the nucleotide at position 3731 and ending at the nucleotide at position 3988 of the nucleotide sequence of SEQ ID No 4. This second transcription product harbors a polyadenylation signal located between the nucleotide at position 3947 and the nucleotide at position 3952 of the nucleotide sequence of SEQ ID No 4.

The 5′-end sequence of this second TBC-1 mRNA, more particularly the nucleotide sequence comprised between the nucleotide in position 1 and the nucleotide in position 458 of the nucleic acid of SEQ ID No 4 molecule corresponds to the nucleotide sequence of a 5′-EST that has been obtained from a human pancreas cDNA library and characterized following the teachings of the PCT Application No WO 96/34981. This 5′-EST is also part of the invention.

Another object of the invention consists of a purified or isolated nucleic acid comprising a polynucleotide selected from,the group consisting of the nucleotide sequences of SEQ ID Nos 3 and 4 and to nucleic acid fragments thereof.

Preferred nucleic acid fragments of the nucleotide sequences of SEQ ID Nos 3 and 4 consist in polynucleotides comprising their respective Open Reading Frames encoding the TBC-1 protein.

Other preferred nucleic acid fragments of the nucleotide sequences of SEQ ID Nos 3 and 4 consist in polynucleotides comprising at least a part of their respective 5′-UTR or 3′-UTR regions.

The invention also pertains to a purified or isolated nucleic acid having at least a 95% of nucleotide identity with any one of the nucleotide sequences of SEQ ID Nos 3 and 4, or a fragment thereof.

Another object of the invention consists of purified, isolated or recombinant nucleic acids comprising a polynucleotide that hybridizes, under the stringent hybridization conditions defined herein, with any one of the nucleotide sequences of SEQ ID Nos 3 and 4, or a sequence complementary thereto or a fragment thereof.

The invention also relates to isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID Nos 3 and 4, or the complements thereof. Particularly preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 3 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 3: 1-500, 501-1000, 1001-1500, 1501-2000, 2001-2500, 2501-3000, 3001-3500, and 3501-3983. Additionally preferred nucleic acids of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 4 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 4: 1-500, 501-1000, 1001-1500, 1501-2000, 2001-2500, 2501-3000, 3001-3500, and 3501-3988. Such a nucleic acid is notably useful as polynucleotide probe or primer specific for the TBC-1 gene or the TBC-1 mRNAs and cDNAs.

While this section is entitled “TBC-1 cDNA Sequences,” it should be noted that nucleic acid fragments of any size and sequence may also be comprised by the polynucleotides described in this section, flanking the genomic sequences of TBC-1 on either side or between two or more such genomic sequences.

Coding Regions

The TBC-1 open reading frame is contained in the two TBC-1 mRNA molecules of about 4 kilobases isolated by the inventors.

More precisely, the effective TBC-1 coding sequence is comprised between the nucleotide at position 171 and the nucleotide at position 3725 of SEQ ID No 3, and between the nucleotide at position 176 and the nucleotide at position 3730 of the nucleotide sequence of SEQ ID No 4.

The invention further provides a purified or isolated nucleic acid comprising a polynucleotide selected from the group consisting of a polynucleotide comprising a nucleic acid sequence located between the nucleotide at position 171 and the nucleotide at position 3725 of SEQ ID No 3, and a polynucleotide comprising a nucleic acid sequence located between the nucleotide at position 176 and the nucleotide at position 3730 of SEQ ID No 4 or a variant or fragment thereof or a sequence complementary thereto.

The present invention concerns a purified or isolated nucleic acid encoding a human TBC-1 protein, wherein said TBC-1 protein comprises an amino acid sequence of SEQ ID No 5, a nucleotide sequence complementary thereto, a fragment or a variant thereof. The present invention also embodies isolated, purified, and recombinant polynucleotides which encode a polypeptides comprising a contiguous span of at least 6 amino acids, preferably at least 8 or 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 5. In a preferred embodiment, the present invention embodies isolated, purified, and recombinant polynucleotides which encode a polypeptides comprising a contiguous span of at least 6 amino acids, preferably at least 8 or 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, or 100 amino acids of SEQ ID No 5 wherein said contiguous span includes at least 1, 2, 3, 5 or 10 of the following amino acid positions in SEQ ID No 5: 1-300, 301-600, 601-900, and 901-1168.

The above disclosed polynucleotide that contains only coding sequences derived from the TBC-1 ORF may be expressed in a desired host cell or a desired host organism, when said polynucleotide is placed under the control of suitable expression signals. Such a polynucleotide, when placed under the suitable expression signals, may be inserted in a vector for its expression.

Regulatory Sequences of TBC-1

The invention further deals with a purified or isolated nucleic acid comprising the nucleotide sequence of a regulatory region which is located either upstream of the first exon of the TBC-1 gene and which is contained in the TBC-1 genomic sequence of SEQ ID No 1, or downstream of the last exon of the TBC-1 gene and which is contained in the TBC-1 genomic sequence of SEQ ID No 2.

The 5′-regulatory sequence of the TBC-1 gene is localized between the nucleotide in position 1 and the nucleotide in position 2000 of the nucleotide sequence of SEQ ID No 1. The 3′-regulatory sequence of the TBC-1 gene is localized between nucleotide position 97961 and nucleotide position 99960 of SEQ ID No 2.

Polynucleotides derived from the 5′ and 3′ regulatory regions are useful in order to detect the presence of at least a copy of a nucleotide sequence of SEQ ID Nos 1 or 2 or a fragment thereof in a test sample.

The promoter activity of the 5′ regulatory regions contained in TBC-1 can be assessed as described below.

Genomic sequences lying upstream of the TBC-1 Exons are cloned into a suitable promoter reporter vector, such as the pSEAP-Basic, pSEAP-Enhancer, pβgal-Basic, pβgal-Enhancer, or pEGFP-1 Promoter Reporter vectors available from Clontech. Briefly, each of these promoter reporter vectors include multiple cloning sites positioned upstream of a reporter gene encoding a readily assayable protein such as secreted alkaline phosphatase, beta galactosidase, or green fluorescent protein. The sequences upstream of the TBC-1 coding region are inserted into the cloning sites upstream of the reporter gene in both orientations and introduced into an appropriate host cell. The level of reporter protein is assayed and compared to the level obtained from a vector which lacks an insert in the cloning site. The presence of an elevated expression level in the vector containing the insert with respect to the control vector indicates the presence of a promoter in the insert. If necessary, the upstream sequences can be cloned into vectors which contain an enhancer for increasing transcription levels from weak promoter sequences. A significant level of expression above that observed with the vector lacking an insert indicates that a promoter sequence is present in the inserted upstream sequence.

Promoter sequences within the upstream genomic DNA may be further defined by constructing nested deletions in the upstream DNA using conventional techniques such as Exonuclease III digestion. The resulting deletion fragments can be inserted into the promoter reporter vector to determine whether the deletion has reduced or obliterated promoter activity. In this way, the boundaries of the promoters may be defined. If desired, potential individual regulatory sites within the promoter may be identified using site directed mutagenesis or linker scanning to obliterate potential transcription factor binding sites within the promoter, individually or in combination. The effects of these mutations on transcription levels may be determined by inserting the mutations into the cloning sites in the promoter reporter vectors.

Thus, the minimal size of the promoter of the TBC-1 gene can be determined through the measurement of TBC-1 expression levels. For this assay, an expression vector comprising decreasing sizes from the promoter generally ranging from 2 kb to 100 bp, with a 3′ end which is constant, operably linked to TBC-1 coding sequence or to a reporter gene is used. Cells, which are preferably prostate cells and more preferably prostate cancer cells, are transfected with this vector and the expression level of the gene is assessed.

The strength and the specificity of the promoter of the TBC-1 gene can be assessed through the expression levels of the gene operably linked to this promoter in different types of cells and tissues. In one embodiment, the efficacy of the promoter of the TBC-1 gene is assessed in normal and cancer cells. In a preferred embodiment, the efficacy of the promoter of the TBC-1 gene is assessed in normal prostate cells and in prostate cancer cells which can present different degrees of malignancy.

Polynucleotides carrying the regulatory elements located both at the 5′ end and at the 3′ end of the TBC-1 cDNAs may be advantageously used to control the transcriptional and translational activity of an heterologous polynucleotide of interest.

Thus, the present invention also concerns a purified or isolated nucleic acid comprising a polynucleotide which is selected from the group consisting of the 5′ and 3′ regulatory regions, or a sequence complementary thereto or a biologically active fragment or variant thereof. “5′ regulatory region” refers to the nucleotide sequence located between positions 1 and 2000 of SEQ ID No 1. “3′ regulatory region” refers to the nucleotide sequence located between positions 97961 and 99960 of SEQ ID No 2.

The invention also pertains to a purified or isolated nucleic acid comprising a polynucleotide having at least 95% nucleotide identity with a polynucleotide selected from the group consisting of the 5′ and 3′ regulatory regions, advantageously 99% nucleotide identity, preferably 99.5% nucleotide identity and most preferably 99.8% nucleotide identity with a polynucleotide selected from the group consisting of the 5′ and 3′ regulatory regions, or a sequence complementary thereto or a variant thereof or a biologically active fragment thereof.

Another object of the invention consists of purified, isolated or recombinant nucleic acids comprising a polynucleotide that hybridizes, under the stringent hybridization conditions defined herein, with a polynucleotide selected from the group consisting of the nucleotide sequences of the 5′- and 3′ regulatory regions, or a sequence complementary thereto or a variant thereof or a biologically active fragment thereof.

The 5′UTR and 3′UTR regions of a gene are of particular importance in that they often comprise regulatory elements which can play a role in providing appropriate expression levels, particularly through the control of mRNA stability.

A 5′ regulatory polynucleotide of the invention may include the 5′-UTR located between the nucleotide at position I and the nucleotide at position 170 of SEQ ID No 3, or a biologically active fragment or variant thereof.

Alternatively, a 5′-regulatory polynucleotide of the invention may include the 5′-UTR located between the nucleotide at position 1 and the nucleotide at position 175 of SEQ ED No 4, or a biologically active fragment or variant thereof.

A 3′ regulatory polynucleotide of the invention may include the 3′-UTR located between the nucleotide at position 3726 and the nucleotide at position 3983 of SEQ ID No 4, or a biologically active fragment or variant thereof.

Thus, the invention also pertains to a purified or isolated nucleic acid which is selected from the group consisting of:

a) a nucleic acid comprising the nucleotide sequence of the 5′ regulatory region;

b) a nucleic acid comprising a biologically active fragment or variant of the nucleic acid of the 5′ regulatory region.

Preferred fragments of the nucleic acid of the 5′ regulatory region have a length of about 1000 nucleotides, more particularly of about 400 nucleotides, more preferably of about 200 nucleotides and most preferably about 100 nucleotides. More particularly, the invention further includes specific elements within this regulatory region, these elements preferably including the promoter region.

Preferred fragments of the 3′ regulatory region are at least 50, 100, 150, 200, 300 or 400 bases in length.

By a “biologically active fragment or variant” of a TBC-1 regulatory polynucleotide according to the present invention is intended a polynucleotide comprising or alternatively consisting in a fragment of said polynucleotide which is functional as a regulatory region for expressing a recombinant polypeptide or a recombinant polynucleotide in a recombinant cell host.

For the purpose of the invention, a nucleic acid or polynucleotide is “functional” as a regulatory region for expressing a recombinant polypeptide or a recombinant polynucleotide if said regulatory polynucleotide contains nucleotide sequences which contain transcriptional and translational regulatory information, and if such sequences are “operatively linked” to nucleotide sequences which encode the desired polypeptide or the desired polynucleotide. An operable linkage is a linkage in which the regulatory nucleic acid and the DNA sequence sought to be expressed are linked in such a way as to permit gene expression.

In order, to identify the relevant biologically active polynucleotide derivatives of the 5′ or 3′ regulatory region, the one skill in the art will refer to the book of Sambrook et al. (Sambrook, 1989) in order to use a recombinant vector carrying a marker gene (i.e. beta galactosidase, chloramphenicol acetyl transferase, etc.) the expression of which will be detected when placed under the control of a biologically active derivative polynucleotide of the 5′ or 3′ regulatory region.

Regulatory polynucleotides of the invention may be prepared from any of the nucleotide sequences of SEQ ID Nos 1 or 2 by cleavage using the suitable restriction enzymes, the one skill in the art being guided by the book of Sambrook et al. (1989). Regulatory polynucleotides may also be prepared by digestion of any of the nucleotide sequences of SEQ ID Nos 1 or 2 by an exonuclease enzyme, such as Ba131 (Wabiko et al., 1986). These regulatory polynucleotides can also be prepared by chemical synthesis, as described elsewhere in the specification, when the synthesis of oligonucleotide probes or primers is disclosed.

The regulatory polynucleotides according to the invention may be advantageously part of a recombinant expression vector that may be used to express a coding sequence in a desired host cell or host organism. The recombinant expression vectors according to the invention are described elsewhere in the specification.

The invention also encompasses a polynucleotide comprising:

a) a nucleic acid comprising a regulatory nucleotide sequence of the 5′ regulatory region, or a biologically active fragment or variant thereof;

b) a polynucleotide encoding a desired polypeptide or nucleic acid, operably linked to the nucleic acid comprising a regulatory nucleotide sequence of the 5′ regulatory region, or its biologically active fragment or variant.

c) Optionally, a nucleic acid comprising a 3′ regulatory polynucleotide, preferably a 3′regulatory polynucleotide of the invention.

The desired polypeptide encoded by the above described nucleic acid may be of various nature or origin, encompassing proteins of prokaryotic or eukaryotic origin. Among the polypeptides expressed under the control of a TBC-1 regulatory region, it may be cited bacterial, fungal or viral antigens. Are also encompassed eukaryotic proteins such as intracellular proteins, such as “house keeping” proteins, membrane-bound proteins, like receptors, and secreted proteins like the numerous endogenous mediators such as cytokines.

The desired nucleic acid encoded by the above described polynucleotide, usually a RNA molecule, may be complementary to a TBC-1 coding sequence and thus useful as an antisense polynucleotide.

Such a polynucleotide may be included in a recombinant expression vector in order to express a desired polypeptide or a desired polynucleotide in host cell or in a host organism. Suitable recombinant vectors that contain a polynucleotide such as described hereinbefore are disclosed elsewhere in the specification.

TBC-1 Polypeptide and Peptide Fragments thereof

It is now easy to produce proteins in high amounts by genetic engineering techniques through expression vectors such as plasmids, phages or phagemids. The polynucleotide that code for one the polypeptides of the present invention is inserted in an appropriate expression vector in order to produce the polypeptide of interest in vitro.

Thus, the present invention also concerns a method for producing one of the polypeptides described herein, and especially a polypeptide of SEQ ID No 5 or a fragment or a variant thereof, wherein said method comprises the steps of:

a) culturing, in an appropriate culture medium, a cell host previously transformed or transfected with the recombinant vector comprising a nucleic acid encoding a TBC-1 polypeptide, or a fragment or a variant thereof;

b) harvesting the culture medium thus conditioned or lyse the cell host, for example by sonication or by an osmotic shock;

c) separating or purifying, from the said culture medium, or from the pellet of the resultant host cell lysate the thus produced polypeptide of interest.

d) Optionally characterizing the produced polypeptide of interest.

In a specific embodiment of the above method, step a) is preceded by a step wherein the nucleic acid coding for a TBC-1 polypeptide, or a fragment or a variant thereof, is inserted in an appropriate vector, optionally after an appropriate cleavage of this amplified nucleic acid with one or several restriction endonucleases. The nucleic acid coding for a TBC-1 polypeptide or a fragment or a variant thereof may be the resulting product of an amplification reaction using a pair of primers according to the invention (by SDA, TAS, 3SR NASBA, TMA etc.).

The polypeptides according to the invention may be characterized by binding onto an immunoaffinity chromatography column on which polyclonal or monoclonal antibodies directed to a polypeptide of SEQ ID No 5, or a fragment or a variant thereof, have previously been immobilized.

Purification of the recombinant proteins or peptides according to the present invention may be carried out by passage onto a Nickel or Cupper affinity chromatography column. The Nickel chromatography column may contain the Ni-NTA resin (Porath et al., 1975).

The polypeptides or peptides thus obtained may be purified, for example by high performance liquid chromatography, such as reverse phase and/or cationic exchange HPLC, as described by Rougeot et al. (1994). The reason to prefer this kind of peptide or protein purification is the lack of byproducts found in the elution samples which renders the resultant purified protein or peptide more suitable for a therapeutic use.

Another object of the present invention consists in a purified or isolated TBC-1 polypeptide or a fragment or a variant thereof.

In a preferred embodiment, the TBC-1 polypeptide comprises an amino acid sequence of SEQ ID No 5 or a fragment or a variant thereof. The present invention also embodies isolated, purified, and recombinant polypeptides comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, 100, 150 or 200 amino acids of SEQ ID No 5. The present invention also embodies isolated, purified, and recombinant polypeptides comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, 100, 150 or 200 amino acids of SEQ ID No 5, wherein said contiguous span includes at least 1, 2, 3, 5 or 10 of the following amino acid positions: 1-200, 201-400, 401-400, 601-800, 801-1000, 1001-1168.

The invention also encompasses a purified, isolated, or recombinant polypeptides comprising an amino acid sequence having at least 90, 95, 98 or 99% amino acid identity with the amino acid sequence of SEQ ID No 5 or a fragment thereof.

The TBC-1 polypeptide of the invention possesses amino acid homologies as regards to the murine TBC-1 protein of 1141 amino acids in length which is described in U.S. Pat. No. 5,700,927. The TBC-1 protein of the invention also possesses some homologies with two other proteins: the Pollux drosophila protein (Zhang et al., 1996) and the CDC16 protein from Caenorhabditis elegans (Wilson et al., 1994). FIG. 1 represents an amino acid alignment of a portion of the amino acid sequence of the TBC-1 protein of SEQ ID No 5 with other proteins sharing amino acid homology with TBC-1. The upper line shows the whole amino acid sequence of the murine tbc-1 protein described in U.S. Pat. No. 5,700,927; the second line represents part of the amino acid sequence of the TBC-1 protein of SEQ ID No 5; the third line (Genbank access No: dmu50542) depicts the amino acid sequence of the Pollux protein mentioned above; the fourth line (Genbank access No: celf35h12) shows the amino acid sequence of the C. elegans protein mentioned above; the fifth line presents positions in which consensus amino acids are identified, i.e. amino acids shared by the sequences presented in the four upper lines, when present.

The TBC-1 polypeptide of the amino acid sequence of SEQ ID No 5 has 1168 amino acids in length. The TBC-1 polypeptide includes a “TBC domain” which is spanning from the amino acid in position 786 to the amino acid in position 974 of the amino acid sequence of SEQ ID No 5. This TBC domain is represented in FIG. 1 as a grey area spanning from the amino acid numbered 758 to the amino acid numbered 949. This TBC domain is likely to regulate protein-protein interactions. Moreover, the TBC-1 TBC domain includes the amino acid sequence EVGYCQGL, spanning from the amino acid in position 886 to the amino acid in position 893 of the amino acid sequence of SEQ ID No 5. The EVGYCQGL amino acid sequence spans from the amino acid numbered 861 to the amino acid numbered 868 of FIG. 1. This site may interact with a kinase. Based on the structural similarity to cdc16, a yeast regulator of mitosis, TBC-1 is likely to regulate mitosis and cytokinesis by interacting with other proteins which also participate with the regulation of mitosis, cytokinesis and septum formation.

Preferred polypeptides of the invention comprise the TBC domain of TBC-1, or alternatively at least the EVGYCQGL amino acid sequence motif.

A further object of the present invention concerns a purified or isolated polypeptide which is encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID Nos 1, 2, 3, and 4 or fragments or variants thereof.

A single variant molecule of the TBC-1 protein is explicitly excluded from the scope of the present invention, which is a polypeptide having the same amino acid sequence than the murine tbc1 protein described in the U.S. Pat. No 5,700,927.

Amino acid deletions, additions or substitutions in the TBC-1 protein are preferably located outside of the TBC domain as defined above. Most preferably, a mutated TBC-1 protein has an intact “EVGYCQGL” amino acid motif.

Such a mutated TBC-1 protein may be the target of diagnostic tools, such as specific monoclonal or polyclonal antibodies, useful for detecting the mutated TBC-1 protein in a sample.

The invention also encompasses a TBC-1 polypeptide or a fragment or a variant thereof in which at least one peptide bound has been modified as described in the “Definitions” section.

Antibodies that Bind TBC-1 Polypeptides of the Invention

Any TBC-1 polypeptide or whole protein may be used to generate antibodies capable of specifically binding to an expressed TBC-1 protein or fragments thereof as described.

One antibody composition of the invention is capable of specifically binding or specifically bind to the variant of the TBC-1 protein of SEQ ID No 5. For an antibody composition to specifically bind to TBC-1, it must demonstrate at least a 5%, 10%, 15%, 20%, 25%, 50%, or 100% greater binding affinity for TBC-1 protein than for another protein in an ELISA, RIA, or other antibody-based binding assay.

In a preferred embodiment, the invention concerns antibody compositions, either polygonal or monoclonal, capable of selectively binding, or selectively bind to an epitope-containing a polypeptide comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, 100, 150 or 200 amino acids of SEQ ID No 5; Optionally said epitope comprises at least 1, 2, 3, 5 or 10 of the following amino acid positions: 1-200, 201-400, 401-600, 601-800, 801-1000, 1001-1168.

The invention also concerns a purified or isolated antibody capable of specifically binding to a mutated TBC-1 protein or to a fragment or variant thereof comprising an epitope of the mutated TBC-1 protein. In another preferred embodiment, the present invention concerns an antibody capable of binding to a polypeptide comprising at least 10 consecutive amino acids of a TBC-1 protein and including at least one of the amino acids which can be encoded by the trait causing mutations.

In a preferred embodiment, the invention concerns the use in the manufacture of antibodies of a polypeptide comprising a contiguous span of at least 6 amino acids, preferably at least 8 to 10 amino acids, more preferably at least 12, 15, 20, 25, 30, 40, 50, 100, 150 or 200 amino acids of SEQ ID No 5; Optionally said polypeptide comprises at least 1, 2, 3, 5 or 10 of the following amino acid positions: 1-200, 201-400, 401-600, 601-800, 801-1000, 1001-1168.

The antibodies of the invention may be labeled by any one of the radioactive, fluorescent or enzymatic labels known in the art.

The TBC-1 polypeptide of SEQ ID No 5 or a fragment thereof can be used for the preparation of polyclonal or monoclonal antibodies.

The TBC-1 polypeptide expressed from a DNA sequence comprising at least one of the nucleic acid sequences of SEQ ID Nos 1, 2, 3 and 4 may also be used to generate antibodies capable of specifically binding to the TBC-1 polypeptide of SEQ ID No 5or a fragment thereof.

Preferred antibodies according to the invention are prepared using TBC-1 peptide fragments that do not comprise the EVGYCQGL amino acid motif.

Other preferred antibodies of the invention are prepared using TBC-1 peptide fragments that do not comprise the TBC domain defined elsewhere in the specification.

The antibodies may be prepared from hybridomas according to the technique described by Kobler and Milstein in 1975. The polyclonal antibodies may be prepared by immunization of a mammal, especially a mouse or a rabbit, with a polypeptide according to the invention that is combined with an adjuvant of immunity, and then by purifying of the specific antibodies contained in the serum of the immunized animal on a affinity chromatography column on which has previously been immobilized the polypeptide that has been used as the antigen.

The present invention also includes, chimeric single chain Fv antibody fragments (Martineau et al., 1998), antibody fragments obtained through phage display libraries (Ridder et al., 1995; Vaughan et al., 1995) and humanized antibodies (Reinmann et al., 1997; Leger et al., 1997).

Antibody preparations prepared according to either protocol are useful in quantitative immunoassays which determine concentrations of antigen-bearing substances in biological samples; they are also used semi-quantitatively or qualitatively to identify the presence of antigen in a biological sample. The antibodies may also be used in therapeutic compositions for killing cells expressing the protein or reducing the levels of the protein in the body.

Consequently, the invention is also directed to a method for detecting specifically the presence of a TBC-1 polypeptide according to the invention in a biological sample, said method comprising the following steps:

a) bringing into contact the biological sample with a polyclonal or monoclonal antibody that specifically binds a TBC-1 polypeptide comprising an amino acid sequence of SEQ ID No 5, or to a peptide fragment or variant thereof; and

b) detecting the antigen-antibody complex formed.

The invention also concerns a diagnostic kit for detecting in vitro the presence of a TBC-1 polypeptide according to the present invention in a biological sample, wherein said kit comprises:

a) a polyclonal or monoclonal antibody that specifically binds a TBC-1 polypeptide comprising an amino acid sequence of SEQ ID No 5, or to a peptide fragment or variant thereof, optionally labeled;

b) a reagent allowing the detection of the antigen-antibody complexes formed, said reagent carrying optionally a label, or being able to be recognized itself by a labeled reagent, more particularly in the case when the above-mentioned monoclonal or polyclonal antibody is not labeled by itself.

TBC-1-Related Biallelic Markers

The inventors have discovered nucleotide polymorphisms located within the genomic DNA containing the TBC-1 gene, and among them SNP that are also termed biallelic markers. The biallelic markers of the invention can be used for example for the generation of genetic map, the linkage analysis, the association studies.

A—Identification of TBC-1-related Biallelic Markers

There are two preferred methods through which the biallelic markers of the present invention can be generated. In a first method, DNA samples from unrelated individuals are pooled together, following which the genomic DNA of interest is amplified and sequenced. The nucleotide sequences thus obtained are then analyzed to identify significant polymorphisms.

One of the major advantages of this method resides in the fact that the pooling of the DNA samples substantially reduces the number of DNA amplification reactions and sequencing which must be carried out. Moreover, this method is sufficiently sensitive so that a biallelic marker obtained therewith usually shows a sufficient degree of informativeness for conducting association studies.

In a second method for generating biallelic markers, the DNA samples are not pooled and are therefore amplified and sequenced individually. The resulting nucleotide sequences obtained are then also analyzed to identify significant polymorphisms.

It will readily be appreciated that when this second method is used, a substantially higher number of DNA amplification reactions must be carried out. It will further be appreciated that including such potentially less informative biallelic markers in association studies to identify potential genetic associations with a trait may allow in some cases the direct identification of causal mutations, which may, depending on their penetrance, be rare mutations. This method is usually preferred when biallelic markers need to be identified in order to perform association studies within candidate genes.

In both methods, the genomic DNA samples from which the biallelic markers of the present invention are generated are preferably obtained from unrelated individuals corresponding to a heterogeneous population of known ethnic background, or from familial cases.

The number of individuals from whom DNA samples are obtained can vary substantially, preferably from about 10 to about 1000, preferably from about 50 to about 200 individuals. It is usually preferred to collect DNA samples from at least about 100 individuals in order to have sufficient polymorphic diversity in a given population to generate as many markers as possible and to generate statistically significant results.

As for the source of the genomic DNA to be subjected to analysis, any test sample can be foreseen without any particular limitation. The preferred source of genomic DNA used in the context of the present invention is the peripheral venous blood of each donor.

The techniques of DNA extraction are well-known to the skilled technician. Details of a preferred embodiment are provided in Example 2.

DNA samples can be pooled or unpooled for the amplification step. DNA amplification techniques are well-known to those skilled in the art.

Amplification techniques that can be used in the context of the present invention include, but are not limited to, the ligase chain reaction (LCR) described in EP-A-320 308, WO 9320227 and EP-A439 182, the polymerase chain reaction (PCR, RT-PCR) and techniques such as the nucleic acid sequence based amplification (NASBA) described in Guatelli J. C., et al.(1990) and in Compton J.(1991), Q-beta amplification as described in European Patent Application No 4544610, strand displacement amplification as described in Walker et al.(1996) and EP A 684 315 and, target mediated amplification as described in PCT Publication WO 9322461.

LCR and Gap LCR are exponential amplification techniques, both depend on DNA ligase to join adjacent primers annealed to a DNA molecule. In Ligase Chain Reaction (LCR), probe pairs are used which include two primary (first and second) and two secondary (third and fourth) probes, all of which are employed in molar excess to target. The first probe hybridizes to a first segment of the target strand and the second probe hybridizes to a second segment of the target strand, the first and second segments being contiguous so that the primary probes abut one another in 5′ phosphate-3′hydroxyl relationship, and so that a ligase can covalently fuse or ligate the two probes into a fused product. In addition, a third (secondary) probe can hybridize to a portion of the first probe and a fourth (secondary) probe can hybridize to a portion of the second probe in a similar abutting fashion. Of course, if the target is initially double stranded, the secondary probes also will hybridize to the target complement in the first instance. Once the ligated strand of primary probes is separated from the target strand, it will hybridize with the third and fourth probes, which can be ligated to form a complementary, secondary ligated product. It is important to realize that the ligated products are functionally equivalent to either the target or its complement. By repeated cycles of hybridization and ligation, amplification of the target sequence is achieved. A method for multiplex LCR has also been described (WO 9320227). Gap LCR (GLCR) is a version of LCR where the probes are not adjacent but are separated by 2 to 3 bases.

For amplification of mRNAs, it is within the scope of the present invention to reverse transcribe mRNA into cDNA followed by polymerase chain reaction (RT-PCR); or, to use a single enzyme for both steps as described in U.S. Pat. No. 5,322,770 or, to use Asymmetric Gap LCR (RT-AGLCR) as described by Marshall et al.(1994). AGLCR is a modification of GLCR that allows the amplification of RNA.

The PCR technology is the preferred amplification technique used in the present invention. A variety of PCR techniques are familiar to those skilled in the art. For a review of PCR technology, see White (1991) and the publication entitled “PCR Methods and Applications” (1991, Cold Spring Harbor Laboratory Press). In each of these PCR procedures, PCR primers on either side of the nucleic acid sequences to be amplified are added to a suitably prepared nucleic acid sample along with dNTPs and a thermostable polymerase such as Taq polymerase, Pfu polymerase, or Vent polymerase. The nucleic acid in the sample is denatured and the PCR primers are specifically hybridized to complementary nucleic acid sequences in the sample. The hybridized primers are extended. Thereafter, another cycle of denaturation, hybridization, and extension is initiated. The cycles are repeated multiple times to produce an amplified fragment containing the nucleic acid sequence between the primer sites. PCR has further been described in several patents including U.S. Pat. Nos. 4,683,195; 4,683,202; and 4,965,188.

The PCR technology is the preferred amplification technique used to identify new biallelic markers. A typical example of a PCR reaction suitable for the purposes of the present invention is provided in Example 3.

One of the aspects of the present invention is a method for the amplification of a TBC-1 gene, particularly the genomic sequences of SEQ ID Nos 1 and 2 or of the cDNA sequence of SEQ ID Nos 3 or 4 or a fragment or variant thereof in a test sample, preferably using the PCR technology. The method comprises the steps of contacting a test sample suspected of containing the target TBC-1 sequence or portion thereof with amplification reaction reagents comprising a pair of amplification primers.

Thus, the present invention also relates to a method for the amplification of a TBC-1 gene sequence, particularly of a fragment of the genomic sequence of SEQ ID No 1 or of the cDNA sequence of SEQ ID No 2 or 3, or a fragment or a variant thereof in a test sample, said method comprising the steps of:

a) contacting a test sample suspected of containing the targeted TBC-1 gene sequence or portion thereof with amplification reaction reagents comprising a pair of amplification primers located on either side of the TBC-1 region to be amplified, and

b) optionally, detecting the amplification products.

The invention also concerns a kit for the amplification of a TBC-1 gene sequence, particularly of a portion of the genomic sequence of SEQ ID Nos 1 or 2, or of the cDNA sequence of SEQ ID Nos 3 or 4, or a variant thereof in a test sample, wherein said kit comprises:

a) a pair of oligonucleotide primers located on either side of the TBC-1 region to be amplified;

b) optionally, the reagents necessary for performing the amplification reaction.

In one embodiment of the above amplification method and kit, the amplification product is detected by hybridization with a labeled probe having a sequence which is complementary to the amplified region. In another embodiment of the above amplification method and kit, primers comprise a sequence which is selected from the group consisting of B1 to B15, C1 to C15, D1 to D19, and E1 to E19.

In a first embodiment of the present invention, biallelic markers are identified using genomic sequence information generated by the inventors. Sequenced genomic DNA fragments are used to design primers for the amplification of 500 bp fragments. These 500 bp fragments are amplified from genomic DNA and are scanned for biallelic markers. Primers may be designed using the OSP software (Hillier L. and Green P., 1991). All primers may contain, upstream of the specific target bases, a common oligonucleotide tail that serves as a sequencing primer. Those skilled in the art are familiar with primer extensions, which can be used for these purposes.

Preferred primers, useful for the amplification of genomic sequences encoding the candidate genes, focus on promoters, exons and splice sites of the genes. A biallelic marker presents a higher probability to be an eventual causal mutation if it is located in these functional regions of the gene. Preferred amplification primers of the invention include the nucleotide sequences of B1 to B15 and C1 to C15 further detailed in Example 3.

The amplification products generated as described above with the primers of the invention are then sequenced using methods known and available to the skilled technician. Preferably, the amplified DNA is subjected to automated dideoxy terminator sequencing reactions using a dye-primer cycle sequencing protocol. Following gel image analysis and DNA sequence extraction, sequence data are automatically processed with adequate software to assess sequence quality.

A polymorphism analysis software is used that detects the presence of biallelic sites among individual or pooled amplified fragment sequences. Polymorphism search is based on the presence of superimposed peaks in the electrophoresis pattern These peaks which present distinct colors correspond to two different nucleotides at the same position on the sequence. The polymorphism has to be detected on both strands for validation.

19 biallelic markers were found in the TBC-1 gene. They are detailed in the Table 2. They are located in intronic regions.

K Genotyping of TBC-1-Related Biallelic Markers

The polymorphisms identified above can be further confirmed and their respective frequencies can be determined through various methods using the previously described primers and probes. These methods can also be useful for genotyping either new populations in association studies or linkage analysis or individuals in the context of detection of alleles of biallelic markers which are known to be associated with a given trait. The genotyping of the biallelic markers is also important for the mapping. Those skilled in the art should note that the methods described below can be equally performed on individual or pooled DNA samples.

Once a given polymorphic site has been found and characterized as a biallelic marker as described above, several methods can be used in order to determine the specific allele carried by an individual at the given polymorphic base.

The identification of biallelic markers described previously allows the design of appropriate oligonucleotides, which can be used as probes and primers, to amplify a TBC-1 gene containing the polymorphic site of interest and for the detection of such polymorphisms.

The biallelic markers according to the present invention may be used in methods for the identification and characterization of an association between alleles for one or several biallelic markers of the sequence of the TBC-1 gene and a trait.

The identified polymorphisms, and consequently the biallelic markers of the invention, may be used in methods for the detection in an individual of TBC-1 alleles associated with a trait, more particularly a trait related to a cell differentiation or abnormal cell proliferation disorders, and most particularly a trait related to cancer diseases, specifically prostate cancer.

In one embodiment the invention encompasses methods of genotyping comprising determining the identity of a nucleotide at a TBC-1-related biallelic marker or the complement thereof in a biological sample; optionally, wherein said TBC-1-related biallelic marker is selected from the group consisting of A1 to A19, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said biological sample is derived from a single subject; optionally, wherein the identity of the nucleotides at said biallelic marker is determined for both copies of said biallelic marker present in said individual's genome; optionally, wherein said biological sample is derived from multiple subjects; Optionally, the genotyping methods of the invention encompass methods with any further limitation described in this disclosure, or those following, specified alone or in any combination; Optionally, said method is performed in vitro; optionally, further comprising amplifying a portion of said sequence comprising the biallelic marker prior to said determining step; Optionally, wherein said amplifying is performed by PCR, LCR, or replication of a recombinant vector comprising an origin of replication and said fragment in a host cell; optionally, wherein said determining is performed by a hybridization assay, a sequencing assay, a microsequencing assay, or an enzyme-based mismatch detection assay.

Source of Nucleic Acids for genotyping

Any source of nucleic acids, in purified or non-purified forth, can be utilized as the starting nucleic acid, provided it contains or is suspected of containing the specific nucleic acid sequence desired. DNA or RNA may be extracted from cells, tissues, body fluids and the like as described above. While nucleic acids for use in the genotyping methods of the invention can be derived from any mammalian source, the test subjects and individuals from which nucleic acid samples are taken are generally understood to be human.

Amplification of DNA Fragments Comprising Biallelic Markers

Methods and polynucleotides are provided to amplify a segment of nucleotides comprising one or more biallelic marker of the present invention. It will be appreciated that amplification of DNA fragments comprising biallelic markers may be used in various methods and for various purposes and is not restricted to genotyping. Nevertheless, many genotyping methods although not all, require the previous amplification of the DNA region carrying the biallelic marker of interest Such methods specifically increase the concentration or total number of sequences that span the biallelic marker or include that site and sequences located either distal or proximal to it. Diagnostic assays may also rely on amplification of DNA segments carrying a biallelic marker of the present invention. Amplification of DNA may be achieved by any method known in the art. Amplification techniques are described above in the section entitled, “Identification of TBC-1-related biallelic markers.”

Some of these amplification methods are particularly suited for the detection of single nucleotide polymorphisms and allow the simultaneous amplification of a target sequence and the identification of the polymorphic nucleotide as it is further described below.

The identification of biallelic markers as described above allows the design of appropriate oligonucleotides, which can be used as primers to amplify DNA fragments comprising the biallelic markers of the present invention. Amplification can be performed using the primers initially used to discover new biallelic markers which are described herein or any set of primers allowing the amplification of a DNA fragment comprising a biallelic marker of the present invention.

In some embodiments the present invention provides primers for amplifying a DNA fragment containing one or more biallelic markers of the present invention. Preferred amplification primers are listed in Example 2. It will be appreciated that the primers listed are merely exemplary and that any other set of primers which produce amplification products containing one or more biallelic markers of the present invention are also of use.

The spacing of the primers determines the length of the segment to be amplified. In the context of the present invention, amplified segments carrying biallelic markers can range in size from at least about 25 bp to 35 kbp. Amplification fragments from 25-3000 bp are typical, fragments from 50-1000 bp are preferred and fragments from 100-600 bp are highly preferred. It will be appreciated that amplification primers for the biallelic markers may be any sequence which allow the specific amplification of any DNA fragment carrying the markers. Amplification primers may be labeled or immobilized on a solid support as described in “Oligonucleotide probes and primers”.

Methods of Genotyping DNA Samples for Biallelic Markers

Any method known in the art can be used to identify the nucleotide present at a biallelic marker site. Since the biallelic marker allele to be detected has been identified and specified in the present invention, detection will prove simple for one of ordinary skill in die art by employing any of a number of techniques. Many genotyping methods require the previous amplification of the DNA region carrying the biallelic marker of interest. While the amplification of target or signal is often preferred at present, ultrasensitive detection methods which do not require amplification are also encompassed by the present genotyping methods. Methods well-known to those skilled in the art that can be used to detect biallelic polymorphisms include methods such as, conventional dot blot analyzes, single strand conformational polymorphism analysis (SSCP) described by Orita et al.(1989), denaturing gradient gel electrophoresis (DGGE), heteroduplex analysis, mismatch cleavage detection, and other conventional techniques as described in Sheffield et al.(1991), White et al.(1992), Grompe et al.(1989 and 1993). Another method for determining the identity of the nucleotide present at a particular polymorphic site employs a specialized exonuclease-resistant nucleotide derivative as described in U.S. Pat. No. 4,656,127.

Preferred methods involve directly determining the identity of the nucleotide present at a biallelic marker site by sequencing assay, enzyme-based mismatch detection assay, or hybridization assay. The following is a description of some preferred methods. A highly preferred method is the microsequencing technique/The term “sequencing” is generally used herein to refer to polymerase extension of duplex primer/template complexes and includes both traditional sequencing and microsequencing.

1) Sequencing Assays

The nucleotide present at a polymorphic site can be determined by sequencing methods. In a preferred embodiment, DNA samples are subjected to PCR amplification before sequencing as described above. DNA sequencing methods are described in “Sequencing Of Amplified Genomic DNA And Identification Of Single Nucleotide Polymorphisms”.

Preferably, the amplified DNA is subjected to automated dideoxy terminator sequencing reactions using a dye-primer cycle sequencing protocol. Sequence analysis allows the identification of the base present at the biallelic marker site.

2) Microsequencing Assays

In microsequencing methods, the nucleotide at a polymorphic site in a target DNA is detected by a single nucleotide primer extension reaction. This method involves appropriate microsequencing primers which, hybridize just upstream of the polymorphic base of interest in the target nucleic acid. A polymerase is used to specifically extend the 3′ end of the primer with one single ddNTP (chain terminator) complementary to the nucleotide at the polymorphic site. Next the identity of the incorporated nucleotide is determined in any suitable way.

Typically, microsequencing reactions are carried out using fluorescent ddNTPs and the extended microsequencing primers are analyzed by electrophoresis on ABI 377 sequencing machines to determine the identity of the incorporated nucleotide as described in EP 412 883, the disclosure of which is incorporated herein by reference in its entirety. Alternatively capillary electrophoresis can be used in order to process a higher number of assays simultaneously. An example of a typical microsequencing procedure that can be used in the context of the present invention is provided in Example 4.

Different approaches can be used for the labeling and detection of ddNTPs. A homogeneous phase detection method based on fluorescence resonance energy transfer has been described by Chen and Kwok (1997) and Chen et al.(1997). In this method, amplified genomic DNA fragments containing polymorphic sites are incubated with a 5′-fluorescein-labeled primer in the presence of allelic dye-labeled dideoxyribonucleoside triphosphates and a modified Taq polymerase. The dye-labeled primer is extended one base by the dye-terminator specific for the allele present on the template. At the end of the genotyping reaction, the fluorescence intensities of the two dyes in the reaction mixture are analyzed directly without separation or purification. All these steps can be performed in the same tube and the fluorescence changes can be monitored in real time. Alternatively, the extended primer may be analyzed by MALDI-TOF Mass Spectrometry. The base at the polymorphic site is identified by the mass added onto the microsequencing primer (see Haff and Smimov, 1997).

Microsequencing may be achieved by the established microsequencing method or by developments or derivatives thereof. Alternative methods include several solid-phase microsequencing techniques. The basic microsequencing protocol is the same as described previously, except that the method is conducted as a heterogeneous phase assay, in which the primer or the target molecule is immobilized or captured onto a solid support. To simplify the primer separation and the terminal nucleotide addition analysis, oligonucleotides are attached to solid supports or are modified in such ways that permit affinity separation as well as polymerase extension. The 5′ ends and internal nucleotides of synthetic oligonucleotides can be modified in a number of different ways to permit different affinity separation approaches, e.g., biotinylation. If a single affinity group is used on the oligonucleotides, the oligonucleotides can be separated from the incorporated terminator regent This eliminates the need of physical or size separation. More than one oligonucleotide can be separated from the terminator reagent and analyzed simultaneously if more than one affinity group is used. This permits the analysis of several nucleic acid species or more nucleic acid sequence information per extension reaction. The affinity group need not be on the priming oligonucleotide but could alternatively be present on the template. For example, immobilization can be carried out via an interaction between biotinylated DNA and streptavidin-coated microtitration wells or avidin-coated polystyrene particles. In the same manner, oligonucleotides or templates may be attached to a solid support in a high-density format. In such solid phase microsequencing reactions, incorporated ddNTPs can be radiolabelled (Syvänen, 1994) or linked to fluorescein (Livak and Hainer, 1994). The detection of radiolabeled ddNTPs can be achieved through scintillation-based techniques. The detection of fluorescein-linked ddNTPs can be based on the binding of antifluorescein antibody conjugated with alkaline phosphatase, followed by incubation with a chromogenic substrate (such as p-nitrophenyl phosphate). Other possible reporter-detection pairs include: ddNTP linked to dinitrophenyl (DNP) and anti-DNP alkaline phosphatase conjugate (Haiju el al., 1993) or biotinylated ddNTP and horseradish peroxidase-conjugated streptavidin with o-phenylenediamine as a substrate (WO 92/15712). As yet another alternative solid-phase microsequencing procedure, Nyren et al.(1993) described a method relying on the detection of DNA polymerase activity by an enzymatic luminometric inorganic pyrophosphate detection assay (ELIDA).

Pastinen et al.(1997) describe a method for multiplex detection of single nucleotide polymorphism in which the solid phase minisequencing principle is applied to an oligonucleotide array format. High-density arrays of DNA probes attached to a solid support (DNA chips) are further described below.

In one aspect the present invention provides polynucleotides and methods to genotype one or more biallelic markers of the present invention by performing a microsequencing assay. Preferred microsequencing primers include the nucleotide sequences D1 to D15 and E1 to E15. It will be appreciated that the microsequencing primers listed in Example 5 are merely exemplary and that, any primer having a 3′ end immediately adjacent to the polymorphic nucleotide may be used. Similarly, it will be appreciated that microsequencing analysis may be performed for any biallelic marker or any combination of biallelic markers of the present invention. One aspect of the present invention is a solid support which includes one or more microsequencing primers listed in Example 5, or fragments comprising at least 8, 12, 15, 20, 25, 30, 40, or 50 consecutive nucleotides thereof, to the extent that such lengths are consistent with the primer described, and having a 3′ terminus immediately upstream of the corresponding biallelic marker, for determining the identity of a nucleotide at a biallelic marker site.

3) Mismatch Detection Assays Based on Polymerases and Ligases

In one aspect the present invention provides polynucleotides and methods to determine the allele of one or more biallelic markers of the present invention in a biological sample, by mismatch detection assays based on polymerases and/or ligases. These assays are based on the specificity of polymerases and ligases. Polymerization reactions places particularly stringent requirements on correct base pairing of the 3′ end of the amplification primer and the joining of two oligonucleotides hybridized to a target DNA sequence is quite sensitive to mismatches close to the ligation site, especially at the 3′end. Methods, primers and various parameters to amplify DNA fragments comprising biallelic markers of the present invention are further described above in “Amplification Of DNA Fragments Comprising Biallelic Markers”.

Allele Specific Amplification Primers

Discrimination between the two alleles of a biallelic marker can also be achieved by allele specific amplification, a selective strategy, whereby one of the alleles is amplified without amplification of the other allele. For allele specific amplification, at least one member of the pair of primers is sufficiently complementary with a region of a TBC-1 gene comprising the polymorphic base of a biallelic marker of the present invention to hybridize therewith and to initiate the amplification. Such primers are able to discriminate between the two alleles of a biallelic marker.

This is accomplished by placing the polymorphic base at the 3′ end of one of the amplification primers. Because the extension forms from the 3′ end of the primer, a mismatch at or near this position has an inhibitory effect on amplification. Therefore, under appropriate amplification conditions, these primers only direct amplification on their complementary allele. Determining the precise location of the mismatch and the corresponding assay conditions are well within the ordinary skill in the art.

Ligation/Amplification Based Methods

The “Oligonucleotide Ligation Assay” (OLA) uses two oligonucleotides which are designed to be capable of hybridizing to abutting sequences of a single strand of a target molecules. One of the oligonucleotides it biotinylated, and the other is detectably labeled. If the precise complementary sequence is found in a target molecule, the oligonucleotides will hybridize such that their termini abut, and create a ligation substrate that can be captured and detected. OLA is capable of detecting single nucleotide polymorphisms and may be advantageously combined with PCR as described by Nickerson et al.(1990). In this method, PCR is used to achieve the exponential amplification of target DNA, which is then detected using OLA.

Other amplification methods which are particularly suited for the detection of single nucleotide polymorphism include LCR (ligase chain reaction), Gap LCR (GLCR) which are described above in “DNA Amplification”. LCR uses two pairs of probes to exponentially amplify a specific target. The sequences of each pair of oligonucleotides, is selected to permit the pair to hybridize to abutting sequences of the same strand of the target. Such hybridization forms a substrate for a template-dependant ligase. In accordance with the present invention, LCR can be performed with oligonucleotides having the proximal and distal sequences of the same strand of a biallelic marker site. In one embodiment, either oligonucleotide will be designed to include the biallelic marker site. In such an embodiment, the reaction conditions are selected such that the oligonucleotides can be ligated together only if the target molecule either contains or lacks the specific nucleotide that is complementary to the biallelic marker on the oligonucleotide. In an alternative embodiment, the oligonucleotides will not include the biallelic marker, such that when they hybridize to the target molecule, a “gap” is created as described in WO 90/01069. This gap is then “filled” with complementary dNTPs (as mediated by DNA polymerase), or by an additional pair of oligonucleotides. Thus at the end of each cycle, each single strand has a complement capable of serving as a target during the next cycle and exponential allele-specific amplification of the desired sequence is obtained.

Ligase/Polymerase-mediated Genetic Bit Analysis™ is another method for determining the identity of a nucleotide at a preselected site in a nucleic acid molecule (WO 95/21271). This method involves the incorporation of a nucleoside triphosphate that is complementary to the nucleotide present at the preselected site onto the terminus of a primer molecule, and their subsequent ligation to a second oligonucleotide. The reaction is monitored by detecting a specific label attached to the reaction's solid phase or by detection in solution.

4) Hybridization Assay Methods

A preferred method of determining the identity of the nucleotide present at a biallelic marker site involves nucleic acid hybridization. The hybridization probes, which can be conveniently used in such reactions, preferably include the probes defined herein. Any hybridization assay may be used including Southern hybridization, Northern hybridization, dot blot hybridization and solid-phase hybridization (see Sambrook et al., 1989).

Hybridization refers to the formation of a duplex structure by two single stranded nucleic acids due to complementary base pairing. Hybridization can occur between exactly complementary nucleic acid strands or between nucleic acid strands that contain minor regions of mismatch. Specific probes can be designed that hybridize to one form of a biallelic marker and not to the other and therefore are able to discriminate between different allelic forms. Allele-specific probes are often used in pairs, one member of a pair showing perfect match to a target sequence containing the original allele and the other showing a perfect match to the target sequence containing the alternative allele. Hybridization conditions should be sufficiently stringent that there is a significant difference in hybridization intensity between alleles, and preferably an essentially binary response, whereby a probe hybridizes to only one of the alleles. Stringent, sequence specific hybridization conditions, under which a probe will hybridize only to the exactly complementary target sequence are well known in the art (Sambrook et al., 1989). Stringent conditions are sequence dependent and will be different in different circumstances. Generally, stringent conditions are selected to be about 5° C. lower than the thermal melting point (Tm) for the specific sequence at a defined ionic strength and pH. Although such hybridization can be performed in solution, it is preferred to employ a solid-phase hybridization assay. The target DNA comprising a biallelic marker of the present invention may be amplified prior to the hybridization reaction. The presence of a specific allele in the sample is determined by detecting the presence or the absence of stable hybrid duplexes formed between the probe and the target DNA. The detection of hybrid duplexes can be carried out by a number of methods. Various detection assay formats are well known which utilize detectable labels bound to either the target or the probe to enable detection of the hybrid duplexes. Typically, hybridization duplexes are separated from unhybridized nucleic acids and the labels bound to the duplexes are then detected. Those skilled in the art will recognize that wash steps may be employed to wash away excess target DNA or probe as well as unbound conjugate. Further, standard heterogeneous assay formats are suitable for detecting the hybrids using the labels present on the primers and probes.

Two recently developed assays allow hybridization-based allele discrimination with no need for separations or washes (see Landegren U. et al., 1998). The TaqMan assay takes advantage of the 5′ nuclease activity of Taq DNA polymerase to digest a DNA probe annealed specifically to the accumulating amplification product. TaqMan probes are labeled with a donor-acceptor dye pair that interacts via fluorescence energy transfer. Cleavage of the TaqMan probe by the advancing polymerase during amplification dissociates the donor dye from the quenching acceptor dye, greatly increasing the donor fluorescence. All reagents necessary to detect two allelic variants can be assembled at the beginning of the reaction and the results are monitored in real time (see Livak et al., 1995). In an alternative homogeneous hybridization based procedure, molecular beacons are used for allele discriminations. Molecular beacons are hairpin-shaped oligonucleotide probes that report the presence of specific nucleic acids in homogeneous solutions. When they bind to their targets they undergo a conformational reorganization that restores the fluorescence of an internally quenched fluorophore (Tyagi et al., 1998).

The polynucleotides provided herein can be used to produce probes which can be used in hybridization assays for the detection of biallelic marker alleles in biological samples. These probes are characterized in that they preferably comprise between 8 and 50 nucleotides, and in that they are sufficiently complementary to a sequence comprising a biallelic marker of the present invention to hybridize thereto and preferably sufficiently specific to be able to discriminate the targeted sequence for only one nucleotide variation. A particularly preferred probe is 25 nucleotides in length. Preferably the biallelic marker is within 4 nucleotides of the center of the polynucleotide probe. In particularly preferred probes, the biallelic marker is at the center of said polynucleotide. Preferred probes comprise a nucleotide sequence selected from the group consisting of amplicons listed in Table 1 and the sequences complementary thereto, or a fragment thereof, said fragment comprising at least about 8 consecutive nucleotides, preferably 10, 15, 20, more preferably 25, 30, 40, 47, or 50 consecutive nucleotides and containing a polymorphic base. Preferred probes comprise a nucleotide sequence selected from the group consisting of P1 to P7, P9 to P13, P15 to P19 and the sequences complementary thereto. In preferred embodiments the polymorphic base(s) are within 5, 4, 3, 2, 1, nucleotides of the center of the said polynucleotide, more preferably at the center of said polynucleotide.

Preferably the probes of the present invention are labeled or immobilized on a solid support. Labels and solid supports are further described in “Oligonucleotide Probes and Primers”. The probes can be non-extendable as described in “Oligonucleotide Probes and Primers”.

By assaying the hybridization to an allele specific probe, one can detect the presence or absence of a biallelic marker allele in a given sample. High-Throughput parallel hybridization in array format is specifically encompassed within “hybridization assays” and are described below.

5) Hybridization to Addressable Arrays of Oligonucleotides

Hybridization assays based on oligonucleotide arrays rely on the differences in hybridization stability of short oligonucleotides to perfectly matched and mismatched target sequence variants. Efficient access to polymorphism information is obtained through a basic structure comprising high-density arrays of oligonucleotide probes attached to a solid support (e.g., the chip) at selected positions. Each DNA chip can contain thousands to millions of individual synthetic DNA probes arranged in a grid-like pattern and miniaturized to the size of a dime.

The chip technology has already been applied with success in numerous cases. For example, the screening of mutations has been undertaken in the BRCA1 gene, in S. cerevisiae mutant strains, and in the protease gene of HIV-1 virus (Hacia et al., 1996; Shoemaker et al., 1996; Kozal et al., 1996). Chips of various formats for use in detecting biallelic polymorphisms can be produced on a customized basis by Affymetrix (GeneChip™), Hyseq (HyChip and HyGnostics), and Protogene Laboratories.

In general, these methods employ arrays of oligonucleotide probes that are complementary to target nucleic acid sequence segments from an individual which, target sequences include a polymorphic marker. EP 785280 describes a tiling strategy for the detection of single nucleotide polymorphisms. Briefly, arrays may generally be “tiled” for a large number of specific polymorphisms. By “tiling” is generally meant the synthesis of a defined set of oligonucleotide probes which is made up of a sequence complementary to the target sequence of interest, as well as preselected variations of that sequence, e.g., substitution of one or more given positions with one or more members of the basis set of nucleotides. Tiling strategies are further described in PCT application No. WO 95/11995. In a particular aspect, arrays are tiled for a number of specific, identified biallelic marker sequences. In particular, the array is tiled to include a number of detection blocks, each detection block being specific for a specific biallelic marker or a set of biallelic markers. For example, a detection block may be tiled to include a number of probes, which span the sequence segment that includes a specific polymorphism. To ensure probes that are complementary to each allele, the probes are synthesized in pairs differing at the biallelic marker. In addition to the probes differing at the polymorphic base, monosubstituted probes are also generally tiled within the detection block These monosubstituted probes have bases at and up to a certain number of bases in either direction from the polymorphism, substituted with the remaining nucleotides (selected from A, T, G, C and U). Typically the probes in a tiled detection block will include substitutions of the sequence positions up to and including those that are 5 bases away from the biallelic marker. The monosubstituted probes provide internal controls for the tiled array, to distinguish actual hybridization from artefactual cross-hybridization. Upon completion of hybridization with the target sequence and washing of the array, the array is scanned to determine the position on the array to which the target sequence hybridizes. The hybridization data from the scanned array is then analyzed to identify which allele or alleles of the biallelic marker are present in the sample. Hybridization and scanning may be carried out as described in PCT application No. WO 92110092 and WO 95/11995 and U.S. Pat. No. 5,424,186.

Thus, in some embodiments, the chips may comprise an array of nucleic acid sequences of fragments of about 15 nucleotides in length. In further embodiments, the chip may comprise an array including at least one of the sequences selected from the group consisting of amplicons listed in table 1 and the sequences complementary thereto, or a fragment thereof, said fragment comprising at least about 8 consecutive nucleotides, preferably 10, 15, 20, more preferably 25, 30, 40, 47, or 50 consecutive nucleotides and containing a polymorphic base. In preferred embodiments the polymorphic base is within 5, 4, 3, 2, 1, nucleotides of the center of the said polynucleotide, more preferably at the center of said polynucleotide. In some embodiments, the chip may comprise an array of at least 2, 3, 4, 5, 6, 7, 8 or more of these polynucleotides of the invention. Solid supports and polynucleotides of the present invention attached to solid supports are further described in “Oligonucleotide Probes And Primers”.

6) Integrated Systems

Another technique, which may be used to analyze polymorphisms, includes multicomponent integrated systems, which miniaturize and compartmentalize processes such as PCR and capillary electrophoresis reactions in a single functional device. An example of such technique is disclosed in U.S. Pat. No. 5,589,136, which describes the integration of PCR amplification and capillary electrophoresis in chips.

Integrated systems can be envisaged mainly when microfluidic systems are used. These systems comprise a pattern of microchannels designed onto a glass, silicon, quartz, or plastic wafer included on a microchip. The movements of the samples are controlled by electric, electroosmotic or hydrostatic forces applied across different areas of the microchip to create functional microscopic valves and pumps with no moving parts.

For genotyping biallelic markers, the microfluidic system may integrate nucleic acid amplification, microsequencing, capillary electrophoresis and a detection method such as laser-induced fluorescence detection.

Association Studies with the Biallelic Markers of the TBC-1 Gene

The identification of genes involved in suspected heterogeneous, polygenic and multifactorial traits such as cancer can be carried out through two main strategies currently used for genetic mapping: linkage analysis and association studies. Association studies examine the frequency of marker alleles in unrelated trait positive (T+) individuals compared with trait negative (T−) controls, and are generally employed in the detection of polygenic inheritance. Association studies as a method of mapping genetic traits rely on the phenomenon of linkage disequilibrium.

If two genetic loci lie on the same chromosome, then sets of alleles of these loci on the same chromosomal segment (called haplotypes) tend to be transmitted as a block from generation to generation. When not broken up by recombination, haplotypes can be tracked not only through pedigrees but also through populations. The resulting phenomenon at the population level is that the occurrence of pairs of specific alleles at different loci on the same chromosome is not random, and the deviation from random is called linkage disequilibrium (LD).

If a specific allele in a given gene is directly involved in causing a particular trait T, its frequency will be statistically increased in a trait positive population when compared to the frequency in a trait negative population. As a consequence of the existence of linkage disequilibrium, the frequency of all other alleles present in the haplotype carrying the trait-causing allele (TCA) will also be increased in trait positive individuals compared to trait negative individuals. Therefore, association between the trait and any allele in linkage disequilibrium with the trait-causing allele will suffice to suggest the presence of a trait-related gene in that particular allele's region. Linkage disequilibrium allows the relative frequencies in trait positive and trait negative populations of a limited number of genetic polymorphisms (specifically biallelic markers) to be analyzed as an alternative to screening all possible functional polymorphisms in order to find trait-causing alleles.

The general strategy to perform association studies using biallelic markers derived from a candidate region is to scan two groups of individuals (trait positive and trait negative control individuals which are characterized by a well defined phenotype as described below) in order to measure and statistically compare the allele frequencies of such biallelic markers in both groups.

If a statistically significant association with a trait is identified for at least one or more of the analyzed biallelic markers, one can assume that: either the associated allele is directly responsible for causing the trait (associated allele is the trait-causing allele), or the associated allele is in linkage disequilibrium with the trait-causing allele. If the evidence indicates that the associated allele within the candidate region is most probably not the trait-causing allele but is in linkage disequilibrium with the real trait-causing allele, then the trait-causing allele, and by consequence the gene carrying the trait-causing allele, can be found by sequencing the vicinity of the associated marker.

Collection of DNA Samples from Trait Positive (Trait+) and Trait Negative (Trait− Individuals (Inclusion Criteria)

In order to perform efficient and significant association studies such as those described herein, the trait under study should preferably follow a bimodal distribution in the population under study, presenting two clear non-overlapping phenotypes, trait positive and trait negative.

Nevertheless, even in the absence of such a bimodal distribution (as may in fact be the case for more complex genetic traits), any genetic trait may still be analyzed by the association method proposed here by carefully selecting the individuals to be included in the trait positive and trait negative phenotypic groups. The selection procedure involves to select individuals at opposite ends of the non-bimodal phenotype spectra of the trait under study, so as to include in these trait positive and trait negative populations individuals which clearly represent extreme, preferably non-overlapping phenotypes.

The definition of the inclusion criteria for the trait positive and trait negative populations is an important aspect of the present invention. The selection of drastically different but relatively uniform phenotypes enables efficient comparisons in association studies and the possible detection of marked differences at the genetic level, provided that the sample sizes of the populations under study are significant enough.

Generally, trait positive and trait negative populations to be included in association studies such as proposed in the present invention consist of phenotypically homogenous populations of individuals each representing 100% of the corresponding trait if the trait distribution is bimodal.

A first group of between 50 and 300 trait positive individuals, preferably about 100 individuals, can be recruited according to clinical inclusion criteria.

In each ease, a similar number of trait negative individuals, preferably more than 100 individuals, are included in such studies who are preferably both ethnically- and age-matched to the trait positive cases. They are checked for the absence of the clinical criteria defined above. Both trait positive and trait negative individuals should correspond to unrelated cases.

Genotyping of Trait Positive and Trait Negative Individuals

Allelic frequencies of the biallelic markers in each of the above described population can be determined using one of the methods described above under the heading “Methods of Genotyping DNA samples for biallelic markers”. Analyses are preferably performed on amplified fragments obtained by genomic PCR performed on the DNA samples from each individual in similar conditions as those described above for the generation of biallelic markers.

In a preferred embodiment, amplified DNA samples are subjected to automated microsequencing reactions using fluorescent ddNTPs (specific fluorescence for each ddNTP) and the appropriate microsequencing oligonucleotides which hybridize just upstream of the polymorphic base.

Genotyping is further described in Example 5.

Associations studies can be carried out by the skilled technician using the biallelic markers of the invention defined above, with different trait positive and trait negative populations. Suitable examples of association studies using biallelic markers of the TBC-1 gene, including the biallelic markers A1 to A19, involve studies on the following populations:

a trait positive population suffering from a cancer, preferably prostate cancer and a healthy unaffected population; or

a trait positive population suffering from prostate cancer treated with agents acting against prostate cancer and suffering from side-effects resulting from this treatment and an trait negative population suffering from prostate cancer treated with same agents without any substantial side-effects, or

a trait positive population suffering from prostate cancer treated with agents acting against prostate cancer showing a beneficial response and a trait negative population suffering from prostate cancer treated with same agents without any beneficial response, or

a trait positive population suffering from prostate cancer presenting highly aggressive prostate cancer tumors and a trait negative population suffering from prostate cancer with prostate cancer tumors devoid of aggressiveness.

It is another object of the present invention to provide a method for the identification and characterization of an association between an allele of one or more biallelic markers of a TBC-1 gene and a trait. The method comprises the steps of:

genotyping a marker or a group of biallelic markers according to the invention in trait positive;

genotyping a marker or a group of biallelic markers according to the invention in and trait negative individuals; and

establishing a statistically significant association between one allele of at least one marker and the trait.

Preferably, the trait positive and trait negative individuals are selected from non-overlapping phenotypes as regards to the trait under study. In one embodiment, the biallelic marker are selected from the group consisting of the biallelic markers A1 to A19.

In a preferred embodiment, the trait is cancer, prostate cancer, an early onset of prostate cancer, a susceptibility to prostate cancer, the level of aggressiveness of prostate cancer tumors, a modified expression of the TBC-1 gene, a modified production of the TBC-1 protein, or the production of a modified TBC-1 protein.

In a further embodiment, the trait negative population can be replaced in the association studies by a random control population.

The step of testing for and detecting the presence of DNA comprising specific alleles of a biallelic marker or a group of biallelic markers of the present invention can be carried out as described further below.

Oligonucleotide Probes and Primers

The invention relates also to oligonucleotide molecules useful as probes or primers, wherein said oligonucleotide molecules hybridize specifically with a nucleotide sequence comprised in the TBC-1 gene, particularly the TBC-1 genomic sequence of SEQ ID Nos 1 and 2 or the TBC-1 cDNAs sequences of SEQ ID Nos 3 and 4. More particularly, the present invention also concerns oligonucleotides for the detection of alleles of biallelic markers of the TBC-1 gene. These oligonucleotides are useful either as primers for use in various processes such as DNA amplification and microsequencing or as probes for DNA recognition in hybridization analyses. Polynucleotides derived from the TBC-1 gene are useful in order to detect the presence of at least a copy of a nucleotide sequence of SEQ ID Nos 1-4, or a fragment, complement, or variant thereof in a test sample.

Particularly preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID Nos 1 and 2, or the complements thereof. Additionally preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 1 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 1: 1-1000, 1001-2000, 2001-3000, 3001-4000, 4001-5000, 5014000, 6001-7000, 7001-8000, 8001-9000, 9001-10000, 10001-11000, 11001-12000, 12001-13000, 13001-14000, 14001-15000, 15001-16000, 16001-17000, and 17001-17590. Other preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 2 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 2: 1-5000, 5001-10000, 10001-15000, 15001-20000, 20001-25000, 25001-30000, 30001-35000, 35001-40000, 40001-45000, 45001-50000, 50001-55000, 55001-60000, 60001-65000, 65001-70000, 70001-75000, 75001-80000, 80001-85000, 85001-90000, 90001-95000, and 95001-99960.

Moreover, preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 35 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID Nos 3 and 4, or the complements thereof. Particularly preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 3 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 3: 1-500, 501-1000, 1001-1500, 1501-2000, 2001-2500, 2501-3000, 3001-3500, and 3501-3983. Additional preferred probes and primers of the invention include isolated, purified, or recombinant polynucleotides comprising a contiguous span of at least 12, 15, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 500, or 1000 nucleotides of SEQ ID No 4 or the complements thereof, wherein said contiguous span comprises at least 1, 2, 3, 5, or 10 of the following nucleotide positions of SEQ ID No 4: 1-500, 501-1000, 1001-1500, 1501-2000, 2001-2500, 2501-3000, 3001-3500, and 3501-3988.

Thus, the invention also relates to nucleic acid probes characterized in that they hybridize specifically, under the stringent hybridization conditions defined above, with a nucleic acid selected from the group consisting of the nucleotide sequences of SEQ ID Nos 1-4 or a variant thereof or a sequence complementary thereto.

In one embodiment the invention encompasses isolated, purified, and recombinant polynucleotides consisting of, or consisting essentially of a contiguous span of 8 to 50 nucleotides of any one of SEQ ID Nos 1 and 2 and the complement thereof, wherein said span includes a TBC-1-related biallelic marker in said sequence; optionally, wherein said TBC-1-related biallelic marker is selected from the group consisting of A1 to A19, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein said contiguous span is 18 to 35 nucleotides in length and said biallelic marker is within 4 nucleotides of the center of said polynucleotide; optionally, wherein said polynucleotide consists of said contiguous span and said contiguous span is 25 nucleotides in length and said biallelic marker is at the center of said polynucleotide; optionally, wherein the 3′ end of said contiguous span is present at the 3′ end of said polynucleotide; and optionally, wherein the 3′ end of said contiguous span is located at the 3′ end of said polynucleotide and said biallelic marker is present at the 3′ end of said polynucleotide. In a preferred embodiment, said probes comprises, consists of, or consists essentially of a sequence selected from the following sequences: P1 to P7, P9 to P13, P15 to P19 and the complementary sequences thereto.

In another embodiment the invention encompasses isolated, purified and recombinant polynucleotides comprising, consisting of, or consisting essentially of a contiguous span of 8 to 50 nucleotides of SEQ ID Nos 1 and 2, or the complements thereof, wherein the 3′ end of said contiguous span is located at the 3′ end of said polynucleotide, and wherein the 3′ end of said polynucleotide is located within 20 nucleotides upstream of a TBC-1-related biallelic marker in said sequence; optionally, wherein said TBC-1-related biallelic marker is selected from the group consisting of A1 to A19, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith; optionally, wherein the 3′ end of said polynucleotide is located 1 nucleotide upstream of said TBC-1-related biallelic marker in said sequence; and optionally, wherein said polynucleotide consists essentially of a sequence selected from the following sequences: D1 to D19 and E1 to E19.

In a further embodiment, the invention encompasses isolated, purified, or recombinant polynucleotides comprising, consisting of, or consisting essentially of a sequence selected from the following sequences: B1 to B15 and C1 to C15.

In an additional embodiment, the invention encompasses polynucleotides for use in hybridization assays, sequencing assays, and enzyme-based mismatch detection assays for determining the identity of the nucleotide at a TBC-1-related biallelic marker in SEQ ID Nos 1 and 2, or the complements thereof, as well as polynucleotides for use in amplifying segments of nucleotides comprising a TBC-1-related biallelic marker in SEQ ID Nos 1 and 2, or the complements thereof; optionally, wherein said TBC-1-related biallelic marker is selected from the group consisting of A1 to A19, and the complements thereof, or optionally the biallelic markers in linkage disequilibrium therewith.

A probe or a primer according to the invention has between 8 and 1000 nucleotides in length, or is specified to be at least 12, 15, 18, 20, 25, 35, 40, 50, 60, 70, 80, 100, 250, 500 or 1000 nucleotides in length. More particularly, the length of these probes and primers can range from 8, 10, 15, 20, or 30 to 100 nucleotides, preferably from 10 to 50, more preferably from 15 to 30 nucleotides. Shorter probes and primers tend to lack specificity for a target nucleic acid sequence and generally require cooler temperatures to form sufficiently stable hybrid complexes with the template. Longer probes and primers are expensive to produce and can sometimes self-hybridize to form hairpin structures. The appropriate length for primers and probes under a particular set of assay conditions may be empirically determined by one of skill in the art. A preferred probe or primer consists of a nucleic acid comprising a polynucleotide selected from the group of the nucleotide sequences of P1 to P7, P9 to P13, P15 to P19 and the complementary sequence thereto, B1 to B15, C1 to C15, D1 to D19, E1 to E19, for which the respective locations in the sequence listing are provided in Tables 2, 3 and 4.

The formation of stable hybrids depends on the melting temperature (Tm) of the DNA. The Tm depends on the length of the primer or probe, the ionic strength of the solution and the G+C content. The higher the G+C content of the primer or probe, the higher is the melting temperature because G:C pairs are held by three H bonds whereas A:T pairs have only two. The GC content in the probes of the invention usually ranges between 10 and 75%, preferably between 35 and 60%, and more preferably between 40 and 55%.

The primers and probes can be prepared by any suitable method, including, for example, cloning and restriction of appropriate sequences and direct chemical synthesis by a method such as the phosphodiester method of Narang et al.(1979), the phosphodiester method of Brown et al.(1979), the diethylphosphoramidite method of Beaucage et al.(1981) and the solid support method described in EP 0 707 592.

Detection probes are generally nucleic acid sequences or uncharged nucleic acid analogs such as, for example peptide nucleic acids which are disclosed in International Patent Application WO 92/20702, morpholino analogs which are described in U.S. Pat. Nos. 5,185,444; 5,034,506 and 5,142,047. The probe may have to be rendered “non-extendable” in that additional dNTPs cannot be added to the probe. In and of themselves analogs usually are non-extendable and nucleic acid probes can be rendered non-extendable by modifying the 3′ end of the probe such that the hydroxyl group is no longer capable of participating in elongation. For example, the 3′ end of the probe can be functionalized with the capture or detection label to thereby consume or otherwise block the hydroxyl group. Alternatively, the 3′ hydroxyl group simply can be cleaved, replaced or modified, U.S. patent application Ser. No. 07/049,061 filed Apr. 19, 1993 describes modifications, which can be used to render a probe non-extendable.

Any of the polynucleotides of the present invention can be labeled, if desired, by incorporating any label known in the art to be detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioactive substances (including, ³²P, ³⁵S, ³H, ¹²⁵I), fluorescent dyes (including, 5-bromodesoxyuridin, fluorescein, acetylaminofluorene, digoxigenin) or biotin. Preferably, polynucleotides are labeled at their 3′ and 5′ ends. Examples of non-radioactive labeling of nucleic acid fragments are described in the French patent No. FR-7810975 or by Urdea et al (1988) or Sanchez-Pescador et al (1988). In addition, the probes according to the present invention may have structural characteristics such that they allow the signal amplification, such structural characteristics being, for example, branched DNA probes as those described by Urdea et al. in 1991 or in the European patent No. EP 0 225 807 (Chiron).

A label can also be used to capture the primer, so as to facilitate the immobilization of either the primer or a primer extension product, such as amplified DNA, on a solid support. A capture label is attached to the primers or probes and can be a specific binding member which forms a binding pair with the solid's phase reagent's specific binding member (e.g. biotin and streptavidin). Therefore depending upon the type of label carried by a polynucleotide or a probe, it may be employed to capture or to detect the target DNA. Further, it will be understood that the polynucleotides, primers or probes provided herein, may, themselves, serve as the capture label. For example, in the case where a solid phase reagent's binding member is a nucleic acid sequence, it may be selected such that it binds a complementary portion of a primer or probe to thereby immobilize the primer or probe to the solid phase. In cases where a polynucleotide probe itself serves as the binding member, those skilled in the art will recognize that the probe will contain a sequence or “tail” that is not complementary to the target. In the case where a polynucleotide primer itself serves as the capture label, at least a portion of the primer will be free to hybridize with a nucleic acid on a solid phase. DNA Labeling techniques are well known to the skilled technician.

The probes of the present invention are useful for a number of purposes. They can be notably used in Southern hybridization to genomic DNA. The probes can also be used to detect PCR amplification products. They may also be used to detect mismatches in the TBC-1gene or mRNA using other techniques.

Any of the polynucleotides, primers and probes of the present invention can be conveniently immobilized on a solid support. Solid supports are known to those skilled in the art and include the walls of wells of a reaction tray, test tubes, polystyrene beads; magnetic beads, nitrocellulose strips, membranes, microparticles such as latex particles, sheep (or other animal) red blood cells, duracytes and others. The solid support is not critical and can be selected by one skilled in the art. Thus, latex particles, microparticles, magnetic or non-magnetic beads, membranes, plastic tubes, walls of microtiter wells, glass or silicon chips, sheep (or other suitable animal's) red blood cells and duracytes are all suitable examples. Suitable methods for immobilizing nucleic acids on solid phases include ionic, hydrophobic, covalent interactions and the like. A solid support, as used herein, refers to any material which is insoluble, or can be made insoluble by a subsequent reaction. The solid support can be chosen for its intrinsic ability to attract and immobilize the capture reagent Alternatively, the solid phase can retain an additional receptor which has the ability to attract and immobilize the capture reagent. The additional receptor can include a charged substance that is oppositely charged with respect to the capture reagent itself or to a charged substance conjugated to the capture reagent. As yet another alternative, the receptor molecule can be any specific binding member which is immobilized upon (attached to) the solid support and which has the ability to immobilize the capture reagent through a specific binding reaction. The receptor molecule enables the indirect binding of the capture reagent to a solid support material before the performance of the assay or during the performance of the assay. The solid phase thus can be a plastic, derivatized plastic, magnetic or non-magnetic metal, glass or silicon surface of a test tube, microtiter well, sheet, bead, microparticle, chip, sheep (or other suitable animal's) red blood cells, duracytes® and other configurations known to those of ordinary skill in the art The polynucleotides of the invention can be attached to or immobilized on a solid support individually or in groups of at least 2, 5, 8, 10, 12, 15, 20, or 25 distinct polynucleotides of the invention to a single solid support. In addition, polynucleotides other than those of the invention may be attached to the same solid support as one or more polynucleotides of the invention.

Consequently, the invention also deals with a method for detecting the presence of a nucleic acid comprising a nucleotide sequence selected from a group consisting of SEQ ID Nos 1-4, a fragment or a variant thereof and a complementary sequence thereto in a sample, said method comprising the following steps of:

a) bringing into contact a nucleic acid probe or a plurality of nucleic acid probes which can hybridize with a nucleotide sequence included in a nucleic acid selected form the group consisting of the nucleotide sequences of SEQ ID Nos 1-4, a fragment or a variant thereof and a complementary sequence thereto and the sample to be assayed; and

b) detecting the hybrid complex formed between the probe and a nucleic acid in the sample.

The invention further concerns a kit for detecting the presence of a nucleic acid comprising a nucleotide sequence selected from a group consisting of SEQ ID Nos 1-4, a fragment or a variant thereof and a complementary sequence thereto in a sample, said kit comprising:

a) a nucleic acid probe or a plurality of nucleic acid probes which can hybridize with a nucleotide sequence included in a nucleic acid selected form the group consisting of the nucleotide sequences of SEQ ID Nos 1-4, a fragment or a variant thereof and a complementary sequence thereto; and

b) optionally, the reagents necessary for performing the hybridization reaction.

In a first preferred embodiment of this detection method and kit, said nucleic acid probe or the plurality of nucleic acid probes are labeled with a detectable molecule. In a second preferred embodiment of said method and kit, said nucleic acid probe or the plurality of nucleic acid probes has been immobilized on a substrate. In a third preferred embodiment, the nucleic acid probe or the plurality of nucleic acid probes comprise either a sequence which is selected from the group consisting of the nucleotide sequences of P1 to P7, P9 to P13, P15 to P19 and the complementary sequence thereto, B1 to B15, C1 to C15, D1 to D19, E1 to E19 or a biallelic marker selected from the group consisting of A1 to A19 and the complements thereto.

Oligonucleotide Arrays

A substrate comprising a plurality of oligonucleotide primers or probes of the invention may be used either for detecting or amplifying targeted sequences in the TBC-1 gene and may also be used for detecting mutations in the coding or in the non-coding sequences of the TBC-1 gene.

Any polynucleotide provided herein may be attached in overlapping areas or at random locations on the solid support Alternatively the polynucleotides of the invention may be attached in an ordered array wherein each polynucleotide is attached to a distinct region of the solid support which does not overlap with the attachment site of any other polynucleotide. Preferably, such an ordered array of polynucleotides is designed to be “addressable” where the distinct locations are recorded and can be accessed as part of an assay procedure. Addressable polynucleotide arrays typically comprise a plurality of different oligonucleotide probes that are coupled to a surface of a substrate in different known locations. The knowledge of the precise location of each polynucleotides location makes these “addressable” arrays particularly useful in hybridization assays. Any addressable array technology known in the art can be employed with the polynucleotides of the invention. One particular embodiment of these polynucleotide arrays is known as the Genechips™, and has been generally described in U.S. Pat. No. 5,143,854; PCT publications WO 90/15070 and 92/10092. These arrays may generally be produced using mechanical synthesis methods or light directed synthesis methods which incorporate a combination of photolithographic methods and solid phase oligonucleotide synthesis (Fodor et al., 1991). The immobilization of arrays of oligonucleotides on solid supports has been rendered possible by the development of a technology generally identified as “Very Large Scale Immobilized Polymer Synthesis” (VLSIPS™) in which, typically, probes are immobilized in a high density array on a solid surface of a chip. Examples of VLSIPS™ technologies are provided in U.S. Pat. Nos. 5,143,854; and 5,412,087 and in PCT Publications WO 90/15070, WO 92/10692 and WO 95/11995, which describe methods for forming oligonucleotide arrays through techniques such as light-directed synthesis techniques. In designing strategies aimed at providing arrays of nucleotides immobilized on solid supports, further presentation strategies were developed to order and display the oligonucleotide arrays on the chips in an attempt to maximize hybridization patterns and sequence information. Examples of such presentation strategies are disclosed in PCT Publications WO 94/12305, WO 94/11530, WO 97/29212 and WO 97/31256.

In another embodiment of the oligonucleotide arrays of the invention, an oligonucleotide probe matrix may advantageously be used to detect mutations occurring in the TBC-1 gene and preferably in its regulatory region. For this particular purpose, probes are specifically designed to have a nucleotide sequence allowing their hybridization to the genes that carry known mutations (either by deletion, insertion or substitution of one or several nucleotides). By known mutations, it is meant, mutations on the TBC-1 gene that have been identified according, for example to the technique used by Huang et al.(1996) or Samson et al.(1996).

Another technique that is used to detect mutations in the TBC-1 gene is the use of a high-density DNA array. Each oligonucleotide probe constituting a unit element of the high density DNA array is designed to match a specific subsequence of the TBC-1 genomic DNA or cDNA. Thus, an array consisting of oligonucleotides complementary to subsequences of the target gene sequence is used to determine the identity of the target sequence with the wild gene sequence, measure its amount, and detect differences between the target sequence and the reference wild gene sequence of the TBC-1 gene. In one such design, termed 4L tiled array, is implemented a set of four probes (A, C, G, T), preferably 15-nucleotide oligomers. In each set of four probes, the perfect complement will hybridize more strongly than mismatched probes. Consequently, a nucleic acid target of length L is scanned for mutations with a tiled array containing 4L probes, the whole probe set containing all the possible mutations in the known wild reference sequence. The hybridization signals of the 15-mer probe set tiled array are perturbed by a single base change in the target sequence. As a consequence, there is a characteristic loss of signal or a “footprint” for the probes flanking a mutation position. This technique was described by Chee et al. in 1996.

Consequently, the invention concerns an array of nucleic acid molecules comprising at least one polynucleotide described above as probes and primers. Preferably, the invention concerns an array of nucleic acid comprising at least two polynucleotides described above as probes and primers.

A further object of the invention consists of an array of nucleic acid sequences comprising either at least one of the sequences selected from the group consisting of P1 to P7, P9 to P13, P15 to P19, B1 to B15, C1 to C15, D1 to D19, E1 to E19, the sequences complementary thereto, a fragment thereof of at least 8, 10, 12, 15, 18, 20, 25, 30, or 40 consecutive nucleotides thereof, and at least one sequence comprising a biallelic marker selected from the group consisting of A1 to A19 and the complements thereto.

The invention also pertains to an array of nucleic acid sequences comprising either at least two of the sequences selected from the group consisting of P1 to P7, P9 to P13, P15 to P19, B1 to B15, C1 to C15, D1 to D19, E1 to E19, the sequences complementary thereto, a fragment thereof of at least 8 consecutive nucleotides thereof, and at least two sequences comprising a biallelic marker selected from the group consisting of A1 to A19 and the complements thereof.

Vectors for the Expression of a Regulatory or a Coding Polynucleotide of TBC-1

Any of the regulatory polynucleotides or the coding polynucleotides of the invention may be inserted into recombinant vectors for expression in a recombinant host cell or a recombinant host organism.

Thus, the present invention also encompasses a family of recombinant vectors that contains either a regulatory polynucleotide selected from the group consisting of any one of the regulatory polynucleotides derived from the TBC-1 genomic sequences of SEQ ID Nos 1 and 2, or a polynucleotide comprising the TBC-1 coding sequence, or both.

In a first preferred embodiment, a recombinant vector of the invention is used as an expression vector: (a) the TBC-1 regulatory sequence comprised therein drives the expression of a coding polynucleotide operably linked thereto; (b) the TBC-1 coding sequence is operably linked to regulation sequences allowing its expression in a suitable cell host and/or host organism.

In a second preferred embodiment, a recombinant vector of the invention is used to amplify the inserted polynucleotide derived from the TBC-1 genomic sequences of SEQ ID Nos 1 and 2 or TBC-1 cDNAs in a suitable cell host, this polynucleotide being amplified at every time that the recombinant vector replicates.

More particularly, the present invention relates to expression vectors which include nucleic acids encoding a TBC-1 protein, preferably the TBC-1 protein of the amino acid sequence of SEQ ID No 5 described therein, under the control of a regulatory sequence selected among the TBC-1 regulatory polynucleotides, or alternatively under the control of an exogenous regulatory sequence.

A recombinant expression vector comprising a nucleic acid selected from the group consisting of 5′ and 3′ regulatory regions, or biologically active fragments or variants thereof is also part of the present invention.

The invention also encompasses a recombinant expression vector comprising:

a) a nucleic acid comprising the 5′ regulatory polynucleotide of the nucleotide sequence SEQ ID No 1, or a biologically active fragment or variant thereof,

b) a polynucleotide encoding a polypeptide or a polynucleotide of interest operably linked with said nucleic acid.

c) optionally, a nucleic acid comprising a 3′-regulatory polynucleotide, preferably a 3′-regulatory polynucleotide of the invention, or a biologically active fragment or variant thereof.

The nucleic acid comprising the 5′ regulatory polynucleotide or a biologically active fragment or variant thereof may also comprises the 5′-UTR sequence from any of the two cDNA of the invention or a biologically active fragment or variant thereof.

The invention also pertains to a recombinant expression vector useful for the expression of the TBC-1 coding sequence, wherein said vector comprises a nucleic acid selected from the group consisting of SEQ ID Nos 3 and 4 or a nucleic acid having at least 95% nucleotide identity with a polynucleotide selected from the group consisting of the nucleotide sequences of SEQ ID Nos 3 and 4.

Another recombinant expression vector of the invention consists in a recombinant vector comprising a nucleic acid comprising the nucleotide sequence beginning at the nucleotide in position 176 and ending in position 3730 of the polynucleotide of SEQ ID No 4.

Generally, a recombinant vector of the invention may comprise any of the polynucleotides described herein, including regulatory sequences, and coding sequences, as well as any TBC-1 primer or probe as defined above. More particularly, the recombinant vectors of the present invention can comprise any of the polynucleotides described in the “TBC-1 cDNA Sequences” section, the “Coding Regions” section, “Genomic sequence of TBC-1” section and the “Oligonucleotide Probes And primers” section.

Some of the elements which can be found in the vectors of the present invention are described in further detail in the following sections.

a) Vectors

A recombinant vector according to the invention comprises, but is not limited to, a YAC (Yeast Artificial Chromosome), a BAC (Bacterial Artificial Chromosome), a phage, a phagemid, a cosmid, a plasmid or even a linear DNA molecule which may consist of a chromosomal, non-chromosomal and synthetic DNA. Such a recombinant vector can comprise a transcriptional unit comprising an assembly of:

(1) a genetic element or elements having a regulatory role in gene expression, for example promoters or enhancers. Enhancers are cis-acting elements of DNA, usually from about 10 to 300 bp in length that act on the promoter to increase the transcription.

(2) a structural or coding sequence which is transcribed into mRNA and eventually translated into a polypeptide, and

(3) appropriate transcription initiation and termination sequences. Structural units intended for use in yeast or eukaryotic expression systems preferably include a leader sequence enabling extracellular secretion of translated protein by a host cell. Alternatively, where a recombinant protein is expressed without a leader or transport sequence, it may include an N-terminal residue. This residue may or may not be subsequently cleaved from the expressed recombinant protein to provide a final product.

Generally, recombinant expression vectors will include origins of replication, selectable markers permitting transformation of the host cell, and a promoter derived from a highly expressed gene to direct transcription of a downstream structural sequence. The heterologous structural sequence is assembled in appropriate phase with translation initiation and termination sequences, and preferably a leader sequence capable of directing secretion of the translated protein into the periplasmic space or the extraccllular medium.

The selectable marker genes for selection of transformed host cells are preferably dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, TRP1 for S. cerevisiae or tetracycline, rifampicin or ampicillin resistance in E. coli, or levan saccharase for mycobacteria.

As a representative but non-limiting example, useful expression vectors for bacterial use can comprise a selectable marker and a bacterial origin of replication derived from commercially available plasmids comprising genetic elements of pBR322 (ATCC 37017). Such commercial vectors include, for example, pKK223-3 (Pharmacia, Uppsala, Sweden), and GEM1 (Promega Biotec, Madison, Wis., USA).

Large numbers of suitable vectors and promoters are known to those of skill in the art, and commercially available, such as bacterial vectors: pQE70, pQE60, pQE-9 (Qiagen), pbs, pD10, phagescript, psiX174, pbluescript SK, pbsks, pNH8A, pNH16A, pNH18A, pNH46A (Stratagene); ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia); or eukaryotic vectors: pWLNEO, pSV2CAT, pOG44, pXT1, pSG (Stratagene); pSVK3, PBPV, pMSG, pSVL (Pharmacia); baculovirus transfer vector pVL1392/1393 (Pharmingen); pQE-30 (QIAexpress).

A suitable vector for the expression of the TBC-1 polypeptide of SEQ ID No 5 is a baculovirus vector that can be propagated in insect cells and in insect cell lines. A specific suitable host vector system is the pVL1392/1393 baculovirus transfer vector (Pharmingen) that is used to transfect the SF9 cell line (ATCC N^(o)CRL 1711) which is derived from Spodoptera frugiperda.

Other suitable vectors for the expression of the TBC-1 polypeptide of SEQ ID No 5 in a baculovirus expression system include those described by Chai et al. (1993), Vlasak et al. (1983) and Lenhard et al. (1996).

Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5′ flanking nontranscribed sequences. DNA sequences derived from the SV40 viral genome, for example SV40 origin, early promoter, enhancer, splice and polyadenylation sites may be used to provide the required nontranscribed genetic elements.

b) Promoters

The suitable promoter regions used in the expression vectors according to the present invention are chosen taking into account the cell host in which the heterologous gene has to be expressed.

A suitable promoter may be heterologous with respect to the nucleic acid for which it controls the expression or alternatively can be endogenous to the native polynucleotide containing the coding sequence to be expressed. Additionally, the promoter is generally heterologous with respect to the recombinant vector sequences within which the construct promoter/coding sequence has been inserted.

Preferred bacterial promoters are the LacI, LacZ, the T3 or T7 bacteriophage RNA polymerase promoters, the polyhedrin promoter, or the p10 protein promoter from baculovirus (Kit Novagen) (Smith et al., 1983; O'Reilly et al., 1992), the lambda P_(R) promoter or also the trc promoter.

Promoter regions can be selected from any desired gene using, for example, CAT (chloramphenicol transferase) vectors and more preferably pKK232-8 and pCM7 vectors. Particularly preferred bacterial promoters include lac, lacZ, T3, T7, gpt, lambda PR, PL and trp. Eukaryotic promoters include CMV immediate early, HSV thymidine kinase, early and late SV40, LTRs from retrovirus, and mouse metallothionein-L. Selection of a convenient vector and promoter is well within the level of ordinary skill in the art.

The choice of a promoter is well within the ability of a person skilled in the field of genetic egineering. For example, one may refer to the book of Sambrook et al. (1989) or also to the procedures described by Fuller et al. (1996).

The vector containing the appropriate DNA sequence as described above, more preferably a TBC-1 gene regulatory polynucleotide, a polynucleotide encoding the TBC-1 polypeptide of SEQ ID No 5 or both of them, can be utilized to transform an appropriate host to allow the expression of the desired polypeptide or polynucleotide.

c) Other Types of Vectors

The in vivo expression of a TBC-1 polypeptide of SEQ ID No 5 may be useful in order to correct a genetic defect related to the expression of the native gene in a host organism or to the production of a biologically inactive TBC-1 protein.

Consequently, the present invention also deals with recombinant expression vectors mainly designed for the in vivo production of the TIC-1 polypeptide of SEQ ID No 5 by the introduction of the appropriate genetic material in the organism of the patient to be treated. This genetic material may be introduced in vitro in a cell that has been previously extracted from the organism, the modified cell being subsequently reintroduced in the said organism, directly in vivo into the appropriate tissue.

By <<vector>> according to this specific embodiment of the invention is intended either a circular or a linear DNA molecule.

One specific embodiment for a method for delivering a protein or peptide to the interior of a cell of a vertebrate in vivo comprises the step of introducing a preparation comprising a physiologically acceptable carrier and a naked polynucleotide operatively coding for the polypeptide of interest into the interstitial space of a tissue comprising the cell, whereby the naked polynucleotide is taken up into the interior of the cell and has a physiological effect.

In a specific embodiment, the invention provides a composition for the in vivo production of the TBC-1 protein or polypeptide described herein. It comprises a naked polynucleotide operatively coding for this polypeptide, in solution in a physiologically acceptable carrier, and suitable for introduction into a tissue to cause cells of the tissue to express the said protein or polypeptide.

Compositions comprising a polynucleotide are described in PCT application N^(o) WO 90/11092 (Vical Inc.) and also in PCT application N^(o) WO 95/11307 (Institut Pasteur, INSERM, Université d'Ottawa) as well as in the articles of Tacson et al. (1996) and of Huygen et al. (1996).

The amount of vector to be injected to the desired host organism varies according to the site of injection. As an indicative dose, it will be injected between 0,1 and 100 μg of the vector in an animal body, preferably a mammal body, for example a mouse body.

In another embodiment of the vector according to the invention, it may be introduced in vitro in a host cell, preferably in a host cell previously harvested from the animal to be treated and more preferably a somatic cell such as a muscle cell. In a subsequent step, the cell that has been transformed with the vector coding for the desired TBC-1 polypeptide or the desired fragment thereof is reintroduced into the animal body in order to deliver the recombinant protein within the body either locally or systemically.

In one specific embodiment, the vector is derived from an adenovirus. Preferred adenovirus vectors according to the invention are those described by Feldman and Steg (1996) or Ohno et al. (1994). Another preferred recombinant adenovirus according to this specific embodiment of the present invention is the human adenovirus type 2 or 5 (Ad 2 or Ad 5) or an adenovirus of animal origin (French patent application N^(o) FR-93.05954).

Retrovirus vectors and adeno-associated virus vectors are generally understood to be the recombinant gene delivery systems of choice for the transfer of exogenous polynucleotides in vivo, particularly to mammals, including humans. These vectors provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal DNA of the host

Particularly preferred retroviruses for the preparation or construction of retroviral in vitro or in vitro gene delivery vehicles of the present invention include retroviruses selected from the group consisting of Mink-Cell Focus Inducing Virus, Murine Sarcona Virus, Reticuloendotheliosis virus and Rous Sarcoma virus. Particularly preferred Murine Leukemia Viruses include the 4070A and the 1504A viruses, Abelson (ATCC No VR-999), Friend (ATCC No VR-245), Gross (ATCC No VR-590), Rauscher (ATCC No VR-998) and Moloney Murine Leukemia Virus (ATCC No VR-190; PCT Application No WO 94/24298). Particularly preferred Rous Sarcoma Viruses include Bryan high titer (ATCC Nos VR-334, VR-657, VR-726, VR459 and VR-728). Other preferred retroviral vectors are those described in Roth et al. (Roth J A. et al., 1996), PCT Application No WO 93/25234, PCT Application No WO 94/06920, Roux et al., 1989, Julan et al., 1992 and Neda et al., 1991.

Yet another viral vector system that is contemplated by the invention consists in the adeno-associated virus (AAV). The adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle (Muzyczka et al., 1992). It is also one of the few viruses that may integrate its DNA into non-dividing cells, and exhibits a high frequency of stable integration (Flotte et al., 1992; Samulski et al., 1989; McLaughlin et al., 1989). One advantageous feature of AAV derives from its reduced efficacy for transducing primary cells relative to transformed cells.

Other compositions containing a vector of the invention advantageously comprise an oligonucleotide fragment of a nucleic sequence selected from the group consisting of SEQ ID Nos 3 or 4 as an antisense tool that inhibits the expression of the corresponding TBC-1 gene. Preferred methods using antisense polynucleotide according to the present invention are the procedures described by Sczakiel et al. (1995) or those described in PCT Application No WO 95/24223.

Host Cells

Another object of the invention consists in host cell that have been transformed or transfected with one of the polynucleotides described therein, and more precisely a polynucleotide either comprising a TBC-1 regulatory polynucleotide or the coding sequence of the TBC-1 polypeptide having the amino acid sequence of SEQ ID No 5. Are included host cells that are transformed (prokaryotic cells) or that are transfected (eukaryotic cells) with a recombinant vector such as one of those described above.

A recombinant host cell of the invention comprises any one of the polynucleotides or the recombinant vectors described therein. More particularly, the cell hosts of the present invention can comprise any of the polynucleotides described in “TBC-1 cDNA Sequences” section, the “Coding Regions” section, “Genomic sequence of TBC-1” section and the “Oligonucleotide Probes And Primers” section.

Another preferred recombinant cell host according to the present invention is characterized in that its genome or genetic background (including chromosome, plasmids) is modified by the nucleic acid coding for the TBC-1 polypeptide of SEQ ID No 5.

Preferred host cells used as recipients for the expression vectors of the invention are the following:

a) Prokaryotic host cells: Escherichia coli strains (I.E. DH5-α strain) or Bacillus subtilis.

b) Eukaryotic host cells: HeLa cells (ATCC N^(o)CCL2; N^(o)CCL2.1; N^(o)CCL2.2), Cv 1 cells (ATCC N^(o)CCL70), COS cells(ATCC N^(o)CRL1650; N^(o)CRL1651), Sf-9cells(ATCC N^(o)CRL1711).

The constructs in the host cells can be used in a conventional manner to produce the gene product encoded by the recombinant sequence.

Following transformation of a suitable host and growth of the host to an appropriate cell density, the selected promoter is induced by appropriate means, such as temperature shift or chemical induction, and cells are cultivated for an additional period.

Cells are typically harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification.

Microbial cells employed in the expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents. Such methods are well known by the skill artisan.

Transgenic Animals

The terms “transgenic animals” or “host animals” are used herein to designate animals that have their genome genetically and artificially manipulated so as to include one of the nucleic acids according to the invention. Preferred animals are non-human mammals and include those belonging to a genus selected from Mus (e.g. mice), Rattus (e.g. rats) and Oryctogalus (e.g. rabbits) which have their genome artificially and genetically altered by the insertion of a nucleic acid according to the invention.

The transgenic animals of the invention all include within a plurality of their cells a cloned recombinant or synthetic DNA sequence, more specifically one of the purified or isolated nucleic acids comprising a TBC-1 coding sequence, a TBC-1 regulatory polynucleotide or a DNA sequence encoding an antisense polynucleotide such as described in the present specification.

More particularly, transgenic animals according to the invention contain in their somatic cells and/or in their germ line cells any of the polynucleotides described in “TBC-1 cDNA Sequences” section, the “Coding Regions” section, “Genomic sequence of TBC-1” section, the “Oligonucleotide Probes And Primers” section and the “Vectors for the expression of a regulatory or coding polynucleotide of TBC-1” section.

The transgenic animals of the invention thus contain specific sequences of exogenous genetic material such as the nucleotide sequences described above in detail.

In a first preferred embodiment, these transgenic animals may be good experimental models in order to study the diverse pathologies related to cell differentiation, in particular concerning the transgenic animals within the genome of which has been inserted one or several copies of a polynucleotide encoding a native TBC-1 protein, or alternatively a mutant TBC-1 protein.

In a second preferred embodiment, these transgenic animals may express a desired polypeptide of interest under the control of the regulatory polynucleotides of the TBC-1 gene, leading to good yields in the-synthesis of this protein of interest, and eventually a tissue specific expression of this protein of interest.

Since it is possible to produce transgenic animals of the invention using a variety of different sequences, a general description will be given of the production of transgenic animals by referring generally to exogenous genetic material. This general description can be adapted by those skilled in the art in order to incorporate the DNA sequences into animals. For more details regarding the production of transgenic animals, and specifically transgenic mice, it may be referred to Sandou et al. (1994) and also to U.S. Pat. No. 4,873,191, issued Oct. 10, 1989, U.S. Pat. No. 5,968,766, issued Dec. 16, 1997 and U.S. Pat. No. 5,387,742, issued Feb. 28, 1995, these documents being herein incorporated by reference to disclose methods for producing transgenic mice.

Transgenic animals of the present invention are produced by the application of procedures which result in an animal with a genome that incorporates exogenous genetic material which is integrated into the genome. The procedure involves obtaining the genetic material, or a portion thereof, which encodes either a TBC-1 coding sequence, a TBC-1 regulatory polynucleotide or a DNA sequence encoding an antisense polynucleotide such as described in the present specification.

A recombinant polynucleotide of the invention is inserted into an embryonic or ES stem cell line. The insertion is made using electroporation. The cells subjected to electroporation are screened (e.g. Southern blot analysis) to find positive cells which have integrated the exogenous recombinant polynucleotide into their genome. An illustrative positive-negative selection procedure that may be used according to the invention is described by Mansour et al. (1988). Then, the positive cells are isolated, cloned and injected into 3.5 days old blastocysts from mice. The blastocysts are then inserted into a female host animal and allowed to grow to term. The offsprings of the female host are tested to determine which animals are transgenic e.g. include the inserted exogenous DNA sequence and which are wild-type.

Screening of Agents Interacting with TBC-1

In a further embodiment, the present invention also concerns a method for the screening of new agents, or candidate substances interacting with TBC-1. These new agents could be useful against cancer.

In a preferred embodiment, the invention relates to a method for the screening of candidate substances comprising the following steps:

providing a cell line, an organ, or a mammal expressing a TBC-1 gene or a fragment thereof, preferably the regulatory region or the promoter region of the TBC-1 gene.

obtaining a candidate substance preferably a candidate substance capable of inhibiting the binding of a transcription factor to the TBC-1 regulatory region,

testing the ability of the candidate substance to decrease the symptoms of prostate cancer and/or to modulate the expression levels of TDC-1.

In some embodiments, the cell line, organ or mammal expresses a heterologous protein, the coding sequence of which is operably linked to the TBC-1 regulatory or promoter sequence. In other embodiments, they express a TBC-1 gene comprising alleles of one or more TBC-1-related biallelic markers.

A candidate substance is a substance which can interact with or modulate, by binding or other intramolecular interactions, expression stability, and function of TBC-1. Such substances may be potentially interesting for patients who are not responsive to existing drugs or develop side effects to them. Screening may be effected using either in vitro methods or in vivo methods.

Such methods can be carried out in numerous ways such as on transformed cells which express the considered alleles of the TBC-1 gene, on tumors induced by said transformed cells, for example in mice, or on a TBC-1 protein encoded by the considered allelic variant of TBC-1.

Screening assays of the present invention generally involve determining the ability of a candidate substance to present a cytotoxic effect, to change the characteristics of transformed cells such as proliferative and invasive capacity, to affect the tumor growth, or to modify the expression level of TBC-1.

Typically, this method includes preparing transformed cells with different forms of TBC-1 sequences containing particular alleles of one or more biallelic markers and/or trait causing mutations described above. This is followed by testing the cells expressing the TBC-1 with a candidate substance to determine the ability of the substance to present cytotoxic effect, to affect the characteristics of transformed cells, the tumor growth, or to modify the expression level of TBC-1.

Typical examples of such drug screening assays are provided below. It is to be understood that the parameters set forth in these examples can be modified by the skilled person without undue experimentation.

Methods for Screening Substances Interacting with a TBC-1 Polypeptide

A method for the screening of a candidate substance according to the invention comprises the following steps:

a) providing a polypeptide comprising the amino acid sequence SEQ ID No 5, or a peptide fragment or a variant thereof;

b) obtaining a candidate substance;

c) bringing into contact said polypeptide with said candidate substance;

d) detecting the complexes formed between said polypeptide and said candidate substance.

For the purpose of the present invention, a ligand means a molecule, such as a protein, a peptide, an antibody or any synthetic chemical compound capable of binding to the TBC-1 protein or one of its fragments or variants or to modulate the expression of the polynucleotide coding for TBC-1 or a fragment or variant thereof.

In the ligand screening method according to the present invention, a biological sample or a defined molecule to be tested as a putative ligand of the TBC-1 protein is brought into contact with a purified TBC-1 protein, for example a purified recombinant TBC-1 protein produced by a recombinant cell host as described hereinbefore, in order to form a complex between the TBC-1 protein and the putative ligand molecule to be tested.

A. Candidate Ligands Obtained Form Random Peptide Libraries

In a particular embodiment of the screening method, the putative ligand is the expression product of a DNA insert contained in a phage vector (Parmley and Smith, 1988). Specifically, random peptide phages libraries are used. The random DNA inserts encode peptides of 8 to 20 aminoacids in length (Oldenburg K. R. et al., 1992,.; Valadon P., et al., 1996; Lucas A. H., 1994; Westerink M. A. J., 1995; Castagnoli L. et al., 1991). According to this particular embodiment, the recombinant phages expressing a protein that binds to the immobilized TBC-1 protein are retained and the complex formed between the TBC-1 protein and the recombinant phage may be subsequently immunoprecipitated by a polyclonal or a monoclonal antibody directed against the TBC-1 protein.

Once the ligand library in recombinant phages has been constructed, the phage population is brought into contact with the immobilized TBC-1 protein. Then the preparation of complexes is washed in order to remove the non-specifically bound recombinant phages. The phages that bind specifically to the TBC-1 protein are then eluted by a buffer (acid pH) or immunoprecipitated by the anti-TBC-1monoclonal antibody produced by a hybridoma, and this phage population is subsequently amplified-by an over-infection of bacteria (for example E. coli). The selection step may be repeated several times, preferably 2-4 times, in order to select the more specific recombinant phage clones. The last step consists in characterizing the peptide produced by the selected recombinant phage clones either by expression in infected bacteria and isolation, expressing the phage insert in another host-vector system, or sequencing the insert contained in the selected recombinant phages.

B. Candidate Ligands Obtained Through a Two-hybrid Screening Assay

The yeast two-hybrid system is designed to study protein-protein interactions in vivo (Fields and Song, 1989), and relies upon the fusion of a bait protein to the DNA binding domain of the yeast Gal4 protein. This technique is also described in U.S. Pat. Nos. 5,667,973 and 5,283,173 (Fields et al.) the technical teachings of both patents being herein incorporated by reference.

The general procedure of library screening by the two-hybrid assay may be performed as described by Harper et al. (Harper J W et al., 1993) or as described by Cho et al. (1998) or also Fromont-Racine et al. (1997).

The bait protein or polypeptide consists of a TBC-1 polypeptide or a fragment or variant thereof.

More precisely, the nucleotide sequence encoding the TBC-1 polypeptide or a fragment or variant thereof is fused to a polynucleotide encoding the DNA binding domain of the GAL4 protein, the fused nucleotide sequence being inserted in a suitable expression vector, for example pAS2 or pM3.

Then, a human cDNA library is constructed in a specially designed vector, such that the human cDNA insert is fused to a nucleotide sequence in the vector that encodes the transcriptional domain of the GAL4 protein. Preferably, the vector used is the pACT vector. The polypeptides encoded by the nucleotide inserts of the human cDNA library are termed “pray” polypeptides.

A third vector contains a detectable marker gene, such as beta galactosidase gene or CAT gene that is placed under the control of a regulation sequence that is responsive to the binding of a complete Gal4 protein containing both the transcriptional activation domain and the DNA binding domain. For example, the vector pG5EC may be used.

Two different yeast strains are also used. As an illustrative but non limiting example the two different yeast strains may be the following:

Y190, the phenotype of which is (MATa, Leu2-3, 112 ura3-12, trpl-901, his3-D200, ade2-101, gal4Dgal180D URA3 GAL-LacZ, LYS GAL-HIS3, cyh^(r));

Y187, the phenotype of which is (MATa gal4 gal80his3 trpl-901 ade2-101 ura3-52 leu2-3, -112 URA3 GAL-lacZmet⁻), which is the opposite mating type of Y190.

Briefly, 20 μg of pAS2/TBC-1 and 20 μg of pACT-cDNA library are co-transformed into yeast strain Y190. The transformants are selected for growth on minimal media lacking histidine, leucine and tryptophan, but containing the histidine synthesis inhibitor 3-AT (50 mM). Positive colonies are screened for beta galactosidase by filter lift assay. The double positive colonies (His⁺, beta-gal⁺) are then grown on plates lacking histidine, leucine, but containing tryptophan and cycloheximide (10 mg/ml) to select for loss of pAS2/TBC-1 plasmids but retention of pACT-cDNA library plasmids. The resulting Y190 strains are mated with Y187 strains expressing TBC-1 or non-related control proteins; such as cyclophilin B, lamin, or SNF1, as Gal4 fusions as described by Harper et al. (1993) and by Bram et al. (1993), and screened for beta galactosidase by filter lift assay. Yeast clones that are beta gal- after mating with the control Gal4 fusions are considered false positives.

In another embodiment of the two-hybrid method according to the invention, the interaction between TBC-1 or a fragment or variant thereof with cellular proteins may be assessed using the Matchmaker Two Hybrid System 2 (Catalog No. K 1604-1, Clontech). ). As described in the manual accompanying the Matchmaker Two Hybrid System 2 (Catalog No. K1604-1, Clontech), the disclosure of which is incorporated herein by reference, nucleic acids encoding the TBC-1 protein or a portion thereof, are inserted into an expression vector such that they are in frame with DNA encoding the DNA binding domain of the yeast transcriptional activator GAL4. A desired cDNA, preferably human cDNA, is inserted into a second expression vector such that they are in frame with DNA encoding the activation domain of GAL4. The two expression plasmids are transformed into the yeast cells and the yeast cells are plated on selection medium which selects for expression of selectable markers on each of the expression vectors as well as GAL4 dependent expression of the HIS3 gene. Transformants capable of growing on medium lacking histidine are screened for GAL4 dependent lacZ expression. Those cells which are positive in both the histidine selection and the lacZ assay are those in which an interaction between TBC-1 and the protein or peptide encoded by the initially selected cDNA insert has taken place.

Method for Screening Ligands that Modulate the Expression of the TBC-1 Gene

Another subject of the present invention is a method for screening molecules that modulate the expression of the TBC-1 protein. Such a screening method comprises the steps of:

a) cultivating a prokaryotic or an eukaryotic cell that has been transfected with a nucleotide sequence encoding the TBC-1 protein, operably linked to a TBC-1 5′-regulatory sequence;

b) bringing into contact the cultivated cell with a molecule to be tested;

c) quantifying the expression of the TBC-1 protein.

Using DNA recombination techniques well known by the one skill in the art, the TBC-1 protein encoding DNA sequence is inserted into an expression vector, downstream from a TBC-1 5′-regulatory sequence that contains a TBC-1 promoter sequence.

The quantification of the expression of the TBC-1 protein may be realized either at the mRNA level or at the protein level. In the latter case, polyclonal or monoclonal antibodies may be used to quantify the amounts of the TBC-1 protein that have been produced, for example in an ELISA or a RIA assay.

In a preferred embodiment, the quantification of the TBC-1 mRNAs is realized by a quantitative PCR amplification of the cDNAs obtained by a reverse transcription of the total mRNA of the cultivated TBC-1-transfected host cell, using a pair of primers specific for TBC-1.

Expression levels and patterns of TBC-1 may be analyzed by solution hybridization with long probes as described in International Patent Application No. WO 97/05277, the entire contents of which are incorporated herein by reference. Briefly, the TBC-1 cDNA or the TBC-1 genomic DNA described above, or fragments thereof, is inserted at a cloning site immediately downstream of a bacteriophage (T3, T7 or SP6) RNA polymerase promoter to produce antisense RNA. Preferably, the TBC-1 insert comprises at least 100 or more consecutive nucleotides of the genomic DNA sequence or the cDNA sequences, particularly those comprising one of the nuceotide sequences of SEQ ID Nos 3, 4 and 6-8 or those encoding a mutated TBC-1. The plasmid is linearized and transcribed in the present of ribonucleotides comprising modified ribonucleotides (i.e. biotin-UTP and DIG-UTP). An excess of this doubly labeled RNA is hybridized in solution with mRNA isolated from cells or tissues of interest The hybridizations are performed under standard stringent conditions (40-50° C. for 16 hours in an 80% formamide, 0.4 M NaCl buffer, pH 7-8). The unhybridized probe is removed by digestion with ribonucleases specific for single-stranded RNA (i.e. RNases CL3, T1, Phy M, U2 or A). The presence of the biotin-UTP modification enables capture of the hybrid on a microtitration plate coated with streptavidin. The presence of the DIG modification enables the hybrid to be detected and quantified by ELISA using an anti-DIG antibody coupled to alkaline phosphatase.

Quantitative analysis of TBC-1 gene expression may also be performed using arrays. As used herein, the term array means a one dimensional, two dimensional, or multidimensional arrangement of a plurality of nucleic acids of sufficient length to permit specific detection of expression of mRNAs capable of hybridizing thereto. For example, the arrays may contain a plurality of nucleic acids derived from genes whose expression levels are to be assessed. The arrays may include the TBC-1 genomic DNA, the TBC-1 cDNA sequences or the sequences complementary thereto or fragments thereof, particularly those comprising at least one of the biallelic markers according the present invention. Preferably, the fragments are at least 15 nucleotides in length. In other embodiments, the fragments are at least 25 nucleotides in length In some embodiments, the fragments are at least 50 nucleotides in length More preferably, the fragments are at least 100 nucleotides in length. In another preferred embodiment, the fragments are more than 100 nucleotides in length. In some embodiments the fragments may be more than 500 nucleotides in length.

For example, quantitative analysis of TBC-1 gene expression may be performed with a complementary DNA microarray as described by Schena et al. (1995). Full length TBC-1 cDNAs or fragments thereof are amplified by PCR and arrayed from a 96well microtiter plate onto silylated microscope slides using high-speed robotics. Printed arrays are incubated in a humid chamber to allow rehydration of the array elements and rinsed, once in 0.2% SDS for 1 min, twice in water for 1 min and once for 5 min in sodium borohydride solution. The ways are submerged in water for 2 min at 95° C., transferred into 0.2% SDS for 1 min, rinsed twice with water, air dried and stored in the dark at 25° C.

Cell or tissue mRNA is isolated or commercially obtained and probes are prepared by a single round of reverse transcription. Probes are hybridized to 1 cm² microarrays under a 14×14 mm glass coverslip for 6-12 hours at 60° C. Arrays are washed for 5 min at 25° C. in low stringency wash buffer (1×SSC/0.2% SDS), then for 10 min at room temperature in high stringency wash buffer (0.1×SSC/0.2% SDS). Arrays are scanned in 0.1×SSC using a fluorescence laser scanning device fitted with a custom filter set. Accurate differential expression measurements are obtained by taking the average of the ratios of two independent hybridizations.

Quantitative analysis of TBC-1 gene expression may also be performed with full length TBC-1 cDNAs or fragments thereof in complementary DNA arrays as described by Pietu et al. (1996). The full length TBC-1 cDNA or fragments thereof is PCR amplified and spotted on membranes. Then, mRNAs originating from various tissues or cells are labeled with radioactive nucleotides. After hybridization and washing in controlled conditions, the hybridized mRNAs are detected by phospho-imaging or autoradiography. Duplicate experiments are performed and a quantitative analysis of differentially expressed mRNAs is then performed.

Alternatively, expression analysis using the TBC-1 genomic DNA, the TBC-1 cDNAs, or fragments thereof can be done through high density nucleotide arrays or chips as described by Lockhart et al. (1996) and Sosnowsky et al. (1997). Oligonucleotides of 15-50 nucleotides from the sequences of the TBC-1 genomic DNA, the TBC-1 cDNA sequences particularly those comprising at least one of biallelic markers according the present invention, preferably at least one of SEQ ID No 7-8 or those comprising the trait causing mutation, or the sequences complementary thereto, are synthesized directly on the chip (Lockhart et al., supra) or synthesized and then addressed to the chip (Sosnowski et al., supra). Preferably, the oligonucleotides are about 20 nucleotides in length.

TBC-1 cDNA probes labeled with an appropriate compound, such as biotin, digoxigenin or fluorescent dye, are synthesized from the appropriate mRNA population and then randomly fragmented to an average size of 50 to 100 nucleotides. The said probes are then hybridized to the chip. After washing as described in Lockhart et al., supra and application of different electric fields (Sosnowsky et al., 1997)., the dyes or labeling compounds are detected and quantified. Duplicate hybridizations are performed. Comparative analysis of the intensity of the signal originating from cDNA probes on the same target oligonucleotide in different cDNA samples indicates a differential expression of TBC-1 mRNAs.

Thus, is also part of the present invention a method for screening of a candidate substance or molecule that modulates the expression of the TBC-1 gene according to the invention, wherein this method comprises the following steps:

a) providing a recombinant cell host containing a nucleic acid, wherein said nucleic acid comprises the 5′ regulatory region sequence or a biologically active fragment or variant thereof, the 5′ regulatory region or its biologically active fragment or variant being operably linked to a polynucleotide encoding a detectable protein;

b) obtaining a candidate substance, and

c) determining the ability of the candidate substance to modulate the expression levels of the polynucleotide encoding the detectable protein.

In a preferred embodiment of the above screening method, the nucleic acid comprising the 5′ regulatory region sequence or a biologically active fragment or variant thereof also includes a 5′UTR region of one of the TBC-1 cDNAs of SEQ ID Nos 3 and 4, or one of their biologically active fragments or variants thereof.

A second method for the screening of a candidate substance or molecule that modulates the expression of the TBC-1 gene comprises the following steps:

a) providing a recombinant cell host containing a nucleic acid, wherein said nucleic acid comprises a 5′UTR sequence of one of the TBC-1 cDNAs of SEQ ID Nos 3 and 4, or one of their biologically active fragments or variants, the 5′UTR sequence or its biologically active fragment or variant being operably linked to a polynucleotide encoding a detectable protein;

b) obtaining a candidate substance, and

c) determining the ability of the candidate substance to modulate the expression levels of the polynucleotide encoding the detectable protein.

In a preferred embodiment of the screening method described above, the nucleic acid that comprises a nucleotide sequence selected from the group consisting of the 5′UTR sequence of one of the TBC-1 cDNAs of SEQ ED Nos 3 and 4 or one of their biologically active fragments or variants, includes a promoter sequence, wherein said promoter sequence can be either endogenous, or in contrast exogenous with respect to the TBC-1 5′UTR sequences defined therein.

Among the preferred polynucleotides encoding a detectable protein, there may be cited polynucleotides encoding beta galactosidase, green fluorescent protein (GFP) and chloramphenicol ace transferase (CAT).

For the design of suitable recombinant vectors useful for performing the screening methods described above, it will be referred to the section of the present specification wherein the preferred recombinant vector of the invention are detailed.

Screening Using Transgenic Animals

In vivo methods can utilize transgenic animals for drug screening. Nucleic acids including at least one of the biallelic polymorphisms of interest can be used to generate genetically modified non-human animals or to generate site specific gene modifications in cell lines. The term “transgenic” is intended to encompass genetically modified animals having a deletion or other knock-out of TBC-1 gene activity, having an exogenous TBC-1 gene that is stably transmitted in the host cells, or having an,exogenous TBC-1 promoter operably linked to a reporter gene. Transgenic animals may be made through homologous recombination, where the TBC-1 locus is altered Alternatively, a nucleic acid construct is randomly integrated into the genome. Vectors for stable integration include for example plasmids, retroviruses and other animal viruses, and YACs. Of interest are transgenic mammals e.g. cows, pigs, goats, horses, and particularly rodents such as rats and mice. Transgenic animals allow to study both efficacy and toxicity of the candidate drug.

Methods for Inhibiting the Expression of a TBC-1 Gene

Other therapeutic compositions according to the present invention comprise advantageously an oligonucleotide fragment of the nucleic sequence of TBC-1 as an antisense tool that inhibits the expression of the corresponding TBC-1 gene. Preferred methods using antisense polynucleotide according to the present invention are the procedures described by Sczakiel et al. (1995).

Preferably, the antisense tools are chosen among the polynucleotides (15-200 bp long) that are complementary to the 5′end of the TBC-1 mRNA. In another embodiment, a combination of different antisense polynucleotides complementary to different parts of the desired targetted gene are used.

Preferred antisense polynucleotides according to the present invention arm complementary to a sequence of the mRNAs of TBC-1 that contains the translation initiation codon ATG.

The antisense nucleic acid molecules to be used in gene therapy may be either DNA or RNA sequences. They comprise a nucleotide sequence complementary to the targeted sequence of the PTCA-1 genomic DNA, the sequence of which can be determined using one of the detection methods of the present invention. The targeted DNA or RNA sequence preferably comprises at least one of the biallelic markers according to the present invention. The antisense nucleic acids should have a length and melting temperature sufficient to permit formation of an intracellular duplex having sufficient stability to inhibit the expression of the TBC-1 mRNA in the duplex. Strategies for designing antisense nucleic acids suitable for use in gene therapy are disclosed in Green et al., (1986) and Izant and Weintraub, (1984), the disclosures of which are incorporated herein by reference.

In some strategies, antisense molecules are obtained by reversing the orientation of the TBC-1 coding region with respect to a promoter so as to transcribe the opposite strand from that which is normally transcribed in the cell. The antisense molecules may be transcribed using in vitro transcription systems such as those which employ T7 or SP6 polymerase to generate the transcript. Another approach involves transcription of TBC-1 antisense nucleic acids in vivo by operably linking DNA containing the antisense sequence to a promoter in a suitable expression vector.

Alternatively, suitable antisense strategies are those described by Rossi et al. (1991), in the International Applications Nos. WO 94/23026, WO 95/04141, WO 92/18522 and in the European Patent Application No. EP 0 572 287 A2

An alternative to the antisense technology that is used according to the present invention consists in using ribozymes that will bind to a target sequence via their complementary polynucleotide tail and that will cleave the corresponding RNA by hydrolyzing its target site (namely <<hammerhead ribozymes>>). Briefly, the simplified cycle of a hammerhead ribozyme consists of (1) sequence specific binding to the target RNA via complementary antisense sequences; (2) site-specific hydrolysis of the cleavable motif of the target strand; and (3) release of cleavage products, which gives rise to another catalytic cycle. Indeed, the use of long-chain antisense polynucleotide (at least 30 bases long) or ribozymes with long antisense arms are advantageous. A preferred delivery system for antisense ribozyme is achieved by covalently linking these antisense ribozymes to lipophilic groups or to use liposomes as a convenient vector. Preferred antisense ribozymes according to the present invention are prepared as described by Sczakiel et al. (1995), the specific preparation procedures being referred to in said article being herein incorporated by reference.

Throughout this application, various publications, patents and published patent applications are cited. The disclosures of these publications, patents and published patent specification referenced in this application are hereby incorporated by reference into the present disclosure to more fully describe the sate of the art to which this invention pertains.

EXAMPLES Example 1 Analysis of the First mRNA encoding a TBC-1 Polypeptide Synthesized by the Cells

TBC-1 cDNA was obtained as follows: 4 μl of ethanol suspension containing 1 mg of human prostate total RNA (Clontech laboratories, Inc., Palo Alto, USA; Catalogue N. 64038-1) was centrifuged, and the resulting pellet was air dried for 30 minutes at room temperature.

First strand cDNA synthesis was performed using the AdvantageTM RT-for-PCR kit (Clontech laboratories Inc., catalogue N. K1402-1). 1 μl of 20 mM solution of a specific oligo dT primer was added to 12.5 μl of RNA solution in water, heated at 74° C. for 2.5 min and rapidly quenched in an ice bath. 10 μl of 5×RT buffer (50 mM Tris-HCl, pH 8.3, 75 mM KCl, 3 mM MgCl₂), 2.5 μl of dNTP mix (10 mM each), 1.25 μl of human recombinant placental RNA inhibitor were mixed with 1 ml of MMLV reverse transcriptase (200 units). 6.5 μl of this solution were added to RNA-primer mix and incubated at 42° C. for one hour. 80 μl of water were added and the solution was incubated at 94° C. for 5 minutes.

5 μl of the resulting solution were used in a Long Range PCR reaction with hot start, in 50 μl final volume, using 2 units of rtTHXL, 20 pmol/μl of each of 5′-TGACCACCATGCCCATGCT-3′ (271-289 in SEQ ID No 3) and 5′-GCATTTATTCACGTCCACGCC-3′ (3929-3949 in SEQ ID No 3) primers with 35 cycles of elongation for 6 minutes at 67° C. in thermocycler.

The amplification products corresponding to both cDNA strands were partially sequenced in order to ensure the specificity of the amplification reaction.

Results of Nothern blot analysis of prostate mRNAs supported the existence of the first TBC-1 cDNA having about 4 kb in length, which is the nucleotide sequence of SEQ ID No 3.

Example 2 Detection of TBC-1 Biallelic Markers: DNA Extraction

Donors were unrelated and healthy. They presented a sufficient diversity for being representative of a French heterogeneous population. The DNA from 100 individuals was extracted and tested for the detection of the biallelic markers.

30 ml of peripheral venous blood were taken from each donor in the presence of EDTA. Cells (pellet) were collected after centrifugation for 10 minutes at 2000 rpm. Red cells were lysed by a lysis solution (50 ml final volume: 10 mM Tris pH7.6; 5 mM MgCl₂; 10 mM NaCl). The solution was centrifuged (10 minutes, 2000 rpm) as many times as necessary to eliminate the residual red cells present in the supernatant, after resuspension of the pellet in the lysis solution.

The pellet of white cells was lysed overnight at 42° C. with 3.7 ml of lysis solution composed of:

3 ml TE 10-2 (Tris-HCl 10 mM, EDTA 2 mM)/NaCl 0.4 M

200 μl SDS 10%

500 μl K-proteinase (2 mg K-proteinase in TE 10-2/NaCl 0.4 M).

For the extraction of proteins, 1 ml saturated NaCl (6M) (1/3.5 v/v) was added. After vigorous agitation, the solution was centrifuged for 20 minutes at 10000 rpm.

For the precipitation of DNA, 2 to 3 volumes of 100% ethanol were added to the previous supernatant, and the solution was centrifuged for 30 minutes at 2000 rpm. The DNA solution was rinsed three times with 70% ethanol to eliminate salts, and centrifuged for 20 minutes at 2000 rpm. The pellet was dried at 37° C., and resuspended in 1 ml TE 10-1 or 1 ml water. The DNA concentration was evaluated by measuring the OD at 260 nm (1 unit OD=50 μl/ml DNA).

To determine the presence of proteins in the DNA solution, the OD 260/OD 280 ratio was determined. Only DNA preparations having a OD 260/OD 280 ratio between 1.8 and 2 were used in the subsequent examples described below.

The pool was constituted by mixing equivalent quantities of DNA from each individual.

Example 3 Detection of the Biallelic Markers: Amplification of Genomic DNA by PCR

The amplification of specific genomic sequences of the DNA samples of example 2 was carried out on the pool of DNA obtained previously. In addition, 50 individual samples were similarly amplified.

PCR assays were performed using the following protocol:

Final volume 25 μl DNA 2 ng/μl MgCl₂ 2 mM dNPT (each) 200 μM primer (each) 2.9 ng/μl Ampli Taq Gold DNA polymerase 0.05 unit/μl PCR buffer (10× = 0.1M TrisHCl 1× pH 8.3 0.5M KCl

Each pair of first primers was designed using the sequence information of the TBC-1 gene disclosed herein and the OSP software (Hillier & Green, 1991). This first pair of primers was about 20 nucleotides in length and had the sequences disclosed in Table 1 in the columns labeled PU and RP.

TABLE 1 Complementary Position position Position range of range of range of the amplification amplification amplicon in Primer primer in Primer primer in Amplicon SEQ ID 1 name SEQ ID No 1 name SEQ ID No 1 99-430 9391 9845 B1  9391 9408 C1  9828 9845 Complementary Position position Position range of range of range of the amplification amplification amplicon in Primer primer in Primer primer in Amplicon SEQ ID 2 name SEQ ID No 2 name SEQ ID No 2 99-20508 988 1529 B2  988 1006 C2  1509 1529 99-20469 5039 5554 B3  5039 5056 C3  5534 5554  5-254 5997 6350 B4  5997 6015 C4  6332 6350  5-257 14371 14817 B5  14371 14390 C5  14798 14817 99-20511 18751 19217 B6  18751 18771 C6  19198 19217 99-20510 19605 20005 B7  19605 19625 C7  19986 20005 99-20504 29529 30061 B8  29529 29547 C8  30041 30061 99-20493 42268 42752 B9  42268 42287 C9  42732 42752 99-20499 69026 69543 B10 69026 69046 C10 69525 69543 99-20473 76323 76790 B11 76323 76343 C11 76771 76790  5-249 78292 78721 B12 78292 78309 C12 78704 78721 99-20485 81893 82372 B13 81893 81912 C13 82353 82372 99-20481 84392 84929 B14 84392 84412 C14 84909 84929 99-20480 89746 90198 B15 89746 89765 C15 90179 90198

Preferably, the primers contained a common oligonucleotide tail upstream of the specific bases targeted for amplification which was useful for sequencing.

Primers PU contain the following additional PU 5′ sequence: TGTAAAACGACGGCCAGT (SEQ ID No 6); primers RP contain the following RP 5′ sequence: CAGGAAACAGCTATGACC (SEQ ID No 7).

The synthesis of these primers was performed following the phosphoramidite method, on a GENSET UFPS 24.1 synthesizer.

DNA amplification was performed on a Genius II thermocycler. After heating at 95° C. for 10 min, 40 cycles were performed. Each cycle comprised: 30 sec at 95° C., 54° C. for 1 min, and 30 sec at 72° C. For final elongation, 10 min at 72° C. ended the amplification. The quantities of the amplification products obtained were determined on 96well microtiter plates, using a fluorometer and Picogreen as intercalant agent (Molecular Probes).

Example 4 Detection of the Biallelic Markers: Sequencing of Amplified Genomic DNA and Identification of Polymorphisms

The sequencing of the amplified DNA obtained in example 3 was carried out on ABI 377 sequencers. The sequences of the amplification products were determined using automated dideoxy terminator sequencing reactions with a dye terminator cycle sequencing protocol. The products of the sequencing reactions were run on sequencing gels and the sequences were determined using gel image analysis [ABI Prism DNA Sequencing Analysis software (2.1.2 version)].

The sequence data were further evaluated to detect the presence of biallelic markers among the pooled amplified fragments. The polymorphism search was based on the presence of superimposed peaks in the electrophoresis pattern resulting from different bases occurring at the same position as described previously.

15 fragments of amplification was analyzed. In this segment, 19 biallelic markers were detected. The localization of the biallelic marker is as shown in Table 2.

TABLE 2 Localization Polymorphism BM position in Amplicon BM Marker Name in TBC-1 gene Allele 1 allele 2 SEQ ID No 1 99-430 A1  99-430-352 Intron 1 A G 9494 Localization Polymorphism BM position in Amplicon BM Marker Name in TBC-1 gene allele 1 allele 2 SEQ ID No 1 99-20508 A2  99-20508-456 Intron C T 1443 upstream to Exon A 99-20469 A3  99-20469-213 Intron A C T 5247  5-254 A4   5-254-227 Intron B A G 6223  5-257 A5   5-257-353 Intron D C T 14723 99-20511 A6  99-20511-32 Intron D C T 19186 99-20511 A7  99-20511-221 Intron D A G 18997 99-20510 A8  99-20510-115 Intron D deletion of 19891 TCT 99-20504 A9  99-20504-90 Intron D A G 29617 99-20493 A10 99-20493-238 Intron D A C 42519 99-20499 A11 99-20499-221 Intron G A G 69324 99-20499 A12 99-20499-364 Intron G A T 69181 99-20499 A13 99-20499-399 Intron G A G 69146 99-20473 A14 99-20473-138 Intron H deletion of 76458 TAACA  5-249 A15  5-249-304 Intron I A G 78595 99-20485 A16 99-20485-269 Intron I A G 82159 99-20481 A17 99-20481-131 Intron I G C 84522 99-20481 A18 99-20481-419 Intron I A T 84810 99-20480 A19 99-20480-233 Intron J A G 89967 BM refers to “biallelic marker”. All1 and all2 refer respectively to allele 1 and allele 2 of the biallelic marker.

TABLE 3 Position range of probes in BM Marker Name SEQ ID No 1 Probes A1 99-430-352 9482 9506 P1  Position range of probes in BM Marker Name SEQ ID No 2 Probes A2 99-20508-456 1431 1455 P2  A3 99-20469-213 5235 5259 P3  A4  5-254-227 6211 6235 P4  A5  5-257-353 14711 14735 P5  A6 99-20511-32 19174 19198 P6  A7 99-20511-221 18985 19009 P7  A9 99-20504-90 29605 29629 P9  A10 99-20493-238 42507 42531 P10 A11 99-20499-221 69312 69336 P11 A12 99-20499-364 69169 69193 P12 A13 99-20499-399 69134 69158 P13 A15  5-249-304 78583 78607 P15 A16 99-20485-269 82147 82171 P16 A17 99-20481-131 84510 84534 P17 A18 99-20481-419 84798 84822 P18 A19 99-20480-233 89955 89979 P19

Example 5

Validation of the Polymorphisms Through Microsequencing

The biallelic markers identified in example 4 were further confirmed and their respective frequencies were determined through microsequencing. Microsequencing was carried out for each individual DNA sample described in Example 2.

Amplification from genomic DNA of individuals was performed by PCR as described above for the detection of the biallelic markers with the same set of PCR primers (Table 1).

The preferred primers used in microsequencing were about 19 nucleotides in length and hybridized just upstream of tie considered polymorphic base. According to the invention, the primers used in microsequencing are detailed in Table 4.

TABLE 4 Complementary Position range of position range of microsequencing microsequencing Biallelic primer mis 1 in primer mis 2 in Marker Name Marker Mis. 1 SEQ ID No 1 Mis. 2 SEQ ID No 1 99-430-352 A1  D1  9475 9493 E1  9495 9513 Complementary Position range of position range of microsequencing microsequencing Biallelic primer mis 1 in primer mis 2 in Marker Name Marker Mis. 1 SEQ ID No 2 Mis. 2 SEQ ID No 2 99-20508-456 A2  D2  1424 1442 E2  1444 1462 99-20469-213 A3  D3  5228 5246 E3  5248 5266  5-254-227 A4  D4  6204 6222 E4  6224 6242  5-257-353 A5  D5  14704 14722 E5  14724 14742 99-20511-32 A6  D6  19167 19185 E6  19187 19205 99-20511-221 A7  D7  18978 18996 E7  18998 19016 99-20510-115 A8  D8  19872 19890 E8  19892 19910 99-20504-90 A9  D9  29598 29616 E9  29618 29636 99-20493-238 A10 D10 42500 42518 E10 42520 42538 99-20499-221 A11 D11 69305 69323 E11 69325 69343 99-20499-364 A12 D12 69162 69180 E12 69182 69200 99-20499-399 A13 D13 69127 69145 E13 69147 69165 99-20473-138 A14 D14 76439 76457 E14 76459 76477  5-249-304 A15 D15 78576 78594 E15 78596 78614 99-20485-269 A16 D16 82140 82158 E16 82160 82178 99-20481-131 A17 D17 84503 84521 E17 84523 84541 99-20481-419 A18 D18 84791 84809 E18 84811 84829 99-20480-233 A19 D19 89948 89966 E19 89968 89986

The microsequencing reaction was performed as follows:

After purification of the amplification products, the microsequencing reaction mixture was prepared by adding, in a 20 μl final volume: 10 pmol microsequencing oligonucleotide, 1 U Thermosequenase (Amersham E79000G), 1.25 μl Thermosequenase buffer (260 mM Tris HCl pH 9.5, 65 mM MgCl₂), and the two appropriate fluorescent ddNTPs (Perkin Elmer, Dye Terminator Set 401095) complementary to the nucleotides at the polymorphic site of each biallelic marker tested, following the manufacturer's recommendations. After 4 minutes at 94° C., 20 PCR cycles of 15 sec at 55° C., 5 sec at 72° C., and 10 sec at 94° C. were carried out in a Tetrad PTC-225 thermocycler (MJ Research). The unincorporated dye terminators were then removed by ethanol precipitation. Samples were finally resuspended in formamide-EDTA loading buffer and heated for 2 min at 95° C. before being loaded on a polyacrylamide sequencing gel. The data were collected by an ABI PRISM 377 DNA sequencer and processed using the GENESCAN software (Perkin Elmer).

Following gel analysis, data were automatically processed with software that allows the determination of the alleles of biallelic markers present in each amplified fragment.

The software evaluates such factors as whether the intensities of the signals resulting from the above microsequencing procedures are weak, normal, or saturated, or whether the signals are ambiguous. In addition, the software identifies significant peaks (according to shape and height criteria). Among the significant peaks, peaks corresponding to the targeted site are identified based on their position. When two significant peaks are detected for the same position, each sample is categorized classification as homozygous or heterozygous type based on the height ratio.

REFERENCES

Altschul et al., 1990, J. Mol. Biol. 215(3):403-410/Altschul et al., 1993, Nature Genetics 3:266-272/Altschul et al., 1997, Nuc. Acids Res. 25:3389-3402/Ausubel et al. (1989)Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y./Beaucage et al., Tetrahedron Lett 1981, 22: 1859-1862/Bram R J et al., 1993, Mol. Cell Biol., 13: 4760-4769./Brown E L, Belagaje R, Ryan M J, Khorana H G, Methods Enzymol 1979;68:109-151/Castagnoli L. et al. (Felici F.), 1991, J. Mol. Biol., 222:301-310/Chai H. et al., 1993, Biotechnol. Appl. Biochem., 18:259-273/Chee et al. (1996) Science. 274:610-614./Chen and Kwok Nucleic Acids Research 25:347-353 1997/Chen et al. Proc. Natl. Acad. Sci. USA 94/20 10756-10761, 1997/Cho R J et al., 1998, Proc. Natl. Acad. Sci. USA, 95(7): 3752-3757./Chumakov I. et al., 1995, Nature. 377(6547 Suppl): 175-297./Compton J. (1991) Nature. 350(6313):91-92./Dib et al., 1996, Nature, 380: III-V./Ellis N A,1997 Curr.Op.Genet.Dev., 7: 354-363/Feldman and Steg, 1996, Medecine/Sciences, synthese, 12:47-55/Fields and Song, 1989, Nature, Vol. 340: 245-246./Fishel R & Wilson T. 1997, Curr.Op.Genet.Dev.7: 105-113/Flotte et al., 1992, Am. J. Respir. Cell Mol. Biol., 7: 349-356./Fodor et al. (1991) Science 251:767-777./Fromont-Racine M. et al., 1997, Nature Genetics, 16(3): 277-282./Fuller S. A. et al., 1996, Immunology in Current Protocols in Molecular Biology, Ausubel et al. Eds, John Wiley & Sons, Inc., USA/Geysen H. Mario et al. 1984. Proc. Natl. Acad. Sci. U.S.A. 81:3998-4002/Gonnet et al., 1992, Science 256:1443-1445/Green et al., Ann. Rev. Biochem. 55:569-597 (1986)/Grompe, M. et al., Proc. Natl. Acad. Sci. U.S.A. 1989; 86:5855-5892/Grompe, M. Nature Genetics 1993; 5:111-117/Guatelli J C et al. Proc. Natl. Acad. Sci. USA. 35:273-286./Haber D & Harlow E, 1997, Nature Genet. 16:320-322./Hacia J G, Brody L C, Chee M S, Fodor S P, Collins F S, Nat Genet 996;14(4):441-447/Haff L. A. and Smirnov I. P. (1997) Genome Research, 7:378-388./Hames B. D. and Higgins S. J. (1985) Nucleic Acid Hybridization: A Practical Approach. Hames and Higgins Ed., IRL Press, Oxford./Harju L, et al., Clin Chem 1993;39(11Pt 1):2282-2287/Harper J W et al., 1993, Cell, Vol. 75: 20 805-816./Harris H et al.,1969,Nature 223:363-368./Henikoff and Henikoff, 1993, Proteins 17:49-61/Higgins et al.,1996, Methods Enzymol. 266:383-402/Hillier L. and Green P. Methods Appl., 1991, 1: 124-8./Huang L. et al. (1996) Cancer Res 56(5):1137-1141./Huygen et al., 1996, Nature Medicine, 2(8):893-898/Izant and Weintraub, Cell 36:1007-1015 (1984)/Julan at al., 1992, J. Gen. Virol., 73: 3251-3255./Karlin and Altschul, 1990, Proc. Natl. Acad. Sci. USA 87:2267-2268/Koch Y., 1977, Biochem. Biophys. Res. Commun., 74:488-491/Kohler G. and Milstein C., 1975, Nature, 256: 495./Kozal M J, et al., Nat Med 1996;2(7):753-759/Landegren U. et al. (1998) Genome Research, 8:769-776./Leger O J, et al., 1997, Hum Antibodies,8(1): 3-16/Lenhard T. et al., 1996, Gene, 169:187-190/Livak et al., Nature Genetics, 9:341-342, 1995/Livak K J, and Hainer J W., 1994, Hum Mutat., 3(4): 379-385./Lockhart et al. Nature Biotechnology 14: 1675-1680, 1996/Lucas A. H., 1994, In: Development and Clinical Uses of Haempophilus b Conjugate./Mansour S L et al., 1988, Nature, 336: 348-352./Marshall R. L. et al. (1994) PCR Methods and Applications. 4:80-84./Martineau P, Jones P, Winter G, 1998, J Mol Biol, 280(1):117-127/Mc Whorter W. P., et al. A screening study of prostate cancer in high risk families. J Urol 1992;148:826-828./McLaughlin et al., 1989, J. Virol., 62: 1963-1973./Muzyczka et al., 1992, Cuur. Topics in Micro. and Immunol., 158: 97-129./Narang S A, Hsiung H M, Brousseau R, Methods Enzymol 1979;68:90-98/Neda et al., 1991, J. Biol. Chem.,266: 14143-14146./Nickerson D. A. et al. (1990) Proc. Natl. Acad. Sci. U.S.A. 87:8923-8927./Nyren P. Pettersson B. Uhlen M, Anal Biochem 1993;208(1):171-175/O'Reilly et al., 1992, Baculovirus expression vectors: a Laboratory Manual. W. H. Freeman and Co., New York/Ohno et al., 1994, Sciences, 265:781-784/Oldenburg K. R. et al., 1992, Proc. Natl. Acad. Sci., 89:5393-5397./Orita et al., Proc. Natl. Acad. Sci. U.S.A. 1989;86: 2776-2770/Parmley and Smith, Gene, 1988, 73:305-318./Pastinen et al., Genome Research 1997; 7:606-614/PCR Methods and Applications”, 1991, Cold Spring Harbor Laboratory Press./Pearson and Lipman, 1988, Proc. Natl. Acad. Sci. USA 85(8):2444-2448/Pietu et al. Genome Research 6:492-503, 1996/Porath J et al., 1975, Nature, 258(5536): 598-599./Reimann K A, et al., 1997, AIDS Res Hum Retroviruses. 13(11): 933-943/Ridder R, et al., 1995, Biotechnology (N Y), 13(3):255-260/Rossi et al., Pharmacol. Ther. 50:245-254, (1991)/Roth J. A. et al., 1996, Nature Medicine, 2(9):985-991/Rougeot, C. et al., Eur. J. Biochem. 219 (3): 765-773, 1994/Roux et al., 1989, Proc. Natl. Acad. Sci. USA, 86: 9079-9083./Sambrook, et al. 1989. Molecular cloning: a laboratory manual. 2ed. Cold Spring Harbor Laboratory, Cold spring Harbor, New York./Samson M, et al. (1996) Nature, 382(6593):722-725./Samulski et al., 1989, J. Virol., 63: 3822-3828./Sanchez-Pescador R., 1988, J. Clin. Microbiol., 26(10):1934-1938/Sandou et al., 1994, Science, 265: 1875-1878./Schena et al. Science 270:467-470, 1995/Schwartz and Dayhoff, eds., 1978, Matrices for Detecting Distance Relationships: Atlas of Protein Sequence and Structure, Washington: National Biomedical Research Foundation/Sczakiel G. et al., 1995, Trends Microbiol., 1995, 3(6):213-217/Sheffield, V. C. et al, Proc. Natl. Acad. Sci. U.S.A 1991; 49:699-706/Shoemaker D D, et al., Nat Genet 1996;14(4):450-456/Smith et al., 1983, Mol. Cell. Biol., 3:2156-2165./Sosnowski R G, et al., Proc Natl Acad Sci USA 1997;94:1119-1123/Steinberg G. D., et al. Family history and the risk of prostate cancer, The prostate 1990;17,337-347./Stryer, L., Biochemistry, 4th edition, 1995/Syvanen A C, et al., 1994, Hum Mutat, 3(3): 172-179./Tacson et al., 1996, Nature Medicine, 2(8):888-892./Thompson et al., 1994, Nucleic Acids Res. 22(2):4673-4680/Tyagi et al. (1998) Nature Biotechnology. 16:49-53./Urdea M. S., 1988, Nucleic Acids Research, 11: 4937-4957/Urdea M S et al., 1991, Nucleic Acids Symp Ser., 24: 197-200./Valadon P., et al., 1996. J. Mol. Biol., Vol. 261:11-22./Vaughan T J, et al., 1996, Nat Biotechnol. 14(3): 309-314/Vlasak R. et al., 1983, Eur. J. Biochem., 135:123-126/Wabiko et al., 1986, DNA, 5(4):305-314./Walker et al. (1996) Clin. Chem. 42:9-13./Wersterink M. A. J., 1995, Proc. Natl. Acad. Sci., 92:4021-4025./White, M. B. et al. (1992) Genomics. 12:301-306./White, M. B. et al. (1997) Genomics. 12:301-306./Wilson R. et al., 1994, Nature, 368(6466): 32-38./Zhang S D et al., 1996, Genes and development, 10: 1108-1119.

SEQUENCE LISTING FREE TEXT

The following free text appears in the accompanying Sequence Listing:

5′ regulatory region

polymorphic base

complement

3′ regulatory region

deletion of

or

probe

homology with Genset 5′ EST in ref

sequencing oligonucleotide PrimerPU

sequencing oligonucleotide PrimerRP

SEQUENCE LISTING <160> NUMBER OF SEQ ID NOS: 7 <210> SEQ ID NO 1 <211> LENGTH: 17590 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: misc_feature <222> LOCATION: 1..2000 <223> OTHER INFORMATION: 5′ regulatory region <221> NAME/KEY: exon <222> LOCATION: 2001..2077 <223> OTHER INFORMATION: exon 1 <221> NAME/KEY: exon <222> LOCATION: 12292..12373 <223> OTHER INFORMATION: exon 1b <221> NAME/KEY: exon <222> LOCATION: 12740..13249 <223> OTHER INFORMATION: exon 2 <221> NAME/KEY: allele <222> LOCATION: 9494 <223> OTHER INFORMATION: 99-430-352 : polymorphic base A or G <221> NAME/KEY: primer_bind <222> LOCATION: 9391..9408 <223> OTHER INFORMATION: 99-430.rp <221> NAME/KEY: primer_bind <222> LOCATION: 9828..9845 <223> OTHER INFORMATION: 99-430.pu complement <221> NAME/KEY: primer_bind <222> LOCATION: 9475..9493 <223> OTHER INFORMATION: 99-430-352.mis <221> NAME/KEY: primer_bind <222> LOCATION: 9495..9513 <223> OTHER INFORMATION: 99-430-352.mis complement <221> NAME/KEY: primer_bind <222> LOCATION: 9482..9506 <223> OTHER INFORMATION: 99-430-352.probe <221> NAME/KEY: misc_feature <222> LOCATION: 3953,4056,4167,4739,6217,6245,6860,9998..9999,10006, 10012,10104,10477,10822,10825,11095,11256,11273,11857..11858, 11895..11896,14057,15912..15913,16217..16218,16329..16330,17504 <223> OTHER INFORMATION: n=a, g, c or t <400> SEQUENCE: 1 aggacagtat ctagcacaat accccaaatc gactaactcc tccgtaaaga atagctacca 60 ctattgtgag agttttaagt caagctgtga ataaaactct tgggtccact taaaaatacc 120 tcccctggat gtaagcatcc agggaaatca gggaatgcca taagacagcc ctaatctaaa 180 agcctacaag aagctcagtg ggcttcaagg aagacactgc tcttggtacg atgaggaaac 240 ctggccctct atttgcctcc tgggccacag taatattgat aatagctgct gcttttagtt 300 gaggaccatg tacgtctgtg tcactgcact ggccacttta cttacacttt cctgctttgt 360 cctcacaaag atcctgtaag gtgtgtattg gtcccattta gcaggtaaga caatgaagac 420 cagaggtcca gcaccttgcc taaaccacac ctgctgggat ttggattcaa gtccaaccgt 480 acagctcaaa cgctcagcca cttccctaaa gtccaccccc agctacatta agtaaaaaaa 540 tccagaaaga tgccacctgg gggtctggaa ctgcctcctc cgagcacccg gctctcccct 600 ccctgcggac tcttctctgg agaggatgtg atgcttctta cttttctcag atccctctcc 660 ccaccctgcg agtgacgttg cgcctctgtg cctggtggga tagggatctg ggagcttcgc 720 ctgttttttg cacactgcca tcccctagtc ttagggagcg agctctgtcc cgcttttcac 780 atctccgcgt ctttccttgc actctacatc accgctggga atgtccccag acctgatcgg 840 ggcatgcaca ctggggtgtg cgtgtgcgtg tggtgtgtgt tcctgcgcgt gtgccgggct 900 cgcggggcag gaaaaagcgc ctaatccagg ctctgcgtca ctcccgcaat tggttagaaa 960 tggagtttcc tggtgtttaa tcccgggagg gcacttcgcc ttcgttgttt cccagagtcc 1020 ctgattttcc tgcctcgcat gccagcgccc catagggcat ccgtgcctca gttcacctct 1080 tgccatcctc caaggacggg gagaaggggt aaggcggggg agagcaaggt ggcttggtcg 1140 cccccggccc ccgcccccca tgttgtgtgc agtttccacc acgtctgttt cggagggaga 1200 agaggagggt gcagatgagg cgaggcgcct tcgggagcgc ggagagcggg caggcagtgc 1260 cacctgctga gagccactca ggccgagcaa gcggcgggca gtgccacctg ctataaatag 1320 gccgccaagg acagggtgtg cgactgtaca tcccgccacg agggcctgca tcacgcgcgg 1380 ggccccgcgc ccccggctcc ccagggaaac gctgtgccca gatcctgcgc aggggtctgg 1440 atggggcggc ggcccgagta cttcccccct attcccccca cagacactgg ctgaggatgg 1500 cccgcgggct tgggggcggg gggtggcaag gaggggaggg aggccgcggc ggacccgcag 1560 tgcagcagct gttgctcgcg tgtgactcgc ccgtccgggc cgtgctgccc aggcacagtc 1620 acacggcgca gtggggagga ggaggacacc gagtccccct cccagctccc cggggaccga 1680 gtggggagat cccggctcct gtcttcccct cgcctccagc gcgctcgccc aggctgggag 1740 gaggaaacca gagccgcgcg cagacacctc ctccttctcc tcctcttctt cctcctcctc 1800 ctcctcctcc tcctcctctt cggctgctgc tcctggtgcc gccaccgtcc gccggtgcct 1860 gttgctgccg ccgccgcggg acctgctgtg tcctcagctg ggtggagaag aggcgggcgc 1920 cgagccgagg ggagccccct ccccgtcccc ccgcggcggg aagagcgcag ccagccgggt 1980 gcgatggact ccccgcccgc ccaggccgtc cccaggatgc ccccaagcac ctgcgcgtcc 2040 cggcccggcc ccgggctctg agcgcgccgc ggcacaggta aggcgcttcc tggggcttcg 2100 tcctggccac cctgctggct cctctcgggg cgtcgcggcc gccccctccc gcagcacgcc 2160 cctgccccgc ctggccgcgg aggggaaggc atctggccgc ccacggacgc gaggccaggg 2220 tctctcgggg gaggaagttc attgccatct cgttgccccc cttacccccc cacccccgcc 2280 gcccttggac gaaagcgaaa ccttaatgtt gctagcgacc cgagagctcc gccggcttct 2340 cccccaaccc ccgccagctc actggtccgc gcatctctcc cctcccccct cccgccaatt 2400 atcctagcgt gtttgcaagg cgaccagatt ggaaagagtg tggtcagagt gaccccaagc 2460 cacgctttaa aagttcaggg tactttgcag tagtaacttt ggcagctcca ccagtgcgcg 2520 caacatttct ttctatgggt acatcctgta ccagtcattt tgaaaccctg cttcattgtt 2580 tctagccgct tcctgatggc tctgtgatta tgagaccccc ctcaaacttc accaggcatt 2640 aaggttttgt ttttgctttt ttttcagaga ggtatcattt cgtttgaaat ccacctagat 2700 gtggcttttc ctgttttgat tttacttaac atagcttatt ctctggaagt tgctttaaaa 2760 agaaattgaa agtgatggtt gttccttcca ccaaacagtt taattttcag ggtgcctcat 2820 attaatggat atgttttccc ttcatagatt tctcattgtt tcccttatga tgggatgatt 2880 tcatttatta ataaaatcag actttgaaag agcatttaaa aatgacctgg tttaaatagg 2940 tcacacccaa gaaactcagc tatctgtaca agttcaaact tctaaacttt ttcaatgagc 3000 taggggtggt ggcacccacc tgtagtccca gctacttggg aggctgaggc aggaggatca 3060 cttgagccca ggagttcgag gccatagtga gctatgactg tgccacctca ctggagcctg 3120 ggtgacaaag tgagatccca tctcttaaaa aaaaagagtt taggggacat tttctgaagt 3180 gaacacaagt agagcattct aacactattg agtgcaagga gacctggaag ggactaagtg 3240 gttcaaagca ggaaataaaa tcatcaggtg ataattaaaa taatttcttt cctgtggatt 3300 tgtccagcca tttgcaaacc aggagaatag gaaaaaaaat cactagtgta gttataaatt 3360 attacattac gttttcaaag gaaaattttg caaatgcgtc tccttgtcat agtctattgt 3420 tatctacccc actgagagtg ctggggcttc cccttttcac cacgacagca tttctggttg 3480 ggtggcagtc atgcagtgtt gacctggtgt cccataaggc acagtttgtc aaaacactag 3540 tgggtattag gaggaaacgt gcaactctga agcaacagag cttgcccctt cttcctcatt 3600 atccagctgg tgataatccc tgtcccccac ttccctagaa gacagctttg accaggaagg 3660 ctgcaatgac aatgagatgt acccctatgc agagccagat gtgggcgggt ggcttttttg 3720 tggtccagat cttctaggat cttctaggat gtaaccctgg caagcagtgg ggagcctgaa 3780 tcaagcagca tggctgttac ctcttctgtg ttcacagcag catcttcagt tgtcttggtg 3840 cctggagcag gcaccacagc tgcctgctct gttggccacc agctttctag agtagatggt 3900 agggaggaga gcaaggggct caagaggatt ctgtctttga acatgctttt aantttgatc 3960 tgacagaatg gcagctccct gaagtccttc ctactctctc cacagcattt ctctgtaggt 4020 ccccagtttt tgctcttttc agattcccag aggacntgaa aatgtatcac ggcccatttg 4080 gggacttcct gtatatgtgt gggtgcctca ggatcatttg ttttgccctt ttccagtcta 4140 ccgtgctgcc cttctcaagt ttaatgnacc acgttagttt caatatttta tatatttctc 4200 agcagttttc atctcttggt cattaaactt gagaagtaaa atctgctcat taaaatgact 4260 gagtccatgg ccaggcatgg tggctcatgc ctgtaatccc agcactttgg gagtccaagg 4320 cgggtggatc acttgaggtc aggagttcga gaccagcctg gccagcatgg caaaaccctg 4380 tctctacaaa aatatagatc tacaaaaact agccaggcat ggtggcatgt gcctgtagtc 4440 ccagctattt gggaggctga gacaggagaa tcgcttgaag ccaggaggcg gaggttgcag 4500 tgaaacatga tcgtgccact gagtccattc agcagcagag tagtgttggg gtttgtatcc 4560 ctgtagtgat gacgaaggat ttaggttttc agtcagaact gttaccttac aatttccttc 4620 actgactttt cttcctttcc aacaccacat tccaataaaa aatatcttta gaccagattc 4680 ttcacgaaag acatgaaggt tttcatgctt caaggttttt gacttttttt ttttttttna 4740 aaggagtctt gctgtgtcac ccaggctgga gtgcagtggc gtgatctcag ctcactgcaa 4800 cctccgcctc ctgggttcaa gtgattctcc tgcctcagcc tcccaagtag ctgggactac 4860 aggcgtgctc taccacggcc ggctaaattt tgtgttttta gtagaggcga ggtttcacca 4920 tcttggccag gctggtcttg aactcccgac cttgtgatcc acccgccttg gcctcccaaa 4980 gtgctgggat tacaggtgtg agccacggcg cccgaccagt ttttgacatt tctaagccaa 5040 aagttccatt tgatgaggtc ttagatgcag gggcaatgtg tcccttttca gatttcagat 5100 gtttagaaaa agatgtgtca tatttgggcc aactgaaaaa ctcttgatat gtaggttttt 5160 atgaagctgt gcagaatgta ggaaatacat tttagaacca acaaagaggc atttaatttt 5220 gagtgtgcct gtctcctttg agatgagcaa cagctatttt tctcttcaaa agacaatgcg 5280 tgtatttatc agcacatttt atataatcag caaatctaaa cctctgaatt aggtaagccc 5340 tataggtttg ttgccagaat tagtgaattt atacatgcaa agtgcttaga acagtgcctg 5400 gtacacagtg agcactcaat attatttatt gctattatta tgtttattta ttttatactt 5460 ttagagtata attttgatgt taggtttgga ttgctgaggc caagcaaaat ttagatagac 5520 caacccagct aatccactag aaagatattt gagggttatt cccatctaaa gatctatggg 5580 atctttggat atcatctgtg agaaacaaca gaagtttgta gataagacag atatagattc 5640 aaatgccacc ttcacaattt attagtgagg gaaccctttg gtaaaatgag catgacaaaa 5700 cctacttctc agctttgtga acgtacagaa gatcatgaat gtaaaatgtc catgaagtgg 5760 taggtggtca acagatattg ctctagcaaa gtggttaaga gcaagcaaac tctggagcca 5820 aagggcctgg gttcaaatcc cgattctgcc acttcttata gtatggcctt gggcaggtga 5880 cctcactttt ctgtgccact attcaatgat aatattcctt tattgtccaa cgttttgtaa 5940 gttaaatcag ttaataaaca cactatgata atgtgttggt aactattctt tttactttta 6000 gcagaataac ttaaaggaac actgcaggta ggagggttat acataatctc tgagggccag 6060 ctaggacact cgcccatttc ccaccctttt tcctgtgcaa tgaagagtat aagaagtgac 6120 agtgccattc taaaggacta gccttgagtt ggctctaatt tatatgactc gtgcctgtaa 6180 tcccagcact ttgggaggcc gaggctggca gatcacnttg aggtcaggag ttggagacca 6240 gcctnggcaa acatgacgaa atctcatctc taccaaaaat acaaagatca gccgggcatg 6300 gtagcacaca cctgtaatcc cagcttctgg ggaggctgag gcagaagaat tgtttgaacc 6360 cagggggcgg aggatgcagt gagctgagat cacgccactg cactacagcc tgggtgacag 6420 agtgagattc tgtctcaaat aataataata atttatatga gaaagaagtc attcaaaagc 6480 atcattactt tacatgtcaa attagaaagg cacaccccag tactaaagca tccttgatga 6540 tgaaaacatt tagaaccact ggtttcagga gctccatgca atggtgaaac agcctctact 6600 ccaagggttg ttgctccctg tgggattcct gggtgaggaa cacactgctc ccgttggggt 6660 ggaatcctgt ggaggaagtg gatgaagagt gtagccaagt cagtgagcct actgcatggg 6720 attagagtac ttcaggttgc agtataattc tgttcaggtg catgctcact ccatctggcg 6780 taaagaacag agaaattaaa ccattgattc acagagcaat atgagtagct gcctggggac 6840 ttcctgtcca ttctggggtn cccaacagcc aatcaatatt ggccggttcc taatctgacc 6900 tagagctaga ggccactagc acccctccat tcatcctttc ttctctccct acccactccc 6960 accagcattc tgaggaggtg agggctgaag ctgcagaggc tgttgtactg tcagttactg 7020 taaagtcccc atcctgctct ctgtagtttg ctgtgaagga gtggaggggg ctgggaacaa 7080 agggggttcc caataagcag cttactaata cctacccttg cttctctcac ttcctgatca 7140 ataattccca tcctttcttc atgtacctcc cccacatttt tgttctttaa gggaagaagg 7200 gagcagcttt ccatccccac acaatgttgg ggacatttgg tattatacat tatgaaaata 7260 agatttacca gattttagag atggaagaaa acttggggat gatcttgttc cattctctta 7320 taagaacaaa caatatttgg agaagctgag taacttgctt tttcaacttc acacttgaaa 7380 gtgttttcat gaggaagttg gggttctctg cagcacttgg atgggagtca gggacttgga 7440 ttgtcccaat tctgtcacta aatttggaca agccacttaa cttttccaga atctagttgc 7500 ctcatttcaa atattaggga aatttctaaa tggcttaaaa ggagcttgtt agctttaaaa 7560 ttttatgatt ctaagtgtat gctgccagag atatgtagca tagcaggaca cattaacaag 7620 attattgaaa ctgttctaat aaaggacatc tttgtgtctt gggtagctac tatgtttaaa 7680 gactgtgcta ggtgggagtt gtgcagaata cacaggtttg ctgtagaggg atagggcgtg 7740 tacacagaca actctactaa caagaacgtt actagaagct tattggaatc acagtatttc 7800 ttgctgaggg tatgaaacat aagagttctc cttggaatat gaggttctat ttggggctta 7860 aagaatggtc aaaggttgag tgcaaataac atggattgag atggctttaa aaaataatca 7920 aatggtttgt tagtattaaa ctggtgcaga aataattgca gtttttgcca ttccttttaa 7980 tggcaaaaat tgcagttact tttaaaccaa atccctaata ttatttgcat agtttatctc 8040 tgttatggaa gtttttattg acaagtaatg tagatattca cctgatctaa gttaccctga 8100 atcttatatt agcagaatct gaattgctta taaataatta tggctatgtt ggatgtagaa 8160 cttattattt gatagtttat gaacagtgct aaggtctaat ctacttttta cagagaagct 8220 aagaacatgc tacagctggt tgaaaaacaa aaacttcagg cattgaaatg ttttgtcaat 8280 gaaatggcag gactcatttg atgactgatt attatcaact gatttaaatg actgaatttt 8340 tggtactgtg tacatctata ctctaagaag gaaattgaaa gtaattctgc tatgcttgtt 8400 gccactatat taataactgc atcatctaaa ataattgata gagctcagat ttatcctttg 8460 taataattct agtacttctt taaacatgtt ttgggattag cagctgtcaa cagttagaac 8520 atgaaacaga ttctgttaca ggagtagaag tcgatccaga catttaatgt cattttcacc 8580 tgtgagagag agaataaaga gaaagagaga tcattattta tgggattatg tgaacttcaa 8640 gtccgttttc attattagga gaagctgtgc tttaaaggac agtcagggac tttactttca 8700 tgaaatgcct gagctgtaaa taaagtattg ctttattttt tatttcttga acatttgaaa 8760 taaaaaatta gctatgagtt atgttcaaat tatattataa aaatttgctc ttagcattgt 8820 gcatatatat tatacagaaa aacacagagt aaaaagaata gacttcagtt cctgttcaga 8880 aaaggtttaa aatttgaata ctgattttgg aaaccccaaa ccttaagaat tcaagaagct 8940 tacggtcttc ttgagggaca cctattcaaa ctcttaaata tggtgattgg gtagaaagtg 9000 cagaaaagcc tgctgataca tgccctaaaa caccttggaa aaaagaggtg gtagttgctt 9060 gaggtaggac ttaagtacta gttggaaata gaagacaagg atggagactg ttggtagatg 9120 actctccatg ggtccttcct gtttctacac accttgtaag cagggcattg agtgcctgtg 9180 ttccaaacta ccttttccat catgtttcta cagcaaacag tcatggaaga tagaaataga 9240 gtcttcctct ggagcaaagg gcagacacgc ttgcttcctg tacttcccac tataagatat 9300 tccggctccc taaactcagc tgcctttcct gtaacccacc atgatacaga tgtcacctga 9360 cctgtgggaa ttgggggtca gggaaccaag agaaatgctg actgtctggc tactgtgact 9420 gccctgagta ataaattgtc cttcgtctcc aacccaggag tctcatgttt tctaccagca 9480 ggataactgt ggcrggctaa cgtgttagtt tgcaagtaag gtaaaatctc agaccctttg 9540 cagtttgtgg cagggattat attctgagga gagaggaacc gtatgcacca tggctcagag 9600 gcatgagaaa cggggaacca taactagttc tctatcttca gagcctttaa aaggtgcacc 9660 aaggagggca ttttagggga gaatataaag ttggagatat agacacagcc agattcctga 9720 gagaccttat atgccaggta gaagacttca gattgtatgg gggaattatt agagaatttt 9780 tagcaggggt gtgatatgat aaattttgtg ttgattaagt tactccagga aatatgcgat 9840 gggtggattg aaggatgggg caccttttct ctaggacgaa aaagaaagag tagttggtga 9900 agtcagttag aggtagtaat aggatgaaga agggatctga atgacccctt ggccattcag 9960 tgagtagtga tgctattcac ctagatacag cacatagnng ggaaangaaa tnctgggaag 10020 gagggagatg agaccgagtt agctttaaaa taactaaatt caggcctagg agcctatagg 10080 ctatccagat agaaatattt aatngcctat atggatctgg aactcaggaa ggaggcttcc 10140 gtgggagcag aacacttggg caccattagg gtgtatgtgg tagatgcatt cttgtgcagc 10200 agtcaagggg atgggattta gactcaagtg caaattgccc cccatctcct gtgataagtg 10260 actgaagctc tccgggcttc agtttcctag ttcatcatag tgggctctag cggataaatg 10320 ttacaaaggt taaatgagac aacataggca aagtgcgtgg tactcaatag aagtcagctg 10380 ctgtcatcag cagcaggatc accagaatgt ggtgcttgac accaaaagat taggtgagat 10440 tgcccaaaac agcaggtgaa atgaggggag aggatgnaag tcaaacacag gaagaaaagc 10500 ctttgaagta tgtggaaaga aacaaccaga aaggtaagat aagaaccaga agagattcaa 10560 gaaggaaggt gtggccgggc gcggtggctc aagcctgtaa tcccagcact ttgggaggcc 10620 gaggcgggcg gaacacgagg tcaggagatc gagaccatcc tggctaacac ggtgaaaccc 10680 cgtctgtact aaagatacaa aagaattagc cgggcgcggt ggcaggcgcc tgtagtccca 10740 gctactcggg aggctgacgc gggagaatgg cgcgaacccg ggaggcggag cttgcagtga 10800 gccgagatcg cgccactgca cntcnagcct gggcgacaga gcgaggagcc gtctcaaaaa 10860 aaaaagaaaa aaaaaaaaaa gtaaggaagg tgtggccaag attgagaaat tcgtcagagc 10920 aaacaaggca gtcaggggct aaatagcctc ctttaaattt tacaaccttg aggacctcgg 10980 caactttaac agaatttcag tggatcccta gggcaaacca ggccttacaa accaggaatg 11040 gatggtcaat aggaagtgga gacagtaagt gtagacctta ccttggaggg aaggnaagag 11100 aaagagccat ggccaaggga agtttgaaat caaaggaaat atcttttttt ttttttttcg 11160 attggagaga cctcagttat tcttttaaaa tacttattga gcccctcagt tattctttta 11220 aaatacgtat tgagtcccta ctttgagtca ggcacnatgg cagacacgag ggngatagca 11280 gtgaatcaga cagatgcaac gcctgccttc atggagtttc accttagcat ctgtccatat 11340 gctaggggag tggggcaggg gcagggagct ggatacagga gagactgaag atccagggag 11400 caagtgagta aagaataggg cttgagatcc cacagacaac tcagctttga acaaaagggt 11460 tttgtcatcc aataggacaa gaaggcgtta ggatacatca aacgtggttg ttgaaaacag 11520 aaaagggctg ggcactgtgg ctcatgccta taatcccagc actttgggag gccaaggtgg 11580 gcagatcact tgaggccagg agttcgagac cagcctggcc aacatggtga aaccccatct 11640 ctactaaaaa tacaaaaatt agccaggtgt ggtggtgcat gcctgtaatc ccagctactt 11700 ggaaggctga ggcaggagaa ttgcttgaac ccagggggtg gaggttgcag tgagccacga 11760 tcgtgccact gcactccagc ccgggcaaca gagcgagact ctgtctcaaa aaaaaaaaaa 11820 ggaagaaaga acatagacag ggaaatgtag ttaaggnnag tttgggtttg ggtttggtag 11880 aagcgttttc tgttnnttgt ttgtttgttt tcagaaagag tctcactctg ttgtccagac 11940 tggagtgcag tggcacaatc ttggcttgct gcagcctctg cctcctggat tcaagcaatt 12000 ctcctgcctc agcctcctga gtagctggga ttacagacac ctaccaccac accaggctaa 12060 tttttgtatt tttagtagag acggggtttc accatgttgg ccaggctggt ctcaaactcc 12120 tgacctcagg tgatccacct atcttggcct ctcaaagtgc tgggattaca ggtgtgagcc 12180 actgcacctg gcctaacatt gatatctgtt gatgagaaga agccaggtgt tggagtgata 12240 gcttatagca catgaactga ataaaacagt gtttaagaca atgtttgcaa cataataggc 12300 actgaagaca tgttaatgga aggtggattt gtgattcaga acctctagac tacctgggcg 12360 agtcttttaa aatgtaagta atatcttaag tgatattact tgtcccagat cagttgttta 12420 aaactgaggt ttaatgctgt cagagtagca ctgtatcgtc ttctatcatg ggggcctttg 12480 ttggctttag gaggtttgtg tttcatagta gtttcccagt gggctctttg ttacctgtaa 12540 tgagtgtgac agttatgcca taaccaggtt ttatatggaa tacaattttg agaaagttct 12600 ttctaggcag agaagcttat ttgaacctct tattatattt gggtttcagg cttttgagtt 12660 cttctgaaat aatagccctt tgaaggtagc tattgctatg acttcattaa attctaatgc 12720 ctctggtttt ctcccccagg tttctgcata tgaagtgtgt aaaatagatt gcttgatcca 12780 aaacagaaaa acagtgataa ctgttttgct gagttcccag acccttccca agatggaacc 12840 aataacattc acagcaagga aacatctgct ttctaacgag gtctcggtgg attttggcct 12900 gcagctggtg ggctccctgc ctgtgcattc cctgaccacc atgcccatgc tgccctgggt 12960 tgtggctgag gtgcgaagac tcagcaggca gtccaccaga aaggaacctg taaccaagca 13020 agtccggctt tgcgtttcac cctctggact gagatgtgaa cctgagccag ggagaagtca 13080 acagtgggat cccctgatct attccagcat ctttgagtgc aagcctcagc gtgttcacaa 13140 actgattcac aacagtcatg acccaagtta ctttgcttgt ctgattaagg aagacgctgt 13200 ccaccggcag agtatctgct atgtgttcaa agccgatgat caaacaaaag taagtgagat 13260 ggagatccaa aagactaagg tgtggctggc tggtttttat tgtatggggg tcaggatatt 13320 tattttaagt atactgaaat gaataaggaa ttaatgctgc agttataaat tgattactta 13380 gctgaatttt tgttttatgg tgatagttta tagttttaaa gcacatttga aaacagatac 13440 gagaaattat cagtttttga gttcaaaaat tcaagagaaa tcagtctaaa actactaatt 13500 aagagcagaa gtgttaagat gtacattatt tcagatgaat gttctaaagc catgcctctc 13560 aaactgaaat gagcttgtga gtcacctggg gatcttgtta aaatgtgaat cttgattcag 13620 taggtctggg gtggacccca agactgcatt tgtaacaagc tgccaagaaa tgctgatgct 13680 gcccttttgc aggttgcact ttgagtggca aagttctaaa tctccacatt tgtaatccta 13740 ttaagaaaaa tatagtcatt cgtaaactgt gtaaaaatgc tactggccag tttcccaagg 13800 cataatgttc acttaggcaa aggtcattga taagaacgct ggatatgcat ctaagttttg 13860 atgcgatcag gggttctttg tgtttttttc tttcgcaaac ctcaggtcag atctgattag 13920 cttgttatta tcacatgata tggctgaaaa aaaatgtgag acatggtaaa agttctgctc 13980 tttcctcgtt catttgtgct tgctttgtta ttagcattcg ttgtagctct gggcaggact 14040 catttgaaga tgcttgnccc attttatgag gattagctta gataaaattg aaaatataat 14100 gcaaatagca actttctcag ttgggctcag ggctccacag ctaaccccat ggactgtgga 14160 gtcttgccgt tgttttgggt gccaagcaag ccaagtcaca tgtgattcaa gctgtctgcc 14220 acatgtacag ggcgaggatg cgagtgtcaa tccacctgtt aactgtcagt gaagccttga 14280 aagcttctca tattttcaag gttaaaatct ggatagaaat gctaaagttt tctctctgca 14340 ctccattagg ttattttatg tactctctag ggtgtaagga ccttatttag aaattaatat 14400 tcttggtatc aagtagatgc ccttttgctt gttcatttgt tggttcttct agtcattcag 14460 aattgctgtt gcaggtactg ttggagatga tattagcaga ggcttgtagg aaggcaggag 14520 catcagtggg gaataggacc aggtgatcta tgtataggac ataatggaag gactgagaag 14580 ggagcctaac acacacccaa agggtagaga aggctttgtg aaataaaggc taatatggag 14640 ctcaaaacca ccatttcact cacagaatca aactctcata ttataaatca tttcatgtta 14700 ttgtccacac atctcaagtg ggcacggcag catcaggctt ggagattcag agggactaac 14760 ttcctgtact ctaatcctac ttctgcaccc ataaactggg tggcctcagg caattgagtc 14820 tgttttctta tctgttaaat ggggataatt acagtattta tccaatagag ttgctggaaa 14880 gactaaatga ggtagcactc gacctgaaac ttagtaagca tttatagcca taaaaacatt 14940 ttcattcaag aaaattttac tagaggcaga ttatatgcta atttcatttc acgtcttagg 15000 taaaaagaaa catgatacct agatgagtgc cttcagcttt caaagatgag attctggtca 15060 tatttgagga acattttaaa aactacacgt ataacttaat ggctcctatt atttggacaa 15120 attccagaat gaaaatgaga ggactgaaca gcctgtacct cagtccagct ctatatagta 15180 tttggactga atttccttgg ggagagtttg tgcgtggaat cgttgttcag cattttacac 15240 atttgactct ttcccaaaat cttttacggc catctgagaa taggcttctg gccagtcatt 15300 cggatgcctg acaagagaaa gagatttata accaaattct gtaattggga cttccagtct 15360 ttccccaagt agagaattgg acttactcta tatgctaaaa acccatggtt gaaatatgaa 15420 ttagttctta agtgattttt ggcttgcata ccatttttgc aaacacaaat tgtcattact 15480 ctgctcattt aataaaagaa taatttgtag tataggtata tacctcaatc agtgattttg 15540 ttgttggaaa cagaacagta aatcacactg gccatgatgc taacagcgtg atagattttc 15600 tgttcttggg acaccaatgt cactgtatct catagcgaag gattatctgc tgtaggagca 15660 ttctcttgac tacttataac atttgctggg tgaaataatt ctccaggtta aggcctcttc 15720 taaacagatg aggtcagcac taactgcatt tgccagagaa gacatatgca tttactgcca 15780 gcatcataaa cacaaaacta cagtttgcga ggaaaccctt tgaccagcat ctaattaatt 15840 cactgagtaa tgtcttggga gaagaggcat gtaaaggaac aattttataa gcatgccatg 15900 agattgtttt cnnattgtat gttccataga atatgaggaa acttcaaaac attttgtgga 15960 aaaattgaat taaaaagtaa aaaacacata tatacataag ctttatttct caagataaac 16020 tttatcaagt tcaagacact tttgtaagca atgttaacag ccattgagtc ggtctctaaa 16080 gaactgaggg tcctgggaat ttaaccatgt ttatacagtc ttttatacat tattaactgg 16140 agaaaaattg gcgctcttta aagatttttt aaaattgaga agcaaaagga cgtcagaagg 16200 agccaaatta ggcctgnnaa gtggatgcct aatgatttcc catggaaact cttgcaaaat 16260 tgctcctgtt tgatgagagg aatgagcagg aacattgtca tggtggacaa ggactctggt 16320 gaagctttnn caggcgattt tctgctaaag ctttggctaa ctttctcaaa acactctcat 16380 gataaacaga tgttatcatt ctttggccct ccagaaagtc aacaaacaaa atgccttggg 16440 catcccaaaa aactattgca accatttgcc cttgaccagt ccactttcgc tttgactgga 16500 ccacttctgc tctcagtagc cattgcttaa atttgtcttg atctttagga ttgcgctggt 16560 aaaactatgt ttcatcacct gttacaattc tttgaagaaa tgcttcagga tcttgatccc 16620 acccgtttaa aatttccatt agaaactctg ctcttgtctg cagctgatct gagggcaatg 16680 gttttggcac ccatctagta aaacgtttgc tcagtgttaa tttttcatcc aggattgtgt 16740 aagctgaacc agcagagatg tctatgatat tggctagttg gtcctcttca atgagggcat 16800 gaacaagatg aatattttcc tcaaacaatt atctggatgg tctgctgctg caggcttcat 16860 cttcaatatt gtctcgtccc ttctttttct tttccccccc gcttgagaca cagtcttgtt 16920 ctgttgccca ggttggagtg cagtggcccg atttcggctc actgcaacct ctgcctcccg 16980 ggctcaagcg attctcctgc ctcagcccac caagtagctg ggattacagg tacacatgat 17040 cgtgcctggc taatttttgt atttttagta gagacagggt ttcaccgtgt tggccaggct 17100 ggtctcgaac tcctgacctc aagtaatcca cctgccttgg cctcccaaag tgctgggatt 17160 ataaacatga gccaccacac ctggcctcat cctttcttaa aatgagttat acatttgtaa 17220 gctgctgatt tctttggaca ttgtgcctat aaactttttg taaagcatca gtgatttcac 17280 cattcttcca cccaaacttc accataagtt tgatgtttct tcttgctttg attttagcag 17340 gattcatgtt tctctgatag ggggtctttt caaactgatg tcttatcctt cttagagcct 17400 catcccagat cctgttcaga catgctacaa gttaatacaa gtttatttgg tgccaaaaaa 17460 tggaaatcca tgcatagttt ttaaataata tgcatttttc atgnactttt tgaagacccc 17520 ttgtatactt aaactgctcc acatggaaaa gcttccatga tcaaatgcag taaggcagca 17580 tctcaaacat 17590 <210> SEQ ID NO 2 <211> LENGTH: 99960 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: exon <222> LOCATION: 4661..4789 <223> OTHER INFORMATION: exon A <221> NAME/KEY: exon <222> LOCATION: 6116..6202 <223> OTHER INFORMATION: exon B <221> NAME/KEY: exon <222> LOCATION: 9919..10199 <223> OTHER INFORMATION: exon C <221> NAME/KEY: exon <222> LOCATION: 14521..14660 <223> OTHER INFORMATION: exon D <221> NAME/KEY: exon <222> LOCATION: 50257..50442 <223> OTHER INFORMATION: exon E <221> NAME/KEY: exon <222> LOCATION: 56256..56417 <223> OTHER INFORMATION: exon F <221> NAME/KEY: exon <222> LOCATION: 63326..63484 <223> OTHER INFORMATION: exon G <221> NAME/KEY: exon <222> LOCATION: 76036..76280 <223> OTHER INFORMATION: exon H <221> NAME/KEY: exon <222> LOCATION: 78364..78523 <223> OTHER INFORMATION: exon I <221> NAME/KEY: exon <222> LOCATION: 85295..85464 <223> OTHER INFORMATION: exon J <221> NAME/KEY: exon <222> LOCATION: 93417..93590 <223> OTHER INFORMATION: exon K <221> NAME/KEY: exon <222> LOCATION: 97476..97960 <223> OTHER INFORMATION: exon L <221> NAME/KEY: misc_feature <222> LOCATION: 97961..99960 <223> OTHER INFORMATION: 3′ regulatory region <221> NAME/KEY: allele <222> LOCATION: 1443 <223> OTHER INFORMATION: 99-20508-456 : polymorphic base C or T <221> NAME/KEY: allele <222> LOCATION: 5247 <223> OTHER INFORMATION: 99-20469-213 : polymorphic base C or T <221> NAME/KEY: allele <222> LOCATION: 6223 <223> OTHER INFORMATION: 5-254-227 : polymorphic base A or G <221> NAME/KEY: allele <222> LOCATION: 14723 <223> OTHER INFORMATION: 5-257-353 : polymorphic base C or T <221> NAME/KEY: allele <222> LOCATION: 19186 <223> OTHER INFORMATION: 99-20511-32 : polymorphic base C or T <221> NAME/KEY: allele <222> LOCATION: 18997 <223> OTHER INFORMATION: 99-20511-221 : polymorphic base A or G <221> NAME/KEY: allele <222> LOCATION: 19891 <223> OTHER INFORMATION: 99-20510-115 : deletion of TCT <221> NAME/KEY: allele <222> LOCATION: 29617 <223> OTHER INFORMATION: 99-20504-90 : polymorphic base A or G <221> NAME/KEY: allele <222> LOCATION: 42519 <223> OTHER INFORMATION: 99-20493-238 : polymorphic base A or C <221> NAME/KEY: allele <222> LOCATION: 69324 <223> OTHER INFORMATION: 99-20499-221 : polymorphic base A or G <221> NAME/KEY: allele <222> LOCATION: 69181 <223> OTHER INFORMATION: 99-20499-364 : polymorphic base A or T <221> NAME/KEY: allele <222> LOCATION: 69146 <223> OTHER INFORMATION: 99-20499-399 : polymorphic base A or G <221> NAME/KEY: allele <222> LOCATION: 76458 <223> OTHER INFORMATION: 99-20473-138 : deletion of TAACA <221> NAME/KEY: allele <222> LOCATION: 78595 <223> OTHER INFORMATION: 5-249-304 : polymorphic base A or G <221> NAME/KEY: allele <222> LOCATION: 82159 <223> OTHER INFORMATION: 99-20485-269 : polymorphic base A or G <221> NAME/KEY: allele <222> LOCATION: 84522 <223> OTHER INFORMATION: 99-20481-131 : polymorphic base G or C <221> NAME/KEY: allele <222> LOCATION: 84810 <223> OTHER INFORMATION: 99-20481-419 : polymorphic base A or T <221> NAME/KEY: allele <222> LOCATION: 89967 <223> OTHER INFORMATION: 99-20480-233 : polymorphic base A or G <221> NAME/KEY: primer_bind <222> LOCATION: 988..1006 <223> OTHER INFORMATION: 99-20508.pu <221> NAME/KEY: primer_bind <222> LOCATION: 1509..1529 <223> OTHER INFORMATION: 99-20508.rp complement <221> NAME/KEY: primer_bind <222> LOCATION: 5039..5056 <223> OTHER INFORMATION: 99-20469.pu <221> NAME/KEY: primer_bind <222> LOCATION: 5534..5554 <223> OTHER INFORMATION: 99-20469.rp complement <221> NAME/KEY: primer_bind <222> LOCATION: 5997..6015 <223> OTHER INFORMATION: 5-254.pu <221> NAME/KEY: primer_bind <222> LOCATION: 6332..6350 <223> OTHER INFORMATION: 5-254.rp complement <221> NAME/KEY: primer_bind <222> LOCATION: 14371..14390 <223> OTHER INFORMATION: 5-257.pu <221> NAME/KEY: primer_bind <222> LOCATION: 14798..14817 <223> OTHER INFORMATION: 5-257.rp complement <221> NAME/KEY: primer_bind <222> LOCATION: 18751..18771 <223> OTHER INFORMATION: 99-20511.rp <221> NAME/KEY: primer_bind <222> LOCATION: 19198..19217 <223> OTHER INFORMATION: 99-20511.pu complement <221> NAME/KEY: primer_bind <222> LOCATION: 19605..19625 <223> OTHER INFORMATION: 99-20510.rp <221> NAME/KEY: primer_bind <222> LOCATION: 19986..20005 <223> OTHER INFORMATION: 99-20510.pu complement <221> NAME/KEY: primer_bind <222> LOCATION: 29529..29547 <223> OTHER INFORMATION: 99-20504.pu <221> NAME/KEY: primer_bind <222> LOCATION: 30041..30061 <223> OTHER INFORMATION: 99-20504.rp complement <221> NAME/KEY: primer_bind <222> LOCATION: 42268..42287 <223> OTHER INFORMATION: 99-20493.rp <221> NAME/KEY: primer_bind <222> LOCATION: 42732..42752 <223> OTHER INFORMATION: 99-20493.pu complement <221> NAME/KEY: primer_bind <222> LOCATION: 69026..69046 <223> OTHER INFORMATION: 99-20499.rp <221> NAME/KEY: primer_bind <222> LOCATION: 69525..69543 <223> OTHER INFORMATION: 99-20499.pu complement <221> NAME/KEY: primer_bind <222> LOCATION: 76323..76343 <223> OTHER INFORMATION: 99-20473.pu <221> NAME/KEY: primer_bind <222> LOCATION: 76771..76790 <223> OTHER INFORMATION: 99-20473.rp complement <221> NAME/KEY: primer_bind <222> LOCATION: 78292..78309 <223> OTHER INFORMATION: 5-249.pu <221> NAME/KEY: primer_bind <222> LOCATION: 78704..78721 <223> OTHER INFORMATION: 5-249.rp complement <221> NAME/KEY: primer_bind <222> LOCATION: 81893..81912 <223> OTHER INFORMATION: 99-20485.pu <221> NAME/KEY: primer_bind <222> LOCATION: 82353..82372 <223> OTHER INFORMATION: 99-20485.rp complement <221> NAME/KEY: primer_bind <222> LOCATION: 84392..84412 <223> OTHER INFORMATION: 99-20481.pu <221> NAME/KEY: primer_bind <222> LOCATION: 84909..84929 <223> OTHER INFORMATION: 99-20481.rp complement <221> NAME/KEY: primer_bind <222> LOCATION: 89746..89765 <223> OTHER INFORMATION: 99-20480.rp <221> NAME/KEY: primer_bind <222> LOCATION: 90179..90198 <223> OTHER INFORMATION: 99-20480.pu complement <221> NAME/KEY: primer_bind <222> LOCATION: 9475..9493 <223> OTHER INFORMATION: 99-430-352.mis <221> NAME/KEY: primer_bind <222> LOCATION: 9495..9513 <223> OTHER INFORMATION: 99-430-352.mis complement <221> NAME/KEY: primer_bind <222> LOCATION: 1431..1455 <223> OTHER INFORMATION: 99-20508-456.probe <221> NAME/KEY: primer_bind <222> LOCATION: 5235..5259 <223> OTHER INFORMATION: 99-20469-213.probe <221> NAME/KEY: primer_bind <222> LOCATION: 6211..6235 <223> OTHER INFORMATION: 5-254-227.probe <221> NAME/KEY: primer_bind <222> LOCATION: 14711..14735 <223> OTHER INFORMATION: 5-257-353.probe <221> NAME/KEY: primer_bind <222> LOCATION: 19174..19198 <223> OTHER INFORMATION: 99-20511-32.probe <221> NAME/KEY: primer_bind <222> LOCATION: 18985..19009 <223> OTHER INFORMATION: 99-20511-221.probe <221> NAME/KEY: primer_bind <222> LOCATION: 29605..29629 <223> OTHER INFORMATION: 99-20504-90.probe <221> NAME/KEY: primer_bind <222> LOCATION: 42507..42531 <223> OTHER INFORMATION: 99-20493-238.probe <221> NAME/KEY: primer_bind <222> LOCATION: 69312..69336 <223> OTHER INFORMATION: 99-20499-221.probe <221> NAME/KEY: primer_bind <222> LOCATION: 69169..69193 <223> OTHER INFORMATION: 99-20499-364.probe <221> NAME/KEY: primer_bind <222> LOCATION: 69134..69158 <223> OTHER INFORMATION: 99-20499-399.probe <221> NAME/KEY: primer_bind <222> LOCATION: 78583..78607 <223> OTHER INFORMATION: 5-249-304.probe <221> NAME/KEY: primer_bind <222> LOCATION: 82147..82171 <223> OTHER INFORMATION: 99-20485-269.probe <221> NAME/KEY: primer_bind <222> LOCATION: 84510..84534 <223> OTHER INFORMATION: 99-20481-131.probe <221> NAME/KEY: primer_bind <222> LOCATION: 84798..84822 <223> OTHER INFORMATION: 99-20481-419.probe <221> NAME/KEY: primer_bind <222> LOCATION: 89955..89979 <223> OTHER INFORMATION: 99-20480-233.probe <221> NAME/KEY: misc_feature <222> LOCATION: 3698,12593,13035,21712,27644,27655,31143,43084,43129, 64585,66950,67301..67302,67926,75425,98821..98822 <223> OTHER INFORMATION: n=a, g, c or t <400> SEQUENCE: 2 ctcaagcttg aatacttgaa tccaaacttt catgcttaga gtttacccca tctgttgaag 60 gatgtgcaat ataatgactg caatagaatt cactgtggag cctccaaatt agaaattatt 120 gtctgtgagg gccaggcacg gtggctcacg cctgtaatcc tagcactttg ggaggctgag 180 atgggaggat tgtttgaggc caggagtttg agaccagctt ggtcaatata gcgagacccc 240 catctctgtt tttttttttt aaagaaatta ttgtctaaga accagtgtca tcttccaagg 300 agaaacttct agatacttgt tttaagataa ataagaaaca agtcatttct aaatgtgaat 360 tattttttaa atgcaatttt ttaaacattt tattttaatt atggcaatag acgtggaaaa 420 gactcttttt tgatagtagg ggagagcaga agaaacattg aattaagtac acagagattc 480 ttcagacctg ctttaaaaac acatgcatac aaatgcactt ctgtctctta ggatctacta 540 actgatgctg cttgctttag tcttttagct aatattttct ttctttcttt ctttcttttt 600 tgttggagac agagtctcgc tctgtcgcca ggctagagtg cagcggcaca atcttggctc 660 actgcaacct ccgcctcccg ggttcaagcg attctcctgc ctcagcctcc tgagtagctg 720 ggactatagg cgtgcgccac cacgcccagc taatttttgt atatttagta gagacggggt 780 ttcactgtgt tggatgggat gttctccgtc tcttgtcctc gtgatccgcc tgccttggcc 840 tcctaaagtg ctgggattac aggcgtgagc cactgcgcct ggctcatatt ttctttatat 900 atcaaaacaa ttcagcttgc ttcactttta tgaaagcttt attatgagtt tgaaagcaat 960 tctgcatttt cttaacattg taactggtgt tgagttgaag gcaggcccct gggagccctt 1020 tgtgggcaat tcccttcact ctggaggctg cctcgagcct ggacaggcac ttacacttgg 1080 tcagtgattg cacagaaccg gttgcaacag attctgtgca cctccctgtg gcgcgtagca 1140 tttagcaggc acttggtcac tatttgctga gtgagtctgt taccttaggc gtgtatttcc 1200 cgtggacctg cctggggatc attgctcatt cactcatttt gaacaagcca atattacatg 1260 tccagggtac gctctatagt gtgaaacaca aaggtaaatg atagttcccc ttctcaaagg 1320 aatttctaag gtagtagcca ttcttttgat gcatattctc attctcatag agagtccaat 1380 tatggataat tggacaaagc tgaatgtcgc ttttatgaga atccattctt tctcttttat 1440 gcyttgaaaa atgtgtagca ttcattagtg aattaggatt tcattattca aagaagacat 1500 aaggtcttcg aacagcagat gactgaataa aataatacct aacagcagta gaatgagggg 1560 aggacatatt caaggaacat tttatgccca ttagattggc agaaattttt aaaaagtgac 1620 aataccgtat aaaggtgaac tttcctatac tgatactggg aacatgaatt tgtaccattc 1680 agggaagaga aacttgataa tatctggtgt agtctgaagg ggcacagtcc ctgtgaccca 1740 gtgaggacat tcctcattat ttcccttgcc aaacatttca catgagtcta taaggagctc 1800 tatataagag aggtcactgc agcctccttt gtaagagcaa gaaaaaaaag caaataagtg 1860 tttaacaata ggaacataga taaattaggt tatgcagtga atatttgcac tctgactaaa 1920 gtgagtgaat caaaaaaaat ttgtcaacag gaataaatct caaaaataat attgaaagaa 1980 gaaagctaat ttacagaagg atgtgtacag tatgacacca ttcatttagt ttcaactaca 2040 tatcttttat ggacacatac atataaaagc agaaaacatg aattgatagg ataaacacca 2100 aatatttctg catatggcca ggtgtgggga agtagtggtg attaagcttc aaagatgtct 2160 gcagtggttc ccattaaaag tagaaagtag gctgggcaca gtggctcacg cctgtaatcc 2220 cagcactttg ggaggccaag gcaggtggat catttaaggc caggagttcg agaacagcct 2280 ggtcaacatg gcgaaacccc atctctacaa aaaaaataca aaaattagcc agatgtggtg 2340 gcgcacactt gtagtcccag ctactcggga ggctgaggca tgagaatcac ttgagcccag 2400 gaggtagagg ttgcagtaag ccaagatcgt accactgcac tccagcctgg gtgacagagt 2460 gagactccat cccaaaaaac aagcaaacaa aaaaagctca tagagtaggt aatagtcatg 2520 atatctgatg ttttttgatt gtctggttta cattttttat ttttattttt tgagacaagt 2580 ctcacgctgt cacccaagct ggagtgcggt ggtgcgatgt cagctcactg caatctctgc 2640 ctcctgggtt cgagcgattc tcctgcctca gcctcccaag tagctgggat tacaggcgtg 2700 caccaccaca cctggctaat ttttatattt ttaatagaga cagggtttca ccatgttggc 2760 caggctggtc tcgaactcct gacctcaagt gattcatctg cctcagcctc ccaaagttct 2820 gggattacag gcatcagcca ctgcacctgg ccttggtata tgtgttttaa tttgtattca 2880 ttcatttaag cctcatgaca gctctgcgag gaaagttcac tatacgtctt caggctgcag 2940 gtagaggacc tgaaagggac aggaggtaac agtctggcca agaccacaga gccagggaat 3000 agcagaggaa catttcacct gggcattgca ctccagagct gggcttctca ctgttctcaa 3060 cccctggcaa atgctcactt gaacaaagcc aggtggtgat acaaaggtat ttgttatatt 3120 agtctctaca cttttctgtg tgcttgaaat aactgcaaca aagaatatat cagtatttag 3180 agtaatgggg gatttgcttg tgtgtgtttg tatttttgag atggagtctc gctctgtcgc 3240 ccaggctgga gtgcagtagc atgatcttgg ctcactgcaa cctccggctt ctgagttcaa 3300 gcgattctcc tgcctcagcc tcctgagtaa ctgggattac aggtgtgcgc cactacaccc 3360 ggctgttttt tgtattttta gtagagacag ggtttccccg tgttggccag gctgatctca 3420 aactcccgac ctcaggtggt ccacccacct tggcctccca aagtgctgag attacaggca 3480 tgagccactg cgcctggccg tttttttttc taacaaaatt attttctaac agaaagcaat 3540 caggtgagaa tccacataag aaacaattta attcagagat ttttgttgca tattaaaaaa 3600 aaaatgtacc ttcggctggg tgtggtagct cactcctgta atcccagcac tttgggaggc 3660 tgaggcaggt agatcacttg agctcaggag tttgaganca gcctggccaa catggtgaaa 3720 ccccgtctct acaaaaacta caaaaaatta gctgtgtgta gtcccagcta ctctgggggc 3780 cgagggagaa ggattgcttg aacctgggag gtcaagactg cagtgagcca tgattgtggc 3840 cctgtactcc agcctgggca acaaagtgag accctggcac cctgtctcaa aaaaaaaaaa 3900 aaagtacctc cttgtaaata agtaacacta agacttcatt tagtggttgt caagcaaact 3960 ccattgtatt tttattttca gtttttatgg ctagtagtta agggagagaa gcttggttgc 4020 agagaagaat gaaaggatga tgggaaaata aaagtaggag agaggaaaac gcaagaaagc 4080 aagagatctg tagaaaggga tgaaggaatt gtataggcag agagaatagg ttctttaatt 4140 gagaaattta tgttgtctca ccttctgaaa tgcccccaaa ggtaagttat tgttttattt 4200 tgaaaagcta atgatagcta cctttctacc acgctgtgtt caatgtttta cacactttac 4260 ctgtttgagt ctcacaacac agtgttatga ttcgatcttg ccattggtct cactttactg 4320 aagaggaagt ttgaggctca gaaaagtaag aaactggccg aagaccacgg ttagtgaaga 4380 cagatctctg atccagttgc agagtctgag caataaacta cttcaactga ttggtttcaa 4440 agcacatttc gtcattttac ttggggtaat caaagcaact ctctgaggca aaattatttc 4500 ctggacttgc agccatgtca ctaaggagca gatgaggtga gatcacagac aggatcagaa 4560 tgatggcctg gtgccaaaaa gatgtgtcct agagattttt cattccttta agaagcagag 4620 aagggagcga taaatgactt ttcgtttttc acttttttag acatcgcaga tggcagcaga 4680 gaatattgga agtgaattac cacccagtgc cactcgattt aggctagata tgctgaaaaa 4740 caaagcaaag agatctttaa cagagtcttt agaaagtatt ttgtcccggg taagtagcat 4800 aatttctcct gatttaagtt aaatcacttt ttaggagagt gtaagattga gttctatgct 4860 tttattccat caatgttcat cataaaggta aaagtataaa accttttttt atgttttctc 4920 aggcttataa cagtattatc tacattttaa attgttttta atttggccta ggtttaaaaa 4980 aaatattcct tactcttttg tattatatcc aatgggattt ttttgccgct ccaaagaata 5040 tttgttagcc agtccctata aagagcatgc attagataca ctgaagtgtg gcttctgttc 5100 tccctactat cactatgtat aacttaaaaa acagttactg tcagctgctg gtgttagcta 5160 tctaaaaggc tatatagtag gggtcagcaa actatgccca tgggccaaat tctacccacc 5220 tcctattttt gtaaataaag ttttgtygaa acaccgccac atccattcat tttccagtta 5280 tctaaggctt cttttttgca gacttcagca gttgccacaa acactatatg cctcacaaag 5340 cataagacac ttactatctg gccctttaca gaaaaagttt gccaaatata gctctataga 5400 aagaacaaag tacacatgta catcaatctg ggagttcttt aagaaattat ccctccctcc 5460 catgagtgta aatagcctga tggcacgtct gagaaatcaa atctgatttt ccctcagagt 5520 ttcacacctt tctggagtgt gcagtatctt attatagttc tttttgattt tatggcacac 5580 ttcttttgaa acatctgatt ttattttatt ttttaattaa ggaaagttaa attttatttt 5640 cttcgaagat gtttctgaga attttgcaat atcttctgag atcatgaaaa acagttgatt 5700 tacaaaacca gagttgggag gggctgcatt tgagagctcc caaagggata gagtgctgtc 5760 cgagtgacat gcggctggcc gttatgatga cttgtgaccc aggggaggga gttagttgct 5820 gagtgggctt gagcacttga ttttccttat agacgaattg tcttgtcttc ctgcctatca 5880 ctcatgccaa attacttagc caccaggtgt tttggaacgt ttaggttagt gtcttattta 5940 ttttttaaaa aaatgatgga aatgttgatt attttaatgt acaaatatcc ttagtagcat 6000 ttctcagtag ataacatttt tttcctgagc ttatttaaat ggaccaatct gcttctagct 6060 gatgcctttg caaaagcctc cagagtcata actcgactgc cttttcttta tgtagggtaa 6120 taaagccaga ggcctgcagg aacactccat cagtgtggat ctggatagct ccctgtctag 6180 tacattaagt aacaccagca aagtaagcac atttctcttt atrcgacacc ctgaagaaac 6240 caacaaatag gtcttgctca tctcctgtct acatacctcc aatcataaaa cgtttgctgc 6300 ttgcaaattt cttggcacag gtggaggact ggtcatgcag ttctatcata acataaaagt 6360 tttacataaa agagcagatg gggctgggtg cagtggctca acgcctgtaa tctcagcact 6420 ttgagaggcg gacgcgggcg gatcatgagg tcaggagatc gagacgctcc tggctagcac 6480 agtgaaaccc cgtctctact aaaaatacaa aaaattaaaa attagccggg cgtggtggcg 6540 ggcacccgta gtcccagcta ctcgggaggc tgaggcagga gaatggcatg aacctgggag 6600 gcggagcttg cagtgagcca agatcacgcc actgcactcc agcctgtgtg acagagagag 6660 actctgtgta aaaaaaaaaa agcagtagat tttcctatta aaaaaataat taatattggg 6720 aaaacatcag aaagtggatt tgtgaattta gagaagtata cagcttaaat ttttcttttt 6780 ttaagaaaat tttattttgg atttgggggt acatgtgcat gtttattacc tgggtatatt 6840 gcatactggt ggggattggg cttctagtgt acccatcacc caaatagtga acattgtacc 6900 cagtaggtaa tttttcaacc ttcacacccc ctttcattct cccccacttg tggggaaatt 6960 aaatttctga aactttatcc tgtagctggc tctatgatta taatgaaaca ttactgtttt 7020 atttaaataa gcaagtatct atgtccttct tttaataact tgctttctag acatttaatc 7080 atatttaagc ctggtcagtt caactttata actcctgaaa agtgggtttg ggttttgtgc 7140 tagggaggcc agctttccct tctgctacca gaggactctc tttggcagta gtgagggagg 7200 gagtgtttgt ggaggccagc tccttaccac aggcagggtt tacagtcctc tgccatccct 7260 cctagacata tggctttcag aatttttcta acctacagta agaagcacat ttaacattgt 7320 ggcgtagttc acaaacacac atacctacac attcacacac aaaattaaaa gttcacaaaa 7380 caatatttac tgtgaacaac atacaataca tactgatatt ttgttctatt ttatttttaa 7440 aatgctcatg gcaaactact cagttgtacc acctactaac atgatagagg gagcagtttg 7500 agaaacactt ccttagatgg atgagtgctt ctcaaatttc aggtgctccg cctcccgggt 7560 tcaggccatt ctcttgcctc agcctcctga gtagctgaga ctggttaaag tgcagattct 7620 ggttcagtag gcagggcggg gggagccctg aaatgctgca tttctgacaa gctccaaggc 7680 aatgctgctg ctcctggtct gcagaccgcc tctggggagt gaggtcctag acagcagtct 7740 tgtaaatgtg agtttctgag ttaaaatcca ggggaacata gtgtcgtcca gcctccatct 7800 aatacacact gatcccaccc tgcaattcat tgcaagtgtg ggaaggctat ttgcttattt 7860 gttgtgtaca gatgaaccac acaccgcccc tttcatgtag gaagttacct aggaggagag 7920 agatgacaga tacagaaaca gccccagcat caagcagagt gtggtaggag cccagaagtt 7980 acaaataaga gacattggta acttcagtgt cagaagagca aggggaaggg aagttaggtt 8040 tggtcagtgg aaccagggaa aaggtgaggg gtgagggggc agtgatgctt ttggactaaa 8100 tcttggtgta ggaattgtgc ctatggaagt gaacagagaa gaaggcattc tagacagacc 8160 agtgtcaata gacataccat gaagacattc atgtcactca gtgggctttc cagtaagcct 8220 tattgcttgc tttttatttt tttccaaaag gcagatctag gaatatatac atattcattc 8280 ttcaggactc gatagttgtg aagattcttt taaaaggatt taaaagtctg tctaagattg 8340 caatttctag agtcattcta agagagatgc aacttttcag aagctgcttg tatgtattgt 8400 atatgtttaa gtgtacttta catctttctt ttattcatct tgaattgaga aactactata 8460 ttctatttta tgtaattgga tcccttctaa aaaattgatc acctaggagt tgcaaagaaa 8520 ccaaatagcc ctgaaacttg acaaatgaaa atggcccttt cagttgtcca attaagctaa 8580 gggttagctc tttgatatga tttggaggga tattagtaag aatttagatc aacaggtttg 8640 catgatggag attgtgttct gtgatgtatt gtcttagaga gacttttaaa tccttaaaag 8700 aatcttcaca actgttgagt cctgaagaat gaaaaacttc agttatgaaa gtaatcaata 8760 tttcatagta tgttgggaat tttttcctaa ttcttataca attaaatgta tgtaacttct 8820 ccctttggta aacacatttc tttttttttt tttttcaaat taaaaccctc aatacttgtt 8880 acctaaaagg cactcaactg tgtaaatgaa caggtagaat tcagagtctc cagtccactg 8940 ttagatgcat tcattcttgt ttactctatt cctgttgatt tattttttct cttccaacaa 9000 tttcaatagg agcaagctgc tacaattcct ctttttgaat attttgaata tattaaaaat 9060 atattggcca ctagccacgt cctgggtgca gtgttaaaca tcagtttgct tgagtggtag 9120 tagttcattc ctttgaaaaa gcgtgcatcg tgaaggcata caactttaaa atattgtcat 9180 gattctcaac aaatgtttga gcactcactc catagattta ttgcatacct aataaaacaa 9240 taacttatgt ttgtgtaaca ttttacaaca taaaaagtac ttttggttgt atcatcttgc 9300 tttgttcttg aaactcagat acatttttac tttaccctct tacagaagaa attgaggtgc 9360 agaaagaaat tatttgccct gaattgcagc agtaagtgcc tacagagtga ttttccatat 9420 tctaagaata ttgatacagt tcttaatctc aaattatgaa gtcgaatctc aacagtagat 9480 cagattcgga gagagcctta aaatgtgggt ttaacatgag tgaacacatg tggcaaagat 9540 aaagaacttg gttaagcagt ggagacaagt tctccagcac tcacacccct tagaagctgc 9600 agtaaacagt cctgttttct agagagaggg cactattcat ggcgttgttc agaacgttac 9660 agattgtggc ttatgtcctt cactcctgca cttggccagt ctccccattt ctccagcaag 9720 ccagcagtgt gtccttgagg agcgggcatt tatttaatgg accttcattt tcttctgctt 9780 ttggtggtgg cttctagatg gcattataat cagaacacat acttagatac tgcaatgttt 9840 gcccgtgcag gaactagaga tttataaatc ccacatattc cccatggtgt gtctgatctg 9900 ctgtgtgttt gctcccagga gccatctgtg tgtgaaaagg aggccttgcc catctctgag 9960 agctccttta agctcctcgg ctcctcggag gacctgtcca gtgactcgga gagtcatctc 10020 ccagaagagc cagctccgct gtcgccccag caggccttca ggaggcgagc aaacaccctg 10080 agtcacttcc ccatcgaatg ccaggaacct ccacaacctg cccgggggtc cccgggggtt 10140 tcgcaaagga aacttatgag gtatcactca gtgagcacag agacgcctca tgaacgaaag 10200 taagatttgt ttaaatttgt tgcataaata gctggggcat atctgtgact agccaggtat 10260 gtgcatccca ggtatgttta ttgagtgaga gaaatgagtc aggctttact cttggtttgg 10320 agataaaact ggaagcagtg acatgttcgt tcgagctgct tgtgagtata caagcaatgg 10380 gtacttgtat tgtcaggaag caagtgaaag tgagcaaaaa tggtacctaa catgcatagt 10440 cattactcct caaacaaagt aagagacgtt gttgactgtg gaactttgct gctgtgagga 10500 agagggcaag cggatgagtc tccccatctg aagccctgga gcagggttat aatgggaggg 10560 agaggcgctg atccttacag gcagagcaag agaggtatgc tggcctcata gggtgacagg 10620 ggtgcttcag cttctggtcc tagctctgcc gtgaactaat tgtgacctgg acgaatttgc 10680 taaattctct gaataacaaa attggagtag atgttttcta aaatctctca ctgtaagaat 10740 tctagattct tctaacaaga tttattcatt gtaatagttg ggttcctgtg accagttaga 10800 atcgtctggt tatggagaag agtaatcaga agttcccccc attccttcca agtgtccctt 10860 agtgattcat ttaattctgt gtgccagaga ctataaatgg acacagttat ctttaaaaac 10920 aactttaaac aattttaaaa atctctcacc taatatgaat caaggtcaca cctgtgtaca 10980 gtcgctgcct tcttctgacc agcagccgca gaagtcccag gacctatgtg ttcgtgtagt 11040 tcatacacgg atcattgaga gtgtgagtta gtacagaagt gtttggaatg ttctgagtaa 11100 agaagtgtga gcattaacag tcctggatga tggagcagag cctcccagct ttgttttctg 11160 tcagccattg gaaagagttc ttggttcttt ggaattcagc ggggtagtgg tgatcccaaa 11220 agcaggggac atgtcagaag gtactgctta ataaatacac gcttttagag acacacatcg 11280 ttgggttgta gctgtgtaag tttcttgtgt ttaacaccct gtctgcacat tacttctgtg 11340 ctgcctcacc actgcctgcc cactcctctg ttgttggcgt tttcagtgat cattgaaaca 11400 ttcctgtctg gagagtccta gttctcttgt gaagtctgct gtttctcaaa agccagagtt 11460 gataggactt agtatcagta cttttccttt ctccatgaag aatgtagctt tataatagat 11520 gatgtcacac atccgtaatg ggagggatga ggagatgcct gtctgtctgc ctctctagca 11580 tggcccattc tgctttcttt cccccttgtg agctcttttc cgatttatct acaggaaata 11640 agacattgaa attcagggca ggatattgtt cattttaaag ggaaatgtat tttttaaagt 11700 tcagtttttt tttgcttttg tttatacttt aattaaaaat tttttttcct gccagttcct 11760 gaaaaagaaa atagagaaag aaatattatt gttcctgggc gaagtggctc actcctgtaa 11820 tcccagagct ttgggagact gaggtgggag gttgcttgag gccaagagtt caaggtcaca 11880 gtcagctgtg atcgtgctac cgcactccag cctgggtgat agagtgagac ctattaaaaa 11940 aaaaaagtat tgttgggagc ataaacacgt gggaaatggt caagaacggc cgtcaatata 12000 ctctgttttt cactgaaaac tacctttgcc agagagcgag cagagatgag gaaaaggagt 12060 ggaagaagtc ctccactctg atagtgttac tggaacaacg agacaaaagc ggtgtgctcc 12120 ttccacctgt ttgctccgtg tccctgtcgg cgccccctct cctgctaacc cccccgtgct 12180 ttctctgatt gctgtttagt gtggatcctt cacctgtggg tgagtctaag caccgcccag 12240 gtcagtcttc agctcctgct cctccacctc gtcttaaccc ctccgcctcc tcgccaaact 12300 tttttaagta cctaaaacat aattccagtg gagaacaaag tgggaatgct gtgccaaaga 12360 ggtgagcaca ctcacgtggc aagtttggtg ttgtctgttt tcctggggag ttcacactga 12420 tgaggatgtg ctgaatgggg ggaatgtcca tgcaggaagc agagccactg tgtgtgtgtg 12480 tgtgtgtgtg tgtgtgtgtg tgtgtgcgcg cgcgcgcgtg tgtctttgtt tatattttgt 12540 cttattttca gctgtcattt gaaccaagtt aattttacta ttgatgactt ttnttaagat 12600 tattatgaaa acagatctta atggcagatt ggtttgtgtt tgtgtttgtt tttttttttt 12660 ttgagacagg gtctcactct gttccccagg ctggagtgca gtggcgtgat ctcggctcac 12720 tgcagcttct gccttgtggg ttcaagcagt tctcctgcct cagcctcccg agtagctggg 12780 actacaggca cacgccacca tgcccggcta atatttttat ttttttttgt agagatgggg 12840 tttcaccatg ttgaccaggt tgttcttgaa ctcctaacct caagtgatcc gcctgcctca 12900 gtctcccaaa gtgctgggat tacaggtgtg agccactgca ccctgctgca aattgttttt 12960 ttatacttat tttcacattt ccttgcccta gtggacactt acatgcatgc gtatatacac 13020 acacacgcgc gcgcngtgcg cgcacacaca cacacacaca cacacacaca cacacacaca 13080 cacacaggat aacatctgtg tttgatcatg tacactgcaa tttgtgccat atcagaaact 13140 tcctgattga tttaggggaa ttatttttcc cagtttgaaa ggaagagtta tttggaaaat 13200 ggatggattt tcttttttaa aaaattattg atcccattca tttaaaatca aattttattg 13260 gtgaaaatga aaattaaatc tcgttcgtga actactttta atttcttacc tagttttctt 13320 ttcttagcat tagaacaaaa atgtttcttt tattttgaag cttatatttt atactttgtg 13380 tttttatgtt tctttatcct aaactctttt ttcaaccaaa ctcttagcat ctcctactgt 13440 aatgccctgc ggaaaaaact tcattcttct tcctctgtgc caaattttct aaaatttctg 13500 gctcctgtag atgaaaataa cacctctgat tttatgaaca caaaaaggta gggcttaatt 13560 tagatatatc aagcctgggt gttactaagt gttgaatatc attagatata caagggtgtt 13620 ttaattacta ttttgccatt taaaaaatca tttcagctaa atctgttgta tcttctttct 13680 tatacttttt tcttactgaa tgccattttt aaaaatgtgc aaccaacctg ttctctagtt 13740 ttgacgagga ttagtttaag tgttgtctta agaaaagtct ttgccaagtc tctgagacca 13800 gtgtttctgg ttagtgagca tatgtctgtt tcaaatcagg atgtctgatc tgttcaggac 13860 gtctaatctg taagttgagg ggattgctta cttacaggta cataacttgg gtataaattg 13920 gaagggcctt ctcaggttgt cctgtgaata ggagaaaaca tttatgattg tgtttatata 13980 ttgataactg tattttgtag tttaaaaaat acacacgtta aaacaattat catcatcaag 14040 tgactgcata gttattgcct tgctggttct gtgtaattaa attgcaagtt ttttcatttt 14100 ttgtgggaat ccttggagac atgggcctgt gctgagcaga tattcccatg cacagaagag 14160 ggcagaatgg ggccccttgg catcaccccc tttccccctt taggcagttt ctctttatca 14220 aagtggcacc aagagaggcc caattggaac tatgatatgt ggaacatgtt tcttaatctc 14280 tgttacaatc gaaatcactt aagggcatgt aatctttctc ttttcatgaa aagaattctg 14340 taagaaagca gttctttagg aatgatgacc cactgtgagc ttgatataac ttctgtgatt 14400 gattatttgt ttatacaaag atagttgata atttagtgat ttgtttaaaa aaatgttaag 14460 ctaacaaaat cccgtgaatt cctccccact agtcataaat caatcatctt ataattttag 14520 ggactttgaa tccaaagcaa accatcttgg tgattctggt gggactcctg tgaagacccg 14580 gaggcattcc tggaggcagc agatattcct ccgagtagcc accccgcaga aggcgtgcga 14640 ttcttccagc agatatgaag gtaaggccgg tacctgaaat gaaacctcaa agagagcacg 14700 ctgacagagg accctgggag ccycatcata ttggtaagaa agcagagcgc cgtcctcttc 14760 agtattggca ggtctgaggc aatcacaaag gtaactaggg agggaattta gaggttaccc 14820 tccatttctt agggaaggaa tttaaagcta atttagggta acctctccat aaacaggagc 14880 agagctctga tgtttagagt ggtcacagtg ttaaccagcg gtgaatccag acaggtctgc 14940 ggcaacctca cttcttgcct cctaggacat aaggcaaaag gagagactga ggcaagtttt 15000 agagcagcag tgaaagttta ttaaaaactt cagagcagga atgaaaggac gtcaagtaca 15060 ctttgaaggt ggttaggcgg gcaacttgag agatgaagtg tgagatttgg ccttttgacc 15120 tggggtttta tatgctgcca tacttccggg gtcttgcgtt ccttcttctc tgattcttcc 15180 cttggggtgg gctgtccgca tgtgcattgg cgtgctagca cacgggggtt gtgggggagc 15240 gtgcgcaggg tgtttactgg agttgtaggc gtgctcactt gaggcgttct tccctgtcca 15300 gtctagcatt cctagaggaa cgtcatgcac caggtaaatt ccgccatgtt gcctcttaat 15360 gcgcatgctt gagcccactc gcccagctcc cgagatctta ttgggaagct gcagctcccc 15420 agttttaggt gttttctatc tactgggagc ccgcccttcc ttggtgcccg ctgtgaccaa 15480 cgatcacttt agagaaacag ttgacaactg cctgaccaac acctgatggt cgcctgacat 15540 tgctggtgca tatctggaaa gggccctctc ctgccgtcct catgtctgac gagctacccg 15600 ctgtaaccaa agcgtgggct tcggagtctg ctttcaaatc ccagcttttc cccttaggag 15660 ctgtgaacta gaataaactg tctaaagtta ccacctataa cctgggatta attatgcctg 15720 ttgccacact gatagagaca aggcagcatg atatcattac tgatacattt tttttaaagc 15780 attcaaaatt catagtactg gaaagaaaat cagtgatgcg aatgtttcca gggtaatgtc 15840 acctcccatg ctgtggaagt ccttcgggtg agcctggccc cttgcttctt ttgccccagc 15900 ctttctatgt gggggcacca tggagctgcc actcaccagc accttttttc cctcaagtag 15960 tttgtaccta taaagtattc ctgccgtggg tggcccctcg gtggagctgc tgagcctagc 16020 cagggtttga tttctcttcc tgccagtgtg agccagatgg ccacatctct cttcccctgc 16080 cccgtggaga ggtctgctta ccgcaaagaa gggctcttcc tcccaggtcc tgtagcaccc 16140 tgttagaggg tgtggagtgg agcagtggga accagagcca ccagagggag gccctggagg 16200 aggaacgaag ctgattcatg tctgaaaggg gtgccagaac ccaagtttcg gtgtttaata 16260 aagagtgcct cggtgttgcg gtggccatac ctcacagggc atggtcgctt ggaaatttct 16320 gctcggaaat gctttgtgca gtggccagga tgcgttaggg gccacagatg actgcttgct 16380 ccatcataga acagttccaa gttttcaaac gagcattcac agactgagcc gcatcctgcc 16440 tccctgtcct ctgattcctg gcttcttctc tggtctctga agccacacgg aaatgtgttt 16500 gcatctgttt cctgcccttc agatgacaga ggaccatgga agctgctgcc tcctttagct 16560 ctcttctcca ggggaattgc cctcgtcact gtttgggaac ccctggtccg agtcctgtcc 16620 tccgaagagc ctctgcccct cctggagtcc tgagttgaac ttggtgttca cttggcctct 16680 ggctctggca gtgtgttgct ccttccgttg acctgccact gctctgttaa tgcagattga 16740 tcttcataat ctgtttctgc tttaagtgat taactcaaac attcttggct cttattctat 16800 cttgtccttt gggatatgaa ccattattta aatttggact ggtttcctgg cttggcacag 16860 ttgaccatgc ctgtaagctc agtgctttgg gaggccaagg caggaggatc cctggaggcc 16920 aggagttcga ggccaccctt ggcaacatag tgagaccctg tctctacaaa aaaataaaaa 16980 ttagctgagc gtggtgttgt gaagctgtag tcctagctac ttgggagact gaggcaggag 17040 gattacttga gcccaggagt ttgagtttac agtgagctgt gatcacaccc ctgcactcca 17100 gcctgggcaa cagagtgaga ccttgtctcg cggggtgggg gagtcatgtc tatacttgag 17160 aagttttttt ccctcgcata gtttgtacct ataaagtatt catcagtttt gagcagtcct 17220 tttgcgattg ttttgagtct tgattctggt gaccagtaag ttgtatatat ttgcctgtca 17280 agtggacaaa catggccttt gtgcctttaa gtaatggcta aaagtaccaa acagaacagg 17340 gcctggcata gatgctgctc ctcctgttcc taggccgtaa tcacccctga ttcatcagac 17400 cccaaacaag tcagctcctc tccctcctgt gccccaccac ccaatctcct gcaggaagat 17460 gtctggagac ccctgtcagc gctaggcaga gatcaccatc catgtccacc tttcctctga 17520 tgcaggctcc cactagcccc tctggcttgt gccatgccag ccatgaactc accctcatgc 17580 cccacccgag ccctggcaca ggctattccc tctgcctgga atgctcttcg tcagtatccc 17640 catggctccc tccctcccct tcccttgtat cctgactctc ccatagcagc tctctccctg 17700 taacacatgt tcacaggttc atcttcgtca cccatctccg gcagctcctg caggcttgat 17760 ggctgctaaa ggcaggcaag tcagtggctc agattcttgc aaacttagtg attagtgatt 17820 tctcaactcc ctcctcatgc ctcctctgtc tctataggca catattattt cttatctctt 17880 ctcagaacca agccgcctga atttctgaat aacattgttt aagtgttctg tgtatgcaaa 17940 agaaaaacga gaataaaagg attattaagg aagaattaat ataataatag ccacatatta 18000 tgctcttttt atactctgct aagtgcttta catgaattat ttcctttaat tagacaatct 18060 taagaacatc gacattttta tgaagcccat tttacaggtg ggtgagtgga ggctgggagt 18120 ggcttaaatc actttcccca aaccagggag ttagtgggag ccagaggcag gacctgagct 18180 cgcgggtctg agctccaaag ctcattctct gaactgtgca cagcactggg ctgcagccag 18240 agatgcagga cgctgcggga ccctctggag gtggtcctgc ctgtgcttcc ctcttcccac 18300 aggaagctcc ctataggcat ctgtgttggg cgtggactct cagtgtacct gcatgtctcc 18360 ctgttggcca gacaccaaca ctgaatggaa aacatgtttc tgggcatttt aatgtacgta 18420 cttgccttca gtcaatctcc tccgccccct tccatcctga ccgcctccct aatagttagc 18480 agtgggactg gagcttgaat ggcaactgat ttctgtctga gaggacaaat caggcatctt 18540 tgtcctctgc cactgtctgt tccccatcct taggatgcac gatgccagag ccctccactg 18600 tggtctgtga ccactttgac ccacactagc aggtctccat atgttccttc cagctgagag 18660 acatcacatc caaagacagt ttagagctct gaggtttctt tccccagagg tccctgcttt 18720 gtgcaaactg tctccagcca agcgtgcaca agactctgtt cctgatttgc ctgggcggct 18780 gagccatggg cagctgagcc tgcagccgct ggactcactg cattcccact ctgactttgg 18840 catgaaagac acacaagtgt gcttgtgaga aatagatctt aacagtacct tttaacacct 18900 atttcaggtg ctcaaaatga ctgcctgttt tacatttata ttctggcagt gcaaacttca 18960 attggacagg aaatcttaca acctctcttc caggtgraaa agcgaggcag ggatgtttat 19020 acagttccat ccatgtcatc ccacttggaa gatactagta aaacacacca acagtaatac 19080 aaaaaccatg gtgtttgcaa tagtgataat gttactagtg aaggaaaaat agaaactttc 19140 tgtaatttgg agattctaat ttttataggt gggctaaaaa aaaaayctgg agagaagggt 19200 gttaagtgag taaggagtgt gtctctaact aaatatagtg taaaaagaga agaaaataca 19260 aagtcaggca cagtggatag aggtggatag tctaatctct aatagtataa tgggcaaaat 19320 tgtctcaaac aaaattagtc tgcctcttgt ttactcaggg atgtgtgact gttttctatg 19380 cacaaaatcc ccatgaaata attaagttgc aagaatctga actttatatt ttggaaacct 19440 atctgaggta ggtaggaagt taatttatat ttagaaattt gcttgcatat gtctagtagc 19500 tccaggacaa atattcccaa atcccagact attttttttt ctttttaaat tcaacagtga 19560 ccagttggtc tcttgtaaga attacagcct taagttagca aagtctaaga gggctggttt 19620 taatcctgaa cctcagaggg tccctgcttc tcaaatacta agtaggtcac gtgcacagca 19680 ggtactacat tgaagggaaa ttgtatgata aataggaaat cagcgatttt tacttggaga 19740 cttggcaagg caaatgtttt tgtaataaaa atagatcgtg aaatagaatc ctgaaagctg 19800 cctgtttaaa tgtaaagcaa atggctttag tgatgcttta agtgtggcag tcacttctgg 19860 ctgccgcaga aactatagaa agtgcattct ctcttggtgc tgtgggttct tagggtgaat 19920 gccttgtgtg acgctgagta tgtggaagga ccattcattc ttggtaacta tacactaggc 19980 agagggtggc gttagcgaag ctactgcagg ttgggtgtgt ttaagatttg gatttatttt 20040 tcttttaatt tttattttta gttccagggt acatgtgcag gatgtgcagg tttgttacat 20100 ggttaaacgt gtgccatggt ggtttgctgt acctatcaac ccatcaccta ggtattaagt 20160 ccagcatgtg gttatttttc gtaatgctct ccctgctccc tgccgccccc caacaggctc 20220 cagtgtttgt tgttcccttt cctatgtcca tgtgttctca tgattcagct cccatctatg 20280 agcaaaaaca tgtggtgttt ggttttctgt tcctgcgtta gtttgctgag gataatggct 20340 ttcagcttca tccatgtccc tgcaaaggac atggtctcat tcatttttat ggctgcatag 20400 tagtccatgg tgtatatgta ccacattttc tttatctagt ctatcattga tgggcatttg 20460 ggttgattcc atgtctttgc tattgtgaat agtgctgcag tgaacatatg catgcatgta 20520 tctttgtaac agagtggttt atattccttt ggttatgtac ccaggaatgg gattgctggg 20580 tcaaatggta tttctagttc tagatctttg aggaattgcc acaccatctt ctacaatgtt 20640 tgaactaatt tacattctca ccaacagtgt aaaagcattc ttacttctcc gcaacctcac 20700 tagcatctgt tgtttcttga ctttttaata atcaccgttc tgactggtgt gagacagtat 20760 ctccttgtgg ttttgatttg catttctcta atgatcagtg atgttgagct ttttttcatg 20820 tttgttggct gtatgaatat cttcttttga gaagtgtctg ttcatgagag agacatattt 20880 gctcctctga gtaaagggta aggatgctta cgtctgtgtg acagccttct ctctttttca 20940 gaacctcact gtggatcgcc atcgttggcc tgtactgaag gtaaagcaga tagaggcagt 21000 ctcatctgtc agatgaagac ctcatacacc tgttgattaa gaggctttct tcagatcatg 21060 gtttagagcg gtgttttaca aacttgacgt gcttggagtc ttctggaaat cttgttaaaa 21120 ggcagactct gttgcagtag gtccgggtgg gttctgaagt tctaacaagc tccccagtga 21180 ggctgatgtt tcaggtccac tgtgaggagg cagggcttag aataaacaac cgtgggaaat 21240 ccagtccaga tctttgatgc atcctaggtt aggcctgtct gtcaggctgc cctgggtctc 21300 tagtgatgga ctccaggagt ctctcaagtc tcaaataagt ctgagtcatc agggatattt 21360 tttgagaaga gttgtgctgt ctgaagaagc aaagagtgag tgtgatgggg aaaatgcagt 21420 gattaaaaac atggtaaggt ttaaagaaag atttgaccat atgccaggtg aacccaaatg 21480 tatggtgctt tgcgtctttc ctgccctttg gttttccagg gaggcaaggc cttatctctt 21540 atggagcaca ggagacacag tgtgggcgtt tgttttctca gccgtgggct ctaacctaat 21600 tgtcaagcct acaaaaaaaa aatgctgaaa atcaacttct gactagatat ctggtagtac 21660 ataatctcca taattttctc tctgggtgta ttatgcaaaa gataatcctt tngttattaa 21720 gaaacaattt ttaaggcaac tcccaacttt gaaacgggga aaaatcattt tatttacctc 21780 tatgtgctag ggaacaatat taaatttagt tttatacttt tcctttaagc atttcagatt 21840 atattgtgca tttcaccaac aatagaagct ttcagacttt atatgtcttg taaaaaaaag 21900 cctaatatag ataagaataa tttattgatt tgaaacccat tgtataagaa atagtccagt 21960 gaaacttaag ttcaaagttt tttttgtctt gtggatgtag ctatgtcaat atgcctagtt 22020 tatagtaaca ttaagtctag tggattagat attagatatc aattgagatg taagcagtaa 22080 taaacagtaa tgcctaaact gaagtatata atctgaatct ttatgatgac caatttatat 22140 tattgtgaaa aacttaggaa ctgatttgaa acatgattta catgttttac atgaaacatg 22200 atttacatgt gtcatatata gttttcaata atttacgtac cagcaggaaa ttttagtgga 22260 taagtggaat aaactgcagg tgaaactttg ctggaaaata caagcatagt gacatctgtg 22320 caccaaaagc acctggggag attttttaaa acatgggcca gacatgcctt cctggctgtc 22380 tccctcactg tcagtgagtg tggggatggg gtctgggcct gaattctttc tttttagact 22440 cctcaggatt ctgattgctg ccacgttgag agggttgacc tcaattcgga cctcagaggg 22500 tgacttgaga aactgtcacc acttggtggc agtgttgctc cccgcatctt gattgccctt 22560 gtttctttcc aatcccggaa aagtgtgctt gttttttttt ttttccctgc gtgtttttgt 22620 ttttgatctt gctataatat ttatattcct tgctcatttg caacttattt gaatggagag 22680 ctactttctg aaatctagat gtttttcttt ttctacaggg ttttagggca tgggcaaaac 22740 acggaagaaa aaagttgtct tcagttggca gagacgtgga tttttaagat tgttcttaat 22800 ttactttctg tataactttg cttttctgtg gtgaacaaag accaggttca agataaaata 22860 ttgcaagcca agaatctgat tgttcatgga tttctatggt taaagatact tgatcacctc 22920 cccatccgcc ccctacccca cccaccctgc gccgccccca caccccattg tgcttcttgg 22980 cttgtcattt caaaagtcaa ggaagtcaca gtgaatggca agattttacc tcgacttgct 23040 atttttgtgc ctgttaacaa ttgtgagtta acactgactg agcttttcct agtgaacctc 23100 cggcgtttaa acagccagtc cataacactg tgtgagggct ggagctaagg ttattggtga 23160 cacaagatag cacctgagcc agtgctgctt ggtaggaggg ctgaggggaa gagggctgag 23220 ggcttggatg ctgagatgct agagtcacat cgcctggatt tgaatccctg ccctcctgtt 23280 ctgataccag ctgacccatg acgatgctac agcacctgac agcagattcc tccttagggc 23340 tggtctaact ctagagtgtg tgcctgtgtg cctgcaggag aatgtccaaa gtgggtgatc 23400 ttgatctgtt aacctttgaa ttttaaccta taccagggag ccattgaaga gtttaaagca 23460 agtgaatgac gagtagtttg aaaatatttc caggtggata gaatttgtgg acatacatga 23520 acatgagcag cctcaaaatc agggctggga ctagagtgag gccagcacgt gtccagggtg 23580 caaaatgtaa ggaggcattc actttcaggg cctggcaggt gtggaccctg aacttccagg 23640 accttgagag tgagtgtctc ctaaggatta caccctgggg gcctatttgc ctcatcctgg 23700 tccctggtcc tctgtgtacc ctattgcctg cttcagtaaa caggcagccc tgcaagggaa 23760 ggaagggttg gatcagctct gaggagggag tttttttaga aggatagatt tgttttgttt 23820 aaaaaacagc tttattgaga tataattcac atcctataca gtttgttcat ttaaaatgta 23880 caattcaatg ttgtgaggtt attttttggt atatccacag agttgtgtga acatgaccac 23940 aatctaattt tttttatttt tttttttttg agacggagta ttgctctgtc gcccaggctg 24000 gagtgcagtg gtgcgatctc ggctcattgc aacctctgcc tcctgggttc aagtgattct 24060 catgcctcag cgacctgagt agctgggatt acaggcatgc cccaccaagc ctggctaatt 24120 tttatatgtt tactagagac ggggtttcac catgttggcc agactggtct ccaactcatg 24180 gcctcaagtg atccttctgc ctcagcctcc caaagtgttg ggattacagg cgtgagcccg 24240 acccaccgca gtctaatttt gaaacatttt ttgtccccct agaaaaaaac ctgtagttgt 24300 cacttgccaa tctactgccg tccacctcta accatagaca gcccctaatc tactttctgt 24360 ctctatagat ttgcctattc tgaacacttc atctaagtgc aatcatataa tatgtggtct 24420 tttgtgtctg gcttctttga tttaacatgt tttcaaaatt cattatgtca taatacatac 24480 cagtaatcca ttctttttta atgacttatt aatattccgt tgtatagaga catcacatat 24540 ggtttatcct ttaccagtcg agaggcattt ggattgtttg cacttttggc tgttacggat 24600 aataccgctg tgaacattga tgtatgtgtt tttgtgtgtt gaatgtgagc tggtgtggaa 24660 actcctcctc caggggggcc ttacctgtga ttctacccac ggggatggtt aagccagcag 24720 ggatgggaag ggtttggtcc tgctggccct aggctttcct gcaggctgcc atgtgccttt 24780 cttctgccta ggctgaaacg gaggctgccc tggtttctgg cactgccctc gtgagtgtgt 24840 gggaaggctg ggggaagcca agtctccatg gtgcctccat cagggaccct gcagctggga 24900 ggcagccaga gggccacagg ttggtagcat tcacacagag ctacatttct tttttttttt 24960 tttttgagac aatcttgctc tgtcgcccag gctggagtgc agtggtgcga tctccgctca 25020 ctgccacctc cacctcccag gttcaaggaa ttctcctgcc tcagcctccc aagtagctgg 25080 gactacaggc gtgcgctgcc atgcccggct aattttttgt gtttttagta gagacggggt 25140 ttcaccacgt tgaccaggat ggtcttcatc tcccgacctc gcgattcacc tgcctcggcc 25200 tcccaaaaag tgctgggatt acaggcgtga gccaccatgc ccagcctaca tttctttttt 25260 ttttttcttt gagatggagt cttgctctgt cacccaggct ggagtgcagg ggcaccatct 25320 ctgctcactg caacctctgc ctcctgagtt caagtgattc tcctgcctca gcctccggag 25380 tagctgggat tacaggcaac tgccaccaca cctggctaat ttttttattt ttatttttta 25440 atagagacgg agtttttcca tgttgaccag gctggtctcg aactcctgac ctcaagtggc 25500 ctcaagaggc caatccgcct tggcctcccc aagtgctggg attataggtg tgagccactg 25560 cacccaccca gcccgtagct acatttctgt cagctgtttg caaactgtgc cccagaatcc 25620 cctggaggac ttgtagaacc accagttact gggttacgcc cccaaatgtc tgatgctgga 25680 gatgaattat cttgggtgga gccctcaagc cgcagcagct gataagcatg gggacctcct 25740 attctgataa aaattccaaa aaagtcctga gtgattaata aacagcacat tgaaaattag 25800 aaatgagttc tatggcaggg gatgaaacag gcaacaaagc ctattttctt tgcaatgaag 25860 cgcatcagat attaataata gccattgtaa ttatctttat catgtattaa gcattttgtg 25920 tttttcactt ttacacaatt agatgatccc cataggtatt accgcctttt tttttttttt 25980 ttttttgaga cagagtcttg ctctatcccc caggctggag tgcagtggca cgatcttggc 26040 tcactgcaac ctctacctcc caggttcaag ctattctcat gcttcaccct ccttagtagc 26100 tgggattaca ggcgcctgcc accagaccca gctaattttt tgtatctttt ttagtagaga 26160 cagggtttcg ccatgttggg caggctggtc tcgaactcct gacctcaggt gatccgccca 26220 cctcggcctc ccaaagtgct gggattatag gcgtgggtca ccacaactgg acttactgcc 26280 catcttttaa gagatgagga cagaaagatt gagtgacaca gttatgtctc ctgcagctct 26340 tggttcacat agccaggatt cgtatcaatc tatttagctc taaatctagt ctcttaatca 26400 cagtaatgaa ccgttgacag ttttacgagt aaattatcaa gagttttgat aggtttgctc 26460 acttaaatta gtgcttgtac agtaatgggc tgtgttagtg tgaaggaatg tatcttatgt 26520 tggaagtact ctagaattaa atgttaactc ttgctaataa agcatacatt tggggcatta 26580 ttagcaactt tttttttttt tttttagcaa aattagaggc ttcctagttg agtggtttat 26640 gttatttata tttatttatt tgtttgtttg tgacagggtc ttgctctgtc acccaggctg 26700 gagtacagta agtagcacaa tcatagctca ctgcagcctc gacctcttgg gctcaagcag 26760 tcccctgcct cagcctccta agtgcctggg accacaggtg cgcatcacca cgccctgcta 26820 aatgtttaca gtttttgtag agacagggtc tcaccatgtt gcccaggctg gtcttgaact 26880 cttgaattaa agcaatcctc ttgcttcaga ctcccaacat gctgggatta caggttgtgc 26940 cactgcgcca ggcctccatg tatttgaatg aaagagcaga catctcctgg aggtggcaaa 27000 gctatgcatg ccccccctgg aggggagctg ggggctctgg ggttacagtg atggcacatt 27060 cagggagctc tccgctttgt gagatcctga gataaagcca aaggatgcat taaactgctt 27120 ctaaatgaac tttttccaag tgaatttgtt atatcacttc tatataaatg aaaatatttg 27180 cagcatgagt actaacaaga tttttttttt cttttacccc gatggagtct cgctctgtcg 27240 ccgggctgga gtgcagtggt gcaatcttgg ctcactgcaa cctccgcctc ctgggttcaa 27300 gcgattctcc tgcctcagcc tcccgagtag ctgggattac aggtgcgcac caccacgccc 27360 agctaatttt tgtattttta gtaaagatgg ggtttcacca tgttaaccag gatggtctct 27420 atctcttgac tttgtgatct gcccgcctcg gcctcccaaa gtgctgggat tacaggtgtg 27480 agccacgctc ccggccaaga ttttaaacat tatttaccaa agtaggaacg tggtaattat 27540 ggtcttatat aattctgaaa atgatttcta gtaccaaact atgaatttta tacttgaaag 27600 aatgatgggt ttttcacaga aagttgaagt tattatggtt tgtnttcctg ttcanggtgt 27660 ttttgctgga gaatgttcga tgaacagcag ttctggtgat aagttatgga tgtacacagc 27720 tggtgtggtt tttaggattt tattttgcag cagcatcttc ctcaaacagt tgccagggga 27780 aggctttcct tcttcttact ggtaccagcc tttctcttgc agacaaggca gtatgggagg 27840 gttgggagac aaaacagaag ctgttggttt cttcagcctg gcaaggattc agattgcagg 27900 ttatagattg gaggccgtca gtggggatac ctttccggac aaagtggtgt ttctgcctgg 27960 cactgcttgc cagagaagtt tcagttcttc attctccgtc agagaaaccc atatggacca 28020 cattctgata gttttcttct gtttccctaa caccgaaggc tcagcccctg gtgcaggtcc 28080 cagtgtacag caggctgcat acagttagac cagatgttct tgtagtacga aaagtcaccg 28140 agtttccatt cacttgtggg tggcaggtat ggccctcctt acctcccatg gcccaggttt 28200 ctctgtcctg ccgttttcac attttccagg ctttcacctc caggtaccaa aattcacatc 28260 atttagagat tgtgtctgcc tgccaatacg cggatgtacc agtgagggat tgttctcgcc 28320 tgacgagagg tctggatgat gagagagcag agctggccct ggggctcagt ggtgacaccc 28380 tcgagcttgg ctgcttctgt tcttctgctt cctctgcttg gattccttcg cctttggctt 28440 cccctccagt tccaagcaga acaaaacagg agatatcaag gaggaaaggg tgacccctct 28500 atatctggag agcaaaactg tcgcggaaat ccctagtgta cttccatttg tgtctcatta 28560 tctgaaaccg agttacctgg ctggtcacgt gcagccacca gaggcaggaa ggtagtgatt 28620 ctgcctgtgt ggaatgttct agcattccct ggtagctttt gtttcttcag gcagccatga 28680 ctttgcatag atcatttcct tttgcccagg acactcctgc tcgttttctc ccctcctcac 28740 caaacccaca gtgcattaac agcgacagac ttctcctcat cctctcaggc cacttggatg 28800 tcaccatttc ttctctttac ccctcaggcg tagtcagcct ctctgtgcct gatgttttat 28860 ggctttgtgt atgccccgat ggagagcgtc ttactgtgtc ttcgggttat ttatctcaac 28920 ctcgcatctg tgctatcctg tacagtaacc aacagccaca tatcactatt taaaattaaa 28980 tacaaactaa ttatacttaa atgtaataaa aatgtagccc ctcacattag cctcatttca 29040 agagccacat gtggctaccg tattgtaagc agagctcaag aacattcagc aatattgtga 29100 gagtggctac catattgaga gcagagctct agaacattcc cttatcccag aaagttctct 29160 tggacatgct gctcaaggtg gtgaactctg agatctccag tccccccagc tccgtcactc 29220 agaaccacaa atgtggcacc atcagccttc agggtggtgc ttgtgttgta ctgtctcctg 29280 actaaagaag taaacttcag gcagtcaaga ttttctacaa cccacactgc tcctaaaact 29340 agtgttactg gatatgtaaa agctattgag cccagtgctt tcaaggaatc ctaaaagcaa 29400 gtggggactg tcatgtatcc aggttccttg ttttgcagaa gaagaaatag aggctttagg 29460 ggaaaggggt ccactcaagg tcatacaggc aaggtcatac agtcagtggt agaatggact 29520 ggaatcttga ttgttcatct cactcccctt tccattaagc cataactgat tgagtatcac 29580 caacctgttt gttttccctg attatgttcc cttctcrcct gtttaatcag gtttcagctc 29640 cttgtgagag gaagttgttt tcagcttctt agccccctac ctgtaggcgg tgctctggga 29700 acgctcagga agcagatgca tgtgagcctg tctcagccaa tgattgctta gttgcaagaa 29760 acaaaaaaat gactcaaact agcttaatca aaaggaggct tttaaacagc aagataaggg 29820 taaaggctgg gaactaggaa gttgtcagga accaaggctg tctctctgga tctctctttg 29880 aggccatgta attttttttt cctctcggtc tctttattct gcacaccagc tcacccagct 29940 tgcttgttac tatatgcagt catgccaacc cccagatctg tatgacctgt tagcctcagg 30000 ggcacccaca tagctggctg ccaatctgtg ttttcttcca ggtttcgaga gggagaaatg 30060 attggcccag ctcagggtca cttacccagg gagaggtggg ggaagtatgg aggcaccgtg 30120 gtatcaggga acccctgggc caagcttgtc caacccgcgg cctgctttct ttcatttttt 30180 ctgttttttg ttttgttttg ttttgttttt ttacagctca tcagctattg ttagtgtatt 30240 ttatgtgtgg cccaagacaa ttcttcttct gctgtggctc agggaagcca aaagattggc 30300 cacccctgtc ctaggccatt atctgggctg tgggaggtgt ggagcagggt cagagctgga 30360 gggggagggc atagcctcca gccaccataa gttggtgtgt tcttggtaat tatattgctt 30420 gtcaaccgaa ggcagaatca ggacaatgaa agtaatgaga atccctagct ttgtaacagt 30480 tagtggttat ctaaaagtag gtgaaattgt acatgagtga gtggcatgaa tttcttatta 30540 ctaaagtgct cagatagctg gctaactttc tgtcaaagat ccctctgcta ggatcaacat 30600 ttgattaata tatttatcct gtaataagaa tttgggattc ttaaagcaaa atagttgtca 30660 tgtggctgac tacacaacca aagatggtcc aggtgtcgct ggaagaggag agactgaaga 30720 gctgttgcca ggttcccacg tggaccttcg gcatgacccg gccatgggga ggcctcacac 30780 gctcctgcat cgcccacatc ttgccaagcc atggaaaaca cttgggattc atatctaaat 30840 cctagtttaa gcttggtgag gacagtggcc tggtgcagag tttgggtcat agatggtgct 30900 tggtttcttt tgtataaagg ggtatatgat tttggaatat ttaccaaatg tgggcatttt 30960 ttctataaaa attattgtat ctactgagat tatagtatgt aaaaaaaaca tacacatgga 31020 gaaagaatac aaagagagca ttgatattct acagaagtgg caagaagatg tggtgatagg 31080 tgatattttt gccttttgtt tcaattttgt attgtagtga cttttttggt agaaaaaact 31140 aantttctaa ttaagggaga aacatttgaa gtacatttag tctttctaga aaacctcatc 31200 ttctcataga agtttaagat ggagacatac ttccattgtg aatcatgatg ctaaccagta 31260 ttcagatttg ttggaaatgg actcagtttt aaaattgctt ctctcttgtg ggctggaact 31320 gcaaatgatt gtttggggat ttttcccctt ttcttctatg gagttattca acttggcatg 31380 accagtgatt tgagctgaga acatggaacc cttgatttgc agaaatcaag cccccaaagg 31440 tacagataca gtggtcattg tctgaagggt ttcttttgtt cttggccctc ctgtccctgc 31500 tcttactgtg gcagctgcag ctgcaggtgc ctctgaagcc ttgccatcca tggtcacttc 31560 ctgcctgctc cccacccacc cctgggaaag agcccccaag tgtccaaaag cactgtgttg 31620 cctaatgctt gttgagagtc tacatttctc tagatctagc agaagtaaaa tttcagtttg 31680 ttatatttat agtttcagga atagtttggg aatggattta ataaaaaatt taaaagccca 31740 tcatttttat atctcttttt cgatatttga tggtttaaaa gacatcaaag ttatcttctc 31800 ccattactca tcctatacaa ttaaaacctg ttttttgaag ttgtaatagg taagttagcc 31860 ttaggtcacc ccatatttat gtaaactcca gcccactgcc acagctactt tgattgtgat 31920 ctgtcattgt gttacccact gtagggcaga aatggttcct gcctcatgcc gttgctgctt 31980 tactcttcct gaagtggtgt ggttctgtct ctgtagtcct tggcacactg taggttctca 32040 gatggcaggg tgaaaagttc ttctgtttgc ttaaatctct cataataccc tgagtctgtg 32100 gagctcaata aattctactt ggtattattg atagattatt tggagccttt tatgttagaa 32160 aagggattct taatccaatg ctccgtttta cagatgagaa gactgaggct caaagaccat 32220 acccccagga gccatgattt gcactgtatt taggaatagt gtctagggtc agcacctggt 32280 gttggccgac tgcagagcag cctggttagg agccctgggg ttgggcgggt ctgggctgct 32340 ggtgccacag cagtctccct cccctgggac tttgggcctg ctacccaccc ctgttccttc 32400 ctttgtgaga tagggctagc agtaactgtc ttgtttcatc agaggcagta ttgcataatg 32460 aatgagagct ggggcctaaa ttaggcacaa gtgcaagccc tcagaaaact atgtacacct 32520 agagagagag agagacacac gtctgtatga cagagaggca gggtttggga atgttctgat 32580 ttcatgtttt gaattggtgt gacctttggg aggatatcct tggaatcgca gagcttcgtt 32640 tacatcatga ctttcctgcc cacccacatt ttctgagaag ccagagtttt aaatgtggac 32700 cccgtgagct tttctctgtt gcctcatttt ggcctgtggc cttttgtttt cttggtatgt 32760 catgaggcaa aataaaatga aactcagtgc tggttaataa ctcccatcat aatgtatatt 32820 tctgtgaatg gctttttagc catttgagag gaaaaagggt catgtaaatt tcagaaaggc 32880 ctgattggct ggagagtcag tgtagtgtca cagttaagag tatagattta aaaaaaattt 32940 tttattgtgg taaaaaacat aaacataata ctaccatcta aaccatattt aagtataaag 33000 ttcagtagtg ttaagtatat tcacattgtt gtgcaatgga tctgcagaat ttttcatctt 33060 gttaaactga aactctatgc ccaataaaca actcctattc cccctctccc agcccctggc 33120 aaccaccatt ctactttctg tttctctgag tttgactact gtagataact catttaagta 33180 gagtcatatg gtatttgtct tcttatttct ggtttatttc gcttagcata atgtcctcaa 33240 ggttcattca cgttgtagca tatgacagga tttctctctt ttttttccgc cttttttttg 33300 agttatattc tgttgtatgt atatttaaca ttttcttcat tcatctgttg acattcatct 33360 gcttccacct tccacctttt ggctattgtg aagactgcag ctatgaacat gggtgtgcaa 33420 atgtctcttc aagatcctgc tttcagttct ttcggatatg tacccagaag tgggtttgct 33480 ggatcgatca tagtgtagtt ctgtgagtaa ccctcatact gttttctgca gctgctgtac 33540 cattttacat tcccaccaac agtgcccaag ggctccagtt cctctacacc ctcacccaca 33600 cttgtaatct tctggattgc agattttctg gatcaatctt ctggattaca cttgattttc 33660 tgtgttgggc ctggatgttt agaacagtat ccctcctttg gagtggtaaa tatgtaagtt 33720 tttattataa aataatggcc atcctagtga gcgtgaggta atatctcatt gtggttttga 33780 tttccttcat agttaatgtg gttgggcatc atttcatgtc ctggtcggcc atttatgttt 33840 catatttggg gaaatgtctt ttcaagtctc aagtcctttg cccatttttt aattgagtta 33900 tttgattttc tactgttgag tatggattat taaatcagac tggcctgaac ttaaatcatg 33960 gcccttccat ttttgaccaa aagcagctgt gtgtcccatt tgtgccttgg cttcttcggt 34020 gtaatgccgg cataatgata gccccacctt gtagttaaga gtgttggggc agtcagtgag 34080 gaagcactca ctccacagga gcttgttacg taaggagaag gcagccggtc cattcctaat 34140 aggggtctga aggaaggaag aagggctgaa ggaagtaaaa agagcctcct ccatgaatgg 34200 cagccattct tgaaatccac cttggctgcc ttcattttta atgtcagtgg acttttaaga 34260 caaccaaaag gatgttcttg gatgaccaga gactgtggca gagggaggat ggtcacattg 34320 ccaaggatct ctctcaacct cttggatagt gtgctgctgg tagtttgcac aattgcttca 34380 gctttttggc aaagtacatg taaaatcctg aagtcactgc cagaggaaac ctggttcctg 34440 agatagcagc ttgatgctcc tgccccatcc caggtgcaca cctcactggg cagctctggc 34500 tctgaattga gggacagcaa aaacctctaa ccaaccatac tgaaaagcag gcattggggg 34560 ctttagggga aggttctttt caaaactcat gatggggaga gaccaaagac tgggaatcat 34620 tgtaaagaag ttagtcatag atgcttcact ctttacaatc atcccaacac aaggttaaac 34680 aacatgcagt tttcacgatg tcccagaaag cgacgagtgc agtgaggtga aacgtggcca 34740 tctgagcaca caatgaccag gcttggaagg atcgatttcc cctgtgctgg ccctcagaat 34800 ttaaggcaca acttttaagc tgagtgtgca gcactcgatt ttctatgttg ggcctggatg 34860 tttagaaaag tatctctcct tcagagtggt aaatatgcaa attttttact gaattacttc 34920 atttaatcaa agcagccgac ttctcctgcc tcccctgttt ctgtcttggg gttgaatatt 34980 tggtcccatg taacaactct tgattcttaa tgatgccaca tggaagctgt gtgtgctggg 35040 atttgccata ttcagttatg gtcagtagag actttcttag tctctctctc tttttttttt 35100 tttttgagac aaattcttgc tctgtcaccc aggctggagt gcagtggccc aatcttggct 35160 cgctgcaacc tctgcctccg ggttcaaatg attctcctgc ctcagcctcc cgagtagctg 35220 ggattgcagg cacgcgccac catacttggc taatttttgt atttttagta gagacagggt 35280 tttgccatgt tgtccagact agtcttgaac tcctgacctc gtcatccgcc tgccttggtc 35340 tcccaaagtg ctgggattac aggcgtgagc caccgcgcct ggccacagtc agtagagact 35400 tttgaaagga aatattacct ctttaatgat gtttttagtc caagtaaatt gtggtaatgt 35460 ttaagaaatt tgcttaccac aaaaacagtt ttcaaggagc atttgaactt gtccacttta 35520 agtcataaaa tggattaaag tgtttgaaat ctattgggat tgtaaattta tgtcagtgta 35580 ctgactttca agagatcttg atgatcatgt cgtctgtttt cattttctac tacatgagaa 35640 cattgaagcc tgaaacttaa cacaaacccg agttccccac ttgcctaaga gtcatggata 35700 cctaaaaagt atgctacttc ccaagttgat ttctttcagg atatgggccc ttcaaaggaa 35760 agcagtgagg ctggggtttt ccaggtggaa aggtcacatt tccacatata actcagcgaa 35820 cattgtgttg ggttgggaga agaattggtt cactatttta aactttttgt ttcatcttga 35880 ggacttcccc atcccctctc ctccgcaaag cacaaaagta tttcctaatt tttaagtcat 35940 gggcttcctt taatggattc tgaactcaga tcacgtccag ataagcattg tgtaatggga 36000 tgggtggggt tagatatttt agtcacagat gcatgagagg agggagggtg gaggacagca 36060 aagtttataa ctggagccta tagtagttta tctcttgtca tcggccaggt cacagagtct 36120 cacttcagga cagctgtgca agcagaaccc ccatcacggt tttcttgatg cctttgacag 36180 tcacctgtac atgcctctgg gacctttcct cctcctttct ctttttgttt tttttccctt 36240 ggtcacatgt ttcattctac taaatgtcta accagctctt ctctgtaaat tacagagctg 36300 tgatggcacc ttgcttgttg attatttctg gttgaatagt ttccaatggg acttctctgg 36360 agataagtcc tgtattagtc cgttctcaca ctgctaataa aaacatacct gagactgggt 36420 aatttataaa ggaaagaggt tgactcacag ttcagcatgg ctggggagac ctcaggaaac 36480 ttacaatcgt ggtggaaggg gaagcaaaca tgtccttcac atggcagcag gagagagaag 36540 tgccgagcaa aaggggggaa agccctttat aaaaccatca gatctcatga gaactaactc 36600 actatcatga gaacaggatg ggggaaactg cccccatgat taaattatct ctgcctgttc 36660 cctcccatga catggggatt atgagaacta caattcaaga tgagaattgg tggtgacata 36720 gccaaaccac attaaatccc aagtgcgcat gtctggccct gatcccttta tgtgagactg 36780 gggtcatgat cctcccgcac ccgtcttctg agccctattc ctacttgggc atgcttaggc 36840 acttcagcat ctgcatccca ttgatgtctt aagggtggtt ccagaccttg gaggtacaca 36900 cgacacactg ctgatgaaaa cctagaatat agaatggaag ttacatttat tcatagagtg 36960 aaaatccaaa aatagaccag agagaagata tgaaaatatc aagaatgctt atcttaggga 37020 ggtaggatta taggtaactt tttttttcct tagataaata tatagataga tatattagtg 37080 tttacagttt ctctgccacc aaccaaaata tttttttcag gaggaaaaaa aaccccagcc 37140 agccaacata cctaaaaacc atctcctggg cccgagaggg aaaaattggg ctccttttct 37200 tgaaattgcc atttgtgcca ctgttgtatt attttaccag taactccaga ttccaggctc 37260 ctgtatctga gttctctctc cttccacagt ggagctcata ccttcctgtt tcctggctgc 37320 cactcagatt taggctccgt ttttcagacc tcagtggctg taatagctgt tccttctacc 37380 tcttaggatg gttctttctg taatagcctt tgtcatcaca tcatcagagg atgatagctc 37440 ttaatgagga tctaaaattt gcaggtaaga tatccctgcc tctgacatga gatagatgta 37500 ttgcatgcta tttaacatac aactatactg agtgtgcagt tgtatgtaaa agcattgttc 37560 taggtattgg gttgaaagtg gatcaaatgc tagacaaagg agcgtacaag tcttgtaagg 37620 aagacagctg ccaagagaga agaaaggatg gggaaatgct gcgtctacta agttcaaggt 37680 tctgaattgg aaagctgcag ctattgagga gaagagtctt ttaaaattcc taaagggttt 37740 ttgttatctt ttattgatgc aaatgctatt ttgtggcata aaccttaata attttggggt 37800 tgaaactctt atcaggataa aatgatcctt ttctatccca agcttaataa atattgttta 37860 agtacaaatt aaatatatga aatctgccca tctatattat aaatgtcata tggcagaaat 37920 tataccttga cttttggttc tttcacaaaa ccttaatttt tttttttttt ttttgccttc 37980 aatgaatttt gtctgatttt acattaaaag cctgtaattt ctcaagtctt gagtctgggg 38040 agccgtcgtc atcctttttt cccctctccc ttgtcttctg gatgttcaag cgattttaat 38100 tagatgttgg gcttttatgt caagtgctgg cattgcactc catgataatc cagggactcg 38160 gaagcacatg ttatgcgtca ccctgggttg gtgcagtgga actggggtgg gttggaagta 38220 gtattctaaa tctgcttcct gcgatggggt aggtcaggtt gtcctgtgtt gacaaggaag 38280 aagtctgggt gaggaagcgg gatgaaagca gaccagacgc tagagtccac tttcaagtcc 38340 gatcccagga cctggcttaa agttaaagaa cagcaaagat gaaaggtgcc gcacagcagc 38400 acaggtcggt ggccacgtta atgacataga aagcaagtgc tgtgaattca aaagaaagga 38460 cagctctgag ccagagtact tggtgacttt gctcaaacaa atccctttct ggcaccccca 38520 ggccttccct cccgcttcaa aaaaattctg aattgtgcca atccattgag gctcagctca 38580 aggccatccc atgcctttcc atcgtaataa agccttgttt cctgggcttt aaacatattc 38640 cttttttctt aggtacagat tgaacttttt taaaagggaa gttgtcagag gctctgtaaa 38700 acgttaaatc aaacctgctt tgttttaggg atggggtagc ttggaatcag atttgctcct 38760 gctatggact gaacatttgt gtccccccaa aattcctatg ttgaagccct aatgcacagt 38820 gttatggtgt ttgaagggag gcccttggga ggtgattaag tttagatgag attgtgtgag 38880 tgaagccctc atgaatggga ttactgtcat cccaaaaaga ggtagagacc ccagagcttc 38940 ctctctcttc accctgtgag gatacagcaa gaaggaagct ctctgcaagt caggaagaga 39000 gagggctctc actagaatac acttgtactg ccaccctgat cttggacttc ccctccagaa 39060 ctgtgagaaa caaatgtgtg ttgtttaagc cacccagtcc ctatgatttt attagagcag 39120 cccgagctcc attctccact ccctggcttc ctgcatggac tttgcaacca gagcttcacg 39180 gggtatagtt taatagctgt ttctctgtaa cgtagccact tttctctttc caggtctagt 39240 tttgaccctc ataacacttt gttaggggag atttgagggt gaggaagttg gcttgctttt 39300 cttttcacca tgtctcagta gaaacagaag cagaaaggcc ctgagatact gagcccacct 39360 ttctcagcag ggtgtgacag cccggagtac cctgggctga ggaggccagg gctggagggg 39420 aggctcccac ggtggagggg ttgaaagctg ggttgtaatg agctgctttt ctgtagatgc 39480 ctaaatgatg tgggttgaga aatcgtgatc ttagctttta gtagtatatt tttctgttta 39540 tgttaggtga gtcatcagtc tgtctctgac tatgttcaga tctggaagtt ttctggaagg 39600 aaatttgtta ttgctgtaat agtgtaggtt gttgatctgg attagcaggg agcggcccct 39660 taatacattc ttaagaaaat ggtatttagt tcagtctttg gctttgaact ttgcctttga 39720 caaagatgaa agtgcgactt gactggtgtt tgaaaaacat ggtgatatgg ccaggtgtgg 39780 tggctcatgc ctgtatccca gcacgttggg aggccgaggc gggcagatca cctgagatca 39840 ggagttcgac acctgacttg gtcaacgtgg tgaaacctca tctctactta aaatacaaaa 39900 aaattagcca ggtgtggtgg tgtgcaccca taattgcagc tacttgggag gctgaggcaa 39960 gggaatcact tgaaccctgg aaggcggagg ttgcaatgag ccaagattgt gccattgcag 40020 tccagcctgg gcaacaagag cgagactcca tctcaaaaaa aaaaagcaag ttatattaca 40080 ttttaaaact ctatttaatg gtcaggtcat ccatccataa tgggtagagt cattgcttaa 40140 ttaatttaaa acaatgtatt taaaaggtac ctttgttccc tagtgtcaca taacgtgaaa 40200 tatccaatta aggtaactgt aatgtaaagt aagtggctaa aaaagtgctg aacgccaaag 40260 gccagagatt caaccttttg tgtgcattag aatttcccaa ttgttcaaat ccaggttgct 40320 ggatctaccc cagagttttt gatccagtag gtttggggtg ggaccaagaa tttgcatttc 40380 taacaagctc ccaggtggtg ttgaggctga agctcgtgtg gggaccacat tttgagaact 40440 tctcccgtag actgaactca tggtctaggt tctgtcagct gtgacccctg tgctgctgga 40500 gggagtggtc agatgtcctg acctctgtgc ccacagtgag gtccaagctg agtaggtttg 40560 accagcagct gtaatcacag agtgaacaat gtaaacgacc aatgttgggt ggtctgacat 40620 cttttaaaaa aaatccacgt ggatgagatc acagggttaa gtgtgggcag cagtcagggt 40680 aactccatgt ggttactgcc catgcactct ctgctgtttt tcacctcttc ttcagagtgt 40740 ggtcaggatg gtggccttgc ccagcacagg aggccctttt ccttctgacc acctgacctg 40800 acccacctct tagcatctgc aggcactccc tgtcccttcg ctgggccccg tggggaacta 40860 cttgcagtca tcaaattcat catgctgctt tcttttaatt cccacacttg ccaaggtggg 40920 actgccccgc atctccttcc cagtcgtgtg tcagaactca gcactggacc tttccccttt 40980 ccccactccc acccctcctc accccgacga acgtctcact tgggatcatc tcttctgagg 41040 ttggacctgc acagccgccc tctgcactct cgccacctta tgggctgccc ttgacccctt 41100 ggcacacaga cctggaagtt ggcctgctca gctgtctcct taggggtgga gcttggtttt 41160 ctttcatcac tgttctgcga tgaattgaat gcatgattgg tcacaggaag gtaggggagg 41220 gataaacacc ttatgatatg tttcttataa ggttttatat gtagaaagtt atatgaaagt 41280 gtcagatatc tatatatgaa gtatatgtga agttttatga tagttttgca taatttaaga 41340 ataaactctt taaaggagct gagtcccaat cccttgggtc gagagttgcg tggctcccgg 41400 ggcctgcttg tttccttcca ctctgcgtgt tcgttgctgg cccctcatag gctgtcccag 41460 acctctttga cttctctcct ttctgcccag tcttccctga gacgctccag gctccctggc 41520 ctcctgcttc tcggagcttc tcttgtgttt gttttctgtg ctcagggcgc catggtgcta 41580 taggccacag aggaggcgtc tggggtccct cggggcaggt gcagcaggag gaagccgtct 41640 ccgagggcat gaccttggaa ctgagcattg acagaggaga gtcagccaga caaagaaagg 41700 ccaaaacccc acccctctcc caccctattt ctacgtgacc atgggccctg gacacagcaa 41760 gacggtgacc ccgggcctcc tattgttgcg aggagcccct gggaaaatgt tggcattttc 41820 ttcatagaac aggtttctct tctccagtat tcttcagtaa atcaactttc ttttttatcc 41880 ccaaccccag tctgattgcg aagaagtcta agcaacagaa agattttgcc aaatagatta 41940 tcttttttag aacaaaatag atcatgatat taataggaat tcagcactta ctcttgtcta 42000 agtactgttt ttaagtgctc tcaaggattt ttcatttaat ccccacaaca aagctgtggg 42060 gggtggatgc tattattatc ggtgatttat gaatgaggaa actgacacag aggggtggtc 42120 gaggagcttg cccatttcct ggtagttagt accagggctg gcatcatcag ttgcctgctc 42180 cttttcctct ttgcttttgt gtccattacc ccaaggcatt aggatgagcc agccaagttc 42240 tagtcctgga ttcaccacct aattagctct gtgtcccatg tcttgccgtg gagggataaa 42300 accaattcct agcttatccg ttggtggtga agatgaaatc agtggggtac ttgtaaagca 42360 cactgcccag cacatagtaa gtgcccagaa aatgtgacgt cggacctctt taagcttcag 42420 tttccacatc tgggaagaga gggggagttg agctaagtca ttttccagtg tccctttcag 42480 ctccatgttc ctgtgagcac tgacagtttc cccacaatmc tgaagaaaga aggaaaataa 42540 gggcggggtg gcgaaggtcg ccactgtgac gtggctgctg gtgggaagtc cctggggagg 42600 caaggcccag cttcccagac acagccctca ggtgctcatc ctggtggcac tgaccagggg 42660 ccatggtggg cttttccacc ccaccatgtc tcataaaatt acaagaacca cagttgaaaa 42720 tcagtgttac agaaatggta ataggatagg gcaaactgtt acaaagatca gcacttaaga 42780 ttctggctga ggcggaatat ttgtttctct ttagttttgt tgtctttaat caagaactga 42840 gagccctgac tttcagctcc tcaaaaaata cagcttcctt ccccttgcag atgcaaaaac 42900 aaacgccact tctttccaag cataattttc tcccatgcgt tatctcctgt ctacagcttt 42960 ttcttgatcc ttctccagct cctgtagacc tcccatttag agccaccagc cgcccatcac 43020 tggggctgcg cagagctctt ggtgctctgt gccctgggct cgcccaccca ggcctgttct 43080 ctgngcctct tcctggttct cttccctgga cttcccactg ccgtgtggnc ttcagtgctc 43140 ctctgagctg ttgtcatgac ctctaaccag actgagtcag gacttttttc ttcctcatct 43200 ctaagtcatc cttacacagc cttggaagtt taccctaaat ggctattttg ggagggagtg 43260 gggataaaga tctgcaggcc tcttgctcct ggtccttgtt tctgcttatc ttggcttctg 43320 tttttaagtg tgtgtgcacc tctttcctca tcacaccctt cccctccgta tggctcccat 43380 ctcaggcaga gttaggtgct ctgttctgtg tccatagctc tttttcgagc ccttcttctc 43440 actgtttggt agtggccttt catgtgtgtc tgatccacta ggctgtgcac tccctgcctg 43500 ccaggatatg gttaaagtgc taaagaatgt atatatgaga tcacttttgc ttaaaaaacc 43560 cccaatcttc tggaattccc aatttctaac caattaatat gtggattgac tagaccttaa 43620 gcaaccaaga gtcagccagc cttgtcttct atattcaggc gcatactatc tggtcgttag 43680 acaaaatggg tcattatcag tgatgagtta ataattacct gcacatcttg tttatgctgg 43740 ttctttacct aaagtggctc ccatcaatta aacctgtatg gattttacct gttcttccag 43800 aaccacccca ctttccacaa aaactgacaa caatgatggt aagaagaatg gtagttgaca 43860 ttttattaaa tgtttactgt gtgcaggctt gtttttttcc acacatttac ctacttaatg 43920 ctcacaataa tcctatgaac tagtcagttt tatgcagatt tcgcagatta ggaaactaag 43980 gtggcaagtg atcagataac ctgtttgagg ttgagtagct agatcatggt agagccaggt 44040 tcaatcccag atacctggct ccagggccca tgctcttgac cttataaacg gctgaaattc 44100 atcttttttt gctgaacttc cagaacactt tctttgtatt tcccttattt tggtagtctt 44160 gtacttctct gctaccctga ttcatacttg gatttctagc agcatgcctg gcatgaggca 44220 acaacttaac agtatttctt tataccaaat gaatgttgtc tttttttttt ttttttttct 44280 tgagacagag tctcgctctg tcgcccaggc tagagtgcag tggcactatc ttggctcact 44340 gcaagctccg cctcccgggt tcatgccatt ctcctgcctc agcctcccaa gtagctggga 44400 ctataggcgc ctgccatggc gcccggctaa ttttttgtat tagtagagac ggggtttcac 44460 cgtgttagcc aggatggtct cgatctcctg acctcatgat ctgcccgcct cggcctccca 44520 aagtgctggg attacaggtg tgagccacca tgcccggcca tgaatgttgt ctttaaaaaa 44580 ttctgttttc ctctagctag actgtcatat aatgcaactg taggaaataa tcaggttctc 44640 tttggagtat tttccataaa agatccacag aagtcatggc agggttgaga gtggacttgg 44700 gcaaatgaat ctgttcattc attgaatatt ccatgcatat ctgctgtttc ccaggcatgg 44760 gatatggcag ggaacacaga aatctctgcc tcctgggctc tgctttctgt tgtagtagag 44820 gtaaagctgc tcatactttg taaacaatat gacaacatta agtctacatg gtcattttac 44880 tttgtttttt tctaagaaat tttgagctgt tcgtaacaac agacgctgca gatgttaatc 44940 ccgttgttgt taacttttct ccagagattt aatgttcaat tttctccttt ccagaatcga 45000 tttatgttgt tcaaacagag gtttgagaat aactggaatt tttttaactt cttttttttt 45060 tttcgcatgg agttcagaat tttcaagagg gatgaagaga gttataaaat gctctatggt 45120 gggtaacaca cagaaaaagc cagaaaattg gagaataagg atctgtctac tcgtttcctt 45180 ctagagctcc tctttcttac agggcactta acatgtgatt taatgtcgtg tctttaaaag 45240 gaggagaact gcagttcaga acttaatgtc agtgctttgt gaaagtgcaa gaaagaagcc 45300 ctgtattctg cacttgagag agccagatac tgggcagata ggaggtggtg tgcacgttgc 45360 tttttgtctt tctcgatcat ggcattgatt ctgttcataa caatgatgca atgtcatcct 45420 cttccccaca catttgtgtg cagatagaaa gaatgcaaca gcacagagtt gttggggaat 45480 aatttggcat ctaaaatatc gacataccag catagatcat atttatgact ctgttgggag 45540 tgtcacagca atgatttaat aggaggcagt tgtctccaag gcctcctgaa ttatgactgg 45600 ttttaaaatt cttagaaccc attggaggct attgtttctg aaaggctaca taatttaagt 45660 gctccacatc cgtcattata ggagatgtca gaatagtaaa atctaatcct ggactaagtt 45720 gttatcgcag ccctttggtt tggtggcttt gccgacttta taaatatgcc tgtcagtgcc 45780 tgtggtctct acagttgggc agtcggcggt gaatatcatt tctcacattt tacactgggg 45840 gactggaacc cagaaggcat atgttttccc aagaggcacc aacacagttg gcccatgagg 45900 tagagcagcc cctccttcgg ctcagcctcc gctgcactga gccaagccaa gcttcctaca 45960 ctggcctctg tgcagctgtc tctcagcaag aatgcaagtc ggggagagaa gccggatccc 46020 tgggattgtt ctagagagta gaaacctcag agtagccctc cttagaccac ctaacgcatt 46080 gcatcgctgc atacatgtaa gggactcaat gctggtagga ttggcttagg aatgatgcaa 46140 gtgaaaacag tgccccggtt tatcattaga acaaggttct tagctgacag ttgcctcaga 46200 ctttgatttt gttctccttg acctgccact ccactcgagt ccacatctct caagactgca 46260 cacgcctgaa ggaggactga ttacaaacca aagccttgtg cccagtctgg atctttttgc 46320 attgttgaga aagcagctta ctttctttgg actgattcag caggccaaat ttagaacaaa 46380 gatttttaac tatctccctt tataaattac tgagctattt tgtagccagg ctactcttaa 46440 tatgaacaaa aaatattata caaatttgtt gttaatcgta aactataaaa aaatcagtaa 46500 ttgttaccac gtgaaatgaa tttggataaa agagatacgt ttttgcccct tcccagggtt 46560 taggagagac gaaatggtga gattttagct ctgaatcaga ggttcttatt agaggtggtt 46620 ttgttcctcc tgacccctag gggatattta gcaatgccta gaggcattga tggtgggcag 46680 atgctactat gccctctgct aaacattcta cagtgtataa aactgttcct cctgacaaag 46740 aatcatccag ccccaaaatg tcagtagtgc tgaggttgag aaaccctcct ttaaactctt 46800 gggtttattt gctgaccttt acagtggatc agcttttatt tagttcatgt agaggtgaaa 46860 ttaatactag tgctcaaata tgtctttgta ttctggactt ggcctggatc ccccgaccaa 46920 atttgggaca agctcctgcc atgtgttgag gacctgaatt caggcagcta acaacagtat 46980 ttgaactgtg ttttcagtgg tgggagtgaa ggagatgagc cgacgtgcta gcaagcgcat 47040 agggttgcat gaggaaatag agagtaaagc tgcagcgtgg agccctgcta ttcagagtgt 47100 gcttggagaa acagcagtgg aggcattact ggggagcttg atggaaatgc tcccctcaga 47160 cttgctgaat caaaatcttt aatttagcaa gatccccagt gaggcttgtg catgtagaag 47220 ttagagaagc acggggtaaa ctcttctttt ttttactttg gaggaaaata cacctttttt 47280 cttattatgg ctctgaccct tactagctgt gtgaccttgg ccaagttata aaacctcact 47340 gcaccttatt tgttttagct ggaaaatgga gatcataata tcacctgtcc tatgagattg 47400 ttgtaagaat caaacaagct tatttatgcc aagaacccat atggtaaaag ctcaacaaac 47460 tgtcactagt gataataaga aaaagatcac aaaagtagaa aacattaggg agacagctta 47520 ggtcttaaat ctcacagttg tcgtccccaa acaatacttg tatttttgca gatccagttt 47580 ctctgaatac taaaataaaa ccggagtttc ataaacttct atagacagtg gtccttgtca 47640 gtagcccaag tggcagagag tacatggatc tggggacaaa cagcctctac tgttaggaat 47700 gttccatcct cctggcctga gttacacctg ctcattgtga ttccgaattt gaaaggaaca 47760 cagtaggaat tttcaagacc ctgggaagag gaaggctgtg gtaaacagga aggatgagat 47820 tagaagaagg agtttaggtg aggtgagccc ttgttttact agtagggttt aagaatatcc 47880 aagtcagctg gacatggtgg ctcacacctg taattctagc actttgggag gccgaggtgg 47940 gcagatcacc tgaggtcagg agttcgagac cagtctggcc aacatggtga aaccccgtct 48000 caactgaaaa tacagaaatt agcagggcat ggtggcgcat gcctgtaatt ccaactactc 48060 actcgggagt ttgaggcagg agaatcgctt gaacttggga ggtagaggtt gcagtgagcc 48120 aagattgggc caccacactc ccacctgggc aacagaatga gattccgtct ccaaaaaaaa 48180 aaaaaaaaga aaaaaaaaaa aagaatatcc aggtcaaccc cacctaaccc tcagcggggc 48240 tcccttctgt tgcctgggtg ggtcctgggt tctcttgacg cacacgagat tgtgagagtg 48300 tatggaaaca ctgccctcgc tatcaggaca gcgcctgcca tgccagccag aacacatcat 48360 aggaattgca aaactctttt gcaaaccagt gagagatatg cttccaatgt gaggtaaagc 48420 agaactttaa tcacagctgc agtgttccac agaattccaa gagccaagat ggtaaaagaa 48480 taaaaaaaaa gaaaggaaag ggctcaaatt aaagacttca agctgcagaa taagattaaa 48540 taaaaggatt caattgaact gcatcatatt cagtaatgac taatcctaag tatacagggt 48600 ttgggggtga aaggatttgt aagtgttttg caggaaaata ttttttccat ctttcatttt 48660 aattagaata gatttgcatt attttttctt agtttttatt tttaaaatat ttattgccac 48720 aaatttagaa aatacaggga aaacataaat aacagtacat gtaaaccaat attttgtccc 48780 ttcttttgtt caacagctat ttctcaggca cctgctgggt gtcagcagct gtgctcagtg 48840 tggtgaccaa aacccttgtc aacaaggcag caaggttcta acctggttag ggcttacagt 48900 tgagtagctg aaattttgat ttcttttctg tgcccctagt aaagatatga tagcaaacaa 48960 taagagctat tttttttatt gtgttcttac tctgtgttgg gccctgttct cagtggttta 49020 tagcctatta actcagtctc tttaccacca ctctgagggg aggctctgtc atacccactt 49080 gacagatcgg gaagtggaag catcaggagg ttaagcaact tgttaaagat cacaaaatca 49140 ataatgacag agttttgatt agaatcccag cagcctgtct ccagaacctg ccctattaag 49200 tgcagtgcaa ctgtactgcc tttcataata tgtatcaaat tgagatgata ctttataatt 49260 tcaattcttg cttttctatt gaacagtaca cagtaacatc ctcctataat gcatataaac 49320 ccccaaaaga tgtagaattt taatttattc atttgtctga taggctcata atgaaataag 49380 actctataaa gctgtgtaat ttagatatag gaaacatttg gattatagtg gtatgtagtg 49440 ggaacaaatg gtcttctgaa tcaggaagac atgagttaga gtatgccggt gtacctcctt 49500 actcactgta tgaccttggg caagtttctg aactttagtt tcctttccag gctaatatct 49560 gccttctgga cttgtcatca ggattaaatg agtctaccta tataaaatgc ccagcgcagt 49620 gcccagcacg tggtagaagg tctgctagtg gttactgtta ctgctggcta ttaaatacat 49680 tttaatcttc cttcagaata cctggccaga tagcacagtg gttaagaatg cacatgaaag 49740 ccagactgtt gggttccagt cctggctcga ctccttccta gctatgtgac attaggcaac 49800 ttacataaac tccttgttcc tcagtttgca tttctttaaa actgcatagt tatcataccc 49860 atgtcttaga gttttgtgag tgtaaattat tgtatataaa gctctgagaa cagtttggta 49920 cacagtaggc actgtatgaa cattttctgt aattatcaat aatataatta ttaaataaca 49980 ttttcagaag gagataaaaa tattacacct taaaaagcag gtatctttaa attcttcctc 50040 agctactgaa gttttgctta ctatttgaca tatcatttgt ttcacgtttg tggctcagac 50100 gtggcttatg ccaatgcata ttaacacagg aattttaaat ttggtgatat tattatattt 50160 tatctgaatg aacagaattt gctgatttga cactgtgttt gaatgtgcat tttttgttga 50220 aaaatgacaa ttctggaatg ccgtctccct ttccagatta ttcagagctg ggagagcttc 50280 ccccacgatc tcctttagaa ccagtttgtg aagatgggcc ctttggcccc ccaccagagg 50340 aaaagaaaag gacatctcgt gagctccgag agctgtggca aaaggctatt cttcaacaga 50400 tactgctgct tagaatggag aaggaaaatc agaagctcca aggttggttt gccatcttga 50460 tattgaacag gcctggtctt atcttggctc tgaagttaat cacatcagac ataagcatgc 50520 tgtcttaaaa atacagcagc acgatagtct aatgtataca tctatctata tctgtttact 50580 ttttcagagt aatattaaca ctgtttactt tctggtgatc taatgatagt ttcaccaaca 50640 atattcatta ttcctctatg gtcactgtta gtacagtgtt tagaacttct gagatccaag 50700 ctttaaatct aagctctaac acgctgaaag gtgcttttca ttttgttttg ttttcccctc 50760 tgtctctctc tctctctcta ctttatcctc agccatggtc tgtgcctgtg tgttaggtat 50820 gaacttttct tgtgtaagtc attaacatac gtaacttcac tctgtgtgct ttttcagtga 50880 tttgcaagta atctgaaaaa aaagaattag ctgagttcta cctgtactga tatcaatagt 50940 gtcaaaatat gacatgaact ttgaaagttt agattttgtt catttcctgt ttccatgctg 51000 acactggaac caattaatgt tatcttcaaa gtagcttaag atgcaaagtt tacatactct 51060 ttggaaagag catgagtctt agggtatcta gagaactgcc cggtgataaa gtagtgaaga 51120 ttttgagcag gaagtctgca taatctcttt caaagggaag atgtagcaga tggttcagtc 51180 accctgccat tgccccagaa caattttgga attacagtac atttcattca gcatcattct 51240 tgattgcaaa ttttgatctt ttaaaatgac cttgatgctt gtatagagct aaaaagtcat 51300 taagacacca actctgagga ataagctcct gagaatgtgt tgcatctgtg agtttcagtt 51360 gcatagctag tgtcatagcg agtggataga cgttctctgt gcatgtccct acaatgcttg 51420 tgagttatga caacactgtg tacgagcaac atagtttctg cagttgaaaa gtacgaattc 51480 atagaatgta aagagatagt gtctatatct tttgactgaa aacagaaaat gagatataaa 51540 ggaataagac ctttcgacat gaaagtaacc ccacagttgg aataggctag taagctttcc 51600 aacatgcagt tttgaagctg agaaagacgg gtcctctcat cagggtgctg tggaagatga 51660 tagcacactg gggggcgttt agagcaggtg agtgctgttt tcttccaacc cagtttttct 51720 gccactttct tatgtttttg tgaaggtaat tttaaaagca gatgtctaaa agatgtttgg 51780 tagtgatggc attactgcat gtgtcatcag ttaaatgaca gctcgggagc acagcagtta 51840 tgttcgtgtg tatcttggga tttttgttga agaggaaaaa ggcagttatg ttcatcatgt 51900 aggtcaaact ttaatgccaa tactggccaa tattcttgca aatgacagcc atgtaaaatc 51960 agggcatagc tataaaatgg gaacggtgct cacagctggc ttctttgtgg tgaggacagc 52020 tataattggt gaggcaaaac cagtgtgcca caaaagcaga atacattctg ctgtgcaagc 52080 aatgaccaga cagactagaa tgaaaaggca agagtttcct aaggttacct ggaacccctt 52140 gccaggtgtt gcattaagtt tactggccct tgccaacatt cttctaatgc ttcctcattt 52200 catctggctt cttggcagtg ttcagttttt gtggtctttt atttttactg tttgacttca 52260 tttctcttct tagctctgta aagttccaca tgtgtttatc tttgtggtga aaacacaata 52320 aacttgctta atataatgtt ggaagtatta atccattgta ttagtgtgta caggacctgg 52380 attgctgata aaaaaataac tagcaataac agcctgattg cttaaaaata tttagtaagt 52440 tttgtcgggg tggattgggg cagggcagaa cttttacatt aaatatagat gcaagatttg 52500 ataagaatca gccagagtgt acagtaagta ttcacttaat gttgccaata ggttcatgga 52560 aactgcgaat ttaagcaaaa tgatgtataa tgaaacaaat tttactaagg gtttattgat 52620 aaaaacaaga gttaagttcc tatggcatat ttctgggcac aaaaacatca ccaaacttct 52680 aaataaagac ccaagacact tctaatatta aatattgatg taaacgtgag atatgcaaac 52740 atttaagcaa gattaataca aatatgataa ttattggctt ggcacagtgg ctcactcctg 52800 taatcccagc actttgggag gctgagacag ggagatcacc tgaggtcagg ggttcgagac 52860 cagcctggcc aatgtggtga aaccctgtct ctactataat tacaaaaaaa aattagccag 52920 gtgtggttgt gcacacctgt aatcccagct acttggaaga gtgaggcagg agaatcgctt 52980 gaacccagga gacgaaggtt gcagtgagcc aagatggtgc cactgcactc cagcctgggc 53040 aacacagtga gactccatct taaaaaaaaa aaaaaaaaga aagaagtaat tatttttcca 53100 cttattccac ttcagggtct cagggggcca gaacctatcc ctacagcttg ggatgcaagg 53160 caggaaccag ccctggaccg aatgccattc catcttgggg tgactcacac acacactcag 53220 actgggacca tgtagacata ctgattaacc taatgtgcac atctttgaga tgtgggagga 53280 aactggagca cttggagaaa acccacacag acatgaagag aacacaaact ccacacagat 53340 aatggccccg ggctaagaat ccattttttt cttgtcaaca ttataagaaa gcgacattga 53400 gcataaagac attatttgag gacctgctgt actatgtact tagagagata ggcattctat 53460 cttgagttcc ttttttttct cccttcttga aggaaggtta aattgcatct gagatggctc 53520 ttgaaattga tcaggggttc aagctgactt gcatactctt tgggaaagaa tttagaagga 53580 tgtgtatgag gaagttctta tggttaagcc tgtttcctga cttgaataga tgaatcaaat 53640 attttttact attctggaag catcgcattc tggaaagaac catactatgt catctcagtc 53700 tacctcactc cattgtaggc acttggaagc tgaagttgtg atttctccaa aattagatag 53760 ctaattttca ttggtgttag aacaaaaagc gctgcctctc tttgaagaca ccagtcctcc 53820 accgtcctcc tctgcaaggc cgttttcccc cccctttttt ttttttttga gacagagttt 53880 tgctcttgtt gcttaggcta cagtacagtg gcacaatctc ggctcactgc aacctccgcc 53940 tcctgggttc aagcgattct cctgtcttag cctccagagt agattacagg cacccaccac 54000 cacacccggc taatttttat tattagtagt agtagtagta gtagagatgg ggtttcacca 54060 tgttggccag aatggtctcg aactcctgac ctcaggtaat cctcccacct tggcctccca 54120 aagttctggg attacaggca tgagccactg tgtccagcca atttttctgt atttttaaat 54180 gaagatgtga gcagcctaat gtaagatcac aacatgtgat tcaatacagc cgtggcttgg 54240 tgttgacatg ttattaccag ttgagctaat ccatgtaact cagcatttta tgctttacta 54300 agattaaaat gatgtgataa cattaaattt tgaattacag ttgatgtttt ttatttaaaa 54360 aacatttttc ttagttaaat aatacatgat ggtttaaaaa tcaaatattc agtgcaattc 54420 ttctaaaatc tctgcaagtg tgggggtcat ttaattgctg agcctcccag cctattagct 54480 ttccattctg agctttcaag agatggtggc agctggcaag gcagttttgt ctgggaaagc 54540 cattgttaac agagcagaat tggggatgga gcagccatag cccacccacc agagtaggca 54600 caaatcagac ctgaacgtta tcacaaagtc caagttggct cagacatttg tgttaaatca 54660 taataaatat tttagagaac ttggttgcaa atttacattt gatctcagtc agtcctcttc 54720 ccctatctct acaagcttac aaaccgcatg ggtgtgtggg ggtcttattt aatattgcga 54780 acagctggtt cctgtatctg aagttcttgc cctggagcct gggtgtttgt tgtagttctg 54840 caccatctgc cttggttgat aaggcatttt ggaggccact gattttaggc agcagtgttg 54900 ttaggatacg gaaacagcag gatgtttgtg gattgagcct tttcagctga atcttctggc 54960 cagttctttc tggctgtgtg aagttgtgtc gactacagag caggatgctc atgttgcctg 55020 ctgggctctg ttagggtggc cagacgtgct tgtagcagcc ttactgccag aggaacgtac 55080 gttggcatcc agagtccagt gctgccgcca gttgcagtgc agcaaggcta gccccaaacc 55140 tgatttgctg caaggattag ctcaactcta gtgacattta ttgtgttttc tcatagccca 55200 aatcacagcc aaaaaaaaaa aaaaaaaaat ctagggttga catttttaaa aattttttta 55260 aaaaacattt ttcttggtta aataatacat gatggtttaa aaatcaaata ttcattgcag 55320 ttctaaaatc tctgcaagtg tgggggtcat ttaattgctg agcctcccag cctcttagct 55380 aaaaaatcta gggttgacat ttttaaaaat gtattcaaca gagtacgagg gaaaagatta 55440 aagatggtgg atggaaaacc ataaaagctg agaggaaggc agcactgggc ttagagtcac 55500 ttggcttccc tctagctagt aaataaccag caccaaatca cctgatcctc ctgaacttca 55560 gtttctgtgg ccatgaaata agaggttggg tccaggaatc aatgtaaatt gtcaatttaa 55620 catttccctt tattgatatt actcccccct gggcttgata atttagttat aattcttcat 55680 gcagctttag gttgagtaag tttggtggga aacagtagct ctcttcatat atttgagaga 55740 tgtcatttga aaggggtaga tttattcagt ttaactccaa gaagcagaaa tgggacccat 55800 ggtagaagct accaaatgga ggtttggctc taaataagaa aacgatcttt ggagtgcctc 55860 tcctagttta gatgaaaaaa attgcatcaa gttgtaacca tgctagtcat tgggaatttt 55920 attaacaaca cgtagctcct gtcctgggga ggctcatagt ttgatagggg taagatggaa 55980 agaattgggc agatgtggat tatgtcttag cagtagagcc aacagagtat gttgggggtg 56040 aaggggtaag agaaatcaca tacctcctag gtttttagca ttttccaaaa tgaggaaaat 56100 gggtagaggc atggacagtg acttatattt agacgcgtta agccagttgt aactgcttga 56160 cgtctcagcg ggataacaag taggcagcca tgttgtgtaa tggaaattcc atagctgtag 56220 cctttactaa tgcgctctgg aatggtctat tccagcctct gaaaatgatt tgctgaacaa 56280 gcgcctgaag ctcgattatg aagaaattac tccctgtctt aaagaagtaa ctacagtgtg 56340 ggaaaagatg cttagcactc caggaagatc aaaaattaag tttgacatgg aaaaaatgca 56400 ctcggctgtt gggcaaggta agcttcattg ggaagcatct agtcaacctc acccctcatt 56460 ggtgattggg gagaagtgtg gaattaaaaa aaagtcaagt ctaattttag tggccatctc 56520 ccttcttttc atcacatctt aatctatttc catatacctt acttaataga catgagtttc 56580 accacctttc atgattcctc ttaattaaaa ttcccagaag gccgggaaat aggaagaaga 56640 cagaaaaacc caagggtttt gttgcctata aactagataa tgatttgatg atatactttg 56700 aattaaatta taaactagaa actaattgta tggcttgtct ctgggtactc tagggagaca 56760 acatagtgtg gggagcacag acttcagaca ggtggtcttg ggcttaaatc tcaggcctgc 56820 cacttacttt gcagtgtgat cttagacaaa tgcctcaccc tctctgagct ccagtttcta 56880 caagtgtaag atgtgggtgc tgacagtgga tgttgtgagg agcacacagc atgtgtctgc 56940 tatactgtaa ggccttagag agcgggcagg attcactgtt ttttcagtga gatctgccag 57000 cccaaactgt tactggtcca agaagagata agtacagaac ttgaaactaa gcttttggaa 57060 atgtttccag caatgtgaca cagtgatcct aattaaaaat gtggacttat attttgtcca 57120 tctgtttttt tttaaatttt gtttttctac taatttattt ttactgtatc gtataaaaat 57180 atcagcctgt agtagattgg aaaattttta aaaagaaaaa aaattgatgc ttcacagata 57240 gtttgagaac cgctattttg aagcttacct tcagtcatta ttagtgttct agtcaaacaa 57300 tgatttcttt aaaaatatat gttaatgtct tctggcaaga gtaaaagcct gagtctaatc 57360 tgattctatg ctactgagtt ctggttgagc tcatcatgaa taaccaggtg ttctgaataa 57420 gggtttcaag tatgtataga atgggttttt cctgagttta tcagttgtgc agtgggaaaa 57480 cgttgtatat gcactttttc ttttttgaga tgtagtttca ctcttgttgc ccaggctgga 57540 gtgcaatggc gcgatctcag ctcactgcaa cccctgcctc ccaggtttaa gctattctcc 57600 tgcctcagcc tcctgactag ctgggattac aggcgcccgg caccatgcct ggctaatttt 57660 ttgtgggttt tttttttttt ttttaagaca gagtcttgct ctgtcgccca ggctggaatg 57720 cagtggcgtg atctcagctc actgcaagct ctgcctcccg ggttcacacc attctcctgc 57780 ctcagcctcc tgagtagctg ggactacagg tgcccgccac catgcccggg taaatttttt 57840 ttgtattttt agtagagatg gggtttcact atgttagcca ggatggtctc gatctcctga 57900 cctcatgatc cacccacctt ggcctcccaa agtgctggga ttacaggtgt gagccaccgt 57960 gcccggccaa ttttttgtgt ttttactaga gacgggtttt cactgtgttg gcaaggctgg 58020 tcttgaactc tggacctcag gtgatctgcc tgcctcggcc tcccaaagtg ctgggattac 58080 agatgtgagc cactgcaccc ggcctgcata tgcatttttc atctctagga gcataaatgg 58140 aacaaagcag tgttttttac tatagttttt taggcatttt taaccttttc tgaattttga 58200 catcaatttt agtaatcatg ggaagttatt gtttgttacg cattttccct ttctatggat 58260 aaggaaactt gggcttagag cagttgaata gtggcttagg gccacagagc tgggttcaca 58320 ccaccgtact gcactgcctc ctgttgaaca ggatctccag gtgcttatct cagaacacgt 58380 atgcagtggt gaagaccgaa gttctggatg gacaccagct ttcagtgtga ctttagcagg 58440 taccctcttt ctgggctctt gcccccttac tgatagaagg agagacttgc actgagtaga 58500 ggatcttgga gctgtcttgg agttctaata ttccttgcac ctgtactttt tcttgaggtt 58560 tacctttaca ccaaatgacc ccaaattgct gttttgaaaa gggagaaagc agagaaaaga 58620 atgagtctgt tcttccccca ttcacagttg cctagatgat caccttcagg tgtctttgct 58680 tctgcgaaag gcaaattgca tgggtctgtg acagctattc caaatatttg agcttcttag 58740 aagcctggca cctggatatt tgtttttcac tgggcatatt ttgtgggggc taatagaaat 58800 actctaggaa tctggaccct gggtagtgaa agttgggcac agatgattga gcattctgta 58860 tactggagtg agctaaggct gacctggaat ttccttatgt gttgcctgac tttgccacat 58920 cactttttac tgcagaagct ctaaccataa agggggcttt gtcagtcagg tggttttaac 58980 acattaagat ttaacaactc caaacaaatg agggcggtct attttgtggt tcagaataaa 59040 aatgtgaatc aaaaaatttg agcctaaatt tgaatcatat ctttgacctt tgaagtagag 59100 gccaactcac ctcagagacc ttgtaagaga ggacagttgt gtggattaag aggcccttcc 59160 tcatagtgac ataaaagacc ctgaagtgat ggaaataaag gaatttataa aattttccca 59220 gttaaaatta gatgaggggc caggattagg gtatcaattt aggagaagat aacataatcc 59280 tatgacatta tagataattc agtttagtac acatcaaaat gatttctcta aagatatcta 59340 gatagaacct tataagctgg aatgtctttt ttaggaatgg gattgcagag gggctgcctg 59400 ggctgctgac agtaggggcc agatgcaaac tctgcttgcc tttgacccgg caatgccatt 59460 tataaaaact tactctagaa actaatcagc caaaaatgta ctgcagtaag aatgcttatt 59520 gtgacattgt ttaatagtca aaacaaaaca aaaaacccaa catgtgacta tcccatgtca 59580 tattccttga aaatgacacc ataagtagat ctgtatttac tgacgtaaaa gatgtctaag 59640 ttgttaaatg aaaagagtac agcatggtct cctgtactgt tgatatttcc atgtgcgtat 59700 acatggaaaa acacccacga tgcagatgtc caggttatag acaggatgac catagggccc 59760 aacctggcat agccctggtt tatgactcct gtcctggcaa aattattaat agccttcctc 59820 ctcttcactg tcaaaagctt cctgctttgg atggtaaata tatgcttatt ctagttatgg 59880 gtggtttttc actttcttct ttatacctct tgcatttcag aggttttttt gcaccacttt 59940 taaacagtga gtgtatatta ttttttaagt gagtaagaag ctatttacat gggggatgga 60000 ggaatggcct cctgccctcc cagaccctgc ctgcaagccg taggtgggct ccactgccag 60060 gtttctcttg ggttaggagt gaaggcagca ccatggtggg gaagggcatt ccaggccatt 60120 cttagcaaaa acattgggtc caacctgcat gatcctgtgc tttaaatcac agaatctaag 60180 cttactcctg aataccacaa tatctggtac tgtccagtga cacagccaat attcttttct 60240 ttcaaaaaat aaaggtctga taagacaatg ggaatgattt agtaatagga aattggacat 60300 ttcataactt gggaaaattt cccagtttga gaaaaagtat tttgtgaaaa aaagccccac 60360 tataaatcac ttatcatgct gactgttttc tagcccacat ttacttctca tcagcatttg 60420 aagtatttgt ggggagggtg tgcgtgtgtg tgtatgtacc caggatatat ctatgagctg 60480 gaatagcaga gggagacaag aaatagaata atagtagaaa gcagagatca gggtatattt 60540 gcttcctgtt gctaccataa caagttacta caaaaatagt gactaaagca acagaaattc 60600 ttctctcagt gttctggagg ccatagctcc aaaaccatgc cgttagcttg tctgtacttg 60660 gcctcttcca gcttctggtg tctgtcagct tcctagactt gtggtcacgg cactccagcc 60720 tctgcctcct tggtcacatt gattcccctt ctcatctcct cctctgtatg tctattataa 60780 gaatgcttgt cactggatat agggcccatc tggataatcc aggatgctct cctcctccca 60840 aagtccttac ttaattatat ctgcaaagaa ggtaacattc acaagctcca gggattagga 60900 agtgaacaca tctcttttga ggggacacca ttcaactcac tctacagggt cattatatta 60960 atgctgagat aaaattacag aaggtatagg atgtggtcat ggtttacagg ggccctgtat 61020 ttcttctaca ggccaactta aaaaaaatga tacgtgaaag ggaaagaaga aagtacttac 61080 tacacagtaa gtatttccaa gaggtggccc agtgagactt ttgaatctgt taataaaatg 61140 attactattt ggttcaaatc cacagatggt tattttatca ttaattgcaa gataggaaca 61200 caaaatattt tttctctagt ccccatttga gtagcagcct tgtttgacat ttctgacatg 61260 gaggacacca agagaaaatg gcagtcagca tccctgggct gtcactcacc ggcctaatga 61320 cctagggcaa gggacctgtt ctcactgcct ctcttttctt taccatgagg ataatcatgt 61380 ttcccttaga gggttatgag tatggtatgg gccaatacac ataacgtgca tggaatggcg 61440 atggtgcata gtggcctcgc aatcagtgct atctgctgct gctacctgcc agagcagaaa 61500 cttttcccaa aggtggccag agacagaaac cagagaaacc atccttctgg acaggctgtc 61560 tgagtggcag ggcagggtac aaagcggcca ctttttttcc cggatggaaa gaaagatcaa 61620 tgcctaactt ggaggcttcc tttctcccaa aagacaagaa agacttggca tcttattctt 61680 cagtcttctt gctctccccc tttccacctt tttggccttg taatagctga gtaatgagct 61740 aaagaatttt ggttcaaaac tgtcaccttt taaaattagg tttgccctaa ataacatcct 61800 tgactttaag agaattttct taagttttag acatttttaa tcactgtgag tattcaaatt 61860 aatcacatgc aaagcattag ttagaggctc ttggacattt tctgttttta gagctttgtt 61920 ggatgctcac atggcaatgt ctgtgcagtc agttcctacc cagcctctgg gctcttcttg 61980 cagcttatct tgcagaaaga agcctcatca gaattccaga atctcagcta tgattagctt 62040 actccacctc agctcagaaa catgcatgat tccctggagc taccaaacgt ggggcaggtt 62100 tcttgccgtc aattttgcct ctcacaataa cccttccagc cttcttgcca gctgctctct 62160 tccacatgca cccttgtgcc tgaggcaaac tgaatcactc tcggttccct ctctcttgta 62220 cttttctctt ccttttccct catccttaag gctcggctca aatgaaggat tctgtggaac 62280 cttgattgct cagttagaaa tgagcaaact gtcgcaagga cagaaaacca aacatcgcat 62340 gttctcactc ataggtggga attgaacaat gagaacactt ggacacagga aggggaacat 62400 caaacactgg ggcctatcgt ggggtggggg gagcggggag ggatagcatt aggagatata 62460 cctaatgtta aatgacgagt taatgggtgc agcacaccaa catggcacac ttatacatat 62520 gtaacaaacc tgcacgttgt gcacatgtac cctaaaattt aaagtataat aataataata 62580 ataaaaagaa atgagccagc ttctctttca tctgagctct acttcctttt gattctctct 62640 gctttctgag atcacatctt acatgacaat ttttcatact tggctttatt tccctagaat 62700 gttgttaatt ggcaccaggt tggagctcag gtcgtatact ttattccttg cagagtctga 62760 cagggtcaga acatgataac acatttgaga agtgagaaga agggaggaag gggccaggga 62820 agtgagggga gaataggggg tggaagtagg ggaagaagca aatagggcaa ggttttagtt 62880 gcctcccttc tgttcttatg ctgttaatta ataatggaac cagtggccag gcatgatggc 62940 tcatccctgt aatcccagga ctttggaggc tgaggcagga gtatcgcttg agcccaggag 63000 tttgagacaa gcctggacag catagtgaga ccctgtctct acaaaaataa aaaaaaaatt 63060 agccaggcat ggtggtgggc acctataatt tcagctactt gggaggccga ggtgggagga 63120 tcattggagc ccacaaggtt gaggctgcag tgagatgtga ttgtgcctct gcactgcagc 63180 tcgggtgaca aagccagact ctgtctcaaa aaaaaaaaaa aaggaacaag aatttggata 63240 aatggaacat gaaacacaat tcatttttat tattaagttg tattctgtgc ataaattatt 63300 tccatgtctt ctctcccttt taaaggtgtg ccacgtcatc accgaggtga aatctggaaa 63360 tttctagctg agcaattcca ccttaaacac cagtttccca gcaaacagca gccaaaggat 63420 gtgccataca aagaactctt aaagcagctg acttcccagc agcatgcgat tcttattgac 63480 cttggtaagt ctgtgccatc gattggagat gacaatggaa gtttcactca catgaaaaat 63540 ctgaagagac tgtccaagtt atgtattgac ctgcctttag gtttagcaat caaaatttac 63600 tactgagact tttaatttaa aaagccctag ggtaatcaca aatgtcatct tcaagcatat 63660 aaaaatctct gtattttcac tggggagctt gttaactttg cttggcatgg agggagggtg 63720 ttcattaagg ctgcagtcat aattgtggtt cagtccagta actcaaatat tgataggagg 63780 tttttacagt caaccgaagg aacatcctgg aaaacgtata gatgttcaga accgaggctt 63840 ggtttaatta caggagccac tccctcgttt ttactgctca caaacagaat tcatcagaaa 63900 aattgtagaa agcagtttgt gtgtgtgcct tgaatgattt tattttggaa actgggtggc 63960 accttgtctc ttgaatagtt tttaaaataa gaagatggga acaatataca gtcagccctc 64020 catatctatg ggttctgaat ttggggactc aaccaacctc agatggaaag tatttgggaa 64080 gaaaaatcaa tgaaaactaa acaataatat agattttaaa atatagtaac tatctatgta 64140 gaatttacat tgtattaggt gttataggta atctagagat gatttaaggt gtgtgggagg 64200 atgtggccgg gcacagtggc tcacgcctgt aatctcagca ctttgggagg ccaaggctgg 64260 tggatcatga agtcaggaga tcgagaccat cctggctgac acggtgaaac cctgtctcta 64320 ctaaaaatac aaaaaaatta gccaggcatg gtggtgggcg cctatagtcc cagctactca 64380 ggaggccgag gcaggagaat ggcgtgaacc caggaggcgg agcttgcagt gagccaagat 64440 catgccacta cgctccagcc tgggtgacag aatgagactc tgtctcaaaa aaaaaaaaaa 64500 aaagtgtatg ggaggatgtg tgtaggttat gtgcaaacat agcaccatct tatagaaggg 64560 ccttgagcac cgtggatttt ggtgntctgt ggggactcct gcaacctatc ccccgaggat 64620 gccaagggat gactgtattg gatagatttg cagttgccac tgtgaaggac ttgttgaact 64680 ggggtgtgat tatgatgcac agagggccct cctgacttgt cagtggccat gcacagggcc 64740 aggtggcaat gcactcccgt ttgcctgccg cctatcaccc aagctgctgt ctctactggt 64800 ggtgagctgg ctcgatgtgg taggagatgg gccctgctgc ttttagagca tgtggccctg 64860 cttccagaat acctgttctg gttgcagctg ctgctgctga aggctccaca gaacacacag 64920 tgctttgggg ccctgcggtg gcccggttct ctgattgttc ctgcagccac gacagaggat 64980 gcagtgtgag ccgcatcagg cagtatgaag tcctttcctc tcaagccacg tagctagcct 65040 taaaggttaa tttcataacc cttaaggtta tttttttttt ttaatttttt tttttgagac 65100 ggtgtctcgc tctgtcgccc aggctagagt gcagtggtgt gatctcagct cactgcaagc 65160 tccgtctcct gggttcacag cattctcctg cctcagtctc ccaagtagct gggactacag 65220 gtgcccgcca ccatgcctag ctaatttttt gtatttttag tagagacggg gtttcaccgt 65280 gttagccagg atggtctcaa tctcctgacc tcgtgatccg cccgccttgg cctctcaaag 65340 tgctgggatt acaggcgtga gccaccacac ccggccccac ttaaggttat tctttagctt 65400 gaacatcatc tctgagaaac tttccctgac tgtggtctcc tctcccacct caagactgga 65460 tgaggtgtct tgctaagccc cctgtagcac cccacactct ccccatggtg cgtatcacat 65520 ttctcatcat caccgttatc tgcttattat catcactgct gctgcctaac ttcaccttgg 65580 gccaaatgtt gtgcaaaggg acttaaactc ctttctttaa tccttacaac atgatcaggt 65640 agatgttgtt ctgtttctct ttagagttga gaaaatagaa acagacaggt tacgtaactt 65700 gctgaaagtg acacagccga tttgccgcta atcagtgtga cttcggaagc tgcacttttt 65760 tttcaacttt tattttagat tccaggattg cgtatgcagg tttcttacaa aggtgtattg 65820 tgtgatgctg aggattggag tgtgattgaa cttgtcaccc aggaaccaag catggtaccc 65880 aataggtagt ttttcaaccc ttgccttcct ccctccctct ccacccccca ggagtccctg 65940 gtgtctgttc tcatctttat gtccatgtgt acccagtgtt cagctctcat ttctaagtga 66000 gaacatgtga tgcttggttt ctgtttctga attagtttac ttagggtaat gacctgcagc 66060 tgcatccatg ttgctgcaaa ggacatgatt ttgtcccttt ctatggctgc agagtattgc 66120 atggtgtcca tatatcacat tttctttatc cggttcactg ttactgggca cctgggttgg 66180 ttccatgtct ttgcaattgt gaatagtgct gtgatgaacg tgtgagtaca tgtgtctttt 66240 tggtaggatg atttattttg ttttgagtat atactcagta atgggattgc agggtcgaat 66300 ggtaattcag ctcttagcag aacctgtatt tcttactcca cctcccccgc ctgtccttag 66360 tatacagcag tggctcttta ttgccttttt cccttatagg atacagccct ctgcggactg 66420 ggctggggct gtttggccat tataccctcg gcttctagga cagtggctgt gacacagcag 66480 atgctcaaag aatatcttta agattcagag tgtgagacac tgcactagca ccgccatctc 66540 atgggccctc acaacagccc tgggaaggtg gcctgcaccc tctctaagaa atgaagaaac 66600 tgaggtcaca tgttgaccat ggtcacaaag tcacctgagg ggaggtgaca ggaactgaac 66660 ccactgtcac tctgtgtttc cctgggaccc tctgagcgca ggaggcccgt gttgctgtgc 66720 agtggcaggc caaggcaatg ccttggtgga gctggggccc atttggccca ctgacctgag 66780 gaaagcagtt ttgtgaattg gcagtagctg catttgctga catggtgagt tacaggaaat 66840 gccatcatgt tcctatcatg tgaaacaaag tgagaaatag gttcagggtg ggaggctgaa 66900 agggaggaat gcagacagcc ccgctcccca cacttgctcc aaggctgggn aggaggaacg 66960 ggaaggtgtc tcccctcctg gattcagtca ccttcttctc ttcattcccc tgcagtatcc 67020 cctcattctt ccacggacac gatcagcccc tgcttcttgt tgctcagatg tcatcacttt 67080 tctgcagagg gaaaagaaga gaccagatca gaacaagggc ctcggcgtgg ctgtgcactc 67140 cgaaggcact gtgtgtgcct gagccccacc acggcctccc ctgcagggct caggcagcct 67200 tccttgagct ggcatgaggt ctgtgggagc ccggtccact ggcagggctg gctgcattca 67260 agtcctctcc atccctgcct ctccccaccc tctccctctg nngccccctt ctctgacagt 67320 gctgaccccc ctctctcttc cccactcttt cccatcctcg cctggcctcc ggtttggatg 67380 ctgtccacac acttcccgag ggcctgagag gacctccgtg tgaggcaatg catttcccag 67440 gtcacctctg tgtctctctc caggcttttt ccagggactc cccggggtca gtctcctctc 67500 cccactggaa cggggaaact gggattggcc tagacccggc agtggagtcc caggtgccct 67560 gcctgcccgg ctgactccgc ccagggaggc ctcccacaga agctcctcca gactccacct 67620 gttacctccc ccactcctct cacccaaggc tgtgctgtgg ccaagtcagt tgtttagtct 67680 acactttctg tttagtctac accatggcta cctcaaggcc cagtgaaggt gtgtagtata 67740 aagcaaaatc aaatccatat ttcagttttc cttaaaaagt gaccttcata ttctggccag 67800 aagaacagaa tggttggttg gatatatttt gagttttcat gggtttttgt tttcctgcct 67860 cttgttatac tttctgaaat tggcttttag tctaaacagg tttttttttt tttttttttt 67920 tttttnggca atgtgttttc ctccaaagag taagaataat aggcctcatg gctgggtcgt 67980 gttctacagt ttgtgaatat tttctcaacc tttgtcaaat ttcatcttta cacatcctgt 68040 gtgaaattgg gcacgtgccg ttatttccaa cttagagggg atgaatgagc ccttaagagc 68100 ttgagttctc tgcccacatt gcgagttact cagtgccaga aggagttctg gaacccaggt 68160 ctcctcagtc tccataccac atcccttcta gggcaccatg ttgcttctgt gtttcttggc 68220 tctgcccact ccatgccagc acaactctcc ccacccctgc tttggtggaa tcatgttcct 68280 ttggggtaga tcacaccagc cagaggcaac tgctctcagc ttagcagatg gtactcatca 68340 cattattctt gaagccttgg gtcaggagcc tgccccaccc atctgcatcc atttgtccag 68400 ccctcagaca attgccactg ttttcatgtc tattctttga ctctctatcc tgggtagaca 68460 acatggactg cccagcatcc tgtcttctgt ctggggctcc cactgtcgtc ctgaccacgc 68520 tgggggctgc cagtgacact gggaaactcc cgagggaccc ccttcaggct tcacatcatc 68580 tgctccctcc ctagcatccc agcctagaac actttccagc catcagctgc attccccagt 68640 gaggcgtgca gcctctccca tgataggagg gcttcagccg aaagaacact tcaacaggcc 68700 cagaaaccca ggagcaccat tagatcagaa agcagaagca agaatgcatc taatctcccc 68760 cacatcaatt gctatagttt tattaatctg catattatag gtcagtaagg ggatggcaca 68820 gtttataatc cctgcaagag tctgatgatc ttttggtgac cagaagtgcc attttttgat 68880 gggcttctag agatcctcca tcagggatac cagacatgtt tggcatgcct gtgctgccgc 68940 gagacgctaa gcgtgtgtcc agactacacg tgtgggtcat gggtccagca gcagagctgt 69000 catattgatt gtttgcttct actaaatgta taaagcctgc ctggtgtcca gaagaaaaga 69060 aactataatc caatttttta gaatccataa aaggtaagaa gtaggagaac atttagaatc 69120 cacaaaagat gagaagtagg agaacrgttg gattttttag aatccataaa agatgagaag 69180 waggagaacc tccaaaagga aggaatcagc tgagagtatt gaagatgacc aagtacaaac 69240 aggcagaggg gagcgcttcc ccttctcctc tcccaggcgg tgggctgcct cgctcggcca 69300 ggacacacag agcagcatcg tgcrctttga ggggcaggtg gagctgctca tcactagcag 69360 gggtgctggc ggggaccaca gtgttctctt ccatctttga gttgaagtcc tgtgtgagaa 69420 atgagaaacc ttcatggcaa aagacagaaa gggacctaga atgtaacatt cagcagtctt 69480 gttatctcac gcacctgtct gtccagttgg ggacgttgct gtatggaggt cagttgaaca 69540 atcacagttg aggagcctaa tgaattcttg caccaccagc cacacacatt attctgaaga 69600 gtgagccatt gtctctgatc ttatcaggat cacatcgtgg gatcatattt atttggtcat 69660 tctgaatata ccctttaagt ccaaagtgaa ataactaaat gtcgttgata aaaggaaaga 69720 ataaagtggg gtatgatttc ctttcacaga ggtctggaat cttcctgcct ttttcaagtc 69780 agtcggtggt gctggcaaat gtttaataac cagctcctct cacccctcag aggaagccct 69840 tggtgttcag tgtttgcaga tttccattgt gcaactagtc ctcccacacc ccattttaaa 69900 ctacccactt gatgtcactg gtcatggagt tgggctcaca gagccagtgg gagtcaactg 69960 gagcagccac tggactcatt caagtgtttc ccaaaacaat ctgctcctag aaggactctc 70020 ccttaatctc ctaaccctgc cattcaggat gattccctgc actctgggaa gcacacgttc 70080 tagtgggaag actgatactg ggcaactgat aaccaagtga cttaaacttc tgagggttac 70140 aaagggtgtt tgtatcctca gtgtctcatt tcagattctg ctcagagcta aatgcaacaa 70200 tgtgagaaga tgttagtatc ccagatcttc atccaggaag gaatcttaga gatcattagg 70260 ttgtagggtt tctcttctgc agaggagata gagggtcggt gtcagattgc tggtttgcca 70320 gtaccactcc ctggagaaaa gagcaaaaga aagaaacttg ttagtcaact gtgcagagcc 70380 accgtgagac tgaatagctt tgtgggtggc cccgtgtttg ctgcaagaga cctctggcct 70440 cttgtagcag ctgccacatg gtaaacagag ccgagatatc aggagtctcg ctgaaaatgc 70500 agtcagatgg gctctgaata gaggaaggca ggacactctt gagatgggat ggggtttctc 70560 acagcaccgt acagggacca cctgcaagat ctcttgaggg gcttgtgaaa aacacatccc 70620 tgaggtcacc attcttgacc tgctgcttat tgagtttctg atgcctggga tgtgcaggtt 70680 taacaagccc ccagatgatc ctaataggat tcctgcctga aaattgctgg gtgaaggctc 70740 ttccccctcc aagtgataaa gaaggaaaag attgatcctg gaagaacatc cgttagatga 70800 gcaaaatttt gtggagcact tcatgaagag gaattactag gtcatttaga aatatgtttg 70860 aattgtggat catcttgtag gcctttctgg catatttctc cacttagatc cacaagacac 70920 atcgaatgtc tttttataaa ggggtttttt aatgcccatg tttgaccctc tccacttaac 70980 agtcccattc tcattttata tgtgaaggta atctgcttta cagaaaaatg taaaggacct 71040 gcacttctct gctttgtggt aagttgtaaa atgcagttta aagaggcagg cctcatatcc 71100 tgatagattt gtaggaagga ttgcacagtt ttacccagct tccctcgagt ttggcagaaa 71160 ttagctttcc ctgagctggt gtcttcccga gctagcatgc ttctcctatg gggtgtgtgg 71220 ccttctctcc tgtctttttg aggcagagct tcaatctaga atctgttcac aaactgaaca 71280 aatgcaacaa acagtaaaca gtcttttgct catagttaag gtgccttgag ttgggtgtga 71340 ggggctgagt gtgttctcag gggtgctctg cccacggctc cggccaactg ctgcaggtgc 71400 gcatcatatg ggtggtcttt gtggaatgcc atcagcacta gcttagtacc tcctaaatgg 71460 gagctggagg gctacagtgc tcaacactgg attatacgaa tgtggattgt ccaggaaatg 71520 cttttaatcc ccctcatcca ctctctaccc acgtgacctg cctctccctc tttacttggt 71580 gtttactcag gaatgtgggt gagttgtcgt gttagcctag aacagccatt cccaaacttt 71640 gatggaagga tgccattcac tttgaaaatt atcgagtagc ccaaagagct tctgtttcca 71700 tggataattc ctatcaatat ttactatatt accaattaat taaaactgag attagtattt 71760 atttgattcg tatttatttt tacatagcta taataaactc atacatataa aaaattatta 71820 aaaaatgact gttttccaaa ataaaattag ttagaaatgt gacattgttt ctacattgaa 71880 aaaatctctt taatgtctga tttaatagaa tccgctgaat tttatttgct tcattcattc 71940 tgttttgctt gttatttgaa gcatataaag caaaagctga ccttgcacag atctatagta 72000 ggaaaagcag ggggagggcc tcatggaccc ctaaaaggat ctcagcgacc tccaggggtc 72060 ctcaggctga ccaaacattg agaactattg acctggaaga atgtaaaata ggaaaacagt 72120 gtctccccca atagaatttc gtgtaaaacg tggactgtgt tacaaagtca gatgggtgca 72180 gttgtcctgc ttaaccgcta atcaggagct gaaggccaga gactcacagc tgttccccag 72240 cctggtagtg aacccagagg cctgtcttgc tgtgcagtgg gacaggaagt tgcatttggg 72300 agtctcatag aacacactgg aagatgtgtt ttagcttggc caggttcatg caggacagat 72360 tttctgcata aagaaaatca atgacagttt ctgaaactgc atcctggaag ccttgaccag 72420 tttgggtaat aacaagagat ttgaaagtgt ggggtgtaca ggtgttttgc tgaatctagg 72480 tggtggtggt gattattatt atttggaatt cagctttcag ttctacctgc ttgtgagttc 72540 caaactttgt gaaaattagt tgcttggacg aaacttttct ttgcctctgg aaggctgtca 72600 gaaagcgaga tttcccagct tatgtgcagt gttatagtta atagagtaat ggctctgcaa 72660 agttgttcct ttactttaaa tgtaatttat tttgcatttg tgctacagaa cggtcataag 72720 tgtgcccttt tgtcctcttg tttggaaact gggtttttat aatgtgtgtg gtctatccga 72780 agattattgc ccattattga acaccattca tagcaaccat ttgcattagg cattgtacgt 72840 gtactctcca ctctgcaaac tatgtgttct gtcccttttt aaaaagagga agctaaggtt 72900 cagagaagct aggtagtcca ttctgagctt cacgtgccag aggccatttt gtacttactt 72960 caaatgccat tgaaataaat gcacatcaga gaattgttct tagcataagg ggcgctacat 73020 gtaacttttt attagtgaaa tggatgatgt tcaagggctg tggttgatta gaaaggcgtc 73080 cagaccctgg ctccagggac tatggagcag aactcgaggc cagtgcctgt cgagcgggtc 73140 cccacactcc atctgtgtga cctgactgtg gatggcctgg ctctgccgtt agattgccac 73200 ggtgccctcc tctggttgaa cctttctcga gaagtgcttg ttggaggctt gagtgcagag 73260 cctgtgagaa gctctatgtg gttcctattg cctgtcagct tgctgataaa ggtcattggt 73320 ttggcaaaat ttggcccaag gtttgccttc tcataacata ccactcggta gcaaggctgg 73380 gaggaaggtg gctatagcta tttctggaag ctgcttaggg ggctgcctcc ccctaaattg 73440 gtacataatt tgcagggcct attgcaagat gaaaatgcag aaccctttct tgaaagatta 73500 ttaggaattt caagacagag acaacagagc atgaagcctt gtgcaaggtc cttctaagca 73560 cagagccagt gtgaccgcac agaacacaca cccgtgaagc cagctctgcc cccaccatct 73620 gaccactctt gagtggccaa ttagcatagg tcactcccca ccctgctagg cccaccctct 73680 taggaatgtt gtgaggctta aataagaaat agccactcta caagcggtgt caattagcat 73740 gggctctggt ttctgtgtga ggtagtttgc taacatgaga gggtatctga ttagctaaaa 73800 cgataacact gacagattaa attcagaata actaaacctt ccctgtgttc ctttatgcca 73860 catgactcct gcatattctg ctaccagcac ctgtttgata ccagacggag gggtccattt 73920 gggatgggac aggagcatca gcagaaatgc agaagtgggg aagtgctcca tcttcttgga 73980 agctgagctg gcaagggtaa tggaatgaaa gagattgtga atatttttga gactatgagg 74040 aaaccagtac actggtgttg cccagtacag aagccacatg tggctgttaa gcacttgaga 74100 tgtggctact ccaaattgag gcgtgctgtc agtataaaga acacactgga tttcaaagac 74160 ttggcatgaa aaaagaatgc ctaatgtctc agtattttta tattgattat gttgaagtga 74220 tagtattttg tgtatgttgg gtgtaacaaa atatctaatt aaaattaact tcacctgtta 74280 ttttctaatg tgggtgctag aaactgttac atcctgcatg ggggtcacat tccagttcag 74340 ttgcatgtgc tgctacccat tgttctacac acacacacac acacacacag ctgcacacaa 74400 cctagagggg tcagagaccc caggagcccc tgcttctggt gcccaggcta agcgctggag 74460 tggaagataa agctgggagg gtgggtaagg aggtgagtgc acggagctcc aggctaacag 74520 agtggataat ttgttctttg agcactgggg agctatggat tgcttactag cagcaaggtg 74580 acttgtgcag ggtatatctg ggggaggttt actgggggaa gagatagagg aggcaagaag 74640 tgaatacaga acgagaaatc aggacagtgg ttaggagacc gtagctttcc tcttgagtca 74700 agttcagata acacatctgg actgatgaaa ttctttttca ggaagctgag gaagagccca 74760 tgaaaatatg ttcctccctg tgctgagacc gaataattgc agtgaacaat taacgtgtgg 74820 cctagatcca ccttttgcct tcgctgatcc aagcaggttc ataattcttg cctgggccca 74880 agcttggccc tggctgccag ctgcctggct ccagatgttt cttaatcgtt tcaagtactt 74940 ctctgctccc tggaaacagg cactcccatc agtcacattc cagaggagga ggaagaggaa 75000 cttgacaagt atcagctaca aaagcctcct gaacaaaaga aatcctttaa gcctatttga 75060 ataacagttt tttgtgaaaa taatcaggat gttgagagct tttttttttt tcttttaaac 75120 tctttttgga aggtaacttt tgtgaaaaga aaacacctgc tgctcctcag gctgtttcaa 75180 aacactgcct atagtttgaa agtacggaga tatgcatgtg gtatgaagca tttgcaggca 75240 taatatgtgt agtctgggaa aagcagatcc agagagtgct tgtagtaagg cgaggccttt 75300 tagctgcatt tagatgatgc tgggattggg gtgggtgcag ggtgcagcag tggggaggaa 75360 gaactgtgtg tgttcctctt gagaataggg gttatgtcta gaggattaac agttttcttt 75420 tttcnttttt tttttttttt ttggagttgg agtttttctc ttgtctccca ggctggagtg 75480 cagtggcatg atctcagctc actgccatct ctgcctccca ggttcaagca attctcctgc 75540 ctcagcctcc cgagtagctg ggattacagg cacctgccac cacgcctgac taattttttc 75600 tattcttagt agcgatgggg tttcgccatg ttgggcaggc tggtctcgaa ctcctgacct 75660 caggcgatcc tcccgcctag gcctctgaaa gtgctgggat tacaggcatg agccaccaca 75720 cctggccaac agttttcttt tttcgattga agttcagcta tttgcaggac cgaaggtagt 75780 tctgattact ttcacctgta cttccaccaa aaaataaata aaacaaccat gagtaattgc 75840 tgatttttaa ttgaaagcat tattccagga ataactggtg gacttcgttt gcagaggaag 75900 tggcaaagac tgattgatat tatgatccag cttctaaaga ttttgctgct taatctgaag 75960 cacattggat ttctggttca ataggctttc tttttttgtt tttattatta caactaatat 76020 gtattctttt cacagggcga acctttccta cacacccata cttctctgcc cagcttggag 76080 caggacagct atcgctttac aacattttga aggcctactc acttctagac caggaagtgg 76140 gatattgcca aggtctcagc tttgtagcag gcattttgct tcttcatatg agtgaggaag 76200 aggcgtttaa aatgctcaag tttctgatgt ttgacatggg gctgcggaaa cagtatcggc 76260 cagacatgat tattttacag gtatagagtg ttccttatgt ctttaataca acaaaatgct 76320 aagaatgttt cttatccctc tccagatgtg cctcaggagc tttttcaccg tcaggtaaca 76380 ttgtaatagc tgtcactgct gataaaggac tctgtgctag gcattattcc aagcgcttca 76440 tctgcacttc cctctaataa caggaagaca ctgttcatcg tctcaatttg tagattggaa 76500 aactgagtct ccaagagatt ataaattggg cccagtcaca cagctagcaa gtgtcagagc 76560 tggactggaa acccaggcct ctctgactct agggccttcc ctcttgcccc catcagccat 76620 cagatgatct cagacctacc tcccagcctc tgcatctgct cttcctctgc ctcaccccca 76680 cccttgtcat ctcaggttca gctcaaatat cacatcctgg gagaagctca ttctgactac 76740 cctgatgttg tgttccccac ttccaccttg ggcacactgc gtcacgttat cctggctgat 76800 ttcttttgca caacacagcc actgccagaa atgatcttgt ttccataatc atctccctgt 76860 ctattttctg atttttcata gcctgtgaac tttaggagag ggaagggatc ttacgggtct 76920 tggagccgag ttcctagttt ctgaaacagt gcgtgggttg aagtaggcac cccataagta 76980 tttgttgaat gaacaattct gtcagagaaa accaaacaca gtagcgtatt gcaaatacca 77040 cgtgctgctc ttgctgcctg tcagagggaa aactctggat cctgcttcag gaatattcct 77100 aaatgttgca gcacatgttg atatgttcat ttactaccag taagatacta tgccttcaga 77160 gctctagaga gtatcctggg agggaataca ttagagccaa ggacttgctt tgagagcacc 77220 aaattatgtg attcaaaatc ttttcacctt gacctgtgaa catggaccac gtgaatgcaa 77280 atatcataga aggaactcat tcactgaaag attttgacca cataacactt tccacatgta 77340 ctgtgaggtt cttcctacat tccctttatt aactttaaag acagtggtca ccaggcagtg 77400 gaatttttga gttttctata atttatgtaa cacacaactc ttttggggtg gtgcctttgg 77460 ttgattagac agtcttcgat atgggagagc cacagctggt gcttatggga ttatattatc 77520 tgagcctctg aaaacggttt tgttttcttt ctctcagttt agataggaca tatccaactt 77580 ggtggatctt agcggattct gaccctctgt aggttgttgt ttctttaggc tcaggccgtg 77640 gcactgctca gatctgggct ggctctcggg cctctgtgag cctgtaactc ttggtggcac 77700 tactaggaac tggcatgaga tttctgccag aatcatgtca ttctgtgaag ttggagttcc 77760 actttagttg gaaaaagttt ttatttcatc ttaagatgca cacttgtctt cttgttttaa 77820 cttgccaggt atctggatat tccatatatt atacaccaaa agaaattatg cttctcctgc 77880 ctattgagta atttcagggg tccagaggga acttgctgag tgaacatgta caatggattc 77940 ctatggaatc ataagatgcc cctaattcag tcttagtaaa gagactggct tcttatttct 78000 aattcctcca ggcttgagtt gtgcaaagag tatgtatttg taagagaatt tatgaaatgt 78060 ttgcacaaga cagattttta gatcttctta gtggaggaat acaagggaac aataaaaagg 78120 aagtggcagt agaagaccca gcgttagcgt cctgggccta cacccagcca gtgcctggca 78180 ccagcaggca cttgggaagc acttgttgga tgaattagta gctgagctca gtggatcgca 78240 agccaaatcg aatgtttaaa gttctagtaa gtcttctctt acacccaccc tgtgagcagt 78300 aggcataact ttattgctgt ggcagatccc taattctcag cccttgtggc tgtcttcctg 78360 cagatccaga tgtaccagct ctcgaggttg cttcatgatt accacagaga cctctacaat 78420 cacctggagg agcacgagat cggccccagc ctctacgctg ccccctggtt cctcaccatg 78480 tttgcctcac agttcccgct gggattcgta gccagagtct ttggtgagca ttagtaaatc 78540 tgtttgccag aaccagcctt ctcttattag aggggaaaca tttcctgtct ctccrtggtg 78600 attcttattt ttatacctgt agctcttacc agaacagggt attgtttgat agtctaagat 78660 tagtcagggg tgggttttgt gactttggag tcctccttaa cttctgataa tcacggggct 78720 tcccttagat gccttcatct tgtgggatgt ggatccgatc cgtgtagatc cgatcgctca 78780 ccatgagggt ctccctagag cagacatttg gaggacttgg ctgaggagcc acaggtgtat 78840 gtttctcatg aattgccttc ctcagccact ctgggttgtg agtattgact gatgctgact 78900 gtgggcctct gggccctttc tagattccct tggcatctct tcctcccctt tctcttcttg 78960 ccctgccctt ggctctacac tttctcccaa gtcactgtct tggagaccag tgtcaggacc 79020 ttgagtaaca cctccgtgtg gatggctcgc tctccccgct cagccttgac acttcatgaa 79080 ggcctcttgc ccctgagccc acatgtcaca gccactgcca ctcccgtgcc cccgctgtta 79140 accttgggtg gttcacatgt aaaacctgcc tttatattct tgatttactt tttgagaaca 79200 ttgtcaaagt taggtgagtg ttcatacaca aagccttcaa cctgccttca tatgcaggga 79260 tagggctgtc cacgtgcgca tcaggaaccg agtggaatgt tgtgagcatg gtcagttcgg 79320 gcacagtttg ttttccctac tgcagaataa aagtgatatt tttgacaatt caggttcttt 79380 tttttattgt aaaggaggag gctactaaaa aaatgatagt tattatatat caaatgtttt 79440 taagcatcac ttgacagctt aaaaacatgt gatctttaaa aaatttgttt ttatgattag 79500 agagcatctt aagggaaatg ttcaaagaca ttgatactac ttcagacatg ctttgggtaa 79560 acatcttaaa tatccaaatt ctagaaatcc taaaatttgc tttttaatat aagtgagcat 79620 ttacccttct tctctctttt cctttccccc caaatactag atttttatta ttcactttta 79680 tctacaagaa cctttaaaga gtttcccatt ttgctttact ataagaattc atattccttc 79740 ttttctgtcc ctgaaaaaat aaaatcacta aattaaaata gatacaaaaa gctatctcct 79800 ggttgagcat atctttagtg agagttcatg aaggtttata ccatggttaa aaaaaaaaaa 79860 agattaacta aaagcctcaa aattgtgtgc ttagtttatt aacaaaagag ttacagaaac 79920 taaaatctca agctctaggc tttaagcttt cttgccaata acttctatgt ttttgacttc 79980 tctaacactg gaaattaaaa gaaaattatt aatctacctt ccttacattt tctccacatt 80040 ttagctatga ttttcataca gggtcatgaa gaggagtgag gatggaaatg gggaggaggg 80100 agcgctgttt gttaatggtt tgtaaacagc tcaggcatta aattacttgg ttagtgaaga 80160 aaattctacc aaggcaacca ggctgaccac agactggagg gctgaggggt catcactgag 80220 tcatctctgc cctggggccc caggcactgg agctgctgct tgcagaaagt tctggggctc 80280 tggaagagaa atttttcctt cggctcataa atgggtaaaa agacgttaac aaacaagcag 80340 actccacttt ggaaatgata gcccttctat tgcagagtaa tttgaagctc tctgaagctc 80400 actctaatga cttcataaat caaagctgca gcttgtaaag gtaagatatt tttctgtaga 80460 ctttgtaggc agtggtgaga ctcggagttt cataaacatt atgcatagag atgccagtgt 80520 ctacatcatt cctggatccc acagactcct gctgtgctaa gtgggtcgtt gtccagctgg 80580 ccaagggctc ctgggattag aggcgggaag tgggatctca aggccgcact ggcttgtgat 80640 gtcactttgc aagaactgct tttttttcca cagtccatcc catctttcag tacttaaaaa 80700 cagaaaagat aggtttttac aaaccatttc tatttttagc actgatgact tagagaatgg 80760 tgatggagat agcttagttt tatatttcaa agcctgccat tcagtcacta tagtcttttt 80820 tggcctaggg cccatttcat tataagcctt taagtctgga taaactctaa aaacatgtag 80880 aactttgttg actaagtaaa atatttcagt ttgcaccacc ttagctcata tattagttaa 80940 taggttacct ggcattaagt atgtatctgc tccttggagg ggcggctgcc agtgatgtgt 81000 gcgccttaac cttcacatga tactcacacc ttgctgaatg gcagttcttc tacctggtgt 81060 cacataatgt caatagcccc ttcctgtatt tttctagctt gagtacagca gggccctggg 81120 agagacgctt gctctgttca ctttctcatc acatctacct ttgggggaaa aaaaatctaa 81180 aaaacaggac ctggcttgct cctgatggag gaggaggctg cagtgttcag cctctgatgt 81240 ttttctatag gacatgctgc caaatagatg agggaggagg aggagtataa aaactaaggg 81300 tttggcaaaa aacacagaag ccacctgcaa tatagtgaag gcttcagaga gactttagga 81360 tgaaaataga ctgaaaacaa gattgtttct gtggccagga aaatctccag ctattcaggt 81420 gacatgatgc cgcgtgatga tgagtgtgtc cagtctgtct gtgctgttgt tctgcacagc 81480 actgtcatca gccttcagcg tcccctttac ccgttactca tagaatgtag cggagccacg 81540 actggaggac cgcagccttc cagaagaaag ttgagaaggc tcagccttga caaagacaaa 81600 ggtggctgga aaaagagatg cagtgcaatc tcacatagga agattgcact ttgagatcat 81660 gaagtttagt ttcaaataga gttccaatac acagtaacgc aataagaggg ttgctgaaat 81720 gtcctcaaag aaaagcagtt cctttgtgtt gttcccagcg aatacagtgc aaagtaatag 81780 agtcagctga atttaagatt cctatttcct gccggataaa acgtcttgcc tgtttctagg 81840 tggcttgaaa aaggagagga gagaaggaag aggcaggaga aaagtcccac tgaaaggacg 81900 tgggctacag tgtagtgagc taggctactg cctcactgcg ctgggcggct ccaacagttc 81960 actgtctcct agggaggttt tcaaatgcag gacatttgct cacttttcca aggagagtta 82020 ttgttttttt gttttgtttt gttttgtttt gttttaaaaa attccagaat gtaaatgtat 82080 aagataccgg aagacaggca aaataaaaat aattggtttg gggcagtggg tttataggta 82140 acatttttct ttactattrt tttaaaatta gatgtgattt aaaaaaattt ccaaagccaa 82200 aaaacggtac aaatgcttta aaggatgaag atgttgtccc caagtgtcat cagacaaatt 82260 taggaggccc ttcctcccaa gcaaagcttc ctgcagtcct tccttcaact ctgaattcaa 82320 gcacattcct gcattgtgca cccaaatgat ctcccgattt aagaccccct gtgtctcaca 82380 gaagcttctg gggctgaact ttctccggcc ttggagggtt ggacgctttg aatgggagga 82440 gtggtggtga gtggagcatc tctggcagca ggcatttggg agtctctggc aggaatcaat 82500 cagcgtagtc tccaaaggtg gcctttctct gacactaact agcccttgca ggggtcatac 82560 ccataacctg catctcatta acatcatctc cttaccagtg cactgaccta gtgagaaaag 82620 gaacaacaag cattcagcga ctcctgcggt gctccagggg aagttagaat tgcttggctg 82680 gggcagaggc ccctggtgat ctggacctgc gtgcccccat ttgcccacct tctgccctgc 82740 acaaccagtg cccctgcctt gccagccaga ctgtttttca ggctcctgca cacctccctg 82800 tattgacacc ctattttcct tttattcaga gtattaatcc tgaggtctga cctaggaaat 82860 tttcattggt tcttcaagca gtcacctttc tgtgggcctt ttctttcctc tttgttctcg 82920 taacaccctg ggcataactc taccgaacca gaactccttg gtgtctctgc agcgtgttct 82980 ttgtgttttg ctcatggctt aatctccaga gcctaataca gtgcctgatg tgtattagat 83040 gctcaataga tgctcattaa gttaaagtag aagacacctc tcagcagagt tctcttaagg 83100 tgttgtgaat agcattggga aagaacattt attttttaat tacattaaat acaaacagat 83160 ataataaaat aaatcatatg cccagtgcta tgtcttaatt ttttaacata tcaataaaga 83220 gactttaaaa cacataacac caccctctcc cctccaaatt tcctttccgg gaaagtctcc 83280 ttttggaatc ataggaagca cttactaagt tgatttattg taaaaaaacc aagatcctaa 83340 taaatctcag aagatctcct gttaacctaa agagaccact gatgtggatt ctgtatttgg 83400 ttgtgctgac aaaagtttcc cagtaattgt ttattttaat tggcgtagat gtggtactgt 83460 acctaattta aggcacttgt ccctctgaga gtagagacca agctatagaa aatcactggt 83520 gttgtaggga aagcctttcc ccaggatccc tgcaaaaaag gtcttgattt ttattctgaa 83580 agatgccctc attttttgtt cagctataaa agttcatata ttgaaaggag gtctaggaag 83640 tctcactgtg taaaccactg aaacttcaaa tttactttag agttttgttt ctggaaatgt 83700 catttctgtt taaaaataca tctttgttat agtattattt tagatctttt tattttctgt 83760 agtggggaat tatacaggta gactacattt tataaaccag atatttcaga ggaatattct 83820 tcaattggcc tgccttggtg tatgtaacac ttaccctgaa aagctctgat ttcaaagaca 83880 cagttagttc tctagtatat cttcccagcc tcaacaacca gacttaagaa ggaagtgaag 83940 gattcatctt tcccactttc ctgcggccac cctgagccat cagtagttgt gatgtttgtg 84000 gaaagagtgt ggaccctgag ctgggtggga gaagcaggct gatctcagcg ctggcatggc 84060 ttagggctgc acccatctca gctcacatgg ttaattaagg gttttgtggt ggttacagag 84120 gatctcgagg gctatcccag ccagcgggct cctgggtctg tcatccctgc ctgtgctttg 84180 ttcagaaact acagggattc agtttcccat ttgcacagca gcacccagtc tttgcttttc 84240 tgtttcttcg tggcttttaa atgttatcat attaaccatc tagagaggca ccctgcaagg 84300 ttattcctct cacctgcttt tgctttcctt gatttgatga aatttacagc ttctttctct 84360 cttccattat ctttcagcca aaagaaacag agaaaagaaa tactgacact tgcctccaat 84420 tatatttcta ctctgatttt taaaattgtt tttttcttat attattattc tagttattag 84480 gtaacctgcc tcagtttagt caaccaataa ttagttatcg tsgctctgct ttaaccccag 84540 gacatcagac tctttttttc cccagcagct tcaactctat gaggaaggtg agacagggct 84600 ggggttgctg ctcggccgct tgccttggcc ggtgccctcc ctcttattct gcagtctgta 84660 tagaagttgc atccatttgc cagccactct aagaacaaaa tatggccaga actaggaagt 84720 aaccttgaca gagttcttga actcctcaga gggaaaaatg ttctttattc cattatcatg 84780 ttaaaaatca gtaaacttgt atttaacaaw gtacttctgc agttgtacag ctgttgtaca 84840 gtttttaaag atctttgaat tctattcctt gtttcaaaac agaggaaaca gagacacttt 84900 ttcacttact ctatcttaat ttctgatgct ttatctataa aaatctttta gtgtgaccca 84960 taaaaacatg ttttagtatc tcctttaaaa cccaggagca ttcctggaaa aatagactaa 85020 taaaaccttt ttccctttcc cagtttaact tttgaagcat gtttgaattt tattttcaga 85080 gtaaaacata atttttaatg tttatgtact tttatttgca atactgtctt gacaacactg 85140 tctgagatat caggctctta aaaatgaaat aaagtttgca atgtggggct atgtctccca 85200 cactcctgct ctgtgatgtg tggaaaaggc aatggaatgg tattgcgtga gaaactggtc 85260 tggtttaact ttctgcattt ctgtgttttc tcagatatga tttttcttca gggaacagag 85320 gtcatattta aagtggcttt aagtctgttg ggaagccata agcccttgat tctgcagcat 85380 gaaaacctag aaaccatagt tgactttata aaaagcacgc tacccaacct tggcttggta 85440 cagatggaaa agaccatcaa tcaggtatga gtcagtccaa accttgcaaa tgcttaagcc 85500 atcctagata tgtagaaact taaatctctc ttgagcagga actgtttcct accactttgt 85560 gttctgaacg gcattctgca tgatgcctgg catggaggag gcatatcaca aacgtgtgga 85620 atgatcgtga gtgtgtgtgt tgtgagcgtc atggtgaaat gccacatgga aacatggtgg 85680 caatgtttag ctgtagaaac cagcacaggt tattagtagt ttcttacatt taagagactt 85740 cagctctagt agcttgttct tctgaaacat atatatattt atgcaatgat gcaatgtagg 85800 gttttgtaca ttgagtgctt tgatttgtgt gtgtgtatgt tgaatggttt taattggaat 85860 tttctccaaa taattctttg ataacaaagt tatgataggg aacatatatt ctatgaattt 85920 gtttcatgat gtgtgtgtgt ggtttttttt taactgaatt cagttcaata tctgtggctt 85980 cattacctct ggtttcagta tacaatagaa ccattatcct ctgaagtgtt agaggctgag 86040 aggtgagttt tactgggaat tacaactaaa ctagatggtg aatgccctgg gttgggcatg 86100 ggagcagatt ttgatcctgt acagtttaag gaagaacctg ccagtaatgg ctgctgatga 86160 tggaggacta tgctccttag tagagaaagg ggcatcattg gaagtgtcta gaggctgggt 86220 agctacgaaa gcactggaag ggatttcatc attgagtcac tgcagagtca gcagtcaagc 86280 ctctcataag cctagaatct gctccagata gtcatgtgtc acttaataat agcaatacgt 86340 tttgagaact gcatcattag gtgatttcat cattgtgcaa acttcataaa gtgtacttaa 86400 acccaagtgg tatagcctac tacacaccta cacatgttgt tcctaggccc tacaaatctg 86460 tatgacatgt gactatactg aatactgttg gtagttgtaa cacaaggtgg agtatttgtg 86520 tatctaaaca taactaaaca tagaaaaggt acaataaaaa tatggtattc taatcttatg 86580 ggaccaccat catatatgca gttcgccatt gaccaaaatg ttgtaatgca acacacaact 86640 gtgtaacgaa agcatagagc aatcaggcaa aaacaaatgg tgaaataaag ctatttttga 86700 aaaatcctta ctctggagat ttctgtagtc caaaaggaat ccatgattcc agtggattgc 86760 atccacatgc agtgtttgtg attttcattt gcagccacac cttaggtgtt aagcacagaa 86820 aaagatgcaa atttggcctg caaaagaaag aggtttcata ccagttgtta actttagatt 86880 tctgtttgca cattgcatat gcccttatga aagaacagtt cttgtctgtt ctgcactcat 86940 ctttaattga gagcctctcc atctcttttc cttccctgga acactcttct tgatgtggat 87000 agctttggct tgttggggcc ttgctttttg ccaggttggg tgggcatcga aatatacgca 87060 tgatcccatt cagtgcaggc cgcactcctg agaggatata aagtggttca ctgactgacc 87120 cacactcact ctgctgcaaa gtggaaaggt aggggttcaa actcaagtcc ctcccacctc 87180 aaagtgcttt agcagctctc ctacactgcc aagagcctct ggaggtcatt taatttagag 87240 tttttcccta ttttaccagg attctaatac tgacttctcc acccttttga ttctttgatt 87300 tctggcattt tcattcattc tttctttcat tcattctctt cttacagctt ttgttgcatg 87360 tacttactta catttacagc ttctagggca gacccccgag agccttggtt acctagactg 87420 agggctatat ccactacctg acatgtcacc ttgctcctgt ccctcaggcc atcccagctg 87480 acattgttta cctcctaagt attgagcctc agaaaaaaat cccattgtct cctattttct 87540 gtaaaaaaca aaaaataaaa cgtattgaga atacttagga tacatcaggt gctgtttcag 87600 tgctggaaga gtggaaatgg acacagcatg ggaagaaaat agctgtgcgt gtacctggtt 87660 tgtttcaagc cgctatctgg ctatttggaa gttgccattc atttttccac tgactttttt 87720 tttttttttt tttttgagac agagtcttgc tctgctaccc aggctggaat gcggtggtgt 87780 gatcttggct cactgcaacc tccaccttct gggctcaagc attctcgtgc ctcagcttcc 87840 tgagtacctg ggactatagg catgtgccac cacgctcagc taatttttgt atttttagta 87900 gaggtggggt ttcgccatgt tggccaggct ggtcttgaac tcctggcctc aagtgatcca 87960 cctgcctcat cctcccaaag tgctgggatt acatgcatga gccactgtgc ccgacctcca 88020 ctgacttaat aactctagga cataggtatt ataattccta tttttataga tgaagctgag 88080 cagagagtaa catgcccggc cccctgtaga aaggcagggt ctgtgggagc cagggctgtg 88140 aggttggagc tgaggtgttt gagtccagct ggacttaaaa gatgacctaa gatcggctgg 88200 cagacatttt ccaaagaagg ccaggcagta tatattttag gcttcacggg tcataacgtc 88260 acaactactc acctctgcga cagctactca cctcagcctt tgcagcacaa acaatccatg 88320 acagcatgta aggggatgat gggtcatgtt gcaaaaaact ttattttaaa aactgtgcag 88380 cgtgatgggc ttggtccaca ggtggtggtt tgctgatccc tgaactaaag gatcacagca 88440 tgtgagaagg tacaggaatg agagcagaga gcaattctca gaacctgagg tgttcaacat 88500 tttgggggta tcgggagcac aaaaatttgc atttagggcc cgggttttta tcagtggtcc 88560 ttatagaaag tagatctacc cgcatctctc ccctctttcc ctctggtgtt tctatctgaa 88620 cttgacatct gagtgttctc tgtcaggctt tctgctttcc cactgccccc tcccatccag 88680 agggtgctgt agtcttaagt tctacacaga aagcagacat ggggtccagc atgattcctc 88740 tgcagcctta gagatccccc aggcccaaat cttgggggtc ttcagagtag atgtaatgga 88800 tgcttccatt gcagatggtg gagcatactg ccctgtgtac agatggggtg gggcaggaag 88860 tgagggcatc tgggtggtcc tctgtgatag ctgtggttcc atttcattaa atgccctccc 88920 tgtatagata gtctcagcct gagcaactgg gacacagctg gatcctgggt ggaagaggtg 88980 gccaaggaca gggctctgga gctctggctc aatgtggaca ggctgaaagc agccagagag 89040 ggcaattcca aaggtgacag agcccaggac agaagaccaa gggtgtctga agcctttgtg 89100 gcagtgtact taccaaagga cctgtccatt gaataaacca tctacatctt ctgacccaag 89160 aagaatggaa actttgggaa taattagtaa caaaggaaag gaggtcagtg ttgtattctt 89220 gtcacagtgg gtgctctgtg gctgtgaagt ctcagctcag tttaaggaag aaaaaaagga 89280 agggtggctg tgggaggcag ggcaaatagc ctattttcag catcctttag gctccactca 89340 gagcatggcc tcagcccagc attgtcatca tatcatgtca gagcttgtta gaaactcagc 89400 atctggggcc acacccgaga cctgctgaat cagaatctgc atttcagtga gatcaccagg 89460 ggattcacat acacacaaac agctgagaaa ccctgctgtg ggcaactctg ttagaaacac 89520 aatgaacaaa ggagcccctg ttccagttga gcttgtaggt tagaaaccag ggttcctgta 89580 ttcagaagac acacctcaaa tcaggggcaa aggtgcctct tctgcctgtg ggggagccgt 89640 cacttcttgg gcagtttgca ccgtggaaaa ggagtagttt tgtacgagga caactggtgc 89700 cataccagga gggtggggcg tggcggggag aagtggttta ccactggcgt tgttgaaaat 89760 tgctcacatg cagtggtaat aacaagcaga gggactttta gtgggtttga tgttttttgt 89820 aattcactac agatagtgtg tgcccccttg ttgctgatac caggccgact gttcccactc 89880 tccagccctt ggtatgacaa tgggaccagc agattggagg gcagggggtt aggaaggcgg 89940 aagctctgtg gcgagttctg caaaccrtca gggttcatga ctttattaat cagtgtccat 90000 ggactgtgaa gagaaatgct gagtctacaa tagcaaatga gccaagaaca taaacagaca 90060 attcaccgaa gaggagatat ctagtaaaca aatatctggg aaagtatttg gcttcatgtg 90120 taatttaaac ttatgtaaca tataatgctt tactctacta gataatagaa agacatttct 90180 tgatgccagt acccagcacc aagggtatac tgtatgcaga acattagcat gttgctgatg 90240 gcagtgcaca ttgattagtg gctgttggga gacaatttgg cgaaacatat cccaagccag 90300 taaaatattc ataccctttg actcagtcat cccgtttctt ggaatgtatc ctcaggaaat 90360 aatccaaaat atgagggaag ccatatgtat aaggatattc tcctagactt gtcacttata 90420 ataacagaaa cttggaacta gatgtctaac acttgatgac tggattaata tgatgatggt 90480 aggttgagct ggtagaatat catgaagcca gttatatata gcgacatgaa aaagctctta 90540 tttgatacaa tgttaagtaa aggaaaagtg ggataggaaa ttttatgttg gttatgttta 90600 gaactagaaa aacatgcttt taggaaatag gaaatatagc tagatataaa agttgtattt 90660 ggtgattttt cttttatttt tcaagcttcc aataatgtag ctctattgct tcagtaactt 90720 aaaatagttt tatcttttcg gcaaaacatc gaaagtatgg aaatagtcat tcctactttg 90780 gcaaacagaa gagaaatttt cttcagtacc aaaattctgg aacttgactg aaaactatga 90840 agaacctaag agccaggatg acaggaaggc tctagatccc cagtaattac aactctagtg 90900 gaattgctct gagatgggcc agcaagaaag aagatgagag ccagtccccc ttgcagaggg 90960 gccaggtacc ttgcagcttt gtgtagtgac cagtgctcag ggaacggctt aggcaagacc 91020 ctgggggagg tgggcactgc acttgtccag cctcaggagt gactcagacc agaaatgaaa 91080 acaccttaaa gtgtatatat cttgttttcc tatcaacacc tagtttttaa tattcgtctg 91140 ttttattcat ctgagacaac ataccaaagg attgggtttt taatgttagg ccttcctgct 91200 ctttctctgg ctgagaactg ctcctggcag tggatcactt gtgctgtcta agtgtgcaag 91260 gacaggcgcc cctcccaatt cttttctttc cccaagtaat tagcccaagg gctgaagccc 91320 tcgtccagtg accagggttc tcctttgacc accagcctca tattgccatg gtttggggta 91380 aattcagggg cataactgca gaatgaaggg cctaggagtc ttggcagtca ggagatcatc 91440 aggcaattaa gcagagatga ttgtgaccca gggtggttcc tagggattaa tggaggcctg 91500 gaagagttta tggctttggg tactgctgag agccattaac ttaacacaga acatcaatcc 91560 gtaggaaaag ccagaggttt tgttcccagg ctttccaggt taggagatca cttaaatctt 91620 tgtgaaagaa aaaaagtaat agtgtacatg acatttattc agcaccatat ttataattat 91680 acatgagtgc caaacaatct cagttttaac atttgtggtt tttactgttc agactattca 91740 gaagttccat gacgtggcat ccattgatga tggttttgct gaggttgaaa tgtgagggtt 91800 ttgtggcagg tgtgtggaag cagatccctt agctaagaga gcgcctgctc aacctgccag 91860 gcgtgtgctg ggaacttcca ggagttgcct cgtttaattc tcacagccat cctgggaggt 91920 aggcgctgtc tgccccaggt gggaggccag gaactgtggc tgagagaggt taagtaccga 91980 gctcaagtca ttcatagagt cgccagtgga gccgcaattt taaggctgac tcaaagcctc 92040 tgagccagtt acctcggctg tcaaatggag ataataatcc ctgctgacct cacggtcgct 92100 ctgaaggaca aaagagaatc agttcaatcc agtaaacaat tctctctctc cctcttactc 92160 ccctcgcaca catgcacaca caccccacag atataatgga ttttagtttt taggcatcaa 92220 atgacttttg tgccttatta atattatcca ctgaatcaaa aacagcaagc tgaaaaattc 92280 atctcaagga agagaaaata agattgttgg gaatggtgag aaaggaaaca tggtttttga 92340 aaattgattc cagggaagat aggctagttt gaatgccagt agggagccat cagaagaagt 92400 agttttacac tgatttttaa caatattgga gttgcttaag gcaatgcaat agagaggcag 92460 tttctgccct tttaaagcct gacttcactt tctgaatgtg tgttctgatc tagcagggtt 92520 tttttttttt ttcttttaag atggtcccag cttgactgca ttctcagatc catcagataa 92580 acgttagggc ttcactgctg tgctgagagg ccccagcccc tggggttctc tcatagaaac 92640 aactggaaag aaaggaaatg ccttgggcag cagcagcagc agctgtcttc tgattctgct 92700 ttccgccctg ccttccttac caagagaaag tacagacacg gacggcttga gtcacttagg 92760 cacttaggag ttgtttttca cacgtgtggt gttttcgtca ccattactat tgtgggaaag 92820 aagacaactc aggcatcgtt tcgtattcac tcatctgtgt gggtgacatg tgggttttgg 92880 ctcatttctg catatttgtg tgcaaaggag agttttttag taaacagtcc cattacttag 92940 ctgttcttgt aactctgaaa acccaactga actataatta aactttgact tggtgactct 93000 gcaaacaggc tatgattctt ttgtttcttt tctcctttta acccatagtt gatgtatcta 93060 acctaacaga attttcagag aaaagaagtg aaataagaac taaaaataaa tttttatgtc 93120 tttaaaaatg agaggttttt tttttttttt tggcttttgg aaggtgagta tcaaaaacct 93180 gtacttaatg ttaccttgga attatttcta gatgtttctt atatcctttt gtcccaagta 93240 aaattattac cttctcagtg cgtagttttt cttatttatt acttctagta ccaagtgtag 93300 agctaagcgt agaggagacg cttcacaggt gcgcattgtc gtgattgcag acgcctgcct 93360 gtacttgtgg ggtttttctc agttttagta cgtgatgact tttctttcta taacaggtat 93420 ttgaaatgga catcgctaaa cagttacaag cttatgaagt tgagtaccac gtccttcaag 93480 aagaacttat cgattcctct cctctcagtg acaaccaaag aatggataaa ttagagaaaa 93540 ccaacagcag cttacgcaaa cagaaccttg acctccttga acagttgcag gtagagcata 93600 tttataaagc agcttcctga atcacaaata tatggtagtt cattaactca ccaaaggcaa 93660 cagcaggctg ggctttccca tgaccagagg acctttccca ccctgatctg tttatagttg 93720 ggatcaaagg tatcccggga gaatgggtcc tttttattat ggagcagaca gattgtcctt 93780 tgctaaggtc aggcagtccc agagctttct gagaggctgt ttctgcactt aactctttta 93840 ggggacaggc ccagagatga acttggattc aggatgccgt ggcctgttag ctgaatgcca 93900 gccgttgtca ttactcaaag agaatctaag agcttttaac ttctatgagc aaaaccagct 93960 aggtccacag agggatggta aaggaggaaa gtaacacaga aataaatata acaaaccaga 94020 agagatgata attctttgtg agtccttggt gcatatacaa agatttgatt aatgaaggtc 94080 tcagttctcc cctctagaaa cttccatttc aacacggata tactcaggtg aggacataca 94140 gaagaaagac cagttgagac tgtgcacgca ggagggtgtg cagagcaagc actgaggtgc 94200 agcacggaga ccagagctgg ccaggtccag catcaccccc acccccacat cacccaggca 94260 cactgcccaa aagaacacct aactgcggag tgcagctctt ttgtcaatct gatggcatga 94320 agcaaccata tgttctactt ttttctactt tttttaatgt cacaagtgtg tagcagtgct 94380 gtccctgtta aggagttgtt ttgagggtgt ttttaaaagt tgtttttgag tggctgtgga 94440 taaaaataca tatttttgcc gaaattttta tggtgttcct gggctgtcct gagaataagt 94500 tccattctga tctaagcctc tgatttttct tcatagaaag atgagctttg cagacacaag 94560 cttggcagca aggtgagaaa ggccagccta gtgagtcaag ctatctgaaa tgcattcctc 94620 ccagcgggca ttccatccca gcatacccta tcagatatgt gaaagagagg aaccaagacc 94680 gaatgctatt cctgcccagc cctaataacc actcacattc tgaaatttaa cttctttttt 94740 tcccctaaga tagagatgtc ctaactgaaa atatgcctgt atacaattta ccctggaagt 94800 ctcagccatc actcaaggga agtctccaga gggtgaagag cctgtctggc ctgtaggggt 94860 acacagtgta ggtggtcatt ttaaatggct tccaagccaa tgataggtcc ctgaaatata 94920 acatggtgga aacttctaat aaagctcaca tttgcattga agtgtttagc ttgttaagat 94980 aggcagttct caaataaaag gtttgtttta ttgggtaaat gaccttgtag ttttttggtg 95040 acagagcata gaaagtaatt tcatgctgct cctgtgctat tgtttttgtg aagacaggga 95100 gctgtgaaaa actgcttagc tacctacatt cctcaataaa ggcatcagac agtaattggt 95160 gattacagat gttctccctg gaatggtcgt tctcttgacc aagtagtcct acacttctgg 95220 aaggatcatt cagaactgtg gtctatgcca acccaccagt agttcctgag tccctgcagt 95280 gctgagtgct gggggccacc aagttgagta agacactgca gctctcaaag agttggatct 95340 aggattgtat tgtatcgatt tgtggtgttt ggatatagtt tttccatgat cccctacgaa 95400 aatatgcctc tcatatgtaa gaatcatgcc tcctccgtgt acacttttca gacactgaca 95460 aggaagggtg ttcaatacag tactgaattt tcatatagct tttctggggg ggccaaaata 95520 ccaaaatcaa cccatttcct acctttattc tgtccataaa attgttagaa atatcaaaat 95580 cccatttcat tccctgttaa atacatgtga acgttgtcta gacgctggag agcaaattct 95640 accacctctt ttgttcagca gtacatcaga cgattgcata gacgtgccag atggaaccaa 95700 ataataatgc acatggattt gtcataatcc gtacaagtca ttgacgccca cactgagcca 95760 ggtgctgtgg gagacaggac catgtgtgaa agagaagaca tgcttgcttc tataaaagca 95820 tcggtgttat tgaggagacc tgacattaat gcagaatagc aaatgaccat gcaaattaat 95880 tcactactaa ctaagctgca ggttgcacct cggaatgcag aggggcttca aagtgatgag 95940 ggtaggccct gagccaggcc ctgatgatgg gtggattttg aggatcagag agtacagctt 96000 agagagatac cccaagtggg accacccctt gcccagtagg ctgacaaact aaggctcttg 96060 gtcccttttt catattttgg gtgttctagt ggcccagcca gagctagact tcgagtcatg 96120 aattttctgg cacaagtgtt gtcacattca aaaaagtatt ttctttgttt gaaaaatgaa 96180 aaatatatat atatgtgtgt gtgtatatat atatgtgtgt gtgtgtgtat atatgtgtgt 96240 gtgtatatat acgtgtgtgt gtatatgtgt gtgtgtgtgt gtgtgtgtgt gtgtatatat 96300 gtgtatatat ataccatttt tcccacctaa aatggagcat ggcaaatctg gactggatta 96360 gtgagataga ccaagtcaca gagcactcca ggatgcagct gtgagctggg gaacaggtca 96420 gaaaggcctc agggacatca gcatacatgt tggagtttct gcagttttct tagggaaccc 96480 tttaatgtca ctagagctaa cacacttgtc acctgggaag caagcctgcc agagcaaatt 96540 agagagacga gggacagttg ctagaaagac acacctggaa gttctattta actagcatta 96600 attatgtgct aggtgctgag gatgtagact gagtgagatc ctcattcctc ctctgtaggg 96660 tggaagagag gatattgctt gtctccatgg ctcgtagtga acagtcagtg agaccaggca 96720 cataaacctc ttagcagaac acttggcctt tctaaggact ccatatgtgt tccggggtaa 96780 atgcctgtgt ttcttgacgt agtgatgtct tgttcctcta gacatcacta actttacaca 96840 gtagctttag atggcgtgga cgtgaataaa tgcaacttag gttttcttgt tggtttcttt 96900 ttgagtatca ttgtgtttgt aaagaatttc agattagagg attgttacca cgtgggcctt 96960 caggaggaaa ctgttttgag tttttgtcag cccgaaatcg atttgtgcgt ttaagtatat 97020 gtgctcatca aaacaggcca ggctctgctg cagtaacaaa cttacaagtc tccgaggctt 97080 ggcacaacgg aagtctttgt gtcactgacg cccacttcag ctttgtgttg ctgaagcatt 97140 ctttggccct atccgagctg tccctctggt ggtggtgcct gggggtttgg gttccctctg 97200 tgttgtgatc caccatctca gcatcggctt ccacagcagc catagcagga gaagaaaatg 97260 ctgggggctc tcagggtgct tttaagggcc tggccaccga cctgcaaggg gtgcgagttg 97320 ccttcctgtg tggccagaac tgatgataaa ctgtagactc atccctgctg aaactcggct 97380 ccagagtgct cccaaggctg gacagcgtgt gggcactgga tcccacctgt gttagcactg 97440 gcaattgtat tctcatttct tcttttattc tccaggtggc aaatggtagg atccaaagcc 97500 ttgaggccac cattgagaag ctcctgagca gtgagagcaa gctgaagcag gccatgctta 97560 ccttagaact ggagcggtcg gccctgctgc agacggtgga ggagctgcgg cggcggagcg 97620 cagagcccag cgaccgggag cctgagtgca cgcagcccga gcccacgggc gactgacagc 97680 tctgcaggag agattgcaac accatcccac actgtccagg ccttaactga gagggacaga 97740 agacgctgga aggagagaag gaagcgggaa gtgtgcttct cagggaggaa accggcttgc 97800 cagcaagtag attcttacga actccaactt gcaattcagg gggcatgtcc cagtgttttt 97860 tttgttgttt ttagatacta aatcgtccct tctccagtcc tgattactgt acacagtagc 97920 tttagatggc gtggacgtga ataaatgcaa cttatgtttt cttgttggtt cctttttgag 97980 tgtcactgtg tttgtaaaga gcattcacaa tacggtggaa tttcaaaagc tggaagagct 98040 cgagatcatg cctcaggcaa aggcgtgggt ccatcgttct tccgagaggg tttgtgtggc 98100 gactacaccc tcagcgtccc tggcaaggtg cagttggctc tcgcccattc ttgttatgga 98160 aacctaagat gatcattggg aagatcagtg atcttgggtc attgatccct ggctcagagg 98220 atagcggttt ccatcataaa ccaagatgat gagttcagcc tttatccctc gtggttccac 98280 tagatgtaac ttaaaggagt taacatttga ggactttgtt ctacatcaga ttttactatt 98340 tgaatgttta agatcacttt attgaatttg aagatcatca aattaaataa aatgatttat 98400 ttaatttgga tatcctgatc actgtcaagt gaaatggatc tctctctttg gtatttaagg 98460 aagtttgtct ttaaaaaaaa aatagagtgt tttcatacat ttttgcttat cccataagta 98520 cagttgatca aagtcatagt aggtaaatgc tttatgggac agctgacacc ttttagaccc 98580 taccaggtat tgctagcatg tgagctgcag ttgtggggtc tgagatattt ctttgtggta 98640 gtttcatacc catactatag agtcatgtat ttatttttgc ctgttgtgtg atgtaatgca 98700 atcatgttcc tttgagtctc catcccttgg aaatctgact tcttgcagaa ggagtaggca 98760 catcaagata ttcaggggtg ccccaagagt ctgggacttt caaaaaaaaa agatcaggct 98820 nnaactgcag tcagatttat gacagctgac agtttttcag aggtcgcaca cagtgactct 98880 cctctctcag gatgacgagg acctgtgcct tcaacaagca aaatgctgct cacggttgtc 98940 ctgcttgcag ccagtcactg tgtaaagcct ctctgatgtg cacttaagag tgggttgctt 99000 tctcacaaag atggggttct gtgcagtcac aggtcacttc cttgacaaca caatcatttc 99060 tgatctttat cactgtaacc acgtcttcta ttccatagga gtttcttttg attctctcag 99120 ttgcgggggg catctcttaa tcctggggta aaaggagaga ttgccatact tagactcact 99180 gtgagtctcc ccggccattt cacgaggaga ccacagtgct gccaccagtg cctaaacagg 99240 tggctggcat tcgagacttc ctcctgttcc ctgggtcaga ggatagcggt ttccatcata 99300 aaccaagatg atgagttcag cctttatccc tcgtggttcc gctagatgta acttatagga 99360 gttaacattt gaggactttg ttctgcatca gatcttacta tttgaatgtt tactgttgga 99420 ttttgggcat cttattactg ttactcaaaa acattgactc tgcatcaaga aagaaacaag 99480 aaagcaataa aacaagaaat aattcatgct cacattttta tggtggtttt tttttttttt 99540 ttaactttgg atttttgctt ttcagcccag gagtaaagga atgccttatg aacacctgtg 99600 gcctacgtgt ggtcatgacc caaccatcag tgagattatt tgagatattg gtgtctgcat 99660 ccagtgttgt tatctgagtg tttattacgt aagttgtaac acctctacac agggtgtgag 99720 tttagcactg atgagaccag ctccatcatt gtatgtggca gtgagtcctg ttacgagatt 99780 gggttgggca gaaaggactg ttgacatgag cctgtggatg taggttggac agtctcagcc 99840 tgtgactgac taggcaagga gcggagaggc aactgtgtga ggattctcag agccaaattt 99900 ttaagccatg ttttgggtta tatttccccc aacactcatt tgtgcacttg gtggtgtcaa 99960 <210> SEQ ID NO 3 <211> LENGTH: 3983 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: 171..3725 <221> NAME/KEY: polyA_signal <222> LOCATION: 3942..3947 <223> OTHER INFORMATION: AATAAA <221> NAME/KEY: misc_feature <222> LOCATION: 36 <223> OTHER INFORMATION: n=a, g, c or t <400> SEQUENCE: 3 ccaggccgtc cccaggatgc ccccaagcac ctgcgngtcc cggcccggcc ccgggctctg 60 agcgcgccgc ggcacaggtt tctgcatatg aagtgtgtaa aatagattgc ttgatccaaa 120 acagaaaaac agtgataact gttttgctga gttcccagac ccttcccaag atg gaa 176 Met Glu 1 cca ata aca ttc aca gca agg aaa cat ctg ctt cct aac gag gtc tcg 224 Pro Ile Thr Phe Thr Ala Arg Lys His Leu Leu Pro Asn Glu Val Ser 5 10 15 gtg gat ttt ggc ctg cag ctg gtg ggc tcc ctg cct gtg cat tcc ctg 272 Val Asp Phe Gly Leu Gln Leu Val Gly Ser Leu Pro Val His Ser Leu 20 25 30 acc acc atg ccc atg ctg ccc tgg gtt gtg gct gag gtg cga aga ctc 320 Thr Thr Met Pro Met Leu Pro Trp Val Val Ala Glu Val Arg Arg Leu 35 40 45 50 agc agg cag tcc acc aga aag gaa cct gta acc aag caa gtc cgg ctt 368 Ser Arg Gln Ser Thr Arg Lys Glu Pro Val Thr Lys Gln Val Arg Leu 55 60 65 tgc gtt tca ccc tct gga ctg aga tgt gaa cct gag cca ggg aga agt 416 Cys Val Ser Pro Ser Gly Leu Arg Cys Glu Pro Glu Pro Gly Arg Ser 70 75 80 caa cag tgg gat ccc ctg atc tat tcc agc atc ttt gag tgc aag cct 464 Gln Gln Trp Asp Pro Leu Ile Tyr Ser Ser Ile Phe Glu Cys Lys Pro 85 90 95 cag cgt gtt cac aaa ctg att cac aac agt cat gac cca agt tac ttt 512 Gln Arg Val His Lys Leu Ile His Asn Ser His Asp Pro Ser Tyr Phe 100 105 110 gct tgt ctg att aag gaa gac gct gtc cac cgg cag agt atc tgc tat 560 Ala Cys Leu Ile Lys Glu Asp Ala Val His Arg Gln Ser Ile Cys Tyr 115 120 125 130 gtg ttc aaa gcc gat gat caa aca aaa gtg cct gag atc atc agc tcc 608 Val Phe Lys Ala Asp Asp Gln Thr Lys Val Pro Glu Ile Ile Ser Ser 135 140 145 atc cgt cag gcg ggg aag atc gcc cgg cag gag gag ctg cac tgc ccg 656 Ile Arg Gln Ala Gly Lys Ile Ala Arg Gln Glu Glu Leu His Cys Pro 150 155 160 tcc gag ttc gac gac acg ttt tcc aag aag ttc gag gtg ctc ttc tgc 704 Ser Glu Phe Asp Asp Thr Phe Ser Lys Lys Phe Glu Val Leu Phe Cys 165 170 175 ggc cgc gtg acg gtg gcg cac aag aag gct ccg ccg gcc ctg atc gac 752 Gly Arg Val Thr Val Ala His Lys Lys Ala Pro Pro Ala Leu Ile Asp 180 185 190 gag tgc atc gag aag ttc aat cac gtc agc ggc agc cgg ggg tcc gag 800 Glu Cys Ile Glu Lys Phe Asn His Val Ser Gly Ser Arg Gly Ser Glu 195 200 205 210 agc ccc cgc ccc aac ccg ccc cat gcc gcg ccc aca ggg agc cag gag 848 Ser Pro Arg Pro Asn Pro Pro His Ala Ala Pro Thr Gly Ser Gln Glu 215 220 225 cct gtg cgc agg ccc atg cgc aag tcc ttc tcc cag ccc ggc ctg cgc 896 Pro Val Arg Arg Pro Met Arg Lys Ser Phe Ser Gln Pro Gly Leu Arg 230 235 240 tcg ctg gcc ttt agg aag gag ctg cag gat ggg ggc ctc cga agc agc 944 Ser Leu Ala Phe Arg Lys Glu Leu Gln Asp Gly Gly Leu Arg Ser Ser 245 250 255 ggc ttc ttc agc tcc ttc gag gag agc gac att gag aac cac ctc att 992 Gly Phe Phe Ser Ser Phe Glu Glu Ser Asp Ile Glu Asn His Leu Ile 260 265 270 agc gga cac aat att gtg cag ccc aca gat atc gag gaa aat cga act 1040 Ser Gly His Asn Ile Val Gln Pro Thr Asp Ile Glu Glu Asn Arg Thr 275 280 285 290 atg ctc ttc acg att ggc cag tct gaa gtt tac ctc atc agt cct gac 1088 Met Leu Phe Thr Ile Gly Gln Ser Glu Val Tyr Leu Ile Ser Pro Asp 295 300 305 acc aaa aaa ata gca ttg gag aaa aat ttt aag gag ata tcc ttt tgc 1136 Thr Lys Lys Ile Ala Leu Glu Lys Asn Phe Lys Glu Ile Ser Phe Cys 310 315 320 tct cag ggc atc aga cac gtg gac cac ttt ggg ttt atc tgt cgg gag 1184 Ser Gln Gly Ile Arg His Val Asp His Phe Gly Phe Ile Cys Arg Glu 325 330 335 tct tcc gga ggt ggc ggc ttt cat ttt gtc tgt tac gtg ttt cag tgc 1232 Ser Ser Gly Gly Gly Gly Phe His Phe Val Cys Tyr Val Phe Gln Cys 340 345 350 aca aat gag gct ctg gtt gat gaa att atg atg acc ctg aaa cag gcc 1280 Thr Asn Glu Ala Leu Val Asp Glu Ile Met Met Thr Leu Lys Gln Ala 355 360 365 370 ttc acg gtg gcc gca gtg cag cag aca gct aag gcg cca gcc cag ctg 1328 Phe Thr Val Ala Ala Val Gln Gln Thr Ala Lys Ala Pro Ala Gln Leu 375 380 385 tgt gag ggc tgc ccc ctg caa agc ctg cac aag ctc tgt gag agg ata 1376 Cys Glu Gly Cys Pro Leu Gln Ser Leu His Lys Leu Cys Glu Arg Ile 390 395 400 gag gga atg aat tct tcc aaa aca aaa cta gaa ctg caa aag cac ctg 1424 Glu Gly Met Asn Ser Ser Lys Thr Lys Leu Glu Leu Gln Lys His Leu 405 410 415 acg aca tta acc aat cag gag cag gcg act att ttt gaa gag gtt cag 1472 Thr Thr Leu Thr Asn Gln Glu Gln Ala Thr Ile Phe Glu Glu Val Gln 420 425 430 aaa ttg aga ccg aga aat gag cag cga gag aat gaa ttg att att tct 1520 Lys Leu Arg Pro Arg Asn Glu Gln Arg Glu Asn Glu Leu Ile Ile Ser 435 440 445 450 ttt ctg aga tgt tta tat gaa gag aaa cag aaa gaa cac atc cat att 1568 Phe Leu Arg Cys Leu Tyr Glu Glu Lys Gln Lys Glu His Ile His Ile 455 460 465 ggg gag atg aag cag aca tcg cag atg gca gca gag aat att gga agt 1616 Gly Glu Met Lys Gln Thr Ser Gln Met Ala Ala Glu Asn Ile Gly Ser 470 475 480 gaa tta cca ccc agt gcc act cga ttt agg cta gat atg ctg aaa aac 1664 Glu Leu Pro Pro Ser Ala Thr Arg Phe Arg Leu Asp Met Leu Lys Asn 485 490 495 aaa gca aag aga tct tta aca gag tct tta gaa agt att ttg tcc cgg 1712 Lys Ala Lys Arg Ser Leu Thr Glu Ser Leu Glu Ser Ile Leu Ser Arg 500 505 510 ggt aat aaa gcc aga ggc ctg cag gaa cac tcc atc agt gtg gat ctg 1760 Gly Asn Lys Ala Arg Gly Leu Gln Glu His Ser Ile Ser Val Asp Leu 515 520 525 530 gat agc tcc ctg tct agt aca tta agt aac acc agc aaa gag cca tct 1808 Asp Ser Ser Leu Ser Ser Thr Leu Ser Asn Thr Ser Lys Glu Pro Ser 535 540 545 gtg tgt gaa aag gag gcc ttg ccc atc tct gag agc tcc ttt aag ctc 1856 Val Cys Glu Lys Glu Ala Leu Pro Ile Ser Glu Ser Ser Phe Lys Leu 550 555 560 ctc ggc tcc tcg gag gac ctg tcc agt gac tcg gag agt cat ctc cca 1904 Leu Gly Ser Ser Glu Asp Leu Ser Ser Asp Ser Glu Ser His Leu Pro 565 570 575 gaa gag cca gct ccg ctg tcg ccc cag cag gcc ttc agg agg cga gca 1952 Glu Glu Pro Ala Pro Leu Ser Pro Gln Gln Ala Phe Arg Arg Arg Ala 580 585 590 aac acc ctg agt cac ttc ccc atc gaa tgc cag gaa cct cca caa cct 2000 Asn Thr Leu Ser His Phe Pro Ile Glu Cys Gln Glu Pro Pro Gln Pro 595 600 605 610 gcc cgg ggg tcc ccg ggg gtt tcg caa agg aaa ctt atg agg tat cac 2048 Ala Arg Gly Ser Pro Gly Val Ser Gln Arg Lys Leu Met Arg Tyr His 615 620 625 tca gtg agc aca gag acg cct cat gaa cga aag gac ttt gaa tcc aaa 2096 Ser Val Ser Thr Glu Thr Pro His Glu Arg Lys Asp Phe Glu Ser Lys 630 635 640 gca aac cat ctt ggt gat tct ggt ggg act cct gtg aag acc cgg agg 2144 Ala Asn His Leu Gly Asp Ser Gly Gly Thr Pro Val Lys Thr Arg Arg 645 650 655 cat tcc tgg agg cag cag ata ttc ctc cga gta gcc acc ccg cag aag 2192 His Ser Trp Arg Gln Gln Ile Phe Leu Arg Val Ala Thr Pro Gln Lys 660 665 670 gcg tgc gat tct tcc agc aga tat gaa gat tat tca gag ctg gga gag 2240 Ala Cys Asp Ser Ser Ser Arg Tyr Glu Asp Tyr Ser Glu Leu Gly Glu 675 680 685 690 ctt ccc cca cga tct cct tta gaa cca gtt tgt gaa gat ggg ccc ttt 2288 Leu Pro Pro Arg Ser Pro Leu Glu Pro Val Cys Glu Asp Gly Pro Phe 695 700 705 ggc ccc cca cca gag gaa aag aaa agg aca tct cgt gag ctc cga gag 2336 Gly Pro Pro Pro Glu Glu Lys Lys Arg Thr Ser Arg Glu Leu Arg Glu 710 715 720 ctg tgg caa aag gct att ctt caa cag ata ctg ctg ctt aga atg gag 2384 Leu Trp Gln Lys Ala Ile Leu Gln Gln Ile Leu Leu Leu Arg Met Glu 725 730 735 aag gaa aat cag aag ctc caa gcc tct gaa aat gat ttg ctg aac aag 2432 Lys Glu Asn Gln Lys Leu Gln Ala Ser Glu Asn Asp Leu Leu Asn Lys 740 745 750 cgc ctg aag ctc gat tat gaa gaa att act ccc tgt ctt aaa gaa gta 2480 Arg Leu Lys Leu Asp Tyr Glu Glu Ile Thr Pro Cys Leu Lys Glu Val 755 760 765 770 act aca gtg tgg gaa aag atg ctt agc act cca gga aga tca aaa att 2528 Thr Thr Val Trp Glu Lys Met Leu Ser Thr Pro Gly Arg Ser Lys Ile 775 780 785 aag ttt gac atg gaa aaa atg cac tcg gct gtt ggg caa ggt gtg cca 2576 Lys Phe Asp Met Glu Lys Met His Ser Ala Val Gly Gln Gly Val Pro 790 795 800 cgt cat cac cga ggt gaa atc tgg aaa ttt cta gct gag caa ttc cac 2624 Arg His His Arg Gly Glu Ile Trp Lys Phe Leu Ala Glu Gln Phe His 805 810 815 ctt aaa cac cag ttt ccc agc aaa cag cag cca aag gat gtg cca tac 2672 Leu Lys His Gln Phe Pro Ser Lys Gln Gln Pro Lys Asp Val Pro Tyr 820 825 830 aaa gaa ctc tta aag cag ctg act tcc cag cag cat gcg att ctt att 2720 Lys Glu Leu Leu Lys Gln Leu Thr Ser Gln Gln His Ala Ile Leu Ile 835 840 845 850 gac ctt ggg cga acc ttt cct aca cac cca tac ttc tct gcc cag ctt 2768 Asp Leu Gly Arg Thr Phe Pro Thr His Pro Tyr Phe Ser Ala Gln Leu 855 860 865 gga gca gga cag cta tcg ctt tac aac att ttg aag gcc tac tca ctt 2816 Gly Ala Gly Gln Leu Ser Leu Tyr Asn Ile Leu Lys Ala Tyr Ser Leu 870 875 880 cta gac cag gaa gtg gga tat tgc caa ggt ctc agc ttt gta gca ggc 2864 Leu Asp Gln Glu Val Gly Tyr Cys Gln Gly Leu Ser Phe Val Ala Gly 885 890 895 att ttg ctt ctt cat atg agt gag gaa gag gcg ttt aaa atg ctc aag 2912 Ile Leu Leu Leu His Met Ser Glu Glu Glu Ala Phe Lys Met Leu Lys 900 905 910 ttt ctg atg ttt gac atg ggg ctg cgg aaa cag tat cgg cca gac atg 2960 Phe Leu Met Phe Asp Met Gly Leu Arg Lys Gln Tyr Arg Pro Asp Met 915 920 925 930 att att tta cag atc cag atg tac cag ctc tcg agg ttg ctt cat gat 3008 Ile Ile Leu Gln Ile Gln Met Tyr Gln Leu Ser Arg Leu Leu His Asp 935 940 945 tac cac aga gac ctc tac aat cac ctg gag gag cac gag atc ggc ccc 3056 Tyr His Arg Asp Leu Tyr Asn His Leu Glu Glu His Glu Ile Gly Pro 950 955 960 agc ctc tac gct gcc ccc tgg ttc ctc acc atg ttt gcc tca cag ttc 3104 Ser Leu Tyr Ala Ala Pro Trp Phe Leu Thr Met Phe Ala Ser Gln Phe 965 970 975 ccg ctg gga ttc gta gcc aga gtc ttt gat atg att ttt ctt cag gga 3152 Pro Leu Gly Phe Val Ala Arg Val Phe Asp Met Ile Phe Leu Gln Gly 980 985 990 aca gag gtc ata ttt aaa gtg gct tta agt ctg ttg gga agc cat aag 3200 Thr Glu Val Ile Phe Lys Val Ala Leu Ser Leu Leu Gly Ser His Lys 995 1000 1005 1010 ccc ttg att ctg cag cat gaa aac cta gaa acc ata gtt gac ttt ata 3248 Pro Leu Ile Leu Gln His Glu Asn Leu Glu Thr Ile Val Asp Phe Ile 1015 1020 1025 aaa agc acg cta ccc aac ctt ggc ttg gta cag atg gaa aag acc atc 3296 Lys Ser Thr Leu Pro Asn Leu Gly Leu Val Gln Met Glu Lys Thr Ile 1030 1035 1040 aat cag gta ttt gaa atg gac atc gct aaa cag tta caa gct tat gaa 3344 Asn Gln Val Phe Glu Met Asp Ile Ala Lys Gln Leu Gln Ala Tyr Glu 1045 1050 1055 gtt gag tac cac gtc ctt caa gaa gaa ctt atc gat tcc tct cct ctc 3392 Val Glu Tyr His Val Leu Gln Glu Glu Leu Ile Asp Ser Ser Pro Leu 1060 1065 1070 agt gac aac caa aga atg gat aaa tta gag aaa acc aac agc agc tta 3440 Ser Asp Asn Gln Arg Met Asp Lys Leu Glu Lys Thr Asn Ser Ser Leu 1075 1080 1085 1090 cgc aaa cag aac ctt gac ctc ctt gaa cag ttg cag gtg gca aat ggt 3488 Arg Lys Gln Asn Leu Asp Leu Leu Glu Gln Leu Gln Val Ala Asn Gly 1095 1100 1105 agg atc caa agc ctt gag gcc acc att gag aag ctc ctg agc agt gag 3536 Arg Ile Gln Ser Leu Glu Ala Thr Ile Glu Lys Leu Leu Ser Ser Glu 1110 1115 1120 agc aag ctg aag cag gcc atg ctt acc tta gaa ctg gag cgg tcg gcc 3584 Ser Lys Leu Lys Gln Ala Met Leu Thr Leu Glu Leu Glu Arg Ser Ala 1125 1130 1135 ctg ctg cag acg gtg gag gag ctg cgg cgg cgg agc gca gag ccc agc 3632 Leu Leu Gln Thr Val Glu Glu Leu Arg Arg Arg Ser Ala Glu Pro Ser 1140 1145 1150 gac cgg gag cct gag tgc acg cag ccc gag ccc acg ggc gac tga 3677 Asp Arg Glu Pro Glu Cys Thr Gln Pro Glu Pro Thr Gly Asp * 1155 1160 1165 cagctctgca ggagagattg caacaccatc ccacactgtc caggccttaa ctgagaggga 3737 cagaagacgc tggaaggaga gaaggaagcg ggaagtgtgc ttctcaggga ggaaaccggc 3797 ttgccagcaa gtagattctt acgaactcca acttgcaatt cagggggcat gtcccagtgt 3857 tttttttgtt gtttttagat actaaatcgt cccttctcca gtcctgatta ctgtacacag 3917 tagctttaga tggcgtggac gtgaataaat gcaacttatg ttttaaaaaa aaaaaaaaaa 3977 aaaaaa 3983 <210> SEQ ID NO 4 <211> LENGTH: 3988 <212> TYPE: DNA <213> ORGANISM: Homo sapiens <220> FEATURE: <221> NAME/KEY: CDS <222> LOCATION: 176..3730 <221> NAME/KEY: polyA_signal <222> LOCATION: 3947..3952 <223> OTHER INFORMATION: AATAAA <221> NAME/KEY: misc_feature <222> LOCATION: 1..458 <223> OTHER INFORMATION: homology with Genset 5′ EST in ref : A35235 <400> SEQUENCE: 4 ataataggca ctgaagacat gttaatggaa ggtggatttg tgattcagaa cctctagact 60 acctgggcga gtcttttaaa atgtttctgc atatgaagtg tgtaaaatag attgcttgat 120 ccaaaacaga aaaacagtga taactgtttt gctgagttcc cagacccttc ccaag atg 178 Met 1 gaa cca ata aca ttc aca gca agg aaa cat ctg ctt cct aac gag gtc 226 Glu Pro Ile Thr Phe Thr Ala Arg Lys His Leu Leu Pro Asn Glu Val 5 10 15 tcg gtg gat ttt ggc ctg cag ctg gtg ggc tcc ctg cct gtg cat tcc 274 Ser Val Asp Phe Gly Leu Gln Leu Val Gly Ser Leu Pro Val His Ser 20 25 30 ctg acc acc atg ccc atg ctg ccc tgg gtt gtg gct gag gtg cga aga 322 Leu Thr Thr Met Pro Met Leu Pro Trp Val Val Ala Glu Val Arg Arg 35 40 45 ctc agc agg cag tcc acc aga aag gaa cct gta acc aag caa gtc cgg 370 Leu Ser Arg Gln Ser Thr Arg Lys Glu Pro Val Thr Lys Gln Val Arg 50 55 60 65 ctt tgc gtt tca ccc tct gga ctg aga tgt gaa cct gag cca ggg aga 418 Leu Cys Val Ser Pro Ser Gly Leu Arg Cys Glu Pro Glu Pro Gly Arg 70 75 80 agt caa cag tgg gat ccc ctg atc tat tcc agc atc ttt gag tgc aag 466 Ser Gln Gln Trp Asp Pro Leu Ile Tyr Ser Ser Ile Phe Glu Cys Lys 85 90 95 cct cag cgt gtt cac aaa ctg att cac aac agt cat gac cca agt tac 514 Pro Gln Arg Val His Lys Leu Ile His Asn Ser His Asp Pro Ser Tyr 100 105 110 ttt gct tgt ctg att aag gaa gac gct gtc cac cgg cag agt atc tgc 562 Phe Ala Cys Leu Ile Lys Glu Asp Ala Val His Arg Gln Ser Ile Cys 115 120 125 tat gtg ttc aaa gcc gat gat caa aca aaa gtg cct gag atc atc agc 610 Tyr Val Phe Lys Ala Asp Asp Gln Thr Lys Val Pro Glu Ile Ile Ser 130 135 140 145 tcc atc cgt cag gcg ggg aag atc gcc cgg cag gag gag ctg cac tgc 658 Ser Ile Arg Gln Ala Gly Lys Ile Ala Arg Gln Glu Glu Leu His Cys 150 155 160 ccg tcc gag ttc gac gac acg ttt tcc aag aag ttc gag gtg ctc ttc 706 Pro Ser Glu Phe Asp Asp Thr Phe Ser Lys Lys Phe Glu Val Leu Phe 165 170 175 tgc ggc cgc gtg acg gtg gcg cac aag aag gct ccg ccg gcc ctg atc 754 Cys Gly Arg Val Thr Val Ala His Lys Lys Ala Pro Pro Ala Leu Ile 180 185 190 gac gag tgc atc gag aag ttc aat cac gtc agc ggc agc cgg ggg tcc 802 Asp Glu Cys Ile Glu Lys Phe Asn His Val Ser Gly Ser Arg Gly Ser 195 200 205 gag agc ccc cgc ccc aac ccg ccc cat gcc gcg ccc aca ggg agc cag 850 Glu Ser Pro Arg Pro Asn Pro Pro His Ala Ala Pro Thr Gly Ser Gln 210 215 220 225 gag cct gtg cgc agg ccc atg cgc aag tcc ttc tcc cag ccc ggc ctg 898 Glu Pro Val Arg Arg Pro Met Arg Lys Ser Phe Ser Gln Pro Gly Leu 230 235 240 cgc tcg ctg gcc ttt agg aag gag ctg cag gat ggg ggc ctc cga agc 946 Arg Ser Leu Ala Phe Arg Lys Glu Leu Gln Asp Gly Gly Leu Arg Ser 245 250 255 agc ggc ttc ttc agc tcc ttc gag gag agc gac att gag aac cac ctc 994 Ser Gly Phe Phe Ser Ser Phe Glu Glu Ser Asp Ile Glu Asn His Leu 260 265 270 att agc gga cac aat att gtg cag ccc aca gat atc gag gaa aat cga 1042 Ile Ser Gly His Asn Ile Val Gln Pro Thr Asp Ile Glu Glu Asn Arg 275 280 285 act atg ctc ttc acg att ggc cag tct gaa gtt tac ctc atc agt cct 1090 Thr Met Leu Phe Thr Ile Gly Gln Ser Glu Val Tyr Leu Ile Ser Pro 290 295 300 305 gac acc aaa aaa ata gca ttg gag aaa aat ttt aag gag ata tcc ttt 1138 Asp Thr Lys Lys Ile Ala Leu Glu Lys Asn Phe Lys Glu Ile Ser Phe 310 315 320 tgc tct cag ggc atc aga cac gtg gac cac ttt ggg ttt atc tgt cgg 1186 Cys Ser Gln Gly Ile Arg His Val Asp His Phe Gly Phe Ile Cys Arg 325 330 335 gag tct tcc gga ggt ggc ggc ttt cat ttt gtc tgt tac gtg ttt cag 1234 Glu Ser Ser Gly Gly Gly Gly Phe His Phe Val Cys Tyr Val Phe Gln 340 345 350 tgc aca aat gag gct ctg gtt gat gaa att atg atg acc ctg aaa cag 1282 Cys Thr Asn Glu Ala Leu Val Asp Glu Ile Met Met Thr Leu Lys Gln 355 360 365 gcc ttc acg gtg gcc gca gtg cag cag aca gct aag gcg cca gcc cag 1330 Ala Phe Thr Val Ala Ala Val Gln Gln Thr Ala Lys Ala Pro Ala Gln 370 375 380 385 ctg tgt gag ggc tgc ccc ctg caa agc ctg cac aag ctc tgt gag agg 1378 Leu Cys Glu Gly Cys Pro Leu Gln Ser Leu His Lys Leu Cys Glu Arg 390 395 400 ata gag gga atg aat tct tcc aaa aca aaa cta gaa ctg caa aag cac 1426 Ile Glu Gly Met Asn Ser Ser Lys Thr Lys Leu Glu Leu Gln Lys His 405 410 415 ctg acg aca tta acc aat cag gag cag gcg act att ttt gaa gag gtt 1474 Leu Thr Thr Leu Thr Asn Gln Glu Gln Ala Thr Ile Phe Glu Glu Val 420 425 430 cag aaa ttg aga ccg aga aat gag cag cga gag aat gaa ttg att att 1522 Gln Lys Leu Arg Pro Arg Asn Glu Gln Arg Glu Asn Glu Leu Ile Ile 435 440 445 tct ttt ctg aga tgt tta tat gaa gag aaa cag aaa gaa cac atc cat 1570 Ser Phe Leu Arg Cys Leu Tyr Glu Glu Lys Gln Lys Glu His Ile His 450 455 460 465 att ggg gag atg aag cag aca tcg cag atg gca gca gag aat att gga 1618 Ile Gly Glu Met Lys Gln Thr Ser Gln Met Ala Ala Glu Asn Ile Gly 470 475 480 agt gaa tta cca ccc agt gcc act cga ttt agg cta gat atg ctg aaa 1666 Ser Glu Leu Pro Pro Ser Ala Thr Arg Phe Arg Leu Asp Met Leu Lys 485 490 495 aac aaa gca aag aga tct tta aca gag tct tta gaa agt att ttg tcc 1714 Asn Lys Ala Lys Arg Ser Leu Thr Glu Ser Leu Glu Ser Ile Leu Ser 500 505 510 cgg ggt aat aaa gcc aga ggc ctg cag gaa cac tcc atc agt gtg gat 1762 Arg Gly Asn Lys Ala Arg Gly Leu Gln Glu His Ser Ile Ser Val Asp 515 520 525 ctg gat agc tcc ctg tct agt aca tta agt aac acc agc aaa gag cca 1810 Leu Asp Ser Ser Leu Ser Ser Thr Leu Ser Asn Thr Ser Lys Glu Pro 530 535 540 545 tct gtg tgt gaa aag gag gcc ttg ccc atc tct gag agc tcc ttt aag 1858 Ser Val Cys Glu Lys Glu Ala Leu Pro Ile Ser Glu Ser Ser Phe Lys 550 555 560 ctc ctc ggc tcc tcg gag gac ctg tcc agt gac tcg gag agt cat ctc 1906 Leu Leu Gly Ser Ser Glu Asp Leu Ser Ser Asp Ser Glu Ser His Leu 565 570 575 cca gaa gag cca gct ccg ctg tcg ccc cag cag gcc ttc agg agg cga 1954 Pro Glu Glu Pro Ala Pro Leu Ser Pro Gln Gln Ala Phe Arg Arg Arg 580 585 590 gca aac acc ctg agt cac ttc ccc atc gaa tgc cag gaa cct cca caa 2002 Ala Asn Thr Leu Ser His Phe Pro Ile Glu Cys Gln Glu Pro Pro Gln 595 600 605 cct gcc cgg ggg tcc ccg ggg gtt tcg caa agg aaa ctt atg agg tat 2050 Pro Ala Arg Gly Ser Pro Gly Val Ser Gln Arg Lys Leu Met Arg Tyr 610 615 620 625 cac tca gtg agc aca gag acg cct cat gaa cga aag gac ttt gaa tcc 2098 His Ser Val Ser Thr Glu Thr Pro His Glu Arg Lys Asp Phe Glu Ser 630 635 640 aaa gca aac cat ctt ggt gat tct ggt ggg act cct gtg aag acc cgg 2146 Lys Ala Asn His Leu Gly Asp Ser Gly Gly Thr Pro Val Lys Thr Arg 645 650 655 agg cat tcc tgg agg cag cag ata ttc ctc cga gta gcc acc ccg cag 2194 Arg His Ser Trp Arg Gln Gln Ile Phe Leu Arg Val Ala Thr Pro Gln 660 665 670 aag gcg tgc gat tct tcc agc aga tat gaa gat tat tca gag ctg gga 2242 Lys Ala Cys Asp Ser Ser Ser Arg Tyr Glu Asp Tyr Ser Glu Leu Gly 675 680 685 gag ctt ccc cca cga tct cct tta gaa cca gtt tgt gaa gat ggg ccc 2290 Glu Leu Pro Pro Arg Ser Pro Leu Glu Pro Val Cys Glu Asp Gly Pro 690 695 700 705 ttt ggc ccc cca cca gag gaa aag aaa agg aca tct cgt gag ctc cga 2338 Phe Gly Pro Pro Pro Glu Glu Lys Lys Arg Thr Ser Arg Glu Leu Arg 710 715 720 gag ctg tgg caa aag gct att ctt caa cag ata ctg ctg ctt aga atg 2386 Glu Leu Trp Gln Lys Ala Ile Leu Gln Gln Ile Leu Leu Leu Arg Met 725 730 735 gag aag gaa aat cag aag ctc caa gcc tct gaa aat gat ttg ctg aac 2434 Glu Lys Glu Asn Gln Lys Leu Gln Ala Ser Glu Asn Asp Leu Leu Asn 740 745 750 aag cgc ctg aag ctc gat tat gaa gaa att act ccc tgt ctt aaa gaa 2482 Lys Arg Leu Lys Leu Asp Tyr Glu Glu Ile Thr Pro Cys Leu Lys Glu 755 760 765 gta act aca gtg tgg gaa aag atg ctt agc act cca gga aga tca aaa 2530 Val Thr Thr Val Trp Glu Lys Met Leu Ser Thr Pro Gly Arg Ser Lys 770 775 780 785 att aag ttt gac atg gaa aaa atg cac tcg gct gtt ggg caa ggt gtg 2578 Ile Lys Phe Asp Met Glu Lys Met His Ser Ala Val Gly Gln Gly Val 790 795 800 cca cgt cat cac cga ggt gaa atc tgg aaa ttt cta gct gag caa ttc 2626 Pro Arg His His Arg Gly Glu Ile Trp Lys Phe Leu Ala Glu Gln Phe 805 810 815 cac ctt aaa cac cag ttt ccc agc aaa cag cag cca aag gat gtg cca 2674 His Leu Lys His Gln Phe Pro Ser Lys Gln Gln Pro Lys Asp Val Pro 820 825 830 tac aaa gaa ctc tta aag cag ctg act tcc cag cag cat gcg att ctt 2722 Tyr Lys Glu Leu Leu Lys Gln Leu Thr Ser Gln Gln His Ala Ile Leu 835 840 845 att gac ctt ggg cga acc ttt cct aca cac cca tac ttc tct gcc cag 2770 Ile Asp Leu Gly Arg Thr Phe Pro Thr His Pro Tyr Phe Ser Ala Gln 850 855 860 865 ctt gga gca gga cag cta tcg ctt tac aac att ttg aag gcc tac tca 2818 Leu Gly Ala Gly Gln Leu Ser Leu Tyr Asn Ile Leu Lys Ala Tyr Ser 870 875 880 ctt cta gac cag gaa gtg gga tat tgc caa ggt ctc agc ttt gta gca 2866 Leu Leu Asp Gln Glu Val Gly Tyr Cys Gln Gly Leu Ser Phe Val Ala 885 890 895 ggc att ttg ctt ctt cat atg agt gag gaa gag gcg ttt aaa atg ctc 2914 Gly Ile Leu Leu Leu His Met Ser Glu Glu Glu Ala Phe Lys Met Leu 900 905 910 aag ttt ctg atg ttt gac atg ggg ctg cgg aaa cag tat cgg cca gac 2962 Lys Phe Leu Met Phe Asp Met Gly Leu Arg Lys Gln Tyr Arg Pro Asp 915 920 925 atg att att tta cag atc cag atg tac cag ctc tcg agg ttg ctt cat 3010 Met Ile Ile Leu Gln Ile Gln Met Tyr Gln Leu Ser Arg Leu Leu His 930 935 940 945 gat tac cac aga gac ctc tac aat cac ctg gag gag cac gag atc ggc 3058 Asp Tyr His Arg Asp Leu Tyr Asn His Leu Glu Glu His Glu Ile Gly 950 955 960 ccc agc ctc tac gct gcc ccc tgg ttc ctc acc atg ttt gcc tca cag 3106 Pro Ser Leu Tyr Ala Ala Pro Trp Phe Leu Thr Met Phe Ala Ser Gln 965 970 975 ttc ccg ctg gga ttc gta gcc aga gtc ttt gat atg att ttt ctt cag 3154 Phe Pro Leu Gly Phe Val Ala Arg Val Phe Asp Met Ile Phe Leu Gln 980 985 990 gga aca gag gtc ata ttt aaa gtg gct tta agt ctg ttg gga agc cat 3202 Gly Thr Glu Val Ile Phe Lys Val Ala Leu Ser Leu Leu Gly Ser His 995 1000 1005 aag ccc ttg att ctg cag cat gaa aac cta gaa acc ata gtt gac ttt 3250 Lys Pro Leu Ile Leu Gln His Glu Asn Leu Glu Thr Ile Val Asp Phe 1010 1015 1020 1025 ata aaa agc acg cta ccc aac ctt ggc ttg gta cag atg gaa aag acc 3298 Ile Lys Ser Thr Leu Pro Asn Leu Gly Leu Val Gln Met Glu Lys Thr 1030 1035 1040 atc aat cag gta ttt gaa atg gac atc gct aaa cag tta caa gct tat 3346 Ile Asn Gln Val Phe Glu Met Asp Ile Ala Lys Gln Leu Gln Ala Tyr 1045 1050 1055 gaa gtt gag tac cac gtc ctt caa gaa gaa ctt atc gat tcc tct cct 3394 Glu Val Glu Tyr His Val Leu Gln Glu Glu Leu Ile Asp Ser Ser Pro 1060 1065 1070 ctc agt gac aac caa aga atg gat aaa tta gag aaa acc aac agc agc 3442 Leu Ser Asp Asn Gln Arg Met Asp Lys Leu Glu Lys Thr Asn Ser Ser 1075 1080 1085 tta cgc aaa cag aac ctt gac ctc ctt gaa cag ttg cag gtg gca aat 3490 Leu Arg Lys Gln Asn Leu Asp Leu Leu Glu Gln Leu Gln Val Ala Asn 1090 1095 1100 1105 ggt agg atc caa agc ctt gag gcc acc att gag aag ctc ctg agc agt 3538 Gly Arg Ile Gln Ser Leu Glu Ala Thr Ile Glu Lys Leu Leu Ser Ser 1110 1115 1120 gag agc aag ctg aag cag gcc atg ctt acc tta gaa ctg gag cgg tcg 3586 Glu Ser Lys Leu Lys Gln Ala Met Leu Thr Leu Glu Leu Glu Arg Ser 1125 1130 1135 gcc ctg ctg cag acg gtg gag gag ctg cgg cgg cgg agc gca gag ccc 3634 Ala Leu Leu Gln Thr Val Glu Glu Leu Arg Arg Arg Ser Ala Glu Pro 1140 1145 1150 agc gac cgg gag cct gag tgc acg cag ccc gag ccc acg ggc gac tga 3682 Ser Asp Arg Glu Pro Glu Cys Thr Gln Pro Glu Pro Thr Gly Asp * 1155 1160 1165 cagctctgca ggagagattg caacaccatc ccacactgtc caggccttaa ctgagaggga 3742 cagaagacgc tggaaggaga gaaggaagcg ggaagtgtgc ttctcaggga ggaaaccggc 3802 ttgccagcaa gtagattctt acgaactcca acttgcaatt cagggggcat gtcccagtgt 3862 tttttttgtt gtttttagat actaaatcgt cccttctcca gtcctgatta ctgtacacag 3922 tagctttaga tggcgtggac gtgaataaat gcaacttatg ttttaaaaaa aaaaaaaaaa 3982 aaaaaa 3988 <210> SEQ ID NO 5 <211> LENGTH: 1168 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 5 Met Glu Pro Ile Thr Phe Thr Ala Arg Lys His Leu Leu Pro Asn Glu 1 5 10 15 Val Ser Val Asp Phe Gly Leu Gln Leu Val Gly Ser Leu Pro Val His 20 25 30 Ser Leu Thr Thr Met Pro Met Leu Pro Trp Val Val Ala Glu Val Arg 35 40 45 Arg Leu Ser Arg Gln Ser Thr Arg Lys Glu Pro Val Thr Lys Gln Val 50 55 60 Arg Leu Cys Val Ser Pro Ser Gly Leu Arg Cys Glu Pro Glu Pro Gly 65 70 75 80 Arg Ser Gln Gln Trp Asp Pro Leu Ile Tyr Ser Ser Ile Phe Glu Cys 85 90 95 Lys Pro Gln Arg Val His Lys Leu Ile His Asn Ser His Asp Pro Ser 100 105 110 Tyr Phe Ala Cys Leu Ile Lys Glu Asp Ala Val His Arg Gln Ser Ile 115 120 125 Cys Tyr Val Phe Lys Ala Asp Asp Gln Thr Lys Val Pro Glu Ile Ile 130 135 140 Ser Ser Ile Arg Gln Ala Gly Lys Ile Ala Arg Gln Glu Glu Leu His 145 150 155 160 Cys Pro Ser Glu Phe Asp Asp Thr Phe Ser Lys Lys Phe Glu Val Leu 165 170 175 Phe Cys Gly Arg Val Thr Val Ala His Lys Lys Ala Pro Pro Ala Leu 180 185 190 Ile Asp Glu Cys Ile Glu Lys Phe Asn His Val Ser Gly Ser Arg Gly 195 200 205 Ser Glu Ser Pro Arg Pro Asn Pro Pro His Ala Ala Pro Thr Gly Ser 210 215 220 Gln Glu Pro Val Arg Arg Pro Met Arg Lys Ser Phe Ser Gln Pro Gly 225 230 235 240 Leu Arg Ser Leu Ala Phe Arg Lys Glu Leu Gln Asp Gly Gly Leu Arg 245 250 255 Ser Ser Gly Phe Phe Ser Ser Phe Glu Glu Ser Asp Ile Glu Asn His 260 265 270 Leu Ile Ser Gly His Asn Ile Val Gln Pro Thr Asp Ile Glu Glu Asn 275 280 285 Arg Thr Met Leu Phe Thr Ile Gly Gln Ser Glu Val Tyr Leu Ile Ser 290 295 300 Pro Asp Thr Lys Lys Ile Ala Leu Glu Lys Asn Phe Lys Glu Ile Ser 305 310 315 320 Phe Cys Ser Gln Gly Ile Arg His Val Asp His Phe Gly Phe Ile Cys 325 330 335 Arg Glu Ser Ser Gly Gly Gly Gly Phe His Phe Val Cys Tyr Val Phe 340 345 350 Gln Cys Thr Asn Glu Ala Leu Val Asp Glu Ile Met Met Thr Leu Lys 355 360 365 Gln Ala Phe Thr Val Ala Ala Val Gln Gln Thr Ala Lys Ala Pro Ala 370 375 380 Gln Leu Cys Glu Gly Cys Pro Leu Gln Ser Leu His Lys Leu Cys Glu 385 390 395 400 Arg Ile Glu Gly Met Asn Ser Ser Lys Thr Lys Leu Glu Leu Gln Lys 405 410 415 His Leu Thr Thr Leu Thr Asn Gln Glu Gln Ala Thr Ile Phe Glu Glu 420 425 430 Val Gln Lys Leu Arg Pro Arg Asn Glu Gln Arg Glu Asn Glu Leu Ile 435 440 445 Ile Ser Phe Leu Arg Cys Leu Tyr Glu Glu Lys Gln Lys Glu His Ile 450 455 460 His Ile Gly Glu Met Lys Gln Thr Ser Gln Met Ala Ala Glu Asn Ile 465 470 475 480 Gly Ser Glu Leu Pro Pro Ser Ala Thr Arg Phe Arg Leu Asp Met Leu 485 490 495 Lys Asn Lys Ala Lys Arg Ser Leu Thr Glu Ser Leu Glu Ser Ile Leu 500 505 510 Ser Arg Gly Asn Lys Ala Arg Gly Leu Gln Glu His Ser Ile Ser Val 515 520 525 Asp Leu Asp Ser Ser Leu Ser Ser Thr Leu Ser Asn Thr Ser Lys Glu 530 535 540 Pro Ser Val Cys Glu Lys Glu Ala Leu Pro Ile Ser Glu Ser Ser Phe 545 550 555 560 Lys Leu Leu Gly Ser Ser Glu Asp Leu Ser Ser Asp Ser Glu Ser His 565 570 575 Leu Pro Glu Glu Pro Ala Pro Leu Ser Pro Gln Gln Ala Phe Arg Arg 580 585 590 Arg Ala Asn Thr Leu Ser His Phe Pro Ile Glu Cys Gln Glu Pro Pro 595 600 605 Gln Pro Ala Arg Gly Ser Pro Gly Val Ser Gln Arg Lys Leu Met Arg 610 615 620 Tyr His Ser Val Ser Thr Glu Thr Pro His Glu Arg Lys Asp Phe Glu 625 630 635 640 Ser Lys Ala Asn His Leu Gly Asp Ser Gly Gly Thr Pro Val Lys Thr 645 650 655 Arg Arg His Ser Trp Arg Gln Gln Ile Phe Leu Arg Val Ala Thr Pro 660 665 670 Gln Lys Ala Cys Asp Ser Ser Ser Arg Tyr Glu Asp Tyr Ser Glu Leu 675 680 685 Gly Glu Leu Pro Pro Arg Ser Pro Leu Glu Pro Val Cys Glu Asp Gly 690 695 700 Pro Phe Gly Pro Pro Pro Glu Glu Lys Lys Arg Thr Ser Arg Glu Leu 705 710 715 720 Arg Glu Leu Trp Gln Lys Ala Ile Leu Gln Gln Ile Leu Leu Leu Arg 725 730 735 Met Glu Lys Glu Asn Gln Lys Leu Gln Ala Ser Glu Asn Asp Leu Leu 740 745 750 Asn Lys Arg Leu Lys Leu Asp Tyr Glu Glu Ile Thr Pro Cys Leu Lys 755 760 765 Glu Val Thr Thr Val Trp Glu Lys Met Leu Ser Thr Pro Gly Arg Ser 770 775 780 Lys Ile Lys Phe Asp Met Glu Lys Met His Ser Ala Val Gly Gln Gly 785 790 795 800 Val Pro Arg His His Arg Gly Glu Ile Trp Lys Phe Leu Ala Glu Gln 805 810 815 Phe His Leu Lys His Gln Phe Pro Ser Lys Gln Gln Pro Lys Asp Val 820 825 830 Pro Tyr Lys Glu Leu Leu Lys Gln Leu Thr Ser Gln Gln His Ala Ile 835 840 845 Leu Ile Asp Leu Gly Arg Thr Phe Pro Thr His Pro Tyr Phe Ser Ala 850 855 860 Gln Leu Gly Ala Gly Gln Leu Ser Leu Tyr Asn Ile Leu Lys Ala Tyr 865 870 875 880 Ser Leu Leu Asp Gln Glu Val Gly Tyr Cys Gln Gly Leu Ser Phe Val 885 890 895 Ala Gly Ile Leu Leu Leu His Met Ser Glu Glu Glu Ala Phe Lys Met 900 905 910 Leu Lys Phe Leu Met Phe Asp Met Gly Leu Arg Lys Gln Tyr Arg Pro 915 920 925 Asp Met Ile Ile Leu Gln Ile Gln Met Tyr Gln Leu Ser Arg Leu Leu 930 935 940 His Asp Tyr His Arg Asp Leu Tyr Asn His Leu Glu Glu His Glu Ile 945 950 955 960 Gly Pro Ser Leu Tyr Ala Ala Pro Trp Phe Leu Thr Met Phe Ala Ser 965 970 975 Gln Phe Pro Leu Gly Phe Val Ala Arg Val Phe Asp Met Ile Phe Leu 980 985 990 Gln Gly Thr Glu Val Ile Phe Lys Val Ala Leu Ser Leu Leu Gly Ser 995 1000 1005 His Lys Pro Leu Ile Leu Gln His Glu Asn Leu Glu Thr Ile Val Asp 1010 1015 1020 Phe Ile Lys Ser Thr Leu Pro Asn Leu Gly Leu Val Gln Met Glu Lys 1025 1030 1035 1040 Thr Ile Asn Gln Val Phe Glu Met Asp Ile Ala Lys Gln Leu Gln Ala 1045 1050 1055 Tyr Glu Val Glu Tyr His Val Leu Gln Glu Glu Leu Ile Asp Ser Ser 1060 1065 1070 Pro Leu Ser Asp Asn Gln Arg Met Asp Lys Leu Glu Lys Thr Asn Ser 1075 1080 1085 Ser Leu Arg Lys Gln Asn Leu Asp Leu Leu Glu Gln Leu Gln Val Ala 1090 1095 1100 Asn Gly Arg Ile Gln Ser Leu Glu Ala Thr Ile Glu Lys Leu Leu Ser 1105 1110 1115 1120 Ser Glu Ser Lys Leu Lys Gln Ala Met Leu Thr Leu Glu Leu Glu Arg 1125 1130 1135 Ser Ala Leu Leu Gln Thr Val Glu Glu Leu Arg Arg Arg Ser Ala Glu 1140 1145 1150 Pro Ser Asp Arg Glu Pro Glu Cys Thr Gln Pro Glu Pro Thr Gly Asp 1155 1160 1165 <210> SEQ ID NO 6 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <221> NAME/KEY: misc_binding <222> LOCATION: 1..18 <223> OTHER INFORMATION: sequencing oligonucleotide PrimerPU <400> SEQUENCE: 6 tgtaaaacga cggccagt 18 <210> SEQ ID NO 7 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: Artificial Sequence <220> FEATURE: <221> NAME/KEY: misc_binding <222> LOCATION: 1..18 <223> OTHER INFORMATION: sequencing oligonucleotide PrimerRP <400> SEQUENCE: 7 caggaaacag ctatgacc 18 

What is claimed is:
 1. A composition comprising: an isolated, purified, or recombinant polynucleotide which encodes a polypeptide comprising 6 amino acids of SEQ ID NO:5 or the complement thereof, provided that said polypeptide is not murine TBC-1.
 2. A composition comprising an isolated, purified, or recombinant human polynucleotide which encodes a polypeptide comprising 6 amino acids of SEQ ID NO:5 or the complement thereof.
 3. An isolated, purified, or recombinant polynucleotide which: a) encodes a polypeptide comprising SEQ ID NO: 5; b) comprises nucleotides 171 to 3725 of SEQ ID NO: 3; or c) the complement thereof.
 4. The isolated, purified, or recombinant polynucleotide according to claim 3 attached to a solid support.
 5. The isolated, purified, or recombinant polynucleotide according to claim 4, wherein said polynucleotide encodes a polypeptide comprising SEQ ID NO:
 5. 6. The isolated, purified, or recombinant polynucleotide according to claim 4, wherein said polynucleotide comprises nucleotides 171 to 3725 of SEQ ID NO:
 3. 7. The isolated, purified, or recombinant polynucleotide according to claim 3, wherein said polynucleotide encodes a polypeptide comprising SEQ ID NO:
 5. 8. The isolated, purified, or recombinant polynucleotide according to claim 3, wherein said polynucleotide comprises nucleotides 171 to 3725 of SEQ ID NO:
 3. 9. An array of polynucleotides comprising at least one isolated, purified, or recombinant polynucleotides which: a) encodes a polypeptide comprising SEQ ID NO: 5; b) comprises nucleotides 171 to 3725 of SEQ ID NO: 3; or e) the complement thereof.
 10. The array according to claim 9, wherein said polynucleotide encodes a polypeptide comprising SEQ ID NO:
 5. 11. The array according to claim 9, wherein said polynucleotide comprises nucleotides 171 to 3725 of SEQ ID NO:
 3. 12. The array according to claim 9, wherein said array is addressable.
 13. The array according to claim 10, wherein said array is addressable.
 14. The array according to claim 11, wherein said array is addressable.
 15. The isolated, purified, or recombinant polynucleotide according to claim 5, further comprising a label.
 16. The isolated, purified, or recombinant polynucleotide according to claim 6, further comprising a label.
 17. A composition comprising: a recombinant vector comprising a polynucleotide which: a) encodes a polypeptide comprising SEQ ID NO: 5; b) comprises nucleotides 171 to 3725 of SEQ ID NO: 3; or c) the complement thereof.
 18. The composition according to claim 17, wherein said recombinant vector comprises a polynucleotide which encodes a polypeptide comprising SEQ ID NO:
 5. 19. The composition according to claim 17, wherein said recombinant vector comprises nucleotides 171 to 3725 of SEQ ID NO:
 3. 20. A composition comprising: a host cell comprising a recombinant vector comprising a polynucleotide which: a) encodes a polypeptide comprising SEQ ID NO: 5; b) comprises nucleotides 171 to 3725 of SEQ ID NO: 3; or c) the complement thereof.
 21. The composition according to claim 20, wherein said recombinant vector comprises a polynucleotide which encodes a polypeptide comprising SEQ ID NO:
 5. 22. The composition according to claim 20, wherein said recombinant vector comprises nucleotides 171 to 3725 of SEQ ID NO:
 3. 23. A method of making a TBC-1 polypeptide comprising the steps of: (i) obtaining a host cell comprising a recombinant vector comprising a polynucleotide which: a) encodes a polypeptide comprising SEQ ID NO: 5 or b) comprises nucleotides 171 to 3725 of SEQ ID NO: 3, (ii) growing said cell under conditions suitable to produce said polypeptide.
 24. The method according to claim 23, wherein said recombinant vector comprises a polynucleotide which encodes a polypeptide comprising SEQ ID NO:
 5. 25. The method according to claim 23, wherein said recombinant vector comprises nucleotides 171 to 3725 of SEQ ID NO:
 3. 26. The method according to claim 24, further comprising the step of purifying of isolating said polypeptide.
 27. The method according to claim 25, further comprising the step of purifying or isolating said polypeptide.
 28. A composition comprising an isolated, purified, or recombinant polynucleotide comprising a nucleotide sequence selected from the group consisting of the nucleotide sequences of SEQ ID NOs: 3 and 4, or the complements thereof.
 29. A method of making a TBC-1 polypeptide comprising the steps of: (i) obtaining a host cell comprising a recombinant vector comprising a polynucleotide comprising a nucleotide sequence selected from the group consisting of the nucleotide sequences of SEQ ID NOs: 3 and 4, or the complements thereof; and (ii) growing said cell under conditions suitable to produce said polypeptide.
 30. A composition comprising an isolated, purified, or recombinant polynucleotide consisting of the nucleotide sequences of SEQ ID NOs: 1, 2, or the complements thereof. 